Prostate-specific membrane antigen cars and methods of use thereof

ABSTRACT

The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.

CROSS-REFERENCE TO RELATED APPLICATION

The present application is divisional of U.S. patent application Ser.No. 16/293,298, filed Mar. 5, 2019, allowed, and is entitled to priorityunder 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No.62/639,321, filed Mar. 6, 2018, which is hereby incorporated byreference in its entirety herein.

BACKGROUND OF THE INVENTION

Breaking the tolerance to self-antigens is a major challenge in theapplication of immunotherapy to solid malignancies. Vaccine strategiesaimed at harnessing endogenous anti-tumor T cells are limited by the Tcell receptor (TCR) repertoire, which can be deleted within the thymusas part of central tolerance or rendered non-functional by post-thymicmechanisms of peripheral tolerance. One strategy to overcome suchobstacles is to produce genetically engineered T cells redirected towardtumor antigens using a chimeric antigen receptor (CAR) approach. CAR Tcells use genetically programmed, patient-derived lymphocytes transducedwith chimeric receptor genes in order to combine the antigen recognitiondomains of a specific antibody with the signaling domains of a TCR.

Prostate-specific membrane antigen (PSMA) is a membrane-bound proteinexpressed on the cell surface and is reported to be highly overexpressedin prostate cancer tissues. PSMA expression is directly correlated withadvancing tumor grade and stage, and is believed to confer a selectivegrowth advantage to prostate cancer cells. As such, PSMA may be an idealtarget for immunotherapies for prostate cancer.

Another major challenge in cancer immunotherapy is the hostilemicroenvironment in which the targeted tumor resides. For example,immunosuppressive receptor ligands such as, PDL1 (CD274) which binds toPD1 (CD279), are up-regulated and negatively regulate T cell activity inthe tumor microenvironment. In addition, TGF-β, which is over-expressedin prostate tumor cells, can act as an immunosuppressive molecule.

Thus, there is a need in the art for novel cancer immunotherapiestargeting PSMA. The present invention satisfies this need.

SUMMARY OF THE INVENTION

The present invention is based on the finding that human and murineprostate-specific membrane antigen (PSMA) chimeric antigen receptor(CAR) T cells exhibit potent anti-tumor activity. The present inventionis also based on the finding that PSMA-CAR T cells comprising a dominantnegative receptor and/or switch receptor exhibit significantly enhancedanti-tumor activity.

Accordingly, in certain aspects, the instant disclosure provides amodified immune cell or precursor cell thereof, comprising a chimericantigen receptor (CAR) having affinity for a prostate specific membraneantigen (PSMA) on a target cell, wherein the CAR comprises a PSMAbinding domain; and a dominant negative receptor and/or switch receptor.

In certain exemplary embodiments, the PSMA binding domain is a murinePSMA binding domain.

In certain exemplary embodiments, the PSMA binding domain is a humanPSMA binding domain.

In certain exemplary embodiments, the PSMA binding domain is selectedfrom the group consisting of an antibody, a Fab, or an scFv.

In certain exemplary embodiments, the scFv comprises the amino acidsequence set forth in any one of SEQ ID NOs:13, 14, 26, 38, 50, or 62.

In certain exemplary embodiments, the CAR comprises a transmembranedomain, and an intracellular domain.

In certain exemplary embodiments, the transmembrane domain comprises atransmembrane region derived from CD8.

In certain exemplary embodiments, the transmembrane region derived fromCD8 comprises the amino acid sequence set forth in SEQ ID NO:88.

In certain exemplary embodiments, the transmembrane domain furthercomprises a hinge region derived from CD8.

In certain exemplary embodiments, the hinge region derived from CD8comprises the amino acid sequence set forth in SEQ ID NO:86.

In certain exemplary embodiments, the transmembrane domain and the hingeregion comprises the amino acid sequence set forth in SEQ ID NO:90.

In certain exemplary embodiments, the intracellular domain comprises a4-1BB signaling domain and a CD3 zeta signaling domain.

In certain exemplary embodiments, the intracellular domain comprises theamino acid sequence set forth in SEQ ID NO:102.

In certain exemplary embodiments, the intracellular domain comprises anICOS signaling domain and a CD3 zeta signaling domain.

In certain exemplary embodiments, the intracellular domain comprises avariant ICOS signaling domain and a CD3 zeta signaling domain.

In certain exemplary embodiments, the 4-1BB signaling domain comprisesthe amino acid sequence set forth in SEQ ID NO:92.

In certain exemplary embodiments, the ICOS signaling domain comprisesthe amino acid sequence set forth in SEQ ID NO:203.

In certain exemplary embodiments, the variant ICOS signaling domaincomprises the amino acid sequence set forth in SEQ ID NO:95.

In certain exemplary embodiments, the CD3 zeta signaling domaincomprises the amino acid sequence set forth in SEQ ID NOs:97 or 100.

In certain exemplary embodiments, the dominant negative receptor is atruncated variant of a wild-type protein associated with a negativesignal.

In certain exemplary embodiments, the truncated variant of a wild-typeprotein associated with a negative signal (e.g. dominant negativereceptor) comprises the amino acid sequence set forth in SEQ ID NO:115.

In certain exemplary embodiments, the switch receptor comprises a firstdomain, wherein the first domain is derived from a first polypeptidethat is associated with a negative signal; and a second domain, whereinthe second domain is derived from a second polypeptide that isassociated with a positive signal.

In certain exemplary embodiments, the first domain comprises at least aportion of the extracellular domain of the first polypeptide that isassociated with a negative signal, and wherein the second domaincomprises at least a portion of the intracellular domain of the secondpolypeptide that is associated with a positive signal.

In certain exemplary embodiments, the switch receptor further comprisesa switch receptor transmembrane domain.

In certain exemplary embodiments, the switch receptor transmembranedomain comprises the transmembrane domain of the first polypeptide thatis associated with a negative signal; or the transmembrane domain of thesecond polypeptide that is associated with a positive signal.

In certain exemplary embodiments, the first polypeptide that isassociated with a negative signal is selected from the group consistingof CTLA4, PD-1, BTLA, TIM-3, and a TGFβR.

In certain exemplary embodiments, the second polypeptide that isassociated with a positive signal is selected from the group consistingof CD28, ICOS, 4-1BB, and a IL-12R.

In certain exemplary embodiments, the switch receptor comprises a firstdomain comprising at least a portion of the extracellular domain of PD1;a switch receptor transmembrane domain comprising at least a portion ofthe transmembrane domain of CD28; and a second domain comprising atleast a portion of the intracellular domain of CD28.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:117.

In certain exemplary embodiments, the switch receptor comprises a firstdomain comprising at least a portion of the extracellular domain of PD1;a switch receptor transmembrane domain comprising at least a portion ofthe transmembrane domain of PD1; and a second domain comprising at leasta portion of the intracellular domain of CD28.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:119.

In certain exemplary embodiments, the first domain comprises at least aportion of the extracellular domain of PD1 comprises an alanine (A) toleucine (L) substitution at amino acid position 132.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:121.

In certain exemplary embodiments, the switch receptor comprises a firstdomain comprising at least a portion of the extracellular domain of PD1comprising an alanine (A) to leucine (L) substitution at amino acidposition 132, and a second domain comprising at least a portion of theintracellular domain of CD28.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:121.

In certain exemplary embodiments, the switch receptor comprises a firstdomain comprising at least a portion of the extracellular domain of PD1comprising an alanine (A) to leucine (L) substitution at amino acidposition 132, and a second domain comprising at least a portion of theintracellular domain of 4-1BB.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:215.

In certain exemplary embodiments, the switch receptor comprises a firstdomain comprising at least a portion of the extracellular domain ofTIM-3; and a second domain comprising at least a portion of theintracellular domain of CD28.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:127.

In certain exemplary embodiments, the switch receptor comprises a firstdomain comprising at least a portion of the extracellular domain of aTGFβR; and a second domain comprising at least a portion of theintracellular domain of IL12Rβ1.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:123.

In certain exemplary embodiments, the switch receptor comprises a firstdomain comprising at least a portion of the extracellular domain of aTGFβR; and a second domain comprising at least a portion of theintracellular domain of IL12Rβ2.

In certain exemplary embodiments, the switch receptor comprises theamino acid sequence set forth in SEQ ID NO:125.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in any one of SEQ IDNOs:13, 14, 16, 38, 50, or 62; and a dominant negative receptorcomprising the amino acid sequence set forth in SEQ ID NO:115.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in any one of SEQ IDNOs:13, 14, 16, 38, 50, or 62; and a switch receptor comprising theamino acid sequence set forth in SEQ ID NO:213 or 215.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in any one of SEQ IDNOs:13, 14, 16, 38, 50, or 62; and a switch receptor comprising theamino acid sequence set forth in SEQ ID NOs:117 or 119.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in any one of SEQ IDNOs:13, 14, 16, 38, 50, or 62; and a switch receptor comprising theamino acid sequence set forth in SEQ ID NO:121.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in any one of SEQ IDNOs:13, 14, 16, 38, 50, or 62; and a switch receptor comprising theamino acid sequence set forth in SEQ ID NO:127.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in any one of SEQ IDNOs:13, 14, 16, 38, 50, or 62; and a switch receptor comprising theamino acid sequence set forth in SEQ ID NO:123.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in any one of SEQ IDNOs:14, 16, 38, 50, or 62; and a switch receptor comprising the aminoacid sequence set forth in SEQ ID NO:125.

In another aspect, the instant disclosure provides a modified immunecell or precursor cell thereof, comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising the amino acid sequence set forth in SEQ ID NO:13, 14; and adominant negative receptor comprising the amino acid sequence set forthin SEQ ID NO:115.

In certain exemplary embodiments, the CAR comprises the amino acidsequence set forth in SEQ ID NO:105.

In certain exemplary embodiments, the modified cell secretes abispecific antibody.

In certain exemplary embodiments, the bispecific antibody comprises afirst antigen binding domain and a second antigen binding domain.

In certain exemplary embodiments, the first antigen binding domain bindsto a negative signal selected from the group consisting of CTLA4, PD-1,BTLA, TIM-3, and TGFβR.

In certain exemplary embodiments, the second antigen binding domainbinds to a co-stimulatory molecule.

In certain exemplary embodiments, the co-stimulatory molecule is CD28.

In certain exemplary embodiments, the modified cell is a modified Tcell.

In certain exemplary embodiments, the modified T cell is an autologouscell.

In certain exemplary embodiments, the modified cell is a cytotoxic Tlymphocyte (CTL).

In certain exemplary embodiments, the modified cell is a Natural Killer(NK) cell.

In certain exemplary embodiments, the modified cell is a hematopoieticstem or hematopoietic progenitor cell.

In certain exemplary embodiments, the modified cell is an autologouscell.

In certain exemplary embodiments, the modified cell is derived from ahuman.

In certain exemplary embodiments, the modified T cell is derived from ahuman.

In another aspect, the instant disclosure provides an isolated nucleicacid, comprising a first nucleic acid sequence encoding a chimericantigen receptor (CAR) having affinity for a prostate specific membraneantigen (PSMA) on a target cell, wherein the CAR comprises a PSMAbinding domain; and a second nucleic acid sequence encoding a dominantnegative receptor and/or a switch receptor.

In certain exemplary embodiments, the first nucleic acid sequencecomprises the nucleic acid sequence set forth in any one of SEQ ID NOs:106, 108, 110, 112, 114, 210, 212.

In certain exemplary embodiments, the second nucleic acid sequencecomprises the nucleic acid sequence set forth in any one of SEQ IDNOs:116, 118, 120, 122, 124, 126, 128, 214 or 216.

In certain exemplary embodiments, the first nucleic acid sequence andthe second nucleic acid sequence are separated by a linker.

In certain exemplary embodiments, the linker comprises a nucleic acidsequence encoding an internal ribosome entry site (IRES).

In certain exemplary embodiments, the linker comprises a nucleic acidsequence encoding a self-cleaving peptide.

In certain exemplary embodiments, the self-cleaving peptide is a 2Apeptide.

In certain exemplary embodiments, the 2A peptide is selected from thegroup consisting of porcine teschovirus-1 2A (P2A), Thoseaasigna virus2A (T2A), equine rhinitis A virus 2A (E2A), and foot-and-mouth diseasevirus 2A (F2A).

In certain exemplary embodiments, the 2A peptide is T2A.

In certain exemplary embodiments, the 2A peptide is F2A.

In certain exemplary embodiments, the isolated nucleic acid comprisesfrom 5′ to 3′ the first nucleic acid sequence, the linker, and thesecond nucleic acid sequence.

In certain exemplary embodiments, the isolated nucleic acid comprisesfrom 5′ to 3′ the second nucleic acid sequence, the linker, and thefirst nucleic acid sequence.

In another aspect, the instant disclosure provides an isolated nucleicacid, comprising a first nucleic acid sequence encoding a chimericantigen receptor (CAR) having affinity for a prostate specific membraneantigen (PSMA) on a target cell, wherein the CAR comprises a PSMAbinding domain comprising the nucleic acid sequence set forth in any oneof SEQ ID NOs:180, 15, 27, 39, 51, or 63; and a second nucleic acidsequence encoding a dominant negative receptor and/or switch receptorcomprising the nucleic acid sequence set forth in any one of SEQ IDNOs:116, 118, 120, 122, 124, 126, 128, 214 or 216.

In another aspect, the instant disclosure provides an isolated nucleicacid, comprising a first nucleic acid sequence encoding a chimericantigen receptor (CAR) having affinity for a prostate specific membraneantigen (PSMA) on a target cell, wherein the CAR comprises a PSMAbinding domain comprising the nucleic acid sequence set forth in SEQ IDNO:180; and a second nucleic acid sequence encoding a dominant negativereceptor and/or switch receptor comprising the nucleic acid sequence setforth in SEQ ID NO:116.

In certain exemplary embodiments, the first nucleic acid sequence andthe second nucleic acid sequence is separated by a linker comprising anucleic acid sequence encoding T2A.

In certain exemplary embodiments, the first nucleic acid sequence andthe second nucleic acid sequence is separated by a linker comprising anucleic acid sequence encoding F2A.

In another aspect, the instant disclosure provides an isolated nucleicacid, comprising the nucleic acid sequence set forth in any one of SEQID NOs:152-168, 210, 212, and 217-226.

In certain exemplary embodiments, the nucleic acid comprises thenucleotide sequence set forth in SEQ ID NO:152.

In another aspect, the instant disclosure provides an isolated nucleicacid, comprising a nucleic acid sequence encoding a bispecific antibodyset forth in any one of SEQ ID NOs:130, 132, 134, 136, or 138.

In another aspect, the instant disclosure provides an expressionconstruct comprising the isolated nucleic acid of any of theabove-described embodiments.

In certain exemplary embodiments, the expression construct is a viralvector selected from the group consisting of a retroviral vector, alentiviral vector, an adenoviral vector, and an adeno-associated viralvector.

In certain exemplary embodiments, the expression construct is alentiviral vector.

In certain exemplary embodiments, the lentiviral vector furthercomprises an EF-1α promoter.

In certain exemplary embodiments, the lentiviral vector furthercomprises a rev response element (RRE).

In certain exemplary embodiments, the lentiviral vector furthercomprises a woodchuck hepatitis virus posttranscriptional regulatoryelement (WPRE).

In certain exemplary embodiments, the lentiviral vector furthercomprises a cPPT sequence.

In certain exemplary embodiments, the lentiviral vector furthercomprises an EF-1α promoter, a rev response element (RRE), a woodchuckhepatitis virus posttranscriptional regulatory element (WPRE), and acPPT sequence.

In certain exemplary embodiments, the lentiviral vector is aself-inactivating lentiviral vector.

In another aspect, the instant disclosure provides a method forgenerating the modified immune cell or precursor cell thereof of any ofthe above-described embodiments, comprising introducing into the immunecell one or more of the nucleic acid of any of the above-describedembodiments, or the expression construct of any of the above-describedembodiments.

In another aspect, the instant disclosure provides a method of treatingcancer in a subject in need thereof, the method comprising administeringto the subject a therapeutically effective composition comprising themodified immune cell of any of the above-described embodiments.

In certain exemplary embodiments, the method further comprisesadministering to the subject a lymphodepleting chemotherapy.

In certain exemplary embodiments, the lymphodepleting chemotherapycomprises administering to the subject a therapeutically effectiveamount of cyclophosphamide and/or fludarabine.

In certain exemplary embodiments, the lymphodepleting chemotherapycomprises administering to the subject a therapeutically effectiveamount of cyclophosphamide at about 200 mg/m²/day to about 2000mg/m²/day, and/or fludarabine at about 20 mg/m²/day to about 900mg/m²/day.

In certain exemplary embodiments, cyclophosphamide is administered atabout 300 mg/m²/day, and fludarabine is administered at about 30mg/m²/day. In certain exemplary embodiments, the cancer is a prostatecancer selected from the group consisting of castrate-resistant prostatecancer, advanced castrate-resistant prostate cancer, and metastaticcastrate-resistant prostate cancer.

In another aspect, the instant disclosure provides a method of treatingprostate cancer in a subject in need thereof. The method comprisesadministering to the subject a lymphodepleting chemotherapy comprising atherapeutically effective amount of cyclophosphamide and a modified Tcell comprising a chimeric antigen receptor (CAR) having affinity for aprostate specific membrane antigen (PSMA) on a target cell, wherein theCAR comprises a PSMA binding domain comprising an amino acid sequenceset forth in SEQ ID NO:13; and a dominant negative receptor comprisingan amino acid sequence set forth in SEQ ID NO:115.

In another aspect, the instant disclosure provides a method of treatingmetastatic castrate resistant prostate cancer in a subject in needthereof, the method comprising administering to the subject alymphodepleting chemotherapy comprising administering to the subject atherapeutically effective amount of cyclophosphamide; and administeringto the subject a modified T cell comprising a chimeric antigen receptor(CAR) having affinity for a prostate specific membrane antigen (PSMA) ona target cell, wherein the CAR comprises a PSMA binding domaincomprising an amino acid sequence set forth in SEQ ID NO:13; and adominant negative receptor comprising an amino acid sequence set forthin SEQ ID NO:115.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other features and advantages of the present inventionwill be more fully understood from the following detailed description ofillustrative embodiments taken in conjunction with the accompanyingdrawings. It should be understood that the present invention is notlimited to the precise arrangements and instrumentalities of theembodiments shown in the drawings.

FIG. 1A illustrates results using purified IVT PSMA RNA CARs and fulllength PSMA RNA resolved on an agarose gel.

FIG. 1B shows results using purified PSMA RNA CARs electroporated intoND444 T cells and CAR expression examined by Flow Cytometry. The meanfluorescence intensity is labeled below the graph.

FIG. 1C illustrates PSMA expression. Purified full length PSMA RNA wereelectroporated into Nalm6 or K562 cells (middle and right panel). PSMAexpression was examined by Flow Cytometry.

FIG. 1D illustrates results using combined PC3.PSMA single cell clones.Limited dilution was performed with PC3.PSMA cells (left panel), sevensingle colonies were isolated and pooled to be a new cell line,PC3.PSMA.7SC (right panel). PSMA expression was examined by FlowCytometry.

FIG. 2A illustrates results using various PSMA RNA CARs incubated withtumor cells and CD107a assays performed. The cells were gated by CD3.

FIG. 2B illustrates results using various PSMA RNA CARs incubated withtumor cells and Luciferase based CTL assays performed. Results arereported as percent killing based on luciferase activity in wells withonly tumor in the absence of T cells.

FIG. 2C shows results using various PSMA RNA CARs incubated with tumorcells and ELISA assays performed. (IL-2, left panel; IFN-γ, rightpanel).

FIG. 3A illustrates results using PSMA Lenti CARs constructed andtransduced into primary human T cells (MOI=3). CAR expression wasexamined by Flow Cytometry on day 8.

FIG. 3B shows results using various PSMA Lenti CARs incubated with orwithout tumor cells and CD107a assays performed. The cells were gated byCD3. Results from day 12 are shown.

FIG. 3C shows results using various PSMA Lenti CARs incubated with tumorcells and Luciferase based CTL assays performed. Results are reported aspercent killing based on luciferase activity in wells with only tumor inthe absence of T cells. Results from day 12 are shown.

FIG. 3D illustrates results using various PSMA Lenti CARs incubated withPC3 or PC3.PSMA cells and ELISA assays performed (IL-2, left panel;IFN-γ, right panel). Results from day 12 are shown.

FIG. 4A illustrates results using switch receptors, PD1*PTM.CD28 orPD1.CD28 linked to each human PSMA Lenti CARs via F2A and transducedinto primary human T cells. PD1 and CAR expression were examined by FlowCytometry on day 12.

FIG. 4B illustrates results using a dominant negative (dn) transforminggrowth factor β receptor II (TGFRβII) sequence linked to each human PSMALenti CAR via T2A. Dn-TGFRβII-PSMA CAR transduced T cells were analyzedby Flow Cytometry on day 7.

FIG. 4C illustrates results using various amounts of purified fulllength PDL1 RNA electroporated into PC3.PSMA cells and PDL1 expressionexamined by Flow Cytometry on day 13.

FIG. 4D shows results using various PSMA Lenti CARs incubated withPC3.PSMA or PDL1 electroporated PC3.PSMA cells and CD107a assaysperformed. The cells were gated by CD3. Results from day 14 are shown.

FIG. 4E shows results using various PSMA Lenti CARs incubated withPC3.PSMA or PDL1 electroporated PC3.PSMA cells and CD107a assaysperformed. The cells were gated by CD3. Results from day 14 are shown.

FIG. 4F shows results using various PSMA Lenti CARs incubated withPC3.PSMA or PDL1 electroporated PC3.PSMA cells and CD107a assaysperformed. The cells were gated by CD3. Results from day 14 are shown.

FIG. 4G shows results using various PSMA Lenti CARs incubated withPC3.PSMA or PDL1 electroporated PC3.PSMA cells and CD107a assaysperformed. The cells were gated by CD3. Results from day 14 are shown.

FIG. 4H shows results using various PSMA Lenti CARs incubated withPC3.PSMA cells and Luciferase based CTL assays performed. Results arereported as percent killing based on luciferase activity in wells withonly tumor in the absence of T cells.

FIG. 4I shows results using various PSMA Lenti CARs incubated withPC3.PSMA or PDL1 electroporated PC3.PSMA cells and ELISA assaysperformed. (IL-2, top panel; IFN-γ, bottom panel).

FIG. 5A shows results using switch receptor PD1.CD28 linked to eachhuman PSMA Lenti CARs via F2A transduced into primary human T cells. PD1and CAR expression were examined by Flow Cytometry.

FIG. 5B shows results using a dominant negative (dn) TGFRβII sequencelinked to human 2A10 PSMA Lenti CARs via T2A. CARs transduced T cellswere analyzed by Flow Cytometry.

FIG. 5C shows results using various PSMA Lenti CARs incubated withPC3.PSMA.7SC cells and CD107a assays performed. The cells were gated byCD3.

FIG. 5D shows results using various PSMA Lenti CARs were incubated withPDL1 electroporated PC3.PSMA.7SC cells and CD107a assay was performed.The cells were gated by CD3.

FIG. 5E shows results using various PSMA Lenti CARs incubated with tumorcells and Luciferase based CTL assays performed. Results are reported aspercent killing based on luciferase activity in wells with only tumor inthe absence of T cells.

FIG. 5F shows results using various PSMA Lenti CARs incubated with PC3,PC3.PSMA.7SC or PDL1 electroporated PC3.PSMA.PDL1 cells and ELISA assaysperformed. (IL-2, top panel; IFN-γ, bottom panel).

FIG. 5G shows results using quantitative PCR for PSMA expression. Thefold changes (delta delta CT) were normalized to Nalm6.CBG cells. SeeTable 1 for the abbreviations.

FIG. 5H shows results using various PSMA Lenti CARs incubated with tumorcells or primary human cells and CD107a assays performed. The cells weregated by CD3.

FIG. 5I shows quantitative data from the experiments shown in FIG. 5H.HSAEpC: Human Small Airway Epithelial Cells. HPMEC: Human PulmonaryMicrovascular Endothelial Cells.

FIG. 5J shows results using various PSMA Lenti CARs incubated withprimary human cells and ELISA assays performed. (IL-2, left panel;IFN-γ, right panel). HREpC: Human Renal Epithelial Cells. HSAEpC: HumanSmall Airway Epithelial Cells. HPMEC: Human Pulmonary MicrovascularEndothelial Cells.

FIG. 5K shows results using 2×10⁶ PC3.PSMA.7SC cells transduced withclick beetle and injected into mice (i.v.). 27 days later, 2×10⁶ PSMACAR-T positive transduced T cells were injected to the tumor bearingmice (i.v.). Bioluminescence imaging (BLI) was conducted at multipletime points. Upper panel with a minimal average radiance of 5×10⁵; Lowerpanel with a minimal average radiance of 3×10⁵.

FIG. 5L illustrates quantitative average radiances of FIG. 5K.

FIG. 6 is a schematic representation of a dn-TGFRβII PSMA CAR constructand pTRPE construct map.

FIG. 7 shows flow cytometry examination of CAR expression in T cellstransduced with 2F5 PSMA CAR alone (2F5 ICOS), or co-transduced 2F5 PSMACAR together with various switch receptors, as indicated.

FIG. 8 shows flow cytometry examination of PD1 and Tim3 expression of Tcells transduced with 2F5 PSMA CAR alone (2F5 ICOS), or co-transduced2F5 PSMA CAR together with various switch receptors, as indicated.

FIG. 9 is a graph depicting CD107a expression in T cells transduced with2F5 PSMA ICOS-CAR alone (ICOS), PSMA 41BB-CAR alone (41BB), orco-transduced 2F5 PSMA CAR together with various switch receptors, asindicated. UTD means untransduced.

FIG. 10 is a graph depicting granzyme B expression in T cells transducedwith 2F5 PSMA ICOS-CAR alone (ICOS), PSMA 41BB-CAR alone (41BB), orco-transduced 2F5 PSMA CAR together with various switch receptors, asindicated. UTD means untransduced.

FIG. 11A is a graph depicting IL-2 secretion of T cells transduced with2F5 PSMA ICOS-CAR alone (ICOS), PSMA 41BB-CAR alone (41BB), orco-transduced 2F5 PSMA CAR together with various switch receptors, asindicated. NTD means untransduced.

FIG. 11B is a graph depicting IFNgamma secretion of T cells transducedwith 2F5 PSMA ICOS-CAR alone (ICOS), PSMA 41BB-CAR alone (41BB), orco-transduced 2F5 PSMA CAR together with various switch receptors, asindicated. UTD means untransduced.

FIG. 12A is a graph depicting the quantification of bioluminescenceobtained from imaging of NSG mice bearing PC3-PSMA.CBG induced tumorstreated with T cells transduced as indicated.

FIG. 12B is a graph depicting the quantification of bioluminescenceobtained from imaging of NSG mice bearing PC3-PSMA.CBG induced tumorstreated with T cells transduced as indicated.

FIG. 13 is a graph depicting tumor sizes of NSG mice bearingPC3-PSMA.CBG induced tumors treated with T cells transduced asindicated.

FIG. 14A is a graph depicting the quantification of bioluminescenceobtained from imaging of NSG mice bearing PC3-PSMA.CBG induced tumorstreated with T cells transduced as indicated.

FIG. 14B is a graph depicting the quantification of bioluminescenceobtained from imaging of NSG mice bearing PC3-PSMA.CBG induced tumorstreated with T cells transduced as indicated.

FIG. 14C is a graph depicting the quantification of bioluminescenceobtained from imaging of NSG mice bearing PC3-PSMA.CBG induced tumorstreated with T cells transduced as indicated.

FIG. 14D is a graph depicting the quantification of bioluminescenceobtained from imaging of NSG mice bearing PC3-PSMA.CBG induced tumorstreated with T cells transduced as indicated.

FIG. 14E is a graph depicting the quantification of bioluminescenceobtained from imaging of NSG mice bearing PC3-PSMA.CBG induced tumorstreated with T cells transduced as indicated.

FIG. 14F is a graph depicting the quantification of bioluminescence(left) and tumor size (right) obtained from imaging of NSG mice bearingPC3-PSMA.CBG induced tumors treated with T cells transduced asindicated.

FIG. 14G is a table listing from top to bottom, T cells transduced asindicated, in order of tumor control capability. ICOS^(YMNM) is superiorto WT ICOS. PD1*BB is better than PD1*CD28 when with ICOSz orICOSzYMNM.FIG. 15A is a graph showing that CART-PSMA-TGFβRdn cells(dnTGFBR2-T2A-Pbbz) demonstrated enhanced antigen-specific proliferationversus CART-PSMA (Pbbz) over 42 days co-culture and repetitivestimulation with PSMA-expressing tumor cells (arrows). CD19-BBz CART(19bbz) and transduced T cells (mock) were used as controls.

FIG. 15B is a graph showing the average radiance detected intumor-bearing mice up to 27 days post T cell injection withCART-PSMA-TGFβRdn cells (dnTGFBR2-T2A-Pbbz), CART-PSMA cells (Pbbz), anduntransduced cells used as control (mock).

FIG. 15C are photographs showing the location and systemic burden oftumor with weekly Bioluminescence imaging (BLI) assessment.

FIG. 16 illustrates the study schema used in a phase 1 clinical trial.

FIG. 17 is a graph showing the evaluation of CAR-T cellular kinetics viaqPCR of CART-PSMA-TGFβRdn DNA in subjects. Subjects 32816-02, -04, and-05 are in Cohort 1, and subjects 32816-06, -07, and -08 are in Cohort2.

FIG. 18A is a graph showing marked increases in inflammatory cytokines(IL-6, IL-15, IL-2, IFNgamma) and ferritin, correlating with a grade 3cytokine release syndrome event in subject 32816-06.

FIG. 18B is a graph showing marked increases in inflammatory cytokines(IL-6, IL-15, IL-2, IFNgamma) and ferritin, correlating with a grade 3cytokine release syndrome event in subject 32816-07.

FIG. 19 is a graph showing the prostate specific antigen (PSA) responseamong Cohort 1 and Cohort 2 patients.

FIG. 20A is a graph showing the expression of PSMA-TGFβRDN CART (lefty-axis in copies/ug of genomic DNA) and the level of IL-6 (right y-axisin pg/ml) in subject 32816-07, indicating cytokine release syndromeexhibited in subject one day post-infusion.

FIG. 20B is a graph showing that cytokine release syndrome managementwas accompanied by transient PSA decrease, as measured by the level ofC-reactive protein (CRP; left y-axis in mg/L) and the level of serumferritin (right y-axis in ng/L).

FIG. 21 is a graph showing the number of PSMA-positive circulating tumorcells (CTCs) detected in each subject over time.

DETAILED DESCRIPTION

The present invention provides compositions and methods for modifiedimmune cells, e.g., T cells and NK cells, or precursors thereof, e.g.,modified T cells, comprising a chimeric antigen receptor (CAR). In someembodiments, the CAR comprises a prostate-specific membrane antigen(PSMA) binding domain (PSMA-CAR), and has affinity for PSMA on a targetcell, e.g., a prostate cancer cell. In some embodiments, the modifiedimmune cell comprises a PSMA-CAR comprising a murine PSMA bindingdomain. In some embodiments, the modified immune cell comprises aPSMA-CAR comprising a human PSMA binding domain. Also provided aremethods of producing such genetically engineered cells. In someembodiments, the cells and compositions can be used in adoptive celltherapy, e.g., adoptive tumor immunotherapy.

In some embodiments, the provided immune cells comprise additionalreceptors, e.g., a dominant negative receptor and/or a switch receptor,to enhance the efficacy of the immune cell in the tumormicroenvironment. Such cells are capable of altering or reducing theeffects of immunosuppressive signals in the tumor microenvironment. Themodified immune cells of the invention counteract the upregulationand/or expression of inhibitor receptor or ligands that can negativelycontrol T cell activation and T cell function. For example, expressionof certain immune checkpoint proteins, e.g., PD-1 or PD-L1, on T cellsand/or in the tumor microenvironment can reduce the potency and efficacyof adoptive T cell therapy. For example, expression of TGF-β on T cellsand/or in the tumor microenvironment can reduce the potency and efficacyof adoptive T cell therapy. Such immunosuppressive signals may otherwiseimpair certain desirable effector functions in the context of adoptivecell therapy. Tumor cells and/or cells in the tumor microenvironmentoften upregulate immunosuppressive proteins, e.g., PD-L1, delivering animmunosuppressive signal. Such immunosuppressive proteins may also beunregulated on T cells in the tumor microenvironment, e.g., ontumor-infiltrating T cells, which can occur following signaling throughthe antigen receptor or certain other activating signals. Such eventsmay contribute to genetically engineered immune cells (e.g., PSMAtargeting) T cells acquiring an exhausted phenotype, such as whenpresent in proximity with other cells that express such protein, whichin turn can lead to reduced functionality. Thus, the modified immunecells of the invention address the T cell exhaustion and/or the lack ofT cell persistence that is a barrier to the efficacy and therapeuticoutcomes of conventional adoptive cell therapies.

The present invention includes a PSMA CAR and its use in treatingcancer. In certain embodiments, the invention includes a human PSMA CARwith a dominant negative receptor and/or a switch receptor. One of themajor obstacles for cancer immunotherapy is the tumor microenvironment.Up-regulation of immunosuppressive molecules, e.g., PD-1, negativelyregulates T cell activity.

The present invention is based on the finding that T cells comprising aPSMA-CAR and a dominant negative receptor and/or a switch receptor arecapable of bypassing the effect of immunosuppressive molecules in thetumor microenvironment, providing continued and potent anti-tumoractivity.

It is to be understood that the methods described in this disclosure arenot limited to particular methods and experimental conditions disclosedherein as such methods and conditions may vary. It is also to beunderstood that the terminology used herein is for the purpose ofdescribing particular embodiments only, and is not intended to belimiting.

Furthermore, the experiments described herein, unless otherwiseindicated, use conventional molecular and cellular biological andimmunological techniques within the skill of the art. Such techniquesare well known to the skilled worker, and are explained fully in theliterature. See, e.g., Ausubel, et al., ed., Current Protocols inMolecular Biology, John Wiley & Sons, Inc., NY, N.Y. (1987-2008),including all supplements, Molecular Cloning: A Laboratory Manual(Fourth Edition) by MR Green and J. Sambrook and Harlow et al.,Antibodies: A Laboratory Manual, Chapter 14, Cold Spring HarborLaboratory, Cold Spring Harbor (2013, 2nd edition).

A. Definitions

Unless otherwise defined, scientific and technical terms used hereinhave the meanings that are commonly understood by those of ordinaryskill in the art. In the event of any latent ambiguity, definitionsprovided herein take precedent over any dictionary or extrinsicdefinition. Unless otherwise required by context, singular terms shallinclude pluralities and plural terms shall include the singular. The useof “or” means “and/or” unless stated otherwise. The use of the term“including,” as well as other forms, such as “includes” and “included,”is not limiting.

Generally, nomenclature used in connection with cell and tissue culture,molecular biology, immunology, microbiology, genetics and protein andnucleic acid chemistry and hybridization described herein is well-knownand commonly used in the art. The methods and techniques provided hereinare generally performed according to conventional methods well known inthe art and as described in various general and more specific referencesthat are cited and discussed throughout the present specification unlessotherwise indicated. Enzymatic reactions and purification techniques areperformed according to manufacturer's specifications, as commonlyaccomplished in the art or as described herein. The nomenclatures usedin connection with, and the laboratory procedures and techniques of,analytical chemistry, synthetic organic chemistry, and medicinal andpharmaceutical chemistry described herein are those well-known andcommonly used in the art. Standard techniques are used for chemicalsyntheses, chemical analyses, pharmaceutical preparation, formulation,and delivery, and treatment of patients.

That the disclosure may be more readily understood, select terms aredefined below.

The articles “a” and “an” are used herein to refer to one or to morethan one (i.e., to at least one) of the grammatical object of thearticle. By way of example, “an element” means one element or more thanone element.

“About” as used herein when referring to a measurable value such as anamount, a temporal duration, and the like, is meant to encompassvariations of ±20% or ±10%, more preferably ±5%, even more preferably±1%, and still more preferably ±0.1% from the specified value, as suchvariations are appropriate to perform the disclosed methods.

“Activation,” as used herein, refers to the state of a T cell that hasbeen sufficiently stimulated to induce detectable cellularproliferation. Activation can also be associated with induced cytokineproduction, and detectable effector functions. The term “activated Tcells” refers to, among other things, T cells that are undergoing celldivision.

As used herein, to “alleviate” a disease means reducing the severity ofone or more symptoms of the disease.

The term “antibody,” as used herein, refers to an immunoglobulinmolecule which specifically binds with an antigen. Antibodies can beintact immunoglobulins derived from natural sources or from recombinantsources and can be immunoreactive portions of intact immunoglobulins(e.g., a binding fragment of an antibody). Antibodies are typicallytetramers of immunoglobulin molecules. The antibodies in the presentinvention may exist in a variety of forms including, for example,polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)2, aswell as single chain antibodies (scFv) and humanized antibodies (Harlowet al., 1999, In: Using Antibodies: A Laboratory Manual, Cold SpringHarbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: ALaboratory Manual, Cold Spring Harbor, N.Y.; Houston et al., 1988, Proc.Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science242:423-426).

The term “antibody fragment” refers to a portion of an intact antibodyand refers to the antigenic determining variable regions of an intactantibody. Examples of antibody fragments include, but are not limitedto, Fab, Fab′, F(ab′)2, and Fv fragments, linear antibodies, scFvantibodies, and multispecific antibodies formed from antibody fragments.

An “antibody heavy chain,” as used herein, refers to the larger of thetwo types of polypeptide chains present in all antibody molecules intheir naturally occurring conformations.

An “antibody light chain,” as used herein, refers to the smaller of thetwo types of polypeptide chains present in all antibody molecules intheir naturally occurring conformations. α and β light chains refer tothe two major antibody light chain isotypes.

By the term “synthetic antibody” as used herein, is meant an antibodywhich is generated using recombinant DNA technology, such as, forexample, an antibody expressed by a bacteriophage as described herein.The term should also be construed to mean an antibody which has beengenerated by the synthesis of a DNA molecule encoding the antibody andwhich DNA molecule expresses an antibody protein, or an amino acidsequence specifying the antibody, wherein the DNA or amino acid sequencehas been obtained using synthetic DNA or amino acid sequence technologywhich is available and well known in the art.

The term “antigen” or “Ag” as used herein is defined as a molecule thatprovokes an immune response. This immune response may involve eitherantibody production, or the activation of specificimmunologically-competent cells, or both. The skilled artisan willunderstand that any macromolecule, including virtually all proteins orpeptides, can serve as an antigen.

Furthermore, antigens can be derived from recombinant or genomic DNA. Askilled artisan will understand that any DNA, which comprises anucleotide sequences or a partial nucleotide sequence encoding a proteinthat elicits an immune response therefore encodes an “antigen” as thatterm is used herein. Furthermore, one skilled in the art will understandthat an antigen need not be encoded solely by a full length nucleotidesequence of a gene. It is readily apparent that the present inventionincludes, but is not limited to, the use of partial nucleotide sequencesof more than one gene and that these nucleotide sequences are arrangedin various combinations to elicit the desired immune response. Moreover,a skilled artisan will understand that an antigen need not be encoded bya “gene” at all. It is readily apparent that an antigen can be generatedsynthesized or can be derived from a biological sample. Such abiological sample can include, but is not limited to a tissue sample, atumor sample, a cell or a biological fluid.

As used herein, the term “autologous” is meant to refer to any materialderived from the same individual to which it is later to bere-introduced into the individual. “Allogeneic” refers to any materialderived from a different animal of the same species. “Xenogeneic” refersto any material derived from an animal of a different species.

The term “chimeric antigen receptor” or “CAR,” as used herein refers toan artificial T cell receptor that is engineered to be expressed on animmune cell and specifically bind an antigen. CARs may be used as atherapy with adoptive cell transfer. T cells are removed from a patientand modified so that they express the receptors specific to an antigenor particular form of an antigen. In some embodiments, the CARs havespecificity to a selected target, e.g., cells expressing aprostate-specific membrane antigen. CARs may also comprise anintracellular activation domain, a transmembrane domain and anextracellular domain comprising a tumor associated antigen bindingregion.

“Co-stimulatory ligand,” as the term is used herein, includes a moleculeon an antigen presenting cell (e.g., an artificial APC (aAPC), dendriticcell, B cell, and the like) that specifically binds a cognateco-stimulatory molecule on a T cell, thereby providing a signal which,in addition to the primary signal provided by, for instance, binding ofa TCR/CD3 complex with an MHC molecule loaded with peptide, mediates a Tcell response, including, but not limited to, proliferation, activation,differentiation, and the like. A co-stimulatory ligand can include, butis not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL,OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesionmolecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM,lymphotoxin beta receptor, 3/TR6, ILT3, ILT4, HVEM, an agonist orantibody that binds Toll ligand receptor and a ligand that specificallybinds with B7-H3. A co-stimulatory ligand also encompasses, inter alia,an antibody that specifically binds with a co-stimulatory moleculepresent on a T cell, such as, but not limited to, CD27, CD28, 4-1BB,OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1(LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specificallybinds with CD83.

A “co-stimulatory molecule” refers to the cognate binding partner on a Tcell that specifically binds with a co-stimulatory ligand, therebymediating a co-stimulatory response by the T cell, such as, but notlimited to, proliferation. Co-stimulatory molecules include, but are notlimited to an MHC class I molecule, BTLA and a Toll ligand receptor.

A “co-stimulatory signal”, as used herein, refers to a signal, which incombination with a primary signal, such as TCR/CD3 ligation, leads to Tcell proliferation and/or upregulation or downregulation of keymolecules.

A “disease” is a state of health of an animal wherein the animal cannotmaintain homeostasis, and wherein if the disease is not ameliorated thenthe animal's health continues to deteriorate. In contrast, a “disorder”in an animal is a state of health in which the animal is able tomaintain homeostasis, but in which the animal's state of health is lessfavorable than it would be in the absence of the disorder. Leftuntreated, a disorder does not necessarily cause a further decrease inthe animal's state of health.

The term “downregulation” as used herein refers to the decrease orelimination of gene expression of one or more genes.

“Effective amount” or “therapeutically effective amount” are usedinterchangeably herein, and refer to an amount of a compound,formulation, material, or composition, as described herein effective toachieve a particular biological result or provides a therapeutic orprophylactic benefit. Such results may include, but are not limited toan amount that when administered to a mammal, causes a detectable levelof immune suppression or tolerance compared to the immune responsedetected in the absence of the composition of the invention. The immuneresponse can be readily assessed by a plethora of art-recognizedmethods. The skilled artisan would understand that the amount of thecomposition administered herein varies and can be readily determinedbased on a number of factors such as the disease or condition beingtreated, the age and health and physical condition of the mammal beingtreated, the severity of the disease, the particular compound beingadministered, and the like.

“Encoding” refers to the inherent property of specific sequences ofnucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, toserve as templates for synthesis of other polymers and macromolecules inbiological processes having either a defined sequence of nucleotides(i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and thebiological properties resulting therefrom. Thus, a gene encodes aprotein if transcription and translation of mRNA corresponding to thatgene produces the protein in a cell or other biological system. Both thecoding strand, the nucleotide sequence of which is identical to the mRNAsequence and is usually provided in sequence listings, and thenon-coding strand, used as the template for transcription of a gene orcDNA, can be referred to as encoding the protein or other product ofthat gene or cDNA.

As used herein “endogenous” refers to any material from or producedinside an organism, cell, tissue or system.

The term “epitope” as used herein is defined as a small chemicalmolecule on an antigen that can elicit an immune response, inducing Band/or T cell responses. An antigen can have one or more epitopes. Mostantigens have many epitopes; i.e., they are multivalent. In general, anepitope is roughly about 10 amino acids and/or sugars in size.Preferably, the epitope is about 4-18 amino acids, more preferably about5-16 amino acids, and even more most preferably 6-14 amino acids, morepreferably about 7-12, and most preferably about 8-10 amino acids. Oneskilled in the art understands that generally the overallthree-dimensional structure, rather than the specific linear sequence ofthe molecule, is the main criterion of antigenic specificity andtherefore distinguishes one epitope from another. Based on the presentdisclosure, a peptide of the present invention can be an epitope.

As used herein, the term “exogenous” refers to any material introducedfrom or produced outside an organism, cell, tissue or system.

The term “expand” as used herein refers to increasing in number, as inan increase in the number of T cells. In one embodiment, the T cellsthat are expanded ex vivo increase in number relative to the numberoriginally present in the culture. In another embodiment, the T cellsthat are expanded ex vivo increase in number relative to other celltypes in the culture. The term “ex vivo,” as used herein, refers tocells that have been removed from a living organism, (e.g., a human) andpropagated outside the organism (e.g., in a culture dish, test tube, orbioreactor).

The term “expression” as used herein is defined as the transcriptionand/or translation of a particular nucleotide sequence driven by itspromoter.

“Expression vector” refers to a vector comprising a recombinantpolynucleotide comprising expression control sequences operativelylinked to a nucleotide sequence to be expressed. An expression vectorcomprises sufficient cis-acting elements for expression; other elementsfor expression can be supplied by the host cell or in an in vitroexpression system. Expression vectors include all those known in theart, such as cosmids, plasmids (e.g., naked or contained in liposomes)and viruses (e.g., Sendai viruses, lentiviruses, retroviruses,adenoviruses, and adeno-associated viruses) that incorporate therecombinant polynucleotide.

“Humanized” forms of non-human (e.g., murine) antibodies are chimericimmunoglobulins, immunoglobulin chains or fragments thereof (such as Fv,Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies)which contain minimal sequence derived from non-human immunoglobulin.For the most part, humanized antibodies are human immunoglobulins(recipient antibody) in which residues from a complementary-determiningregion (CDR) of the recipient are replaced by residues from a CDR of anon-human species (donor antibody) such as mouse, rat or rabbit havingthe desired specificity, affinity, and capacity. In some instances, Fvframework region (FR) residues of the human immunoglobulin are replacedby corresponding non-human residues. Furthermore, humanized antibodiescan comprise residues which are found neither in the recipient antibodynor in the imported CDR or framework sequences. These modifications aremade to further refine and optimize antibody performance. In general,the humanized antibody will comprise substantially all of at least one,and typically two, variable domains, in which all or substantially allof the CDR regions correspond to those of a non-human immunoglobulin andall or substantially all of the FR regions are those of a humanimmunoglobulin sequence. The humanized antibody may also comprise atleast a portion of an immunoglobulin constant region (Fc), typicallythat of a human immunoglobulin. For further details, see Jones et al.,Nature, 321: 522-525, 1986; Reichmann et al., Nature, 332: 323-329,1988; Presta, Curr. Op. Struct. Biol., 2: 593-596, 1992. “Fully human”refers to an immunoglobulin, such as an antibody, or binding fragmentthereof, where the whole molecule is of human origin or consists of anamino acid sequence identical to a human form of the antibody.

The term “immunoglobulin” or “Ig,” as used herein is defined as a classof proteins, which function as antibodies. The five members included inthis class of proteins are IgA, IgG, IgM, IgD, and IgE. IgA is theprimary antibody that is present in body secretions, such as saliva,tears, breast milk, gastrointestinal secretions and mucus secretions ofthe respiratory and genitourinary tracts. IgG is the most commoncirculating antibody. IgM is the main immunoglobulin produced in theprimary immune response in most subjects. It is the most efficientimmunoglobulin in agglutination, complement fixation, and other antibodyresponses, and is important in defense against bacteria and viruses. IgDis the immunoglobulin that has no known antibody function, but may serveas an antigen receptor. IgE is the immunoglobulin that mediatesimmediate hypersensitivity by causing release of mediators from mastcells and basophils upon exposure to allergen.

“Identity” as used herein refers to the subunit sequence identitybetween two polymeric molecules particularly between two amino acidmolecules, such as, between two polypeptide molecules. When two aminoacid sequences have the same residues at the same positions; e.g., if aposition in each of two polypeptide molecules is occupied by anarginine, then they are identical at that position. The identity orextent to which two amino acid sequences have the same residues at thesame positions in an alignment is often expressed as a percentage. Theidentity between two amino acid sequences is a direct function of thenumber of matching or identical positions; e.g., if half (e.g., fivepositions in a polymer ten amino acids in length) of the positions intwo sequences are identical, the two sequences are 50% identical; if 90%of the positions (e.g., 9 of 10), are matched or identical, the twoamino acids sequences are 90% identical.

The term “immune response” as used herein is defined as a cellularresponse to an antigen that occurs when lymphocytes identify antigenicmolecules as foreign and induce the formation of antibodies and/oractivate lymphocytes to remove the antigen.

The term “immunosuppressive” is used herein to refer to reducing overallimmune response.

“Isolated” means altered or removed from the natural state. For example,a nucleic acid or a peptide naturally present in a living animal is not“isolated,” but the same nucleic acid or peptide partially or completelyseparated from the coexisting materials of its natural state is“isolated.” An isolated nucleic acid or protein can exist insubstantially purified form, or can exist in a non-native environmentsuch as, for example, a host cell.

A “lentivirus” as used herein refers to a genus of the Retroviridaefamily. Lentiviruses are unique among the retroviruses in being able toinfect non-dividing cells; they can deliver a significant amount ofgenetic information into the DNA of the host cell, so they are one ofthe most efficient methods of a gene delivery vector. HIV, SIV, and FIVare all examples of lentiviruses. Vectors derived from lentivirusesoffer the means to achieve significant levels of gene transfer in vivo.

By the term “modified” as used herein, is meant a changed state orstructure of a molecule or cell of the invention. Molecules may bemodified in many ways, including chemically, structurally, andfunctionally. Cells may be modified through the introduction of nucleicacids.

By the term “modulating,” as used herein, is meant mediating adetectable increase or decrease in the level of a response in a subjectcompared with the level of a response in the subject in the absence of atreatment or compound, and/or compared with the level of a response inan otherwise identical but untreated subject. The term encompassesperturbing and/or affecting a native signal or response therebymediating a beneficial therapeutic response in a subject, preferably, ahuman.

In the context of the present invention, the following abbreviations forthe commonly occurring nucleic acid bases are used. “A” refers toadenosine, “C” refers to cytosine, “G” refers to guanosine, “T” refersto thymidine, and “U” refers to uridine.

Unless otherwise specified, a “nucleotide sequence encoding an aminoacid sequence” includes all nucleotide sequences that are degenerateversions of each other and that encode the same amino acid sequence. Thephrase nucleotide sequence that encodes a protein or an RNA may alsoinclude introns to the extent that the nucleotide sequence encoding theprotein may in some version contain an intron(s).

The term “operably linked” or “operatively linked” refers to functionallinkage between a regulatory sequence and a heterologous nucleic acidsequence resulting in expression of the latter. For example, a firstnucleic acid sequence is operably linked with a second nucleic acidsequence when the first nucleic acid sequence is placed in a functionalrelationship with the second nucleic acid sequence. For instance, apromoter is operably linked to a coding sequence if the promoter affectsthe transcription or expression of the coding sequence.

The term “polynucleotide” as used herein is defined as a chain ofnucleotides. Furthermore, nucleic acids are polymers of nucleotides.Thus, nucleic acids and polynucleotides as used herein areinterchangeable. One skilled in the art has the general knowledge thatnucleic acids are polynucleotides, which can be hydrolyzed into themonomeric “nucleotides.” The monomeric nucleotides can be hydrolyzedinto nucleosides. As used herein polynucleotides include, but are notlimited to, all nucleic acid sequences which are obtained by any meansavailable in the art, including, without limitation, recombinant means,i.e., the cloning of nucleic acid sequences from a recombinant libraryor a cell genome, using ordinary cloning technology and PCR, and thelike, and by synthetic means.

As used herein, the terms “peptide,” “polypeptide,” and “protein” areused interchangeably, and refer to a compound comprised of amino acidresidues covalently linked by peptide bonds. A protein or peptide mustcontain at least two amino acids, and no limitation is placed on themaximum number of amino acids that can comprise a protein's or peptide'ssequence. Polypeptides include any peptide or protein comprising two ormore amino acids joined to each other by peptide bonds. As used herein,the term refers to both short chains, which also commonly are referredto in the art as peptides, oligopeptides and oligomers, for example, andto longer chains, which generally are referred to in the art asproteins, of which there are many types. “Polypeptides” include, forexample, biologically active fragments, substantially homologouspolypeptides, oligopeptides, homodimers, heterodimers, variants ofpolypeptides, modified polypeptides, derivatives, analogs, fusionproteins, among others. The polypeptides include natural peptides,recombinant peptides, synthetic peptides, or a combination thereof.

By the term “specifically binds,” as used herein with respect to anantibody, is meant an antibody which recognizes a specific antigen, butdoes not substantially recognize or bind other molecules in a sample.For example, an antibody that specifically binds to an antigen from onespecies may also bind to that antigen from one or more species. But,such cross-species reactivity does not itself alter the classificationof an antibody as specific. In another example, an antibody thatspecifically binds to an antigen may also bind to different allelicforms of the antigen. However, such cross reactivity does not itselfalter the classification of an antibody as specific. In some instances,the terms “specific binding” or “specifically binding,” can be used inreference to the interaction of an antibody, a protein, or a peptidewith a second chemical species, to mean that the interaction isdependent upon the presence of a particular structure (e.g., anantigenic determinant or epitope) on the chemical species; for example,an antibody recognizes and binds to a specific protein structure ratherthan to proteins generally. If an antibody is specific for epitope “A”,the presence of a molecule containing epitope A (or free, unlabeled A),in a reaction containing labeled “A” and the antibody, will reduce theamount of labeled A bound to the antibody.

By the term “stimulation,” is meant a primary response induced bybinding of a stimulatory molecule (e.g., a TCR/CD3 complex) with itscognate ligand thereby mediating a signal transduction event, such as,but not limited to, signal transduction via the TCR/CD3 complex.Stimulation can mediate altered expression of certain molecules, such asdownregulation of TGF-beta, and/or reorganization of cytoskeletalstructures, and the like.

A “stimulatory molecule,” as the term is used herein, means a moleculeon a T cell that specifically binds with a cognate stimulatory ligandpresent on an antigen presenting cell.

A “stimulatory ligand,” as used herein, means a ligand that when presenton an antigen presenting cell (e.g., an aAPC, a dendritic cell, aB-cell, and the like) can specifically bind with a cognate bindingpartner (referred to herein as a “stimulatory molecule”) on a T cell,thereby mediating a primary response by the T cell, including, but notlimited to, activation, initiation of an immune response, proliferation,and the like. Stimulatory ligands are well-known in the art andencompass, inter alia, an MHC Class I molecule loaded with a peptide, ananti-CD3 antibody, a superagonist anti-CD28 antibody, and a superagonistanti-CD2 antibody.

The term “subject” is intended to include living organisms in which animmune response can be elicited (e.g., mammals). A “subject” or“patient,” as used herein, may be a human or non-human mammal. Non-humanmammals include, for example, livestock and pets, such as ovine, bovine,porcine, canine, feline and murine mammals. Preferably, the subject ishuman.

A “target site” or “target sequence” refers to a genomic nucleic acidsequence that defines a portion of a nucleic acid to which a bindingmolecule may specifically bind under conditions sufficient for bindingto occur.

The term “therapeutic” as used herein means a treatment and/orprophylaxis. A therapeutic effect is obtained by suppression, remission,or eradication of a disease state.

“Transplant” refers to a biocompatible lattice or a donor tissue, organor cell, to be transplanted. An example of a transplant may include butis not limited to skin cells or tissue, bone marrow, and solid organssuch as heart, pancreas, kidney, lung and liver. A transplant can alsorefer to any material that is to be administered to a host. For example,a transplant can refer to a nucleic acid or a protein.

The term “transfected” or “transformed” or “transduced” as used hereinrefers to a process by which exogenous nucleic acid is transferred orintroduced into the host cell. A “transfected” or “transformed” or“transduced” cell is one which has been transfected, transformed ortransduced with exogenous nucleic acid. The cell includes the primarysubject cell and its progeny.

To “treat” a disease as the term is used herein, means to reduce thefrequency or severity of at least one sign or symptom of a disease ordisorder experienced by a subject.

A “vector” is a composition of matter which comprises an isolatednucleic acid and which can be used to deliver the isolated nucleic acidto the interior of a cell. Numerous vectors are known in the artincluding, but not limited to, linear polynucleotides, polynucleotidesassociated with ionic or amphiphilic compounds, plasmids, and viruses.Thus, the term “vector” includes an autonomously replicating plasmid ora virus. The term should also be construed to include non-plasmid andnon-viral compounds which facilitate transfer of nucleic acid intocells, such as, for example, polylysine compounds, liposomes, and thelike. Examples of viral vectors include, but are not limited to, Sendaiviral vectors, adenoviral vectors, adeno-associated virus vectors,retroviral vectors, lentiviral vectors, and the like.

Ranges: throughout this disclosure, various aspects of the invention canbe presented in a range format. It should be understood that thedescription in range format is merely for convenience and brevity andshould not be construed as an inflexible limitation on the scope of theinvention. Accordingly, the description of a range should be consideredto have specifically disclosed all the possible subranges as well asindividual numerical values within that range. For example, descriptionof a range such as from 1 to 6 should be considered to have specificallydisclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numberswithin that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. Thisapplies regardless of the breadth of the range.

B. Chimeric Antigen Receptors

The present invention provides compositions and methods for modifiedimmune cells or precursors thereof, e.g., modified T cells, comprising achimeric antigen receptor (CAR). Thus, in some embodiments, the immunecell has been genetically modified to express the CAR. CARs of thepresent invention comprise an antigen binding domain, a transmembranedomain, a hinge domain, and an intracellular signaling domain.

The antigen binding domain may be operably linked to another domain ofthe CAR, such as the transmembrane domain or the intracellular domain,both described elsewhere herein, for expression in the cell. In oneembodiment, a first nucleic acid sequence encoding the antigen bindingdomain is operably linked to a second nucleic acid encoding atransmembrane domain, and further operably linked to a third a nucleicacid sequence encoding an intracellular domain.

The antigen binding domains described herein can be combined with any ofthe transmembrane domains described herein, any of the intracellulardomains or cytoplasmic domains described herein, or any of the otherdomains described herein that may be included in a CAR of the presentinvention. A subject CAR of the present invention may also include aspacer domain as described herein. In some embodiments, each of theantigen binding domain, transmembrane domain, and intracellular domainis separated by a linker.

Antigen Binding Domain

The antigen binding domain of a CAR is an extracellular region of theCAR for binding to a specific target antigen including proteins,carbohydrates, and glycolipids. In some embodiments, the CAR comprisesaffinity to a target antigen on a target cell. The target antigen mayinclude any type of protein, or epitope thereof, associated with thetarget cell. For example, the CAR may comprise affinity to a targetantigen on a target cell that indicates a particular disease state ofthe target cell.

In an exemplary embodiment, the target cell antigen is aprostate-specific membrane antigen (PSMA). PSMA is a membrane-boundprotein expressed on the cell surface and is reported to be highlyoverexpressed in prostate cancer tissues. PSMA expression is directlycorrelated with advancing tumor grade and stage, and is believed toconfer a selective growth advantage to prostate cancer cells. As such,an exemplary CAR of the present disclosure has affinity for PSMA on atarget cell.

As described herein, a CAR of the present disclosure having affinity fora specific target antigen on a target cell may comprise atarget-specific binding domain. In some embodiments, the target-specificbinding domain is a murine target-specific binding domain, e.g., thetarget-specific binding domain is of murine origin. In some embodiments,the target-specific binding domain is a human target-specific bindingdomain, e.g., the target-specific binding domain is of human origin. Inan exemplary embodiment, a CAR of the present disclosure having affinityfor PSMA on a target cell may comprise a PSMA binding domain. In someembodiments, the PSMA binding domain is a murine PSMA binding domain,e.g., the PSMA binding domain is of murine origin. In some embodiments,the PSMA binding domain is a human PSMA binding domain, e.g., the PSMAbinding domain is of human origin.

In some embodiments, a CAR of the present disclosure may have affinityfor one or more target antigens on one or more target cells. In someembodiments, a CAR may have affinity for one or more target antigens ona target cell. In such embodiments, the CAR is a bispecific CAR, or amultispecific CAR. In some embodiments, the CAR comprises one or moretarget-specific binding domains that confer affinity for one or moretarget antigens. In some embodiments, the CAR comprises one or moretarget-specific binding domains that confer affinity for the same targetantigen. For example, a CAR comprising one or more target-specificbinding domains having affinity for the same target antigen could binddistinct epitopes of the target antigen. When a plurality oftarget-specific binding domains is present in a CAR, the binding domainsmay be arranged in tandem and may be separated by linker peptides. Forexample, in a CAR comprising two target-specific binding domains, thebinding domains are connected to each other covalently on a singlepolypeptide chain, through an oligo- or polypeptide linker, an Fc hingeregion, or a membrane hinge region.

In some embodiments, the antigen binding domain is selected from thegroup consisting of an antibody, an antigen binding fragment (Fab), anda single-chain variable fragment (scFv). In some embodiments, a PSMAbinding domain of the present invention is selected from the groupconsisting of a PSMA-specific antibody, a PSMA-specific Fab, and aPSMA-specific scFv. In one embodiment, a PSMA binding domain is aPSMA-specific antibody. In one embodiment, a PSMA binding domain is aPSMA-specific Fab. In one embodiment, a PSMA binding domain is aPSMA-specific scFv.

The antigen binding domain can include any domain that binds to theantigen and may include, but is not limited to, a monoclonal antibody, apolyclonal antibody, a synthetic antibody, a human antibody, a humanizedantibody, a non-human antibody, and any fragment thereof. In someembodiments, the antigen binding domain portion comprises a mammalianantibody or a fragment thereof. The choice of antigen binding domain maydepend upon the type and number of antigens that are present on thesurface of a target cell.

As used herein, the term “single-chain variable fragment” or “scFv” is afusion protein of the variable regions of the heavy (VH) and lightchains (VL) of an immunoglobulin (e.g., mouse or human) covalentlylinked to form a VH:VL heterodimer. The heavy (VH) and light chains (VL)are either joined directly or joined by a peptide-encoding linker, whichconnects the N-terminus of the VH with the C-terminus of the VL, or theC-terminus of the VH with the N-terminus of the VL. In some embodiments,the antigen binding domain (e.g., PSMA binding domain) comprises an scFvhaving the configuration from N-terminus to C-terminus, VH-linker-VL. Insome embodiments, the antigen binding domain (e.g., PSMA binding domain)comprises an scFv having the configuration from N-terminus toC-terminus, VL-linker-VH. Those of skill in the art would be able toselect the appropriate configuration for use in the present invention.

The linker is usually rich in glycine for flexibility, as well as serineor threonine for solubility. The linker can link the heavy chainvariable region and the light chain variable region of the extracellularantigen-binding domain. Non-limiting examples of linkers are disclosedin Shen et al., Anal. Chem. 80(6):1910-1917 (2008) and WO 2014/087010,the contents of which are hereby incorporated by reference in theirentireties. Various linker sequences are known in the art, including,without limitation, glycine serine (GS) linkers such as (GS)_(n),(GSGGS)_(n) (SEQ ID NO:1), (GGGS)_(n) (SEQ ID NO:2), and (GGGGS)_(n)(SEQ ID NO:3), where n represents an integer of at least 1. Exemplarylinker sequences can comprise amino acid sequences including, withoutlimitation, GGSG (SEQ ID NO:4), GGSGG (SEQ ID NO:5), GSGSG (SEQ IDNO:6), GSGGG (SEQ ID NO:7), GGGSG (SEQ ID NO:8), GSSSG (SEQ ID NO:9),GGGGS (SEQ ID NO:10), GGGGSGGGGSGGGGS (SEQ ID NO:11) and the like. Thoseof skill in the art would be able to select the appropriate linkersequence for use in the present invention. In one embodiment, an antigenbinding domain (e.g., PSMA binding domain) of the present inventioncomprises a heavy chain variable region (VH) and a light chain variableregion (VL), wherein the VH and VL is separated by the linker sequencehaving the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:11), which maybe encoded by the nucleic acid sequence

(SEQ ID NO: 12) GGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCT.

Despite removal of the constant regions and the introduction of alinker, scFv proteins retain the specificity of the originalimmunoglobulin. Single chain Fv polypeptide antibodies can be expressedfrom a nucleic acid comprising VH- and VL-encoding sequences asdescribed by Huston, et al. (Proc. Nat. Acad. Sci. USA, 85:5879-5883,1988). See, also, U.S. Pat. Nos. 5,091,513, 5,132,405 and 4,956,778; andU.S. Patent Publication Nos. 20050196754 and 20050196754. AntagonisticscFvs having inhibitory activity have been described (see, e.g., Zhao etal., Hyrbidoma (Larchmt) 2008 27(6):455-51; Peter et al., J CachexiaSarcopenia Muscle 2012 August 12; Shieh et al., J Imunol 2009183(4):2277-85; Giomarelli et al., Thromb Haemost 2007 97(6):955-63;Fife et al., J Clin Invst 2006 116(8):2252-61; Brocks et al.,Immunotechnology 1997 3(3):173-84; Moosmayer et al., Ther Immunol 19952(10:31-40). Agonistic scFvs having stimulatory activity have beendescribed (see, e.g., Peter et al., J Bioi Chem 2003 25278(38):36740-7;Xie et al., Nat Biotech 1997 15(8):768-71; Ledbetter et al., Crit RevImmunol 1997 17(5-6):427-55; Ho et al., BioChim Biophys Acta 20031638(3):257-66).

As used herein, “Fab” refers to a fragment of an antibody structure thatbinds to an antigen but is monovalent and does not have a Fc portion,for example, an antibody digested by the enzyme papain yields two Fabfragments and an Fc fragment (e.g., a heavy (H) chain constant region;Fc region that does not bind to an antigen).

As used herein, “F(ab′)2” refers to an antibody fragment generated bypepsin digestion of whole IgG antibodies, wherein this fragment has twoantigen binding (ab′) (bivalent) regions, wherein each (ab′) regioncomprises two separate amino acid chains, a part of a H chain and alight (L) chain linked by an S—S bond for binding an antigen and wherethe remaining H chain portions are linked together. A “F(ab′)2” fragmentcan be split into two individual Fab′ fragments.

In some embodiments, the antigen binding domain may be derived from thesame species in which the CAR will ultimately be used. For example, foruse in humans, the antigen binding domain of the CAR may comprise ahuman antibody as described elsewhere herein, or a fragment thereof.

In an exemplary embodiment, a PSMA-CAR of the present inventioncomprises a PSMA binding domain, e.g., PSMA-specific scFv.

(A) Murine PSMA Binding Domains and Variants Thereof

In certain embodiments, a PSMA-CAR of the present invention comprises amurine PSMA binding domain or variant thereof.

In certain embodiments, a PSMA-CAR of the present invention comprises aPSMA binding domain of a non-human PSMA antibody (e.g., a mouse or ratPSMA antibody), or a variant thereof. As is well known in the art, amurine or other non-human antibody may be raised by immunizing thenon-human (e.g., a mouse) with human PSMA or a fragment thereof.

In one embodiment, the PSMA binding domain is a murine J591 PSMA bindingdomain that is comprised in the amino acid sequence set forth below:

(SEQ ID NO: 14) MALPVTALLLPLALLLHAARPGSDIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYNSYPLTFGAGTMLDLKGGGGSGGGGSSGGGSEVQLQQSGPELVKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNGGTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGW NFDYWGQGTTLTVSS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 15) ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCACGCCGCCAGACCTGGATCTGACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCATCTGTAAGGCCAGTCAAGATGTGGGTACTGCTGTAGACTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTATTGGGCATCCACTCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGACTTCACTCTCACCATTACTAACGTTCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAACAGCTATCCTCTCACGTTCGGTGCTGGGACCATGCTGGACCTGAAAGGAGGCGGAGGATCTGGCGGCGGAGGAAGTTCTGGCGGAGGCAGCGAGGTGCAGCTGCAGCAGAGCGGACCCGAGCTCGTGAAGCCTGGAACAAGCGTGCGGATCAGCTGCAAGACCAGCGGCTACACCTTCACCGAGTACACCATCCACTGGGTCAAGCAGTCCCACGGCAAGAGCCTGGAGTGGATCGGCAATATCAACCCCAACAACGGCGGCACCACCTACAACCAGAAGTTCGAGGACAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGCGAGGACAGCGCCGTGTACTATTGTGCCGCCGGTTGGAACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTGTCTAGC.

Tolerable variations of the murine J591 PSMA binding domain will beknown to those of skill in the art, while maintaining binding to PSMA.For example, in some embodiments, the PSMA binding domain is a murineJ591 PSMA binding domain comprising an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe murine J591 PSMA binding domain amino acid sequence that iscomprised in SEQ ID NO:14. In one embodiment, the PSMA binding domain isa murine J591 PSMA binding domain that is comprised in the amino acidsequence set forth in SEQ ID NO:14.

In some embodiments, the PSMA binding domain is a murine J591 PSMAbinding domain encoded by a nucleic acid sequence that has at least 60%,at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the murineJ591 PSMA binding domain coding sequence comprised in SEQ ID NO:15. Inone embodiment, the PSMA binding domain is a murine J591 PSMA bindingdomain encoded by the coding sequence comprised in the nucleic acidsequence set forth in SEQ ID NO:15.

In an exemplary embodiment, a PSMA-CAR of the present inventioncomprises a PSMA binding domain, e.g., PSMA-specific scFv. In oneembodiment, the PSMA binding domain is a murine J591 PSMA binding domaincomprising the amino acid sequence set forth below:

(SEQ ID NO: 13) DIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYNSYPLTFGAGTMLDLKGGGGSGGGGSSGGGSEVQLQQSGPELVKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNGGTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGWNFDYWGQGTTLTVSS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 180) GACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCATCTGTAAGGCCAGTCAAGATGTGGGTACTGCTGTAGACTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTATTGGGCATCCACTCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGACTTCACTCTCACCATTACTAACGTTCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAACAGCTATCCTCTCACGTTCGGTGCTGGGACCATGCTGGACCTGAAAGGAGGCGGAGGATCTGGCGGCGGAGGAAGTTCTGGCGGAGGCAGCGAGGTGCAGCTGCAGCAGAGCGGACCCGAGCTCGTGAAGCCTGGAACAAGCGTGCGGATCAGCTGCAAGACCAGCGGCTACACCTTCACCGAGTACACCATCCACTGGGTCAAGCAGTCCCACGGCAAGAGCCTGGAGTGGATCGGCAATATCAACCCCAACAACGGCGGCACCACCTACAACCAGAAGTTCGAGGACAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGCGAGGACAGCGCCGTGTACTATTGTGCCGCCGGTTGGAACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTGTCTAGC

Tolerable variations of the murine J591 PSMA binding domain will beknown to those of skill in the art, while maintaining binding to humanPSMA. For example, in some embodiments, the PSMA binding domain is amurine J591 PSMA binding domain comprising an amino acid sequence thathas at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 81%, at least 82%, at least 83%, at least 84%, at least85%, at least 86%, at least 87%, at least 88%, at least 89%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% sequenceidentity to the amino acid sequence set forth in in SEQ ID NO:13. In oneembodiment, the PSMA binding domain is a murine J591 PSMA binding domaincomprising the amino acid sequence set forth in SEQ ID NO: 13.

In some embodiments, the PSMA binding domain is a murine J591 PSMAbinding domain encoded by a nucleic acid sequence that has at least 60%,at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the nucleicacid sequence set forth in SEQ ID NO:180. In one embodiment, the PSMAbinding domain is a murine J591 PSMA binding domain encoded by thenucleic acid sequence set forth in SEQ ID NO:180.

In one embodiment, the murine J591 PSMA binding domain comprises a lightchain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 16) DIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYNSYPLTF GAGTMLDLK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 17) GACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCATCTGTAAGGCCAGTCAAGATGTGGGTACTGCTGTAGACTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTATTGGGCATCCACTCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGACTTCACTCTCACCATTACTAACGTTCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAACAGCTATCCTCTCACGTTCGGTGCTGGGACCATGCTGGACCTGAAA.

Tolerable variations of the light chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the murine J591PSMA binding domain comprises a light chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:16. In one embodiment, the murine J591 PSMA binding domaincomprises a light chain variable region comprising the amino acidsequence set forth in SEQ ID NO:16.

In some embodiments, the murine J591 PSMA binding domain comprises alight chain variable region encoded by a nucleic acid sequence that hasat least 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:17. In one embodiment,the murine J591 PSMA binding domain comprises a light chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:17.

In one embodiment, the murine J591 PSMA binding domain comprises thelight chain variable region described in NCBI GenBank sequence databaseID: CCA78125.1, comprising the amino acid sequence set forth below:

(SEQ ID NO: 181) DIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLAITNVQSEDLADYFCQQYNSYPLTFGA GTKLEIKR

Tolerable variations of the light chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the murine J591PSMA binding domain comprises a light chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:181. In one embodiment, the murine J591 PSMA binding domaincomprises a light chain variable region comprising the amino acidsequence set forth in SEQ ID NO:181. The light chain variable region ofthe murine J591 PSMA binding domain comprises three light chaincomplementarity-determining regions (CDRs). As used herein, a“complementarity-determining region” or “CDR” refers to a region of thevariable chain of an antigen binding molecule that binds to a specificantigen. Accordingly, a murine J591 PSMA binding domain may comprise alight chain variable region that comprises a CDR1 represented by theamino acid sequence KASQDVGTAVD (SEQ ID NO:18); a CDR2 represented bythe amino acid sequence WASTRHT (SEQ ID NO:19); and a CDR3 representedby the amino acid sequence QQYNSYPLT (SEQ ID NO:20). Tolerablevariations to the CDRs of the light chain will be known to those ofskill in the art, while maintaining its contribution to the binding ofPSMA. For example, a murine J591 PSMA binding domain may comprise alight chain variable region comprising a CDR1 that comprises an aminoacid sequence that has at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the CDR1 amino acidsequence set forth in SEQ ID NO:18. For example, a murine J591 PSMAbinding domain may comprise a light chain variable region comprising aCDR2 that comprises an amino acid sequence that has at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe CDR2 amino acid sequence set forth in SEQ ID NO:19. For example, amurine J591 PSMA binding domain may comprise a light chain variableregion comprising a CDR3 that comprises an amino acid sequence that hasat least 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the CDR3 amino acid sequence set forth in SEQ IDNO:20. In one embodiment, the murine J591 PSMA binding domain comprisesa light chain variable region comprising the three aforementioned lightchain variable region CDRs.

In one embodiment, the murine J591 PSMA binding domain comprises a heavychain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 21) EVQLQQSGPELVKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNGGTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGW NFDYWGQGTTLTVSS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 22) GAGGTGCAGCTGCAGCAGAGCGGACCCGAGCTCGTGAAGCCTGGAACAAGCGTGCGGATCAGCTGCAAGACCAGCGGCTACACCTTCACCGAGTACACCATCCACTGGGTCAAGCAGTCCCACGGCAAGAGCCTGGAGTGGATCGGCAATATCAACCCCAACAACGGCGGCACCACCTACAACCAGAAGTTCGAGGACAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGCGAGGACAGCGCCGTGTACTATTGTGCCGCCGGTTGGAACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTGTCTAGC.

Tolerable variations of the heavy chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the murine J591PSMA binding domain comprises a heavy chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:21. In one embodiment, the murine J591 PSMA binding domaincomprises a heavy chain variable region comprising the amino acidsequence set forth in SEQ ID NO:21.

In some embodiments, the murine J591 PSMA binding domain comprises aheavy chain variable region encoded by a nucleic acid sequence that hasat least 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:22. In one embodiment,the murine J591 PSMA binding domain comprises a heavy chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:22.

In one embodiment, the murine J591 PSMA binding domain comprises theheavy chain variable region described in NCBI GenBank sequence databaseID: CCA78124.1, comprising the amino acid sequence set forth below:

(SEQ ID NO: 182) EVQLQQSGPELVKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNGGTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGW NFDYWGQGTTLTVSS

Tolerable variations of the heavy chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of PSMA. For example, in some embodiments, the murine J591 PSMAbinding domain comprises a heavy chain variable region comprising anamino acid sequence that has at least 60%, at least 65%, at least 70%,at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the amino acid sequence set forth in SEQID NO:182. In one embodiment, the murine J591 PSMA binding domaincomprises a heavy chain variable region comprising the amino acidsequence set forth in SEQ ID NO:182.

The heavy chain variable region of the murine J591 PSMA binding domaincomprises three heavy chain complementarity-determining regions (CDRs).Accordingly, a murine J591 PSMA binding domain may comprise a heavychain variable region that comprises a CDR1 represented by the aminoacid sequence GYTFTEYTIH (SEQ ID NO:23); a CDR2 represented by the aminoacid sequence NINPNNGGTTYNQKFED (SEQ ID NO:24); and a CDR3 representedby the amino acid sequence GWNFDY (SEQ ID NO:25). Tolerable variationsto the CDRs of the heavy chain will be known to those of skill in theart, while maintaining its contribution to the binding of human PSMA.For example, a murine J591 PSMA binding domain may comprise a heavychain variable region comprising a CDR1 that comprises an amino acidsequence that has at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the CDR1 amino acid sequence setforth in SEQ ID NO:23. For example, a murine J591 PSMA binding domainmay comprise a heavy chain variable region comprising a CDR2 thatcomprises an amino acid sequence that has at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the CDR2amino acid sequence set forth in SEQ ID NO:24. For example, a murineJ591 PSMA binding domain may comprise a heavy chain variable regioncomprising a CDR3 that comprises an amino acid sequence that has atleast 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the CDR3 amino acid sequence set forth in SEQ IDNO:25. In one embodiment, the murine J591 PSMA binding domain comprisesa heavy chain variable region comprising the three aforementioned heavychain variable region CDRs.

In one embodiment, the PSMA binding domain is a murine J591 PSMA bindingdomain comprising an amino acid sequence that comprises at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the aminoacid sequences set forth in SEQ ID NOs:16 and 21.

In one embodiment, the PSMA binding domain is a murine J591 PSMA bindingdomain comprising an amino acid sequence that comprises at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the aminoacid sequences set forth in SEQ ID NOs:181 and 182

(b) Humanized PSMA Binding Domains

In certain embodiments, a PSMA-CAR of the present invention comprises ahumanized variant of a PSMA binding domain of a non-human PSMA antibody,or a variant or fragment thereof. In certain exemplary embodiments, thePSMA CAR comprises a humanized variant of the murine J591 antibody whichbinds human PSMA. Methods for humanizing murine antibodies are wellknown in the art.

In one embodiment, the PSMA binding domain is a humanized PSMA-specificbinding domain. In certain embodiments, the PSMA binding domain is ahumanized J591 PSMA binding domain. In certain embodiments, the PSMAbinding domain comprises any of the heavy and light chain variableregions disclosed in PCT Publication Nos. WO2017212250A1 andWO2018033749A1, the disclosures of which are hereby incorporated hereinby reference in their entirety. For example, a PSMA binding domain ofthe present invention can comprise an scFv comprising any of the heavyand light chain variable regions disclosed therein. Accordingly, aPSMA-CAR of the present invention comprises a humanized variant of themurine J591 antibody which binds human PSMA, as disclosed inWO2017212250A1 and WO2018033749A1.

In certain embodiments, a PSMA binding domain of the present inventioncan comprise a heavy chain variable region and a light chain variableregion of any of those set forth in Table 19:

TABLE 19 Humanized PSMA binding heavy and light chain variable sequencesHeavy Chain Variable Region SequencesLight Chain Variable Region Sequences VH Consensus SequenceVL Consensus Sequence SEQ ID NO: 183 SEQ ID NO: 184EVQLVQSGX₁EX₂KKPGASVKVSCKX₃ DIX₁MTQSPSX₂LSASVGDRVTITCKASQDVSGYTFTEYTIHWVX₄QAX₅GKGLEWIG GTAVDWYQQKPGQAPKLLIYWASTRHTGNINPNX₆GGTTYNQKFEDRX₇TX₈TVD VPDRFX₃GSGSGTDFTLTISRLQX₄EDFAX₅YKSTSTAYMELSSLRSEDTAVYYCAAG X₆CQQYNSYPLTFGQGTX₇VDIK WNFDYWGQGTTVTVSSwherein: wherein: X₁ is Q or V; X₁ is A or P; X₂ is T or F;X₂ iS V or L; X₃ is S or T; X₃ is A or T; X₄ is P or S; X₄ is R or K;X₅ iS V or D; X₅ is P or H; X₆ is Y or F; and X₆ is N or Q;X₇ is K or M. X₇ iS V or A; and X₈ is I or L. SEQ ID NO: 185SEQ ID NO: 186 EVQLVQSGPELKKPGASVKVSCKTSG DIVMTQSPSFLSASVGDRVTITCKASQDVGYTFTEYTIHWVKQAHGKGLEWIGNIN TAVDWYQQKPGQAPKLLIYWASTRHTGVPNNGGTTYNQKFEDRATLTVDKSTST PDRFTGSGSGTDFTLTISRLQSEDFADYFCQAYMELSSLRSEDTAVYYCAAGWNFD QYNSYPLTFGQGTMVDIK YWGQGTTVTVSS SEQ ID NO: 187SEQ ID NO: 188 EVQLVQSGAEVKKPGASVKVSCKTSG DIVMTQSPSTLSASVGDRVTITCKASQDVGYTFTEYTIHWVKQAPGKGLEWIGNIN TAVDWYQQKPGQAPKLLIYWASTRHTGVPNNGGTTYNQKFEDRATITVDKSTST PDRFTGSGSGTDFTLTISRLQSEDFADYFCQAYMELSSLRSEDTAVYYCAAGWNFD QYNSYPLTFGQGTKVDIK YWGQGTTVTVSS SEQ ID NO: 189SEQ ID NO: 190 EVQLVQSGAEVKKPGASVKVSCKTSG DIVMTQSPSTLSASVGDRVTITCKASQDVGYTFTEYTIHWVRQAPGKGLEWIGNIN TAVDWYQQKPGQAPKLLIYWASTRHTGVPNNGGTTYNQKFEDRATITVDKSTST PDRFSGSGSGTDFTLTISRLQPEDFADYYCQAYMELSSLRSEDTAVYYCAAGWNFD QYNSYPLTFGQGTKVDIK YWGQGTTVTVSS SEQ ID NO: 191SEQ ID NO: 192 EVQLVQSGAEVKKPGASVKVSCKAS DIQMTQSPSTLSASVGDRVTITCKASQDVGGYTFTEYTIHWVRQAPGKGLEWIGNI TAVDWYQQKPGQAPKLLIYWASTRHTGVNPNNGGTTYNQKFEDRVTITVDKSTS PDRFSGSGSGTDFTLTISRLQPEDFAVYYCQTAYMELSSLRSEDTAVYYCAAGWNF QYNSYPLTFGQGTKVDIK DYWGQGTTVTVSSSEQ ID NO: 193 EVQLVQSGAEVKKPGASVKVSCKAS GYTFTEYTIHWVRQAPGKGLEWIGNINPNQGGTTYNQKFEDRVTITVDKSTS TAYMELSSLRSEDTAVYYCAAGWNF DYWGQGTTVTVSSVH Consensus Sequence VL Consensus Sequence SEQ ID NO: 194SEQ ID NO: 195 EVQLVQSGX₁EX₂KKPGASVKVSCKX₃DIX₁MTQSPSX₂LSASVGDRVTITCKASQDV SGYTFTEYTIHWVX₄QAX₅GKGLEWIGGTAVDWYQQKPGQAPKLLIYWASTRHTG NINPNX₆GGTTYNQKFEDRX₇TX₈TVDVPDRFX₃GSGSGTDFTLTISRLQX₄EDFAX₅Y KSTSTAYMELSSX₉RSEDTAVYYCAX₁₀X₆CQQX₇X₈X0X₁₀X₁₁LTFGQGTX₁₂VDIK X₁₁X₁₂X₁₃X₁₄DYWGQGTTVTVSS wherein:wherein: X₁ is Q or V; X₁ is A or P; X₂ is T or F; X₂ iS V or L;X₃ is S or T; X₃ is A or T; X₄ is P or S; X₄ is R or K; X₅ iS V or D;X₅ is P or H; X₆ is Y or F; X₆ is N or Q; X₇-X₁₁ is FTRYP or YNAYS; andX₇ is V or A; X₁₂ is K or M. X₈ iS I or L; X₉ is L or P; andX₁₀-X₁₄ is AYWLF, GGWTF, or GAWTM. SEQ ID NO: 196 SEQ ID NO: 197EVQLVQSGAEVKKPGASVKVSCKAS DIQMTQSPSTLSASVGDRVTITCKASQDVGGYTFTEYTIHWVRQAPGKGLEWIGNI TAVDWYQQKPGQAPKLLIYWASTRHTGVNPNNGGTTYNQKFEDRVTITVDKSTS PDRFSGSGSGTDFTLTISRLQPEDFAVYYCQTAYMELSSLRSEDTAVYYCAAYWLF QYNSYPLTFGQGTKVDIK DYWGQGTTVTVSSSEQ ID NO: 198 SEQ ID NO: 199 EVQLVQSGAEVKKPGASVKVSCKASDIQMTQSPSTLSASVGDRVTITCKASQDVG GYTFTEYTIHWVRQAPGKGLEWIGNITAVDWYQQKPGQAPKLLIYWASTRHTGV NPNNGGTTYNQKFEDRVTITVDKSTSPDRFSGSGSGTDFTLTISRLQPEDFAVYYCQ TAYMELSSLRSEDTAVYYCAGGWTFQFTRYPLTFGQGTKVDIK DYWGQGTTVTVSS SEQ ID NO: 200 SEQ ID NO: 201EVQLVQSGAEVKKPGASVKVSCKAS DIQMTQSPSTLSASVGDRVTITCKASQDVGGYTFTEYTIHWVRQAPGKGLEWIGNI TAVDWYQQKPGQAPKLLIYWASTRHTGVNPNNGGTTYNQKFEDRVTITVDKSTS PDRFSGSGSGTDFTLTISRLQPEDFAVYYCQTAYMELSSLRSEDTAVYYCAGAWTM QYNAYSLTFGQGTKVDIK DYWGQGTTVTVSSSEQ ID NO: 202 EVQLVQSGAEVKKPGASVKVSCKAS GYTFTEYTIHWVRQAPGKGLEWIGNINPNNGGTTYNQKFEDRVTITVDKSTS TAYMELSSPRSEDTAVYYCAAGWNF DYWGQGTTVTVSS

(c) Human PSMA Binding Domains

In certain embodiments, a PSMA-CAR of the present invention comprises aPSMA binding domain of a human PSMA antibody, or a variant thereof. Inone embodiment, the PSMA binding domain is a human 1C3 PSMA bindingdomain comprising the amino acid sequence set forth below:

(SEQ ID NO: 26) MALPVTALLLPLALLLHAARPQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPWGSRYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKSGKAPKLLIFDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ FNSYPLTFGGGTKVEIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 27) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAA A.

Tolerable variations of the human 1C3 PSMA binding domain will be knownto those of skill in the art, while maintaining binding to human PSMA.For example, in some embodiments, the PSMA binding domain is a human 1C3PSMA binding domain comprising an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theamino acid sequence set forth in SEQ ID NO:26. In one embodiment, thePSMA binding domain is a human 1C3 PSMA binding domain comprising theamino acid sequence set forth in SEQ ID NO:26.

In some embodiments, the PSMA binding domain is a human 1C3 PSMA bindingdomain encoded by a nucleic acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the nucleicacid sequence set forth in SEQ ID NO:27. In one embodiment, the PSMAbinding domain is a human 1C3 PSMA binding domain encoded by the nucleicacid sequence set forth in SEQ ID NO:27.

In one embodiment, the human 1C3 PSMA binding domain comprises a heavychain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 28) PQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPWGSRYYYYGMDVWGQGTTVTVSS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 29) CCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA.

Tolerable variations of the heavy chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 1C3PSMA binding domain comprises a heavy chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:28. In one embodiment, the human 1C3 PSMA binding domaincomprises a heavy chain variable region comprising the amino acidsequence set forth in SEQ ID NO:28.

In some embodiments, the human 1C3 PSMA binding domain comprises a heavychain variable region encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:29. In one embodiment,the human 1C3 PSMA binding domain comprises a heavy chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:29.

The heavy chain variable region of the human 1C3 PSMA binding domaincomprises three heavy chain complementarity-determining regions (CDRs).Accordingly, a human 1C3 PSMA binding domain may comprise a heavy chainvariable region that comprises a CDR1 represented by the amino acidsequence SYAMH (SEQ ID NO:30); a CDR2 represented by the amino acidsequence VISYDGNNKYYADSVKG (SEQ ID NO:31); and a CDR3 represented by theamino acid sequence AVPWGSRYYYYGMDV (SEQ ID NO:32). Tolerable variationsto the CDRs of the heavy chain will be known to those of skill in theart, while maintaining its contribution to the binding of PSMA. Forexample, a human 1C3 PSMA binding domain may comprise a heavy chainvariable region comprising a CDR1 that comprises an amino acid sequencethat has at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the CDR1 amino acid sequence set forth inSEQ ID NO:30. For example, a human 1C3 PSMA binding domain may comprisea heavy chain variable region comprising a CDR2 that comprises an aminoacid sequence that has at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the CDR2 amino acidsequence set forth in SEQ ID NO:31. For example, a human 1C3 PSMAbinding domain may comprise a heavy chain variable region comprising aCDR3 that comprises an amino acid sequence that has at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe CDR3 amino acid sequence set forth in SEQ ID NO:32. In oneembodiment, the human 1C3 PSMA binding domain comprises a heavy chainvariable region comprising the three aforementioned heavy chain variableregion CDRs.

In one embodiment, the human 1C3 PSMA binding domain comprises a lightchain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 33) AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKSGKAPKLLIFDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGG GTKVEIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 34) GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA.

Tolerable variations of the light chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 1C3PSMA binding domain comprises a light chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:33. In one embodiment, the human 1C3 PSMA binding domaincomprises a light chain variable region comprising the amino acidsequence set forth in SEQ ID NO:33.

In some embodiments, the human 1C3 PSMA binding domain comprises a lightchain variable region encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:34. In one embodiment,the human 1C3 PSMA binding domain comprises a light chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:34.

The light chain variable region of the human 1C3 PSMA binding domaincomprises three light chain complementarity-determining regions (CDRs).Accordingly, a human 1C3 PSMA binding domain may comprise a light chainvariable region that comprises a CDR1 represented by the amino acidsequence RASQGISSALA (SEQ ID NO:35); a CDR2 represented by the aminoacid sequence DASSLES (SEQ ID NO:36); and a CDR3 represented by theamino acid sequence QQFNSYPLT (SEQ ID NO:37). Tolerable variations tothe CDRs of the light chain will be known to those of skill in the art,while maintaining its contribution to the binding of PSMA. For example,a human 1C3 PSMA binding domain may comprise a light chain variableregion comprising a CDR1 that comprises an amino acid sequence that hasat least 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the CDR1 amino acid sequence set forth in SEQ IDNO:35. For example, a human 1C3 PSMA binding domain may comprise a lightchain variable region comprising a CDR2 that comprises an amino acidsequence that has at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the CDR2 amino acid sequence setforth in SEQ ID NO:36. For example, a human 1C3 PSMA binding domain maycomprise a light chain variable region comprising a CDR3 that comprisesan amino acid sequence that has at least 85%, at least 86%, at least87%, at least 88%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99% sequence identity to the CDR3 amino acidsequence set forth in SEQ ID NO:37. In one embodiment, the human 1C3PSMA binding domain comprises a light chain variable region comprisingthe three aforementioned light chain variable region CDRs.

In one embodiment, the PSMA binding domain is a human 2A10 PSMA bindingdomain comprising the amino acid sequence set forth below:

(SEQ ID NO: 38) MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQTGFLWSSDLWGRGTLVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGYGSGTDFTLTINSLQPEDFATYYCQQFNSYP LTFGGGTKVEIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 39) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA.

Tolerable variations of the human 2A10 PSMA binding domain will be knownto those of skill in the art, while maintaining binding to human PSMA.For example, in some embodiments, the PSMA binding domain is a human2A10 PSMA binding domain comprising an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe amino acid sequence set forth in SEQ ID NO:38. In one embodiment,the PSMA binding domain is a human 2A10 PSMA binding domain comprisingthe amino acid sequence set forth in SEQ ID NO:38.

In some embodiments, the PSMA binding domain is a human 2A10 PSMAbinding domain encoded by a nucleic acid sequence that has at least 60%,at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the nucleicacid sequence set forth in SEQ ID NO:39. In one embodiment, the PSMAbinding domain is a human 2A10 PSMA binding domain encoded by thenucleic acid sequence set forth in SEQ ID NO:39. In one embodiment, thehuman 2A10 PSMA binding domain comprises a heavy chain variable regioncomprising the amino acid sequence set forth below:

(SEQ ID NO: 40) PEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQ TGFLWSSDLWGRGTLVTVSS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 41) CCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCAC TGTCTCCTCA.

Tolerable variations of the heavy chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 2A10PSMA binding domain comprises a heavy chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:40. In one embodiment, the human 2A10 PSMA binding domaincomprises a heavy chain variable region comprising the amino acidsequence set forth in SEQ ID NO:40.

In some embodiments, the human 2A10 PSMA binding domain comprises aheavy chain variable region encoded by a nucleic acid sequence that hasat least 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:41. In one embodiment,the human 2A10 PSMA binding domain comprises a heavy chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:41.

The heavy chain variable region of the human 2A10 PSMA binding domaincomprises three heavy chain complementarity-determining regions (CDRs).Accordingly, a human 2A10 PSMA binding domain may comprise a heavy chainvariable region that comprises a CDR1 represented by the amino acidsequence SNWIG (SEQ ID NO:42); a CDR2 represented by the amino acidsequence IIYPGDSDTRYSPSFQG (SEQ ID NO:43); and a CDR3 represented by theamino acid sequence QTGFLWSSDL (SEQ ID NO:44). Tolerable variations tothe CDRs of the heavy chain will be known to those of skill in the art,while maintaining its contribution to the binding of human PSMA. Forexample, a human 2A10 PSMA binding domain may comprise a heavy chainvariable region comprising a CDR1 that comprises an amino acid sequencethat has at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the CDR1 amino acid sequence set forth inSEQ ID NO:42. For example, a human 2A10 PSMA binding domain may comprisea heavy chain variable region comprising a CDR2 that comprises an aminoacid sequence that has at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the CDR2 amino acidsequence set forth in SEQ ID NO:43. For example, a human 2A10 PSMAbinding domain may comprise a heavy chain variable region comprising aCDR3 that comprises an amino acid sequence that has at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe CDR3 amino acid sequence set forth in SEQ ID NO:44. In oneembodiment, the human 2A10 PSMA binding domain comprises a heavy chainvariable region comprising the three aforementioned heavy chain variableregion CDRs.

In one embodiment, the human 2A10 PSMA binding domain comprises a lightchain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 45) AIQLTQSPSSLSASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGYGSGTDFTLTINSLQPEDFATYYCQQFNSYPLTFGG GTKVEIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 46) GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA.

Tolerable variations of the light chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 2A10PSMA binding domain comprises a light chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:45. In one embodiment, the human 2A10 PSMA binding domaincomprises a light chain variable region comprising the amino acidsequence set forth in SEQ ID NO:45.

In some embodiments, the human 2A10 PSMA binding domain comprises alight chain variable region encoded by a nucleic acid sequence that hasat least 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:46. In one embodiment,the human 2A10 PSMA binding domain comprises a light chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:46.

The light chain variable region of the human 2A10 PSMA binding domaincomprises three light chain complementarity-determining regions (CDRs).Accordingly, a human 2A10 PSMA binding domain may comprise a light chainvariable region that comprises a CDR1 represented by the amino acidsequence CRASQDISSAL (SEQ ID NO:47); a CDR2 represented by the aminoacid sequence YDASSLES (SEQ ID NO:48); and a CDR3 represented by theamino acid sequence CQQFNSYPLT (SEQ ID NO:49). Tolerable variations tothe CDRs of the light chain will be known to those of skill in the art,while maintaining its contribution to the binding of PSMA. For example,a human 2A10 PSMA binding domain may comprise a light chain variableregion comprising a CDR1 that comprises an amino acid sequence that hasat least 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the CDR1 amino acid sequence set forth in SEQ IDNO:47. For example, a human 2A10 PSMA binding domain may comprise alight chain variable region comprising a CDR2 that comprises an aminoacid sequence that has at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the CDR2 amino acidsequence set forth in SEQ ID NO:48. For example, a human 2A10 PSMAbinding domain may comprise a light chain variable region comprising aCDR3 that comprises an amino acid sequence that has at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe CDR3 amino acid sequence set forth in SEQ ID NO:49. In oneembodiment, the human 2A10 PSMA binding domain comprises a light chainvariable region comprising the three aforementioned light chain variableregion CDRs.

In one embodiment, the PSMA binding domain is a human 2F5 PSMA bindingdomain comprising the amino acid sequence set forth below:

(SEQ ID NO: 50) MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGITYPGDSDTRYSPSFQGQVTISADKSISTAYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYP LTFGGGTKVEIKIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 51) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAA.

Tolerable variations of the human 2F5 PSMA binding domain will be knownto those of skill in the art, while maintaining binding to human PSMA.For example, in some embodiments, the PSMA binding domain is a human 2F5PSMA binding domain comprising an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theamino acid sequence set forth in SEQ ID NO:50. In one embodiment, thePSMA binding domain is a human 2F5 PSMA binding domain comprising theamino acid sequence set forth in SEQ ID NO:50.

In some embodiments, the PSMA binding domain is a human 2F5 PSMA bindingdomain encoded by a nucleic acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the nucleicacid sequence set forth in SEQ ID NO:51. In one embodiment, the PSMAbinding domain is a human 2F5 PSMA binding domain encoded by the nucleicacid sequence set forth in SEQ ID NO:51.

In one embodiment, the human 2F5 PSMA binding domain comprises a heavychain variable region comprising the amino acid sequence set forthbelow: PEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWNSLKASDTAMYYCARQTGFLWSFD LWGRGTLVTVSS (SEQID NO:52),

which may be encoded by the nucleic acid sequence set forth below:CCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCA (SEQ ID NO:53).

Tolerable variations of the heavy chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 2F5PSMA binding domain comprises a heavy chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:52. In one embodiment, the human 2F5 PSMA binding domaincomprises a heavy chain variable region comprising the amino acidsequence set forth in SEQ ID NO:52.

In some embodiments, the human 2F5 PSMA binding domain comprises a heavychain variable region encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:53. In one embodiment,the human 2F5 PSMA binding domain comprises a heavy chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:53.

The heavy chain variable region of the human 2F5 PSMA binding domaincomprises three heavy chain complementarity-determining regions (CDRs).Accordingly, a human 2F5 PSMA binding domain may comprise a heavy chainvariable region that comprises a CDR1 represented by the amino acidsequence SNWIG (SEQ ID NO:54); a CDR2 represented by the amino acidsequence IIYPGDSDTRYSPSFQG (SEQ ID NO:55); and a CDR3 represented by theamino acid sequence QTGFLWSFDL (SEQ ID NO:56). Tolerable variations tothe CDRs of the heavy chain will be known to those of skill in the art,while maintaining its contribution to the binding of PSMA. For example,a human 2F5 PSMA binding domain may comprise a heavy chain variableregion comprising a CDR1 that comprises an amino acid sequence that hasat least 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the CDR1 amino acid sequence set forth in SEQ IDNO:54. For example, a human 2F5 PSMA binding domain may comprise a heavychain variable region comprising a CDR2 that comprises an amino acidsequence that has at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the CDR2 amino acid sequence setforth in SEQ ID NO:55. For example, a human 2F5 PSMA binding domain maycomprise a heavy chain variable region comprising a CDR3 that comprisesan amino acid sequence that has at least 85%, at least 86%, at least87%, at least 88%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99% sequence identity to the CDR3 amino acidsequence set forth in SEQ ID NO:56. In one embodiment, the human 2F5PSMA binding domain comprises a heavy chain variable region comprisingthe three aforementioned heavy chain variable region CDRs.

In one embodiment, the human 2F5 PSMA binding domain comprises a lightchain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 57) AIQLTQSPSSLSASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGG GTKVEIKIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 58) GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAA.

Tolerable variations of the light chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 2F5PSMA binding domain comprises a light chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:57. In one embodiment, the human 2F5 PSMA binding domaincomprises a light chain variable region comprising the amino acidsequence set forth in SEQ ID NO:57.

In some embodiments, the human 2F5 PSMA binding domain comprises a lightchain variable region encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:58. In one embodiment,the human 2F5 PSMA binding domain comprises a light chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:58.

The light chain variable region of the human 2F5 PSMA binding domaincomprises three light chain complementarity-determining regions (CDRs).Accordingly, a human 2F5 PSMA binding domain may comprise a light chainvariable region that comprises a CDR1 represented by the amino acidsequence RASQDISSALA (SEQ ID NO:59); a CDR2 represented by the aminoacid sequence DASSLES (SEQ ID NO:60); and a CDR3 represented by theamino acid sequence QQFNSYPLT (SEQ ID NO:61). Tolerable variations tothe CDRs of the light chain will be known to those of skill in the art,while maintaining its contribution to the binding of PSMA. For example,a human 2F5 PSMA binding domain may comprise a light chain variableregion comprising a CDR1 that comprises an amino acid sequence that hasat least 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the CDR1 amino acid sequence set forth in SEQ IDNO:59. For example, a human 2F5 PSMA binding domain may comprise a lightchain variable region comprising a CDR2 that comprises an amino acidsequence that has at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the CDR2 amino acid sequence setforth in SEQ ID NO:60. For example, a human 2F5 PSMA binding domain maycomprise a light chain variable region comprising a CDR3 that comprisesan amino acid sequence that has at least 85%, at least 86%, at least87%, at least 88%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99% sequence identity to the CDR3 amino acidsequence set forth in SEQ ID NO:61. In one embodiment, the human 2F5PSMA binding domain comprises a light chain variable region comprisingthe three aforementioned light chain variable region CDRs.

In one embodiment, the PSMA binding domain is a human 2C6 PSMA bindingdomain comprising the amino acid sequence set forth below:

(SEQ ID NO: 62) MALPVTALLLPLALLLHAARPEVQLVQSGSEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCASPGYTSSWTSFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSN WPLFTFGPGTKVDIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 63) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGATCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA.

Tolerable variations of the human 2C6 PSMA binding domain will be knownto those of skill in the art, while maintaining binding to human PSMA.For example, in some embodiments, the PSMA binding domain is a human 2C6PSMA binding domain comprising an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theamino acid sequence set forth in SEQ ID NO:62. In one embodiment, thePSMA binding domain is a human 2C6 PSMA binding domain comprising theamino acid sequence set forth in SEQ ID NO:62.

In some embodiments, the PSMA binding domain is a human 2C6 PSMA bindingdomain encoded by a nucleic acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the nucleicacid sequence set forth in SEQ ID NO:63. In one embodiment, the PSMAbinding domain is a human 2C6 PSMA binding domain encoded by the nucleicacid sequence set forth in SEQ ID NO:63.

In one embodiment, the human 2C6 PSMA binding domain comprises a heavychain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 64) PEVQLVQSGSEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCASPGYTSSWTSFDYWGQGTLVTVSS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 65) CCGGAGGTGCAGCTGGTGCAGTCTGGATCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGGGGCCAGGGAACCCT GGTCACCGTCTCCTCA.

Tolerable variations of the heavy chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 2C6PSMA binding domain comprises a heavy chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:64. In one embodiment, the human 2C6 PSMA binding domaincomprises a heavy chain variable region comprising the amino acidsequence set forth in SEQ ID NO:64.

In some embodiments, the human 2C6 PSMA binding domain comprises a heavychain variable region encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:65. In one embodiment,the human 2C6 PSMA binding domain comprises a heavy chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:65.

The heavy chain variable region of the human 2C6 PSMA binding domaincomprises three heavy chain complementarity-determining regions (CDRs).Accordingly, a human 2C6 PSMA binding domain may comprise a heavy chainvariable region that comprises a CDR1 represented by the amino acidsequence TNYWI (SEQ ID NO:66); a CDR2 represented by the amino acidsequence GIIYPGDSDTRYSPSFQG (SEQ ID NO:67); and a CDR3 represented bythe amino acid sequence SPGYTSSWTS (SEQ ID NO:68). Tolerable variationsto the CDRs of the heavy chain will be known to those of skill in theart, while maintaining its contribution to the binding of PSMA. Forexample, a human 2C6 PSMA binding domain may comprise a heavy chainvariable region comprising a CDR1 that comprises an amino acid sequencethat has at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the CDR1 amino acid sequence set forth inSEQ ID NO:66. For example, a human 2C6 PSMA binding domain may comprisea heavy chain variable region comprising a CDR2 that comprises an aminoacid sequence that has at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the CDR2 amino acidsequence set forth in SEQ ID NO:67. For example, a human 2C6 PSMAbinding domain may comprise a heavy chain variable region comprising aCDR3 that comprises an amino acid sequence that has at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe CDR3 amino acid sequence set forth in SEQ ID NO:68. In oneembodiment, the human 2C6 PSMA binding domain comprises a heavy chainvariable region comprising the three aforementioned heavy chain variableregion CDRs.

In one embodiment, the human 2C6 PSMA binding domain comprises a lightchain variable region comprising the amino acid sequence set forthbelow:

(SEQ ID NO: 69) EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLFTFG PGTKVDIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 70) GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA.

Tolerable variations of the light chain variable region will be known tothose of skill in the art, while maintaining its contribution to thebinding of human PSMA. For example, in some embodiments, the human 2C6PSMA binding domain comprises a light chain variable region comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:69. In one embodiment, the human 2C6 PSMA binding domaincomprises a light chain variable region comprising the amino acidsequence set forth in SEQ ID NO:69.

In some embodiments, the human 2C6 PSMA binding domain comprises a lightchain variable region encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:70. In one embodiment,the human 2C6 PSMA binding domain comprises a light chain variableregion encoded by the nucleic acid sequence set forth in SEQ ID NO:70.

The light chain variable region of the human 2C6 PSMA binding domaincomprises three light chain complementarity-determining regions (CDRs).Accordingly, a human 2C6 PSMA binding domain may comprise a light chainvariable region that comprises a CDR1 represented by the amino acidsequence CRASQSVSSYL (SEQ ID NO:71); a CDR2 represented by the aminoacid sequence YDASNRAT (SEQ ID NO:72); and a CDR3 represented by theamino acid sequence CQQRSNWPLFT (SEQ ID NO:73). Tolerable variations tothe CDRs of the light chain will be known to those of skill in the art,while maintaining its contribution to the binding of PSMA. For example,a human 2C6 PSMA binding domain may comprise a light chain variableregion comprising a CDR1 that comprises an amino acid sequence that hasat least 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the CDR1 amino acid sequence set forth in SEQ IDNO:71. For example, a human 2C6 PSMA binding domain may comprise a lightchain variable region comprising a CDR2 that comprises an amino acidsequence that has at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the CDR2 amino acid sequence setforth in SEQ ID NO:72. For example, a human 2C6 PSMA binding domain maycomprise a light chain variable region comprising a CDR3 that comprisesan amino acid sequence that has at least 85%, at least 86%, at least87%, at least 88%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99% sequence identity to the CDR3 amino acidsequence set forth in SEQ ID NO:73. In one embodiment, the human 2C6PSMA binding domain comprises a light chain variable region comprisingthe three aforementioned light chain variable region CDRs.

Transmembrane Domain

CARs (e.g., PSMA-CARs) of the present invention comprise may comprise atransmembrane domain that connects the antigen binding domain of the CARto the intracellular domain of the CAR. The transmembrane domain of asubject CAR is a region that is capable of spanning the plasma membraneof a cell (e.g., an immune cell or precursor thereof). The transmembranedomain is for insertion into a cell membrane, e.g., a eukaryotic cellmembrane. In some embodiments, the transmembrane domain is interposedbetween the antigen binding domain and the intracellular domain of aCAR.

In some embodiments, the transmembrane domain is naturally associatedwith one or more of the domains in the CAR. In some embodiments, thetransmembrane domain can be selected or modified by one or more aminoacid substitutions to avoid binding of such domains to the transmembranedomains of the same or different surface membrane proteins, to minimizeinteractions with other members of the receptor complex.

The transmembrane domain may be derived either from a natural or asynthetic source. Where the source is natural, the domain may be derivedfrom any membrane-bound or transmembrane protein, e.g., a Type Itransmembrane protein. Where the source is synthetic, the transmembranedomain may be any artificial sequence that facilitates insertion of theCAR into a cell membrane, e.g., an artificial hydrophobic sequence.Examples of the transmembrane domain of particular use in this inventioninclude, without limitation, transmembrane domains derived from (i.e.comprise at least the transmembrane region(s) of) the alpha, beta orzeta chain of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5,CD7, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134 (OX-40),CD137 (4-1BB), CD154 (CD40L), Toll-like receptor 1 (TLR1), TLR2, TLR3,TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9. In some embodiments, thetransmembrane domain may be synthetic, in which case it will comprisepredominantly hydrophobic residues such as leucine and valine.Preferably a triplet of phenylalanine, tryptophan and valine will befound at each end of a synthetic transmembrane domain.

The transmembrane domains described herein can be combined with any ofthe antigen binding domains described herein, any of the intracellulardomains described herein, or any of the other domains described hereinthat may be included in a subject CAR.

In some embodiments, the transmembrane domain further comprises a hingeregion. A subject CAR of the present invention may also include an hingeregion. The hinge region of the CAR is a hydrophilic region which islocated between the antigen binding domain and the transmembrane domain.In some embodiments, this domain facilitates proper protein folding forthe CAR. The hinge region is an optional component for the CAR. Thehinge region may include a domain selected from Fc fragments ofantibodies, hinge regions of antibodies, CH2 regions of antibodies, CH3regions of antibodies, artificial hinge sequences or combinationsthereof. Examples of hinge regions include, without limitation, a CD8ahinge, artificial hinges made of polypeptides which may be as small as,three glycines (Gly), as well as CH1 and CH3 domains of IgGs (such ashuman IgG4).

In some embodiments, a subject CAR of the present disclosure includes ahinge region that connects the antigen binding domain with thetransmembrane domain, which, in turn, connects to the intracellulardomain. The hinge region is preferably capable of supporting the antigenbinding domain to recognize and bind to the target antigen on the targetcells (see, e.g., Hudecek et al., Cancer Immunol. Res. (2015) 3(2):125-135). In some embodiments, the hinge region is a flexible domain,thus allowing the antigen binding domain to have a structure tooptimally recognize the specific structure and density of the targetantigens on a cell such as tumor cell (Hudecek et al., supra). Theflexibility of the hinge region permits the hinge region to adopt manydifferent conformations.

In some embodiments, the hinge region is an immunoglobulin heavy chainhinge region. In some embodiments, the hinge region is a hinge regionpolypeptide derived from a receptor (e.g., a CD8-derived hinge region).

The hinge region can have a length of from about 4 amino acids to about50 amino acids, e.g., from about 4 aa to about 10 aa, from about 10 aato about 15 aa, from about 15 aa to about 20 aa, from about 20 aa toabout 25 aa, from about 25 aa to about 30 aa, from about 30 aa to about40 aa, or from about 40 aa to about 50 aa.

Suitable hinge regions can be readily selected and can be of any of anumber of suitable lengths, such as from 1 amino acid (e.g., Gly) to 20amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acidsto 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8amino acids, and can be 1, 2, 3, 4, 5, 6, or 7 amino acids.

For example, hinge regions include glycine polymers (G)_(n),glycine-serine polymers (including, for example, (GS)_(n), (GSGGS)_(n)(SEQ ID NO:1) and (GGGS)_(n) (SEQ ID NO:2), where n is an integer of atleast one), glycine-alanine polymers, alanine-serine polymers, and otherflexible linkers known in the art. Glycine and glycine-serine polymerscan be used; both Gly and Ser are relatively unstructured, and thereforecan serve as a neutral tether between components. Glycine polymers canbe used; glycine accesses significantly more phi-psi space than evenalanine, and is much less restricted than residues with longer sidechains (see, e.g., Scheraga, Rev. Computational. Chem. (1992) 2:73-142). Exemplary hinge regions can comprise amino acid sequencesincluding, but not limited to, GGSG (SEQ ID NO:4), GGSGG (SEQ ID NO:5),GSGSG (SEQ ID NO:6), GSGGG (SEQ ID NO:7), GGGSG (SEQ ID NO:8), GSSSG(SEQ ID NO:9), and the like.

In some embodiments, the hinge region is an immunoglobulin heavy chainhinge region. Immunoglobulin hinge region amino acid sequences are knownin the art; see, e.g., Tan et al., Proc. Natl. Acad. Sci. USA (1990)87(1):162-166; and Huck et al., Nucleic Acids Res. (1986) 14(4):1779-1789. As non-limiting examples, an immunoglobulin hinge region caninclude one of the following amino acid sequences: DKTHT (SEQ ID NO:74);CPPC (SEQ ID NO:75); CPEPKSCDTPPPCPR (SEQ ID NO:76) (see, e.g., Glaseret al., J. Biol. Chem. (2005) 280:41494-41503); ELKTPLGDTTHT (SEQ IDNO:77); KSCDKTHTCP (SEQ ID NO:78); KCCVDCP (SEQ ID NO:79); KYGPPCP (SEQID NO:80); EPKSCDKTHTCPPCP (SEQ ID NO:81) (human IgG1 hinge);ERKCCVECPPCP (SEQ ID NO:82) (human IgG2 hinge); ELKTPLGDTTHTCPRCP (SEQID NO:83) (human IgG3 hinge); SPNMVPHAHHAQ (SEQ ID NO:84) (human IgG4hinge); and the like.

The hinge region can comprise an amino acid sequence of a human IgG1,IgG2, IgG3, or IgG4, hinge region. In one embodiment, the hinge regioncan include one or more amino acid substitutions and/or insertionsand/or deletions compared to a wild-type (naturally-occurring) hingeregion. For example, His229 of human IgG1 hinge can be substituted withTyr, so that the hinge region comprises the sequence EPKSCDKTYTCPPCP(SEQ ID NO:85); see, e.g., Yan et al., J. Biol. Chem. (2012) 287:5891-5897. In one embodiment, the hinge region can comprise an aminoacid sequence derived from human CD8, or a variant thereof.

The transmembrane domain may be combined with any hinge region and/ormay comprise one or more transmembrane domains described herein. In oneembodiment, the transmembrane domain comprises a CD8 transmembranedomain. In one embodiment, the transmembrane domain comprises a CD8hinge region and a CD8 transmembrane domain. In some embodiments, asubject CAR comprises a CD8 hinge region having the amino acid sequenceset forth below: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ IDNO:86), which may be encoded by the nucleic acid sequence set forthbelow:

(SEQ ID NO: 87) ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT.

Tolerable variations of the transmembrane domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises a transmembrane domain comprising a CD8 hinge regioncomprising an amino acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the amino acid sequence setforth in SEQ ID NO:86. In one embodiment, the CAR comprises atransmembrane domain comprising a CD8 hinge region comprising the aminoacid sequence set forth in SEQ ID NO:86.

In some embodiments, a subject CAR of the present invention comprises atransmembrane domain comprising a CD8 hinge region encoded by a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the nucleic acid sequence set forth inSEQ ID NO:87. In one embodiment, the CAR comprises a transmembranedomain comprising a CD8 hinge region encoded by the nucleic acidsequence set forth in SEQ ID NO:87.

In some embodiments, a subject CAR comprises a CD8 transmembrane domainhaving the amino acid sequence set forth below: IYIWAPLAGTCGVLLLSLVITLYC(SEQ ID NO:88),

which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 89) ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC.

Tolerable variations of the transmembrane domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises a transmembrane domain comprising a CD8 transmembrane domaincomprising an amino acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the amino acid sequence setforth in SEQ ID NO:88. In one embodiment, the CAR comprises atransmembrane domain comprising a CD8 transmembrane domain comprisingthe amino acid sequence set forth in SEQ ID NO:88.

In some embodiments, a subject CAR of the present invention comprises atransmembrane domain comprising a CD8 transmembrane domain encoded by anucleic acid sequence that has at least 60%, at least 65%, at least 70%,at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the nucleic acid sequence set forth inSEQ ID NO:89. In one embodiment, the CAR comprises a transmembranedomain comprising a CD8 transmembrane domain encoded by the acidsequence set forth in SEQ ID NO:89.

In some embodiments, the transmembrane domain comprises a CD8 hingeregion and a CD8 transmembrane domain, having the amino acid sequenceset forth below:

(SEQ ID NO: 90) TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 91) ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC.

Tolerable variations of the transmembrane domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises a transmembrane domain comprising a CD8 hinge region and a CD8transmembrane domain, comprising an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe amino acid sequence set forth in SEQ ID NO:90. In one embodiment,the CAR comprises a transmembrane domain comprising a CD8 hinge regionand a CD8 transmembrane domain, comprising the amino acid sequence setforth in SEQ ID NO:90.

In some embodiments, a subject CAR of the present invention comprises atransmembrane domain comprising a CD8 hinge region and a CD8transmembrane domain, encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:91. In one embodiment,the CAR comprises a transmembrane domain comprising a CD8 hinge regionand a CD8 transmembrane domain, encoded by the nucleic acid sequence setforth in SEQ ID NO:91.

Between the extracellular domain and the transmembrane domain of theCAR, or between the intracellular domain and the transmembrane domain ofthe CAR, there may be incorporated a spacer domain. As used herein, theterm “spacer domain” generally means any oligo- or polypeptide thatfunctions to link the transmembrane domain to, either the extracellulardomain or, the intracellular domain in the polypeptide chain. A spacerdomain may comprise up to 300 amino acids, e.g., 10 to 100 amino acids,or 25 to 50 amino acids. In some embodiments, the spacer domain may be ashort oligo- or polypeptide linker, e.g., between 2 and 10 amino acidsin length. For example, glycine-serine doublet provides a particularlysuitable linker between the transmembrane domain and the intracellularsignaling domain of the subject CAR.

Intracellular Signaling Domain

A subject CAR of the present invention also includes an intracellularsignaling domain. The terms “intracellular signaling domain” and“intracellular domain” are used interchangeably herein. Theintracellular signaling domain of the CAR is responsible for activationof at least one of the effector functions of the cell in which the CARis expressed (e.g., immune cell). The intracellular signaling domaintransduces the effector function signal and directs the cell (e.g.,immune cell) to perform its specialized function, e.g., harming and/ordestroying a target cell.

Examples of an intracellular domain for use in the invention include,but are not limited to, the cytoplasmic portion of a surface receptor,co-stimulatory molecule, and any molecule that acts in concert toinitiate signal transduction in the T cell, as well as any derivative orvariant of these elements and any synthetic sequence that has the samefunctional capability.

Examples of the intracellular signaling domain include, withoutlimitation, the ζ chain of the T cell receptor complex or any of itshomologs, e.g., η chain, FcsRIγ and β chains, MB 1 (Iga) chain, B29 (Ig)chain, etc., human CD3 zeta chain, CD3 polypeptides (Δ, δ and ε), sykfamily tyrosine kinases (Syk, ZAP 70, etc.), src family tyrosine kinases(Lck, Fyn, Lyn, etc.), and other molecules involved in T celltransduction, such as CD2, CD5 and CD28. In one embodiment, theintracellular signaling domain may be human CD3 zeta chain, FcyRIII,FcsRI, cytoplasmic tails of Fc receptors, an immunoreceptortyrosine-based activation motif (ITAM) bearing cytoplasmic receptors,and combinations thereof.

In one embodiment, the intracellular signaling domain of the CARincludes any portion of one or more co-stimulatory molecules, such as atleast one signaling domain from CD3, CD8, CD27, CD28, ICOS, 4-1BB, PD-1,any derivative or variant thereof, any synthetic sequence thereof thathas the same functional capability, and any combination thereof.

Other examples of the intracellular domain include a fragment or domainfrom one or more molecules or receptors including, but not limited to,TCR, CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, CD86, common FcRgamma, FcR beta (Fc Epsilon Rib), CD79a, CD79b, Fcgamma Rlla, DAP10, DAP12, T cell receptor (TCR), CD8, CD27, CD28, 4-1BB (CD137), OX9, OX40,CD30, CD40, PD-1, ICOS, a MR family protein, lymphocytefunction-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, aligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM(LIGHTR), SLAMF7, NKp80 (KLRF1), CD127, CD 160, CD19, CD4, CD8alpha,CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4,IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1 Id, ITGAE, CD 103, ITGAL, CD11 a, LFA-1, ITGAM, CD lib, ITGAX, CD 11c, ITGB1, CD29, ITGB2, CD 18,LFA-1, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4),CD84, CD 96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55),PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150,IPO-3), BLAME (SLAMF8), SELPLG (CD 162), LTBR, LAT, GADS, SLP-76,PAG/Cbp, NKp44, NKp30, NKp46, NKG2D, Toll-like receptor 1 (TLR1), TLR2,TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, other co-stimulatory moleculesdescribed herein, any derivative, variant, or fragment thereof, anysynthetic sequence of a co-stimulatory molecule that has the samefunctional capability, and any combination thereof.

Additional examples of intracellular domains include, withoutlimitation, intracellular signaling domains of several types of variousother immune signaling receptors, including, but not limited to, first,second, and third generation T cell signaling proteins including CD3, B7family costimulatory, and Tumor Necrosis Factor Receptor (TNFR)superfamily receptors (see, e.g., Park and Brentjens, J. Clin. Oncol.(2015) 33(6): 651-653). Additionally, intracellular signaling domainsmay include signaling domains used by NK and NKT cells (see, e.g.,Hermanson and Kaufman, Front. Immunol. (2015) 6: 195) such as signalingdomains of NKp30 (B7-H6) (see, e.g., Zhang et al., J. Immunol. (2012)189(5): 2290-2299), and DAP 12 (see, e.g., Topfer et al., J. Immunol.(2015) 194(7): 3201-3212), NKG2D, NKp44, NKp46, DAP10, and CD3z.

Intracellular signaling domains suitable for use in a subject CAR of thepresent invention include any desired signaling domain that provides adistinct and detectable signal (e.g., increased production of one ormore cytokines by the cell; change in transcription of a target gene;change in activity of a protein; change in cell behavior, e.g., celldeath; cellular proliferation; cellular differentiation; cell survival;modulation of cellular signaling responses; etc.) in response toactivation of the CAR (i.e., activated by antigen and dimerizing agent).In some embodiments, the intracellular signaling domain includes atleast one (e.g., one, two, three, four, five, six, etc.) ITAM motifs asdescribed below. In some embodiments, the intracellular signaling domainincludes DAP10/CD28 type signaling chains. In some embodiments, theintracellular signaling domain is not covalently attached to themembrane bound CAR, but is instead diffused in the cytoplasm.

Intracellular signaling domains suitable for use in a subject CAR of thepresent invention include immunoreceptor tyrosine-based activation motif(ITAM)-containing intracellular signaling polypeptides. In someembodiments, an ITAM motif is repeated twice in an intracellularsignaling domain, where the first and second instances of the ITAM motifare separated from one another by 6 to 8 amino acids. In one embodiment,the intracellular signaling domain of a subject CAR comprises 3 ITAMmotifs.

In some embodiments, intracellular signaling domains includes thesignaling domains of human immunoglobulin receptors that containimmunoreceptor tyrosine based activation motifs (ITAMs) such as, but notlimited to, FcgammaRI, FcgammaRllA, FcgammaRIIC, FcgammaRIIIA, FcRL5(see, e.g., Gillis et al., Front. Immunol. (2014) 5:254).

A suitable intracellular signaling domain can be an ITAMmotif-containing portion that is derived from a polypeptide thatcontains an ITAM motif. For example, a suitable intracellular signalingdomain can be an ITAM motif-containing domain from any ITAMmotif-containing protein. Thus, a suitable intracellular signalingdomain need not contain the entire sequence of the entire protein fromwhich it is derived. Examples of suitable ITAM motif-containingpolypeptides include, but are not limited to: DAP12, FCERIG (Fc epsilonreceptor I gamma chain), CD3D (CD3 delta), CD3E (CD3 epsilon), CD3G (CD3gamma), CD3Z (CD3 zeta), and CD79A (antigen receptor complex-associatedprotein alpha chain).

In one embodiment, the intracellular signaling domain is derived fromDAP12 (also known as TYROBP; TYRO protein tyrosine kinase bindingprotein; KARAP; PLOSL; DNAX-activation protein 12; KAR-associatedprotein; TYRO protein tyrosine kinase-binding protein; killer activatingreceptor associated protein; killer-activating receptor-associatedprotein; etc.). In one embodiment, the intracellular signaling domain isderived from FCERIG (also known as FCRG; Fc epsilon receptor I gammachain; Fc receptor gamma-chain; fc-epsilon RI-gamma; fcRgamma; fceRlgamma; high affinity immunoglobulin epsilon receptor subunit gamma;immunoglobulin E receptor, high affinity, gamma chain; etc.). In oneembodiment, the intracellular signaling domain is derived from T-cellsurface glycoprotein CD3 delta chain (also known as CD3D; CD3-DELTA;T3D; CD3 antigen, delta subunit; CD3 delta; CD3d antigen, deltapolypeptide (TiT3 complex); OKT3, delta chain; T-cell receptor T3 deltachain; T-cell surface glycoprotein CD3 delta chain; etc.). In oneembodiment, the intracellular signaling domain is derived from T-cellsurface glycoprotein CD3 epsilon chain (also known as CD3e, T-cellsurface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3epsilon chain, AI504783, CD3, CD3epsilon, T3e, etc.). In one embodiment,the intracellular signaling domain is derived from T-cell surfaceglycoprotein CD3 gamma chain (also known as CD3G, T-cell receptor T3gamma chain, CD3-GAMMA, T3G, gamma polypeptide (TiT3 complex), etc.). Inone embodiment, the intracellular signaling domain is derived fromT-cell surface glycoprotein CD3 zeta chain (also known as CD3Z, T-cellreceptor T3 zeta chain, CD247, CD3-ZETA, CD3H, CD3Q, T3Z, TCRZ, etc.).In one embodiment, the intracellular signaling domain is derived fromCD79A (also known as B-cell antigen receptor complex-associated proteinalpha chain; CD79a antigen (immunoglobulin-associated alpha); MB-1membrane glycoprotein; ig-alpha; membrane-boundimmunoglobulin-associated protein; surface IgM-associated protein;etc.). In one embodiment, an intracellular signaling domain suitable foruse in an FN3 CAR of the present disclosure includes a DAP10/CD28 typesignaling chain. In one embodiment, an intracellular signaling domainsuitable for use in an FN3 CAR of the present disclosure includes aZAP70 polypeptide. In some embodiments, the intracellular signalingdomain includes a cytoplasmic signaling domain of TCR zeta, FcR gamma,FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, orCD66d. In one embodiment, the intracellular signaling domain in the CARincludes a cytoplasmic signaling domain of human CD3 zeta.

While usually the entire intracellular signaling domain can be employed,in many cases it is not necessary to use the entire chain. To the extentthat a truncated portion of the intracellular signaling domain is used,such truncated portion may be used in place of the intact chain as longas it transduces the effector function signal. The intracellularsignaling domain includes any truncated portion of the intracellularsignaling domain sufficient to transduce the effector function signal.

The intracellular signaling domains described herein can be combinedwith any of the antigen binding domains described herein, any of thetransmembrane domains described herein, or any of the other domainsdescribed herein that may be included in the CAR.

In one embodiment, the intracellular domain of a subject CAR comprises a4-1BB domain comprising the amino acid sequence set forth below:

(SEQ ID NO: 92) KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 93) AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG,or the nucleic acid sequence set forth below:

(SEQ ID NO: 94) AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG.

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising a 4-1BB domain comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:92. In one embodiment, the CAR comprises an intracellulardomain comprising a 4-1BB domain comprising the amino acid sequence setforth in SEQ ID NO:92.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising a 4-1BB domain encoded by a nucleic acidsequence that has at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 81%, at least 82%, at least 83%, at least84%, at least 85%, at least 86%, at least 87%, at least 88%, at least89%, at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least99% sequence identity to the nucleic acid sequence set forth in SEQ IDNOs:93 or 94. In one embodiment, the CAR comprises an intracellulardomain comprising a 4-1BB domain encoded by the nucleic acid sequenceset forth in SEQ ID NOs:93 or 94.

In one embodiment, the intracellular domain of a subject CAR comprisesan ICOS domain comprising the amino acid sequence set forth below:

(SEQ ID NO: 203) TKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 204) ACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTC ACAGATGTGACCCTA.

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising an ICOS domain comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:203. In one embodiment, the CAR comprises an intracellulardomain comprising an ICOS domain comprising the amino acid sequence setforth in SEQ ID NO:203.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising an ICOS domain encoded by a nucleic acidsequence that has at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 81%, at least 82%, at least 83%, at least84%, at least 85%, at least 86%, at least 87%, at least 88%, at least89%, at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least99% sequence identity to the nucleic acid sequence set forth in SEQ IDNO:204. In one embodiment, the CAR comprises an intracellular domaincomprising an ICOS domain encoded by the nucleic acid sequence set forthin SEQ ID NO:204.

In one embodiment, the intracellular domain of a subject CAR comprises avariant ICOS domain comprising the amino acid sequence set forth below:

(SEQ ID NO: 95) TKKKYSSSVHDPNGEYMNMRAVNTAKKSRLTDVTL,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 96) ACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTC ACAGATGTGACCCTA.

The variant ICOS domain is also referred to herein as ICOS(YMNM).

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising an ICOS domain comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:95. In one embodiment, the CAR comprises an intracellulardomain comprising an ICOS domain comprising the amino acid sequence setforth in SEQ ID NO:95.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising an ICOS domain encoded by a nucleic acidsequence that has at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 81%, at least 82%, at least 83%, at least84%, at least 85%, at least 86%, at least 87%, at least 88%, at least89%, at least 90%, at least 91%, at least 92%, at least 93%, at least94%, at least 95%, at least 96%, at least 97%, at least 98%, at least99% sequence identity to the nucleic acid sequence set forth in SEQ IDNO:96. In one embodiment, the CAR comprises an intracellular domaincomprising an ICOS domain encoded by the nucleic acid sequence set forthin SEQ ID NO:96.

In one embodiment, the intracellular domain of a subject CAR comprises aCD3 zeta domain comprising the amino acid sequence set forth below:

(SEQ ID NO: 97) RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLY QGLSTATKDTYDALHMQALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 98) AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCAC ATGCAGGCCCTGCCCCCTCGC,or the nucleic acid sequence set forth below:

(SEQ ID NO: 99) AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCAC ATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising a CD3 zeta domaincomprising an amino acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the amino acid sequence setforth in SEQ ID NO:97. In one embodiment, a subject CAR of the presentinvention comprises an intracellular domain comprising a CD3 zeta domaincomprising the amino acid sequence set forth in SEQ ID NO:97.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising a CD3 zeta domain encoded by a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the nucleic acid sequence set forth inSEQ ID NOs:98 or 99. In one embodiment, a subject CAR of the presentinvention comprises an intracellular domain comprising a CD3 zeta domainencoded by the nucleic acid sequence set forth in SEQ ID NOs:98 or 99 ACD3 zeta domain may comprise an amino acid sequence set forth below:

(SEQ ID NO: 100) RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLY QGLSTATKDTYDALHMQALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 101) AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCAC ATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising a CD3 zeta domaincomprising an amino acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the amino acid sequence setforth in SEQ ID NO:100. In one embodiment, a subject CAR of the presentinvention comprises an intracellular domain comprising a CD3 zeta domaincomprising the amino acid sequence set forth in SEQ ID NO:100.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising a CD3 zeta domain encoded by a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the nucleic acid sequence set forth inSEQ ID NO:101. In one embodiment, a subject CAR of the present inventioncomprises an intracellular domain comprising a CD3 zeta domain encodedby the nucleic acid sequence set forth in SEQ ID NO:101.

In one embodiment, the CAR comprises an intracellular domain comprisinga CD3 zeta domain comprising the amino acid sequence set forth in SEQ IDNOs:97 or 100.

In one exemplary embodiment, the intracellular domain of a subject CARcomprises a 4-1BB domain and a CD3 zeta domain, comprising the aminoacid sequence set forth below:

(SEQ ID NO: 102) KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 103) AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCC CTGCCCCCTCGC,or the nucleic acid sequence set forth below:

(SEQ ID NO: 104) AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising a 4-1BB domain and a CD3zeta domain, comprising an amino acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the aminoacid sequence set forth in SEQ ID NO:102. In one embodiment, the CARcomprises an intracellular domain comprising a 4-1BB domain and a CD3zeta domain, comprising the amino acid sequence set forth in SEQ IDNO:102.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising a 4-1BB domain and a CD3 zeta domain,encoded by a nucleic acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the nucleic acid sequenceset forth in SEQ ID NOs:103 or 104. In one embodiment, the CAR comprisesan intracellular domain comprising a 4-1BB domain and a CD3 zeta domain,encoded by the nucleic acid sequence set forth in SEQ ID NOs:103 or 104.

In one exemplary embodiment, the intracellular domain of a subject CARcomprises an ICOS domain and a CD3 zeta domain, comprising the aminoacid sequence set forth below:

(SEQ ID NO: 205) TKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTLRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQA LPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 206) ACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCC CTGCCCCCTCGC.

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising an ICOS domain and a CD3zeta domain, comprising an amino acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the aminoacid sequence set forth in SEQ ID NO:205. In one embodiment, the CARcomprises an intracellular domain comprising an ICOS domain and a CD3zeta domain, comprising the amino acid sequence set forth in SEQ IDNO:205.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising an ICOS domain and a CD3 zeta domain,encoded by a nucleic acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the nucleic acid sequenceset forth in SEQ ID NO:206. In one embodiment, the CAR comprises anintracellular domain comprising an ICOS domain and a CD3 zeta domain,encoded by the nucleic acid sequence set forth in SEQ ID NO:206.

In one exemplary embodiment, the intracellular domain of a subject CARcomprises a variant ICOS domain and a CD3 zeta domain, comprising theamino acid sequence set forth below:

(SEQ ID NO: 207) TKKKYSSSVHDPNGEYMNMRAVNTAKKSRLTDVTLRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQA LPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 208) ACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCC CTGCCCCCTCGC.

Tolerable variations of the intracellular domain will be known to thoseof skill in the art, while maintaining its intended function. Forexample, in some embodiments, a subject CAR of the present inventioncomprises an intracellular domain comprising a variant ICOS domain and aCD3 zeta domain, comprising an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theamino acid sequence set forth in SEQ ID NO:207. In one embodiment, theCAR comprises an intracellular domain comprising a variant ICOS domainand a CD3 zeta domain, comprising the amino acid sequence set forth inSEQ ID NO:207.

In some embodiments, a subject CAR of the present invention comprises anintracellular domain comprising a variant ICOS domain and a CD3 zetadomain, encoded by a nucleic acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the nucleicacid sequence set forth in SEQ ID NO:208. In one embodiment, the CARcomprises an intracellular domain comprising a variant ICOS domain and aCD3 zeta domain, encoded by the nucleic acid sequence set forth in SEQID NO:208.

CAR Sequences

A subject CAR of the present invention may be selected from the groupconsisting of a J591 murine PSMA-CAR, a humanized J591 PSMA-CAR, a 1C3human PSMA-CAR, a 2A10 human PSMA-CAR, a 2F5 human PSMA-CAR, and a 2C6human PSMA-CAR.

In one embodiment, a subject CAR of the present invention is a J591murine PSMA-CAR. In one embodiment, the J591 murine PSMA-CAR comprisesthe amino acid sequence set forth below:

(SEQ ID NO: 105) MALPVTALLLPLALLLHAARPGSDIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYNSYPLTFGAGTMLDLKGGGGSGGGGSSGGGSEVQLQQSGPELVKPGTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNGGTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGWNFDYWGQGTTLTVSSASSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH MQALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 106) ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCACGCCGCCAGACCTGGATCTGACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCATCTGTAAGGCCAGTCAAGATGTGGGTACTGCTGTAGACTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTATTGGGCATCCACTCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGACTTCACTCTCACCATTACTAACGTTCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAACAGCTATCCTCTCACGTTCGGTGCTGGGACCATGCTGGACCTGAAAGGAGGCGGAGGATCTGGCGGCGGAGGAAGTTCTGGCGGAGGCAGCGAGGTGCAGCTGCAGCAGAGCGGACCCGAGCTCGTGAAGCCTGGAACAAGCGTGCGGATCAGCTGCAAGACCAGCGGCTACACCTTCACCGAGTACACCATCCACTGGGTCAAGCAGTCCCACGGCAAGAGCCTGGAGTGGATCGGCAATATCAACCCCAACAACGGCGGCACCACCTACAACCAGAAGTTCGAGGACAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGCGAGGACAGCGCCGTGTACTATTGTGCCGCCGGTTGGAACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTGTCTAGCGCTAGCTCCGGAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCAC ATGCAGGCCCTGCCCCCTCGC.

In one embodiment, a subject CAR of the present invention is a humanizedPSMA-CAR, e.g., a humanized J591 PSMA-CAR. In such an embodiment, thehumanized PSMA-CAR comprises any of the heavy and light chain variableregions disclosed in PCT Publication Nos. WO2017212250A1 andWO2018033749A1. For example, a humanized PSMA-CAR of the presentinvention can comprise an scFv comprising any of the heavy and lightchain variable regions disclosed therein, see, e.g., sequences set forthin Table 19 of the present disclosure.

In one embodiment, a subject CAR of the present invention is a 1C3 humanPSMA-CAR. In one embodiment, the 1C3 human PSMA-CAR comprises the aminoacid sequence set forth below:

(SEQ ID NO: 107) MALPVTALLLPLALLLHAARPQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPWGSRYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKSGKAPKLLIFDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD ALHMQALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 108) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In one embodiment, a subject CAR of the present invention is a 2A10human PSMA-CAR. In one embodiment, the 2A10 human PSMA-CAR comprises theamino acid sequence set forth below:

(SEQ ID NO: 109) MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARQTGFLWSSDLWGRGTLVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGYGSGTDFTLTINSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 110) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAG GCCCTGCCCCCTCGC.

In one embodiment, a subject CAR of the present invention is a 2F5 humanPSMA-CAR. In one embodiment, the 2F5 human PSMA-CAR comprises a 4-1BBdomain and a CD3 zeta domain comprising the amino acid sequence setforth below:

(SEQ ID NO: 111) MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH MQALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 112) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCAC ATGCAGGCCCTGCCCCCTCGC.

In one embodiment, a subject CAR of the present invention is a 2F5 humanPSMA-CAR. In one embodiment, the 2F5 human PSMA-CAR comprises an ICOSdomain and a CD3 zeta domain comprising the amino acid sequence setforth below:

(SEQ ID NO: 209) MALPVTALLLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTLRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPP R,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 210) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCT CGC.

In one embodiment, a subject CAR of the present invention is a 2F5 humanPSMA-CAR. In one embodiment, the 2F5 human PSMA-CAR comprises a variantICOS domain and a CD3 zeta domain comprising the amino acid sequence setforth below:

(SEQ ID NO: 211) MALPVTALLLPLALLLHAARPEVQLVQSGAEVKXPGESLKJSCKGSGYSFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTIS ADKSISTAYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVTV SSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDI SSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTI SSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKIKTTTPAPRPPTPA PTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWLPIGCAAFVVV CILGCILICWLTKKKYSSSVHDPNGEYMNMRAVNTAKKSRLTDVTL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG GKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQ  GLSTATKDTYDALHMQALPPR, which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 212) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAG CAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAG GGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCG CCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATC CTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAG GTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTG CGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGT GGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGG TGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGT CTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTA TCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATG CCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGT GGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCC TGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACC CGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAA ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAG CGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGT GATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTG CATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGT ATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATG AGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGAC CCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACC AGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGA AGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCC TGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAG GCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTAC AGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCA CGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In one embodiment, a subject CAR of the present invention is a 2C6 humanPSMA-CAR. In one embodiment, the 2C6 human PSMA-CAR comprises the aminoacid sequence set forth below:

(SEQ ID NO: 113) MALPVTALLLPLALLLHAARPEVQLVQSGSEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKS ISTAYLQWSSLKASDTAMYYCASPGYTSSWTSFDYWGQGTLVTVSSGG GGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAW YQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDF AVYYCQQRSNWPLFTFGPGTKVDIKTTTPAPRPPTPAPTIASQPLSLR PEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKR GRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL HMQALPPR,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 114) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAT CAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAG GGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCG CCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATC CTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAG GTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCA GTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTG CGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGG GGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGCGGTGGCTC GGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGC CTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCT ATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGT GGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCT AGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCA ACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATC AAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCAC CATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGC CAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCC TGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGT CCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCA GAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCA GTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCC AGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCA GGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTC TATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTT GGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGA GAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAA GATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCC  CTGCCCCCTCGC.

Tolerable variations of the sequences of the subject CARs will be knownto those of skill in the art, while maintaining its function.

For example, in some embodiments, a subject CAR of the present inventionis a J591 murine PSMA-CAR comprising an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe amino acid sequence set forth in SEQ ID NO:105. In one embodiment,the CAR is a J591 murine PSMA-CAR comprising the amino acid sequence setforth in SEQ ID NO:105.

For example, in some embodiments, a subject CAR of the present inventionis a humanized J591 PSMA-CAR. A humanized J591 PSMA-CAR comprises ahumanized J591 PSMA binding domain comprising a heavy and light chainvariable region selected from any of the heavy and light chain variableregion sequences set forth in Table 19. In some embodiments, thehumanized J591 PSMA-CAR comprises a 4-1BB domain and a CD3zeta domain.

For example, in some embodiments, a subject CAR of the present inventionis a 1C3 human PSMA-CAR comprising an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe amino acid sequence set forth in SEQ ID NO:107. In one embodiment,the CAR is a 1C3 human PSMA-CAR comprising the amino acid sequence setforth in SEQ ID NO:107.

For example, in some embodiments, a subject CAR of the present inventionis a 2A10 human PSMA-CAR comprising an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe amino acid sequence set forth in SEQ ID NO:109. In one embodiment,the CAR is a 2A10 human PSMA-CAR comprising the amino acid sequence setforth in SEQ ID NO:109.

For example, in some embodiments, a subject CAR of the present inventionis a 2F5 human PSMA-CAR. In one embodiment, the CAR is a 2F5 humanPSMA-CAR that comprises a 4-1BB domain and a CD3zeta domain comprisingan amino acid sequence that has at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 81%, at least 82%, at least83%, at least 84%, at least 85%, at least 86%, at least 87%, at least88%, at least 89%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, at least 99% sequence identity to the amino acid sequence set forthin SEQ ID NO:111. In one embodiment, the CAR is a 2F5 human PSMA-CARthat comprises a 4-1BB domain and a CD3zeta domain comprising the aminoacid sequence set forth in SEQ ID NO:111. In one embodiment, the CAR isa 2F5 human PSMA-CAR that comprises an ICOS domain and a CD3zeta domaincomprising an amino acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the amino acid sequence setforth in SEQ ID NO:209. In one embodiment, the CAR is a 2F5 humanPSMA-CAR that comprises an ICOS domain and a CD3zeta domain comprisingthe amino acid sequence set forth in SEQ ID NO:209. In one embodiment,the CAR is a 2F5 human PSMA-CAR that comprises a variant ICOS domain anda CD3zeta domain comprising an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theamino acid sequence set forth in SEQ ID NO:211. In one embodiment, theCAR is a 2F5 human PSMA-CAR that comprises a variant ICOS domain and aCD3zeta domain comprising the amino acid sequence set forth in SEQ IDNO:211. For example, in some embodiments, a subject CAR of the presentinvention is a 2C6 human PSMA-CAR comprising an amino acid sequence thathas at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 81%, at least 82%, at least 83%, at least 84%, at least85%, at least 86%, at least 87%, at least 88%, at least 89%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% sequenceidentity to the amino acid sequence set forth in SEQ ID NO:113. In oneembodiment, the CAR is a 2C6 human PSMA-CAR comprising the amino acidsequence set forth in SEQ ID NO:113.

In some embodiments, a subject CAR of the present invention is a J591murine PSMA-CAR encoded by a nucleic acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thenucleic acid sequence set forth in SEQ ID NO:106. In one embodiment, theCAR is a J591 murine PSMA-CAR encoded by the nucleic acid sequence setforth in SEQ ID NO:106.

For example, in some embodiments, a subject CAR of the present inventionis a 1C3 human PSMA-CAR encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:108. In one embodiment,the CAR is a 1C3 human PSMA-CAR encoded by the nucleic acid sequence setforth in SEQ ID NO:108. For example, in some embodiments, a subject CARof the present invention is a 2A10 human PSMA-CAR encoded by a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the nucleic acid sequence set forth inSEQ ID NO:110. In one embodiment, the CAR is a 2A10 human PSMA-CARencoded by the nucleic acid sequence set forth in SEQ ID NO:110. Forexample, in some embodiments, a subject CAR of the present invention isa 2F5 human PSMA-CAR. In one embodiment, the CAR is a 2F5 human PSMA-CARthat comprises a 4-1BB domain and a CD3zeta domain, encoded by a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the nucleic acid sequence set forth inSEQ ID NO:112. In one embodiment, the CAR is a 2F5 human PSMA-CAR thatcomprises a 4-1BB domain and a CD3zeta domain, encoded by the nucleicacid sequence set forth in SEQ ID NO:112. In one embodiment, the CAR isa 2F5 human PSMA-CAR that comprises an ICOS domain and a CD3zeta domain,encoded by a nucleic acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the nucleic acid sequenceset forth in SEQ ID NO:210. In one embodiment, the CAR is a 2F5 humanPSMA-CAR that comprises an ICOS domain and a CD3zeta domain, encoded bythe nucleic acid sequence set forth in SEQ ID NO:210. In one embodiment,the CAR is a 2F5 human PSMA-CAR that comprises a variant ICOS domain anda CD3zeta domain, encoded by a nucleic acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thenucleic acid sequence set forth in SEQ ID NO:212. In one embodiment, theCAR is a 2F5 human PSMA-CAR that comprises a variant ICOS domain and aCD3zeta domain, encoded by the nucleic acid sequence set forth in SEQ IDNO:212. For example, in some embodiments, a subject CAR of the presentinvention is a 2C6 human PSMA-CAR encoded by a nucleic acid sequencethat has at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 81%, at least 82%, at least 83%, at least 84%, atleast 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the nucleic acid sequence set forth in SEQ IDNO:114. In one embodiment, the CAR is a 2C6 human PSMA-CAR encoded bythe nucleic acid sequence set forth in SEQ ID NO:114.

In certain embodiments, a subject CAR of the present invention maycomprise any one of the amino acid sequences corresponding to SEQ IDNOs: 209, 211, or 227-236.

SEQ  ID  NO:  CAR  Sequence  227  PD1-CD28- MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFS  2F5-ICOSZ PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND SGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVFWVLVVVGGVLACYSLLVTVAFIIFWVR SKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYR SVKQTLNFDLLKLAGDVESNPGPMALPVTALLLPLALLLH AARPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGW VRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSI STAYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTL VTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVT ITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGT KVEIKIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV HTRGLDFACDFWLPIGCAAFVVVCILGCILICWLTKKKYS SSVHDPNGEYMFMRAVNTAKKSRLTDVTLRVKFSRSADA PAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK PQRRKNPQEGLYNELQKDRMAEAYSEIGMKGERRRGKG  HDGLYQGLSTATKDTYDALHMQALPPR 228  PD1*CD28-  MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFS  2F5-lCOSz PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND SGTYLCGAISLAPKLQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVIRSKRSR LLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSVKQT LNFDLLKLAGDVESNPGPMALPVTALLLPLALLLHAARPE VQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQM PGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYL QWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVTVSS GGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRA SQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKI KTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGL DFACDFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHD PNGEYMFMRAVNTAKKSRLTDVTLRVKFSRSADAPAYQ QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL  YQGLSTATKDTYDALHMQALPPR  229 PD1*BB-  MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFS  2F5-1COSz PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND SGTYLCGAISLAPKLQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFOTLVIYIWAPLAGTCGVLLLSLVITLYCKKRGR KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELVK QTLNFDLLKLAGDVESNPGPMALPVTALLLPLALLLHAA RPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVR QMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSIST AYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVT VSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTIT CRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTK VEIKIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVH TRGLDFACDFWLPIGCAAFVVVCILGCILICWLTKKKYSSS VHDPNGEYMFMRAVNTAKKSRLTDVTLRVKFSRSADAP AYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP QRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH  DGLYQGLSTATKDTYDALHMQALPPR  230 TIM3-CD28  MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFY  -2F5-ICOSz TPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYW TSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMN DEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGP AETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIR FWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDY MNMTPRRPGPTRKHYQPYAPPRDFAAYRSVKQTLNFDLL KLAGDVESNPGPMALPVTALLLPLALLLHAARPEVQLVQ SGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGL EWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWNSL KASDTAMYYCARQTGFLWSFDLWGRGTLVTVSSGGGGS GGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDISS ALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDF TLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKIKTTTP APRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD FWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEY MFMRAVNTAKKSRLTDVTLRVKFSRSADAPAYQQGQNQ LYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQE GLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLS  TATKDTYDALHMQALPPR  231 PDI*BB-  MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFS  TIM3-CD28 PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK  -2F5-ICOSz LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND SGTYLCGAISLAPKLQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVIYIWAPLAGTCGVLLLSLVITLYCKKRGR KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELVK QTLNFDLLKLAGDVESNPGPMFSHLPFDCVLLLLLLLLTR SSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACP VFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIE NVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPT RQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLA NELRDSRLANDLRDSGATIRFWVLVVVGGVLACYSLLVT VAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAP PRDFAAYRSVKQTLNFDLLKLAGDVESNPGPMALPVTAL LLPLALLLHAARPEVQLVQSGAEVKKPGESLKJSCKGSGY SFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG QVTISADKSISTAYLQWNSLKASDTAMYYCARQTGFLYVS FDLWGRGTLVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSL SASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDA SSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNS YPLTFGGGTKVEIKIKTTTPAPRPPTPAPTIASQPLSLRPEA CRPAAGGAVHTRGLDFACDFWLPIGCAAFVVVCILGCILI CWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR RGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGFIDGLYQGLSTATKDTYDALHMQALPPR  232  PD1-CD28- MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFS  2F5-ICOSz PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK  YMNM LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND SGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVFWVLVVVGGVLACYSLLVTVAFIIFWVR SKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYR SVKQTLNFDLLKLAGDVESNPGPMALPVTALLLPLALLLH AARPEVQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGW VRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSI STAYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTL VTVSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVT ITCRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGT KVEIKIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV HTRGLDFACDFWLPIGCAAFVVVCILGCILICWLTKKKYS SSVHDPNGEYMNMRAVNTAKKSRLTDVTLRVKFSRSAD APAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGG KPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGK  GHDGLYQGLSTATKDTYDALHMQALPPR 233  PDI*CD28-  MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFS  2F5-ICOSZ PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK  YMNM LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND SGTYLCGAISLAPKLQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVIRSKRSR LLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSVKQT LNFDLLKLAGDVESNPGPMALPVTALLLPLALLLHAARPE VQLVQSGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQM PGKGLEWMGTIYPGDSDTRYSPSFQGQVTISADKSISTAYL QWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVTVSS GGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRA SQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKI KTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGL DFACDFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHD PNGEYMNMRAVNTAKKSRLTDVTLRVKFSRSADAPAYQ QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL  YQGLSTATKDTYDALHMQALPPR  234 PD1*BB-  MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFS  2F5-1COSZ PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK  YMNM LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND SGTYLCGAISLAPKLQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVIYIWAPLAGTCGVLLLSLVITLYCKKRGR KKLLYIFKQPFMRPVQTTQEEDGC'SCRFPEEEEGGCELVK QTLNFDLLKLAGDVESNPGPMALPVTALLLPLALLLHAA RPEVQLVQSGAEVKKPGESLKJSCKGSGYSFTSNWIGWVR QMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSIST AYLQWNSLKASDTAMYYCARQTGFLWSFDLWGRGTLVT VSSGGGGSGGGGSGGGGSAIQLTQSPSSLSASVGDRVTIT CRASQDISSALAWYQQKPGKAPKLLIYDASSLESGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTK VEIKIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVH TRGLDFACDFWLPIGCAAFVVVCILGCILICWLTKKKYSSS VHDPNGEYMNMRAVNTAKKSRLTDVTLRVKFSRSADAP AYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP QRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH  DGLYQGLSTATKDTYDALHMQALPPR  235 TIM3-CD28  MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFY  -2F5-ICOSz TPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYW  YMNM TSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMN DEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGP AETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIR FWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDY MNMTPRRPGPTRKHYQPYAPPRDFAAYRSVKQTLNFDLL KLAGDVESNPGPMALPVTALLLPLALLLHAARPEVQLVQ SGAEVKKPGESLKISCKGSGYSFTSNWIGWVRQMPGKGL EWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWNSL KASDTAMYYCARQTGFLWSFDLWGRGTLVTVSSGGGGS GGGGSGGGGSAIQLTQSPSSLSASVGDRVTITCRASQDISS ALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDF TLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKIKTTTP APRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD FWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEY MNMRAVNTAKKSRLTDVTLRVKFSRSADAPAYQQGQNQ LYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQE GLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLS  TATKDTYDALHMQALPPR  236 PD1*BB-  MQIPQAPWPVVWAVLOLGWRPGWFLDSPDRPWNPPTFS  TIM3-CD28 PALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDK  -2F5-ICOSz LAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRND  YMNM SGTYLCGAISLAPKLQIKESLRAELRVTERRAEVPTAHPSP SPRPAGQFQTLVIYIWAPLAGTCGVLLLSLVITLYCKKRGR KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELVK QTLNFDLLKLAGDVESNPGPMFSHLPFDCVLLLLLLLLTR SSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACP VFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIE NVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPT RQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLA NELRDSRLANDLRDSGATIRFWVLVVVGGVLACYSLLVT VAFUFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAP PRDFAAYRSVKQTLNFDLLKLAGDVESNPGPMALPVTAL LLPLALLLHAARPEVQLVQSGAEVKKPGESLKISCKGSGY SFTSNWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG QVTISADKSISTAYLQWNSLKASDTAMYYCARQTGFLVVS FDLWGRGTLVTVSSGGGGSGGGGSGGGGSAIQLTQSPSSL SASVGDRVTITCRASQDISSALAWYQQKPGKAPKLLIYDA SSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNS YPLTFGGGTKVEIKIKTTTPAPRPPTPAPTIASQPLSLRPEA CRPAAGGAVHTRGLDFACDFWLPIGCAAFVVVCILGCILI CWLTKKKYSSSVHDPNGEYMNMRAVNTAKKSRLTDVTL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR RGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR

Accordingly, the present invention provides a modified immune cell orprecursor cell thereof, e.g., a modified T cell, comprising a chimericantigen receptor (CAR) having affinity for a prostate-specific membraneantigen (PSMA) on a target cell (e.g., a prostate cancer cell). In someembodiments, the CAR comprises a PSMA binding domain. In someembodiments, the CAR comprises a murine PSMA binding domain. In oneembodiment, the CAR comprises a J591 murine PSMA binding domain. In oneembodiment, the CAR comprises a humanized J591 PSMA binding domain. Insome embodiments, the CAR comprises a human PSMA binding domain. In someembodiments, the CAR comprises a human PSMA binding domain selected fromthe group consisting of a 1C3, a 2A10, a 2F5, and a 2C6 human PSMAbinding domain.

Accordingly, a subject CAR of the present invention comprises a PSMAbinding domain and a transmembrane domain. In one embodiment, the CARcomprises a PSMA binding domain and a transmembrane domain, wherein thetransmembrane domain comprises a CD8 hinge region. In one embodiment,the CAR comprises a PSMA binding domain and a transmembrane domain,wherein the transmembrane domain comprises a CD8 transmembrane domain.In one embodiment, the CAR comprises a PSMA binding domain and atransmembrane domain, wherein the transmembrane domain comprises a CD8hinge region and a CD8 transmembrane domain.

Accordingly, a subject CAR of the present invention comprises a PSMAbinding domain, a transmembrane domain, and an intracellular domain. Inone embodiment, the CAR comprises a PSMA binding domain, a transmembranedomain, and an intracellular domain, wherein the intracellular domaincomprises a 4-1BB domain. In one embodiment, the CAR comprises a PSMAbinding domain, a transmembrane domain, and an intracellular domain,wherein the intracellular domain comprises a CD3 zeta domain. In oneembodiment, the CAR comprises a PSMA binding domain, a transmembranedomain, and an intracellular domain, wherein the intracellular domaincomprises a 4-1BB domain and a CD3 zeta domain.

C. Dominant Negative Receptors and Switch Receptors

The present invention provides compositions and methods for modifiedimmune cells or precursors thereof, e.g., modified T cells, comprising adominant negative receptor and/or a switch receptor. Thus, in someembodiments, the immune cell has been genetically modified to expressthe dominant negative receptor and/or switch receptor. As used herein,the term “dominant negative receptor” refers to a molecule designed toreduce the effect of a negative signal transduction molecule, e.g., theeffect of a negative signal transduction molecule on a modified immunecell of the present invention. A dominant negative receptor of thepresent invention may bind a negative signal transduction molecule,e.g., TGF-β or PD-1, by virtue of an extracellular domain associatedwith the negative signal, and reduce the effect of the negative signaltransduction molecule. Such dominant negative receptors are describedherein. For example, a modified immune cell comprising a dominantnegative receptor may bind a negative signal transduction molecule inthe microenvironment of the modified immune cell, and reduce the effectthe negative signal transduction molecule may have on the modifiedimmune cell.

A switch receptor of the present invention may be designed to, inaddition to reducing the effects of a negative signal transductionmolecule, to convert the negative signal into a positive signal, byvirtue of comprising an intracellular domain associated with thepositive signal. Switch receptors designed to convert a negative signalinto a positive signal are described herein. Accordingly, switchreceptors comprise an extracellular domain associated with a negativesignal and/or an intracellular domain associated with a positive signal.

Tumor cells generate an immunosuppressive microenvironment that servesto protect them from immune recognition and elimination. Thisimmunosuppressive microenvironment can limit the effectiveness ofimmunosuppressive therapies such as CAR-T cell therapy. The secretedcytokine Transforming Growth Factor β (TGFβ) directly inhibits thefunction of cytotoxic T cells and additionally induces regulatory T cellformation to further suppress immune responses. T cell immunosuppressiondue to TGFβ in the context of prostate cancers has been previouslydemonstrated (Donkor et al., 2011; Shalapour et al., 2015). To reducethe immunosuppressive effects of TGFβ, immune cells can be modified toexpress a dominant negative receptor that is a dominant negativereceptor for TGF-β.

In some embodiments, the dominant negative receptor is a truncatedvariant of a wild-type protein associated with a negative signal. Insome embodiments, the dominant negative receptor is a dominant negativereceptor for TGF-β. Accordingly, in some embodiments, the dominantnegative receptor for TGF-β is a truncated variant of a wild-type TGF-βreceptor. In some embodiments, the dominant negative receptor is atruncated dominant negative variant of the TGF-β receptor type II(TGFβRII-DN). In one embodiment, the TGFβRII-DN comprises the amino acidsequence set forth below:

(SEQ ID NO: 115) MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSC SSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVII  IFYCYRVNRQQKLSSSG,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 116) ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCA GTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTC CACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCA CCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGA CCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTT CTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACT TTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACAT CATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCTACCGCGT TAACCGGCAGCAGAAGCTGAGTTCATCCGGA.

Tolerable variations of the sequence of TGFβRII-DN will be known tothose of skill in the art, while maintaining its intended function. Forexample, in some embodiments, a dominant negative receptor of thepresent invention is TGFβRII-DN comprising an amino acid sequence thathas at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 81%, at least 82%, at least 83%, at least 84%, at least85%, at least 86%, at least 87%, at least 88%, at least 89%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% sequenceidentity to the amino acid sequence set forth in SEQ ID NO:115 In oneembodiment, the dominant negative receptor is TGFβRII-DN comprising theamino acid sequence set forth in SEQ ID NO:115.

In some embodiments, a dominant negative receptor of the presentinvention is TGFβRII-DN encoded by a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:116. In one embodiment,the dominant negative receptor is TGFβRII-DN encoded by the nucleic acidsequence set forth in SEQ ID NO:116.

In one embodiment, a switch receptor suitable for use in the presentinvention is a PD1-CTM-CD28 receptor. The PD1-CTM-CD28 receptor convertsa negative PD1 signal into a positive CD28 signal when expressed in acell. The PD1-CTM-CD28 receptor comprises a variant of the PD1extracellular domain, a CD28 transmembrane domain, and a CD28cytoplasmic domain. In one embodiment, the PD1-CTM-CD28 receptorcomprises an amino acid sequence set forth below:

(SEQ ID NO: 117) MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLA AFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGT YLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSP RPAGQFQTLVFWVLVVVGGVLACYSLLVTVAFIIFWVRSK RSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 118) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAG ACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCC CCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCAC CTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCG TGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACG GACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCA ACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGG CGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTC CCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGG CAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCC ACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCA GTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTG GTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAG GCTCCTGCACAGTGACTACATGAACATGACTCCCCGCC GCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCC  CCACCACGCGACTTCGCAGCCTATCGCTCC.

Tolerable variations of the PD1-CTM-CD28 receptor will be known to thoseof skill in the art, while maintaining its intended biological activity(e.g., converting a negative PD1 signal into a positive CD28 signal whenexpressed in a cell). Accordingly, a PD1-CTM-CD28 receptor of thepresent invention may comprise an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thePD1-CTM-CD28 receptor amino acid sequence set forth in SEQ ID NO:117.Accordingly, a PD1-CTM-CD28 receptor of the present invention may beencoded by a nucleic acid comprising a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe PD1-CTM-CD28 receptor nucleic acid sequence set forth in SEQ IDNO:118.

In one embodiment, a switch receptor suitable for use in the presentinvention is a PD1-PTM-CD28 receptor. The PD1-PTM-CD28 receptor convertsa negative PD1 signal into a positive CD28 signal when expressed in acell. The PD1-PTM-CD28 receptor comprises a variant of the PD1extracellular domain, a PD1 transmembrane domain, and a CD28 cytoplasmicdomain. In one embodiment, the PD1-PTM-CD28 receptor comprises an aminoacid sequence set forth below:

(SEQ ID NO: 119) MQIPQAPWPVVWAVLQLGWRPWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQ TDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVR ARRNDSGTYLCGAISLAPKLQIKESLRAELRVTERRA EVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVW VLAVIRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAP  PRDFAAYRS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 120) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTT AGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTC TCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACG CCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAG CTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAAC CAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCA GCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACA ACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTC AGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTG GGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGA GAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGG GCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCA GGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGT CGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTC TGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGC TCCTGCACAGTGACTACATGAACATGACTCCCCGCCG CCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCC  CCACCACGCGACTTCGCAGCCTATCGCTCC.

Tolerable variations of the PD1-PTM-CD28 receptor will be known to thoseof skill in the art, while maintaining its intended biological activity(e.g., converting a negative PD1 signal into a positive CD28 signal whenexpressed in a cell). Accordingly, a PD1-PTM-CD28 receptor of thepresent invention may comprise an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thePD1-PTM-CD28 receptor amino acid sequence set forth in SEQ ID NO:119.Accordingly, a PD1-PTM-CD28 receptor of the present invention may beencoded by a nucleic acid comprising a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe PD1-PTM-CD28 receptor nucleic acid sequence set forth in SEQ IDNO:120.

In one embodiment, a switch receptor suitable for use in the presentinvention is a PD1^(A132L)-PTM-CD28 receptor. The PD1^(A132L)-PTM-CD28receptor converts a negative PD1 signal into a positive CD28 signal whenexpressed in a cell. A point mutation at amino acid position 132,substituting alanine with leucine (A132L), of PD1 was found to increaseits affinity with PD-L1 by two fold (see, e.g., Zhang et al., Immunity(2004) 20(3), 337-347). The PD1^(A132L)-PTM-CD28 receptor comprises avariant of the PD1 extracellular domain that has an amino acidsubstitution at position 132 (A132L), a PD1 transmembrane domain, and aCD28 cytoplasmic domain. In one embodiment, the PD1^(A132L)-PTM-CD28receptor comprises an amino acid sequence set forth below:

(SEQ ID NO: 121) MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPG QDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKLQIK ESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGS LVLLVWVLAVIRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPP RDFAAYRS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 122) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCC CAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTG CTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAG CTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACC GCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTC CCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCG TGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAG CCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAG TGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGC CAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCT GGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAAC ATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCA GCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGC.

Tolerable variations of the PD1^(A132L)-PTM-CD28 receptor will be knownto those of skill in the art, while maintaining its intended biologicalactivity (e.g., converting a negative PD1 signal into a positive CD28signal when expressed in a cell). Accordingly, a PD1^(A132L)-PTM-CD28receptor of the present invention may comprise an amino acid sequencethat has at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 81%, at least 82%, at least 83%, at least 84%, atleast 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the PD1^(A132L)-PTM-CD28 receptor amino acidsequence set forth in SEQ ID NO:121. Accordingly, a PD1^(A132L)-PTM-CD28receptor of the present invention may be encoded by a nucleic acidcomprising a nucleic acid sequence that has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the PD1^(A132L)-PTM-CD28receptor nucleic acid sequence set forth in SEQ ID NO:122.

In one embodiment, a switch receptor suitable for use in the presentinvention is a PD1-4-1BB receptor. The PD1-4-1BB receptor (also referredto herein as PD1-BB) converts a negative PD1 signal into a positive4-1BB signal when expressed in a cell. In one embodiment, the PD1-4-1BBreceptor comprises an amino acid sequence set forth below:

(SEQ ID NO: 213) MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPE DRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAI SLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQT LVIYIWAPLAGTCGVLLLSLVITLYCKKRGRKKLLYIFKQPF MRPVQTTQEEDGCSCRFPEEEEGGCEL,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 214) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCC CAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTG CTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAG CTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACC GCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTC CCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCG TGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCG TGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGT GGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAG CCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAG TGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGC CAGTTCCAAACCCTGGTTATCTACATCTGGGCGCCCTTGGC CGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCC TTTACTGCAAAAAACGGGGCAGAAAGAAACTCCTGTATATA TTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGA GGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAG  GAGGATGTGAACTG.

Tolerable variations of the PD1-4-1BB receptor will be known to those ofskill in the art, while maintaining its intended biological activity(e.g., converting a negative PD1 signal into a positive 4-1BB signalwhen expressed in a cell). Accordingly, a PD1-4-1BB receptor of thepresent invention may comprise an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thePD1-4-1BB receptor amino acid sequence set forth in SEQ ID NO:213.Accordingly, a PD1-4-1BB receptor of the present invention may beencoded by a nucleic acid comprising a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe PD1-4-1BB receptor nucleic acid sequence set forth in SEQ ID NO:214.

In one embodiment, a switch receptor suitable for use in the presentinvention is a PD1^(A132L)-4-1BB receptor. The PD1^(A132L)-4-1BBreceptor (also referred to herein as PD1*BB) converts a negative PD1signal into a positive 4-1BB signal when expressed in a cell. In oneembodiment, the PD1^(A132L)-4-1BB receptor comprises an amino acidsequence set forth below:

(SEQ ID NO: 215) MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKLQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVIYIWAPLAGTCGVLLLSLVITLYCKKRGRKKLLYIFKQPFMRPVQ TTQEEDGCSCRFPEEEEGGCEL,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 216) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTTATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAAAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAG AAGAAGAAGGAGGATGTGAACTG.

Tolerable variations of the PD1^(A132L)-4-1BB receptor will be known tothose of skill in the art, while maintaining its intended biologicalactivity (e.g., converting a negative PD1 signal into a positive 4-1BBsignal when expressed in a cell). Accordingly, a PD1^(A132L)-4-1BBreceptor of the present invention may comprise an amino acid sequencethat has at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 81%, at least 82%, at least 83%, at least 84%, atleast 85%, at least 86%, at least 87%, at least 88%, at least 89%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%sequence identity to the PD1^(A132L)-4-1BB receptor amino acid sequenceset forth in SEQ ID NO:215. Accordingly, a PD1^(A132L)-4-1BB receptor ofthe present invention may be encoded by a nucleic acid comprising anucleic acid sequence that has at least 60%, at least 65%, at least 70%,at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the PD1^(A132L)-4-1BB receptor nucleicacid sequence set forth in SEQ ID NO:216.

In one embodiment, a switch receptor suitable for use in the presentinvention is a TGFβR-IL12Rβ1 receptor. The TGFβR-IL12Rβ1 receptorconverts a negative TGF-β signal into a positive IL-12 signal whenexpressed in a cell. In one embodiment, the TGFβR-IL12Rβ1 receptorcomprises an amino acid sequence set forth below:

(SEQ ID NO: 123) MEAAVAAPRPRLLLLVLAAAAAAAAALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVELAAVIAGPVCFVCISLMLMVYIRAARHLCPPLPTPCASSAIEFPGGKETWQWINPVDFQEEASLQEALVVEMSWDKGERTEPLEKTELPE GAPELALDTELSLEDGDRCKAKM,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 124) ATGGAGGCGGCGGTCGCTGCTCCGCGTCCCCGGCTGCTCCTCCTCGTGCTGGCGGCGGCGGCGGCGGCGGCGGCGGCGCTGCTCCCGGGGGCGACGGCGTTACAGTGTTTCTGCCACCTCTGTACAAAAGACAATTTTACTTGTGTGACAGATGGGCTCTGCTTTGTCTCTGTCACAGAGACCACAGACAAAGTTATACACAACAGCATGTGTATAGCTGAAATTGACTTAATTCCTCGAGATAGGCCGTTTGTATGTGCACCCTCTTCAAAAACTGGGTCTGTGACTACAACATATTGCTGCAATCAGGACCATTGCAATAAAATAGAACTTCCAACTACTGTAAAGTCATCACCTGGCCTTGGTCCTGTGGAACTGGCAGCTGTCATTGCTGGACCAGTGTGCTTCGTCTGCATCTCACTCATGTTGATGGTCTATATCAGGGCCGCACGGCACCTGTGCCCGCCGCTGCCCACACCCTGTGCCAGCTCCGCCATTGAGTTCCCTGGAGGGAAGGAGACTTGGCAGTGGATCAACCCAGTGGACTTCCAGGAAGAGGCATCCCTGCAGGAGGCCCTGGTGGTAGAGATGTCCTGGGACAAAGGCGAGAGGACTGAGCCTCTCGAGAAGACAGAGCTACCTGAGGGTGCCCCTGAGCTGGCCCTGGATACAGAGTTGTCCTTGGAGG ATGGAGACAGGTGCAAGGCCAAGATG.

Tolerable variations of the TGFβR-IL12Rβ1 receptor will be known tothose of skill in the art, while maintaining its intended biologicalactivity (e.g., converting a negative TGF-β signal into a positive IL-12signal when expressed in a cell). Accordingly, a TGFβR-IL12Rβ1 receptorof the present invention may comprise an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe TGFβR-IL12Rβ1 receptor amino acid sequence set forth in SEQ IDNO:123. Accordingly, a TGFβR-IL12Rβ1 receptor of the present inventionmay be encoded by a nucleic acid comprising a nucleic acid sequence thathas at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 81%, at least 82%, at least 83%, at least 84%, at least85%, at least 86%, at least 87%, at least 88%, at least 89%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% sequenceidentity to the TGFβR-IL12Rβ1 receptor nucleic acid sequence set forthin SEQ ID NO:124.

In one embodiment, a switch receptor suitable for use in the presentinvention is a TGFβR-IL12Rβ2 receptor. The TGFβR-IL12Rβ2 receptorconverts a negative TGF-β signal into a positive IL-12 signal whenexpressed in a cell. In one embodiment, the TGFβR-IL12Rβ2 receptorcomprises an amino acid sequence set forth below:

(SEQ ID NO: 125) MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYQQKVFVLLAALRPQWCSREIPDPANSTCAKKYPIAEEKTQLPLDRLLIDWPTPEDPEPLVISEVLHQVTPVFRHPPCSNWPQREKGIQGHQASEKDMMHSASSPPPPRALQAESRQLVDLYKVLESRGSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQHISLSVFPSSSLHPLTFSCG DKLTLDQLKMRCDSLML,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 126) ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACCAGCAAAAGGTGTTTGTTCTCCTAGCAGCCCTCAGACCTCAGTGGTGTAGCAGAGAAATTCCAGATCCAGCAAATAGCACTTGCGCTAAGAAATATCCCATTGCAGAGGAGAAGACACAGCTGCCCTTGGACAGGCTCCTGATAGACTGGCCCACGCCTGAAGATCCTGAACCGCTGGTCATCAGTGAAGTCCTTCATCAAGTGACCCCAGTTTTCAGACATCCCCCCTGCTCCAACTGGCCACAAAGGGAAAAAGGAATCCAAGGTCATCAGGCCTCTGAGAAAGACATGATGCACAGTGCCTCAAGCCCACCACCTCCAAGAGCTCTCCAAGCTGAGAGCAGACAACTGGTGGATCTGTACAAGGTGCTGGAGAGCAGGGGCTCCGACCCAAAGCCAGAAAACCCAGCCTGTCCCTGGACGGTGCTCCCAGCAGGTGACCTTCCCACCCATGATGGCTACTTACCCTCCAACATAGATGACCTCCCCTCACATGAGGCACCTCTCGCTGACTCTCTGGAAGAACTGGAGCCTCAGCACATCTCCCTTTCTGTTTTCCCCTCAAGTTCTCTTCACCCACTCACCTTCTCCTGTGGTGATAAGCTGACTCTGGATCAGTTAAAGATGAGGTGTGACTCCCTCA TGCTC.

Tolerable variations of the TGFβR-IL12Rβ2 receptor will be known tothose of skill in the art, while maintaining its intended biologicalactivity (e.g., converting a negative TGF-β signal into a positive IL-12signal when expressed in a cell). Accordingly, a TGFβR-IL12Rβ2 receptorof the present invention may comprise an amino acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe TGFβR-IL12Rβ2 receptor amino acid sequence set forth in SEQ IDNO:125. Accordingly, a TGFβR-IL12Rβ2 receptor of the present inventionmay be encoded by a nucleic acid comprising a nucleic acid sequence thathas at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 81%, at least 82%, at least 83%, at least 84%, at least85%, at least 86%, at least 87%, at least 88%, at least 89%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% sequenceidentity to the TGFβR-IL12Rβ2 receptor nucleic acid sequence set forthin SEQ ID NO:126.

In one embodiment, a switch receptor suitable for use in the presentinvention is a TIM3-CD28 receptor. The TIM3-CD28 receptor converts anegative TIM-3 signal into a positive CD28 signal when expressed in acell. In one embodiment, the TIM3-CD28 receptor comprises an amino acidsequence set forth below:

(SEQ ID NO: 127) MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIRFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYA PPRDFAAYRS,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 128) ATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCC. 

Tolerable variations of the TIM3-CD28 receptor will be known to those ofskill in the art, while maintaining its intended biological activity(e.g., converting a negative TIM-3 signal into a positive CD28 signalwhen expressed in a cell). Accordingly, a TIM3-CD28 receptor of thepresent invention may comprise an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theTIM3-CD28 receptor amino acid sequence set forth in SEQ ID NO:127.Accordingly, a TIM3-CD28 receptor of the present invention may beencoded by a nucleic acid comprising a nucleic acid sequence that has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe TIM3-CD28 receptor nucleic acid sequence set forth in SEQ ID NO:128.

Other suitable dominant negative receptors and switch receptors for usein the present invention are described in PCT Publication No.WO2013019615A2, the disclosure of which is incorporated herein byreference.

D. Bispecific Antibodies

The present invention provides compositions and methods for modifiedimmune cells or precursors thereof, e.g., modified T cells, comprising anucleic acid encoding a bispecific antibody. Thus, in some embodiments,the immune cell has been genetically modified to express the bispecificantibody. A “bispecific antibody,” as used herein, refers to an antibodyhaving binding specificities for at least two different antigenicepitopes. In one embodiment, the epitopes are from the same antigen. Inanother embodiment, the epitopes are from two different antigens.Methods for making bispecific antibodies are known in the art. Forexample, bispecific antibodies can be produced recombinantly using theco-expression of two immunoglobulin heavy chain/light chain pairs. See,e.g., Milstein et al. (1983) Nature 305: 537-39. Alternatively,bispecific antibodies can be prepared using chemical linkage. See, e.g.,Brennan et al. (1985) Science 229:81. Bispecific antibodies includebispecific antibody fragments. See, e.g., Holliger et al. (1993) Proc.Natl. Acad. Sci. U.S.A. 90:6444-48, Gruber et al. (1994) J. Immunol.152:5368.

In certain embodiments, the modified cell of the present inventioncomprises a CAR having affinity for a prostate specific membrane antigen(PSMA) on a target cell and a bispecific antibody. In certainembodiments, the modified cell of the present invention secretes abispecific antibody.

In one embodiment, the bispecific antibody comprises a first antigenbinding domain that binds to a first antigen and a second antigenbinding domain that binds to a second antigen. In some embodiments, thebispecific antibody comprises an antigen binding domain comprising afirst and a second single chain variable fragment (scFv) molecules. Inone embodiment, the first and a second antigen binding domains bind anantigen on a target cell and an antigen on an activating T cell.

In one embodiment, the bispecific antibody comprises specificity to atleast one antigen on an activating T cell. The activating T cell antigenincludes antigens found on the surface of a T cell that can activateanother cell. The activating T cell antigen may bind a co-stimulatorymolecule. A costimulatory molecule is a cell surface molecule, otherthan an antigen receptor or their ligands, that is required for anefficient response of lymphocytes to an antigen. Examples of theactivating T cell antigen can include but are not limited to CD3, CD4,CD8, T cell receptor (TCR), CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40,PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7,LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, or anyfragment thereof. In some embodiments, the bispecific antibody comprisesspecificity to the T cell antigen CD28.

Other costimulatory elements are also within the scope of the invention.In these examples, the bispecific antibody recognizes a T cell antigenand may be referred to as a Bispecific T Cell Engager (BiTE). However,the present invention is not limited by the use of any particularbispecific antibody. Rather, any bispecific antibody or BiTE can beused. The bispecific antibody or BiTE molecule may also be expressed asa soluble protein with specificity for at least one target cellassociated antigen.

In one embodiment, the bispecific antibody comprises more than oneantigen binding domain. In this embodiment, at least one antigen bindingdomain includes a synthetic antibody, human antibody, a humanizedantibody, single chain variable fragment, single domain antibody, anantigen binding fragment thereof, and any combination thereof.Techniques for making human and humanized antibodies are describedelsewhere herein.

In some embodiments, the bispecific antibody comprises more than oneantigen binding domain, wherein at least one antigen binding domainbinds to a negative signal transduction molecule (e.g., a negativesignal transduction molecule that may be found in the microenvironmentof the cell secreting the bispecific antibody) or an interacting partnerthereof (e.g., receptor). In some embodiments, at least one antigenbinding domain of the bispecific antibody binds to TGF-β or aninteracting partner thereof (e.g., receptor). In some embodiments, atleast one antigen binding domain of the bispecific antibody binds toPD-1 or an interacting partner thereof. In one embodiment, at least oneantigen binding domain of the bispecific antibody binds to TGF-βR. Inanother embodiment, at least one antigen binding domain of thebispecific antibody binds to PD-L1.

In some embodiments, the bispecific antibody comprises at least oneantigen binding domain that binds to a molecule on a T cell andactivates the T cell. For example, a bispecific antibody of the presentdisclosure may comprise a superagonistic anti-CD28 binding domain asdescribed in U.S. Pat. No. 7,585,960, contents of which are incorporatedherein in its entirety.

In some embodiments, the bispecific antibody comprises at least oneantigen binding domain that binds PD-L1. For example, a bispecificantibody of the present disclosure may comprise, without limitation, aPD-L1 binding domain derived from 10A5, 13G4, or 1B12 as described inPCT Publication No. WO2007005874A2, contents of which are incorporatedherein in its entirety. In some embodiments, the bispecific antibodycomprises at least one antigen binding domain that binds a TGF-βreceptor, e.g., TGFβRII. For example, a bispecific antibody of thepresent disclosure may comprise, without limitation, a TGFβRII bindingdomain derived from TGF1 or TGF3 as described in U.S. Pat. No.8,147,834, contents of which are incorporated herein in its entirety.

Accordingly, in one embodiment, a bispecific antibody of the presentdisclosure comprises at least one antigen binding domain that bindsPD-L1 or TGFβRII, and an antigen binding domain that binds CD28.

In some embodiments, the target cell antigen may be the same antigenthat a T cell receptor binds to or may be a different antigen. Thetarget cell antigen includes any tumor associated antigen (TAA) orviral, bacterial and parasitic antigen, or any fragment thereof. Thetarget cell antigen may include any type of ligand that defines thetarget cell. For example, the target cell antigen may be chosen torecognize a ligand that acts as a cell marker on target cells associatedwith a particular disease state. Thus, cell markers may act as ligandsfor the antigen binding domain in the bispecific antibody, includingthose associated with viral, bacterial and parasitic infections,autoimmune disease and cancer cells.

In some embodiments, the target cell antigen is the same antigen as theactivating T cell antigen including, but not limited to, CD3, CD4, CD8,T cell receptor (TCR), CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40,PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7,LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, andfragments thereof. In one aspect, the invention includes a nucleic acidencoding a bispecific antibody comprising bispecificity for an antigenon a target cell and an antigen on an activating T cell, wherein the Tcell transiently secretes the bispecific antibody. Techniques forengineering and expressing bispecific antibodies include, but are notlimited to, recombinant co-expression of two immunoglobulin heavychain-light chain pairs having different specificities (see, e.g.,Milstein and Cuello, Nature 305: 537 (1983), WO 93/08829, and Trauneckeret al, EMBO J. 10: 3655 (1991)), and “knob-in-hole” engineering (see,e.g., U.S. Pat. No. 5,731,168). Multi-specific antibodies may also bemade by engineering electrostatic steering effects for making antibodyFc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or moreantibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennanet al, Science 229:81 (1985)); using leucine zippers to producebispecific antibodies (see, e.g., Kostelny et al, J. Immunol. 148(5):1547-1553 (1992)); using “diabody” technology for making bispecificantibody fragments (see, e.g., Hollinger et al, Proc. Natl. Acad. Sci.USA, 90:6444-6448 (1993)); and using single-chain FAT (scFv) dimers(see, e.g. Gruber et al, J. Immunol, 152:5368 (1994)); and preparingtrispecific antibodies as described, e.g., in Tutt et al. J. Immunol.147: 60 (1991). Engineered antibodies with three or more functionalantigen binding sites, including “Octopus antibodies,” are also includedherein (see, e.g. US 2006/0025576A1). Bispecific antibodies can beconstructed by linking two different antibodies, or portions thereof.For example, a bispecific antibody can comprise Fab, F(ab′)2, Fab′,scFv, and sdAb from two different antibodies.

A bispecific antibody of the present invention includes a bispecificantibody having affinity for PD-L1 and CD28. In one embodiment, a13G4-1211 PD-L1/CD28 bispecific antibody of the present inventioncomprises an amino acid sequence set forth below:

(SEQ ID NO: 129) MGWSCIILFLVATATGVHSAIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGRSLRLSCAASGITFDDYGMHWVRQAPGKGLEWVSGISWNRGRIEYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGRFRYFDWFLDYWGQGTLVTVSSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSVEGGSGGSGGSGGSGGVMDDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFGGGTKVEI,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 130) ATGGGGTGGTCGTGTATCATCCTGTTCCTGGTCGCGACAGCAACCGGCGTGCATTCGGCCATACAGCTGACCCAGAGCCCCTCCTCCCTCTCCGCTTCCGTGGGGGACCGCGTGACAATCACGTGCCGCGCCAGCCAGGGAATCTCCTCGGCCCTCGCCTGGTACCAGCAGAAACCCGGGAAGGCTCCCAAGCTGCTCATCTACGATGCCTCCTCGCTTGAGTCGGGCGTGCCATCCAGGTTCTCCGGATCCGGGTCCGGAACCGACTTTACACTCACGATTTCCTCTCTGCAGCCCGAGGACTTCGCCACATACTACTGTCAGCAGTTCAACTCCTACCCATTCACCTTCGGCCCGGGCACCAAGGTGGACATCAAGTCTGGCGGGGGAGGCTCCGAAGTCCAGCTCGTGGAATCCGGGGGCGGTCTCGTGCAGCCAGGCCGGAGTCTGCGCCTGTCTTGCGCTGCCTCGGGGATCACTTTCGACGACTACGGCATGCATTGGGTTCGCCAGGCCCCAGGGAAGGGGTTGGAGTGGGTCAGTGGCATTTCATGGAACAGGGGGCGCATCGAATACGCCGACTCCGTTAAGGGCAGATTCACCATCTCGCGCGATAACGCCAAAAACAGTCTCTACCTCCAGATGAACTCGCTTCGAGCAGAGGATACTGCCCTGTACTATTGCGCGAAGGGACGCTTCCGCTACTTTGACTGGTTTCTGGACTACTGGGGCCAGGGGACACTGGTGACGGTGTCGTCGGGGGGCGGGGGGAGTCAGGTGCAGCTGGTGCAGTCCGGAGCCGAGGTAAAGAAGCCAGGCGCTTCCGTCAAGGTGTCATGCAAGGCCTCAGGCTACACCTTCACAAGCTATTACATCCACTGGGTGCGCCAAGCTCCCGGTCAGGGCTTGGAGTGGATCGGGTGCATTTACCCAGGGAACGTCAACACAAACTACAACGAGAAGTTCAAGGATCGGGCAACCCTGACCGTGGACACATCCATCTCTACCGCCTACATGGAGCTGTCACGCCTGCGCTCTGATGACACCGCAGTGTACTTCTGTACCAGGAGTCACTACGGCCTGGACTGGAACTTTGATGTCTGGGGCCAGGGAACCACCGTGACGGTGTCCAGTGTGGAGGGCGGTAGTGGCGGCTCTGGTGGGTCCGGAGGCTCAGGCGGCGTGATGGATGACATTCAGATGACCCAGAGTCCCTCCTCCCTCTCCGCTTCCGTCGGAGACCGCGTGACCATCACTTGTCACGCCTCACAGAATATCTACGTGTGGCTGAACTGGTACCAACAGAAGCCCGGCAAGGCCCCCAAGCTGCTTATCTATAAAGCGTCCAACCTCCACACGGGAGTCCCTTCCCGCTTCTCCGGATCCGGCAGTGGGACGGACTTCACACTCACAATCTCGTCGCTGCAGCCAGAGGACTTTGCGACGTACTACTGCCAGCAGGGCCAGACCTACCCATATACTTTCGGCGGCGGGACCAAGGTGGA GAT.

Tolerable variations of the 13G4-1211 PD-L1/CD28 bispecific antibodywill be known to those of skill in the art, while maintaining itsintended biological activity (e.g., binding to PD-L1 and CD28).Accordingly, a 13G4-1211 PD-L1/CD28 bispecific antibody of the presentinvention may comprise an amino acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the 13G4-1211PD-L1/CD28 bispecific antibody amino acid sequence set forth in SEQ IDNO:129. Accordingly, a 13G4-1211 PD-L1/CD28 bispecific antibody of thepresent invention may be encoded by a nucleic acid comprising a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the 13G4-1211 PD-L1/CD28 bispecificantibody nucleic acid sequence set forth in SEQ ID NO:130.

A bispecific antibody of the present invention includes a bispecificantibody having affinity for PD-L1 and CD28. In one embodiment, a10A5-1412 PD-L1/CD28 bispecific antibody of the present inventioncomprises an amino acid sequence set forth below:

(SEQ ID NO: 131) MGWSCIILFLVATATGVHSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIKSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDVHWVRQAPGQRLEWMGWLHADTGITKFSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARERIQLWFDYWGQGTLVTVSSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSVEGGSGGSGGSGGSGGVMDDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQ PEDFATYYCQQGQTYPYTFGGGTKVEI,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 132) ATGGGCTGGAGTTGCATCATTCTCTTCCTCGTGGCGACCGCAACAGGGGTGCACTCCGACATCCAGATGACCCAGTCCCCGAGTTCCCTGTCTGCTTCCGTGGGAGATCGCGTGACTATCACCTGCCGGGCTTCCCAGGGCATCTCTTCCTGGCTGGCGTGGTACCAGCAGAAACCAGAAAAGGCTCCTAAGTCCCTGATCTACGCAGCTTCGTCCCTCCAATCCGGCGTCCCCTCTCGCTTCTCCGGCTCCGGATCCGGCACCGACTTCACGCTGACAATCTCGAGTTTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACCCTTACACCTTCGGCCAGGGCACAAAGCTCGAAATCAAGTCGGGGGGGGGCGGGTCGCAGGTCCAGCTGGTGCAGTCCGGCGCCGAAGTCAAGAAGCCCGGAGCAAGTGTGAAAGTGTCGTGCAAGGCAAGTGGGTATACCTTCACCTCATACGACGTACACTGGGTGCGCCAGGCGCCCGGTCAGCGCCTTGAGTGGATGGGCTGGCTCCACGCCGACACCGGCATTACCAAGTTCTCTCAGAAGTTCCAGGGAAGAGTGACCATAACACGCGACACCAGTGCTTCCACAGCTTACATGGAACTTTCGAGTCTGAGATCCGAGGACACAGCCGTGTATTACTGTGCCCGTGAGCGCATCCAGCTGTGGTTCGACTACTGGGGGCAGGGCACCCTCGTGACGGTGTCGTCGGGGGGCGGGGGGAGTCAGGTGCAGCTGGTGCAGTCCGGAGCCGAGGTAAAGAAGCCAGGCGCTTCCGTCAAGGTGTCATGCAAGGCCTCAGGCTACACCTTCACAAGCTATTACATCCACTGGGTGCGCCAAGCTCCCGGTCAGGGCTTGGAGTGGATCGGGTGCATTTACCCAGGGAACGTCAACACAAACTACAACGAGAAGTTCAAGGATCGGGCAACCCTGACCGTGGACACATCCATCTCTACCGCCTACATGGAGCTGTCACGCCTGCGCTCTGATGACACCGCAGTGTACTTCTGTACCAGGAGTCACTACGGCCTGGACTGGAACTTTGATGTCTGGGGCCAGGGAACCACCGTGACGGTGTCCAGTGTGGAGGGCGGTAGTGGCGGCTCTGGTGGGTCCGGAGGCTCAGGCGGCGTGATGGATGACATTCAGATGACCCAGAGTCCCTCCTCCCTCTCCGCTTCCGTCGGAGACCGCGTGACCATCACTTGTCACGCCTCACAGAATATCTACGTGTGGCTGAACTGGTACCAACAGAAGCCCGGCAAGGCCCCCAAGCTGCTTATCTATAAAGCGTCCAACCTCCACACGGGAGTCCCTTCCCGCTTCTCCGGATCCGGCAGTGGGACGGACTTCACACTCACAATCTCGTCGCTGCAGCCAGAGGACTTTGCGACGTACTACTGCCAGCAGGGCCAGACCTACCCATATACTTTCGGCGGCGGGACCAAGGTGGAGAT.

Tolerable variations of the 10A5-1412 PD-L1/CD28 bispecific antibodywill be known to those of skill in the art, while maintaining itsintended biological activity (e.g., binding to PD-L1 and CD28).Accordingly, a 10A5-1412 PD-L1/CD28 bispecific antibody of the presentinvention may comprise an amino acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the 10A5-1412PD-L1/CD28 bispecific antibody amino acid sequence set forth in SEQ IDNO:131. Accordingly, a 10A5-1412 PD-L1/CD28 bispecific antibody of thepresent invention may be encoded by a nucleic acid comprising a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the 10A5-1412 PD-L1/CD28 bispecificantibody nucleic acid sequence set forth in SEQ ID NO:132.

A bispecific antibody of the present invention includes a bispecificantibody having affinity for PD-L1 and CD28. In one embodiment, a1B12-1412 PD-L1/CD28 bispecific antibody of the present inventioncomprises an amino acid sequence set forth below:

(SEQ ID NO: 133) MGWSCIILFLVATATGVHSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIKSGGGGSQVQLVQSGAEVKKPGSSVKVSCKTSGDTFSSYAISWVRQAPGQGLEWMGGIIPIFGRAHYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTVTVSSGGSSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSVEGGSGGSGGSGGSGGVMDDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFG GGTKVEI,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 134) ATGGGCTGGAGTTGCATCATCCTCTTTCTAGTCGCCACGGCCACCGGCGTACACTCAGAGATCGTGCTGACACAGTCGCCTGCGACGCTGTCGCTCAGTCCAGGGGAGCGCGCTACTCTCTCCTGCCGCGCGTCGCAGAGCGTGTCGTCCTACTTGGCCTGGTACCAGCAGAAGCCTGGCCAGGCTCCGCGCCTGCTGATATACGACGCCTCGAACAGAGCCACGGGCATCCCCGCCCGTTTTAGTGGCTCCGGGTCGGGGACCGACTTCACTCTGACAATCTCATCCCTCGAGCCCGAGGATTTCGCCGTGTACTACTGTCAGCAGCGCTCGAATTGGCCAACCTTCGGGCAGGGGACGAAAGTTGAGATCAAAAGCGGCGGCGGGGGCAGCCAGGTCCAGCTCGTCCAGTCTGGCGCCGAGGTCAAAAAGCCGGGCTCTTCGGTCAAGGTCTCCTGCAAGACTTCCGGCGACACCTTCTCCTCCTATGCTATCTCCTGGGTGCGGCAGGCCCCGGGGCAGGGCCTGGAGTGGATGGGAGGCATCATCCCAATCTTTGGGAGGGCCCACTACGCCCAGAAGTTCCAGGGACGCGTGACAATCACCGCAGACGAGTCCACATCCACTGCCTACATGGAGTTGTCCTCGCTCCGGTCGGAGGATACTGCCGTGTACTTCTGCGCCCGGAAGTTCCACTTCGTGTCAGGCTCCCCCTTCGGGATGGACGTGTGGGGACAAGGAACCGTGACGGTGTCGTCGGGGGGCTCGTCGGGGGGCGGGGGGAGTCAGGTGCAGCTGGTGCAGTCCGGAGCCGAGGTAAAGAAGCCAGGCGCTTCCGTCAAGGTGTCATGCAAGGCCTCAGGCTACACCTTCACAAGCTATTACATCCACTGGGTGCGCCAAGCTCCCGGTCAGGGCTTGGAGTGGATCGGGTGCATTTACCCAGGGAACGTCAACACAAACTACAACGAGAAGTTCAAGGATCGGGCAACCCTGACCGTGGACACATCCATCTCTACCGCCTACATGGAGCTGTCACGCCTGCGCTCTGATGACACCGCAGTGTACTTCTGTACCAGGAGTCACTACGGCCTGGACTGGAACTTTGATGTCTGGGGCCAGGGAACCACCGTGACGGTGTCCAGTGTGGAGGGCGGTAGTGGCGGCTCTGGTGGGTCCGGAGGCTCAGGCGGCGTGATGGATGACATTCAGATGACCCAGAGTCCCTCCTCCCTCTCCGCTTCCGTCGGAGACCGCGTGACCATCACTTGTCACGCCTCACAGAATATCTACGTGTGGCTGAACTGGTACCAACAGAAGCCCGGCAAGGCCCCCAAGCTGCTTATCTATAAAGCGTCCAACCTCCACACGGGAGTCCCTTCCCGCTTCTCCGGATCCGGCAGTGGGACGGACTTCACACTCACAATCTCGTCGCTGCAGCCAGAGGACTTTGCGACGTACTACTGCCAGCAGGGCCAGACCTACCCATATACTTTCGGC GGCGGGACCAAGGTGGAGAT.

Tolerable variations of the 1B12-1412 PD-L1/CD28 bispecific antibodywill be known to those of skill in the art, while maintaining itsintended biological activity (e.g., binding to PD-L1 and CD28).Accordingly, a 1B12-1412 PD-L1/CD28 bispecific antibody of the presentinvention may comprise an amino acid sequence that has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the 1B12-1412PD-L1/CD28 bispecific antibody amino acid sequence set forth in SEQ IDNO:133. Accordingly, a 1B12-1412 PD-L1/CD28 bispecific antibody of thepresent invention may be encoded by a nucleic acid comprising a nucleicacid sequence that has at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the 1B12-1412 PD-L1/CD28 bispecificantibody nucleic acid sequence set forth in SEQ ID NO:134.

A bispecific antibody of the present invention includes a bispecificantibody having affinity for TGF-β receptor type II (TGFβRII) and CD28.In one embodiment, a TGFβR-1-1412 TGFβRII/CD28 bispecific antibody ofthe present invention comprises an amino acid sequence set forth below:

(SEQ ID NO: 135) MGWSCIILFLVATATGVHSEIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKSGGGGSQLQVQESGPGLVKPSETLSLTCTVSGGSISNSYFSWGWIRQPPGKGLEWIGSFYYGEKTYYNPSLKSRATISIDTSKSQFSLKLSSVTAADTAVYYCPRGPTMIRGVIDSWGQGTLVTVSSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSVEGGSGGSGGSGGSGGVMDDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFGGGTK VEIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 136) ATGGGTTGGTCCTGCATCATCCTGTTTCTCGTGGCCACCGCCACCGGCGTGCACTCCGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTCGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAAGTGGAGGGGGCGGTTCACAGCTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAACAGTTATTTCTCCTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGAGTTTCTATTATGGTGAAAAAACCTACTACAACCCGTCCCTCAAGAGCCGAGCCACCATATCCATTGACACGTCCAAGAGCCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTCCGAGAGGGCCTACTATGATTCGGGGAGTTATAGACTCCTGGGGCCAGGGAACCCTGGTGACGGTGTCGTCGGGGGGCGGGGGGAGTCAGGTGCAGCTGGTGCAGTCCGGAGCCGAGGTAAAGAAGCCAGGCGCTTCCGTCAAGGTGTCATGCAAGGCCTCAGGCTACACCTTCACAAGCTATTACATCCACTGGGTGCGCCAAGCTCCCGGTCAGGGCTTGGAGTGGATCGGGTGCATTTACCCAGGGAACGTCAACACAAACTACAACGAGAAGTTCAAGGATCGGGCAACCCTGACCGTGGACACATCCATCTCTACCGCCTACATGGAGCTGTCACGCCTGCGCTCTGATGACACCGCAGTGTACTTCTGTACCAGGAGTCACTACGGCCTGGACTGGAACTTTGATGTCTGGGGCCAGGGAACCACCGTGACGGTGTCCAGTGTGGAGGGCGGTAGTGGCGGCTCTGGTGGGTCCGGAGGCTCAGGCGGCGTGATGGATGACATTCAGATGACCCAGAGTCCCTCCTCCCTCTCCGCTTCCGTCGGAGACCGCGTGACCATCACTTGTCACGCCTCACAGAATATCTACGTGTGGCTGAACTGGTACCAACAGAAGCCCGGCAAGGCCCCCAAGCTGCTTATCTATAAAGCGTCCAACCTCCACACGGGAGTCCCTTCCCGCTTCTCCGGATCCGGCAGTGGGACGGACTTCACACTCACAATCTCGTCGCTGCAGCCAGAGGACTTTGCGACGTACTACTGCCAGCAGGGCCAGACCTACCCATATACTTTCGGCGGCGGGACCAAG GTGGAGATTAAG.

Tolerable variations of the TGFβR-1-1412 TGFβRII/CD28 bispecificantibody will be known to those of skill in the art, while maintainingits intended biological activity (e.g., binding to TGFβRII and CD28).Accordingly, a TGFβR-1-1412 TGFβRII/CD28 bispecific antibody of thepresent invention may comprise an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theTGFβR-1-1412 TGFβRII/CD28 bispecific antibody amino acid sequence setforth in SEQ ID NO:135. Accordingly, a TGFβR-1-1412 TGFβRII/CD28bispecific antibody of the present invention may be encoded by a nucleicacid comprising a nucleic acid sequence that has at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 81%, at least82%, at least 83%, at least 84%, at least 85%, at least 86%, at least87%, at least 88%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99% sequence identity to the TGFβR-1-1412TGFβRII/CD28 bispecific antibody nucleic acid sequence set forth in SEQID NO:136.

A bispecific antibody of the present invention includes a bispecificantibody having affinity for TGF-β receptor type II (TGFβRII) and CD28.In one embodiment, a TGFβR-3-1412 TGFβRII/CD28 bispecific antibody ofthe present invention comprises an amino acid sequence set forth below:

(SEQ ID NO: 137) MGWSCIILFLVATATGVHSEIVLTQSPATLSLSPGERATLSCRASQSVRSFLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKSGGGGSQLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYSWGWIRQPPGKGLEWIGSFYYSGITYYSPSLKSRIIISEDTSKNQFSLKLSSVTAADTAVYYCASGFTMIRGALDYWGQGTLVTVSSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGCIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVTVSSVEGGSGGSGGSGGSGGVMDDIQMTQSPSSLSASVGDRVTITCHASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQTYPYTFGGGTK VEIK,which may be encoded by the nucleic acid sequence set forth below:

(SEQ ID NO: 138) ATGGGTTGGTCCTGCATCATCCTGTTTCTCGTGGCCACCGCCACCGGCGTGCACTCCGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGAAGTTTCTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAAGTGGAGGGGGCGGTTCACAGCTACAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTATCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTCCTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGGGAGTTTCTATTACAGTGGGATCACCTACTACAGCCCGTCCCTCAAGAGTCGAATTATCATATCCGAAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGAGCGGGTTTACTATGATTCGGGGAGCCCTTGACTACTGGGGCCAGGGAACCCTGGTGACGGTGTCGTCGGGGGGCGGGGGGAGTCAGGTGCAGCTGGTGCAGTCCGGAGCCGAGGTAAAGAAGCCAGGCGCTTCCGTCAAGGTGTCATGCAAGGCCTCAGGCTACACCTTCACAAGCTATTACATCCACTGGGTGCGCCAAGCTCCCGGTCAGGGCTTGGAGTGGATCGGGTGCATTTACCCAGGGAACGTCAACACAAACTACAACGAGAAGTTCAAGGATCGGGCAACCCTGACCGTGGACACATCCATCTCTACCGCCTACATGGAGCTGTCACGCCTGCGCTCTGATGACACCGCAGTGTACTTCTGTACCAGGAGTCACTACGGCCTGGACTGGAACTTTGATGTCTGGGGCCAGGGAACCACCGTGACGGTGTCCAGTGTGGAGGGCGGTAGTGGCGGCTCTGGTGGGTCCGGAGGCTCAGGCGGCGTGATGGATGACATTCAGATGACCCAGAGTCCCTCCTCCCTCTCCGCTTCCGTCGGAGACCGCGTGACCATCACTTGTCACGCCTCACAGAATATCTACGTGTGGCTGAACTGGTACCAACAGAAGCCCGGCAAGGCCCCCAAGCTGCTTATCTATAAAGCGTCCAACCTCCACACGGGAGTCCCTTCCCGCTTCTCCGGATCCGGCAGTGGGACGGACTTCACACTCACAATCTCGTCGCTGCAGCCAGAGGACTTTGCGACGTACTACTGCCAGCAGGGCCAGACCTACCCATATACTTTCGGCGGCGGGACCAAG GTGGAGATTAAG.

Tolerable variations of the TGFβR-3-1412 TGFβRII/CD28 bispecificantibody will be known to those of skill in the art, while maintainingits intended biological activity (e.g., binding to TGFβRII and CD28).Accordingly, a TGFβR-3-1412 TGFβRII/CD28 bispecific antibody of thepresent invention may comprise an amino acid sequence that has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to theTGFβR-3-1412 TGFβRII/CD28 bispecific antibody amino acid sequence setforth in SEQ ID NO:137. Accordingly, a TGFβR-3-1412 TGFβRII/CD28bispecific antibody of the present invention may be encoded by a nucleicacid comprising a nucleic acid sequence that has at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 81%, at least82%, at least 83%, at least 84%, at least 85%, at least 86%, at least87%, at least 88%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99% sequence identity to the TGFβR-3-1412TGFβRII/CD28 bispecific antibody nucleic acid sequence set forth in SEQID NO:138.

Other suitable bispecific antibodies for use in the present inventionare described in PCT Publication No. WO2016122738A1, the disclosure ofwhich is incorporated herein by reference.

E. Nucleic Acids and Expression Vectors

The present invention provides a nucleic acid encoding a CAR and/or adominant negative receptor and/or a switch receptor. In one embodiment,a nucleic acid of the present disclosure comprises a nucleic acidsequence encoding a subject CAR of the present invention (e.g.,PSMA-CAR). In one embodiment, a nucleic acid of the present disclosurecomprises a nucleic acid sequence encoding a dominant negative receptorand/or a switch receptor (e.g., a PD1-PTM-CD28 receptor).

In some embodiments, a nucleic acid of the present disclosure providesfor the production of a CAR and/or dominant negative receptor and/or aswitch receptor as described herein, e.g., in a mammalian cell. In someembodiments, a nucleic acid of the present disclosure provides foramplification of the CAR and/or dominant negative receptor and/or aswitch receptor-encoding nucleic acid.

As described herein, a subject CAR comprises an antigen binding domain,a transmembrane domain, and an intracellular domain. Accordingly, thepresent disclosure provides a nucleic acid encoding an antigen bindingdomain, a transmembrane domain, and an intracellular domain of a subjectCAR. As described herein, various dominant negative receptors and switchreceptors are provided. Accordingly, the present invention provides anucleic acid encoding a dominant negative receptor and/or a switchreceptor.

In some embodiments, the nucleic acid encoding a CAR is separate fromthe nucleic acid encoding a dominant negative receptor and/or a switchreceptor. In an exemplary embodiment, the nucleic acid encoding a CAR,and the nucleic acid encoding a dominant negative receptor and/or aswitch receptor, resides within the same nucleic acid.

In some embodiments, a nucleic acid of the present invention comprises anucleic acid comprising a CAR coding sequence and a dominant negativereceptor and/or a switch receptor coding sequence. In some embodiments,a nucleic acid of the present invention comprises a nucleic acidcomprising a CAR coding sequence and a dominant negative receptor and/ora switch receptor coding sequence that is separated by a linker. Alinker for use in the present invention (e.g., in the context of linkinga CAR coding sequence and a dominant negative receptor and/or a switchreceptor coding sequence) allows for multiple proteins to be encoded bythe same nucleic acid sequence (e.g., a multicistronic or bicistronicsequence), which are translated as a polyprotein that is dissociatedinto separate protein components. For example, a linker for use in anucleic acid of the present disclosure comprising a CAR coding sequenceand a dominant negative receptor and/or a switch receptor codingsequence, allows for the CAR and dominant negative receptor and/orswitch receptor to be translated as a polyprotein that is dissociatedinto separate CAR and dominant negative receptor and/or switch receptorcomponents.

In some embodiments, the linker comprises a nucleic acid sequence thatencodes for an internal ribosome entry site (IRES). As used herein, “aninternal ribosome entry site” or “IRES” refers to an element thatpromotes direct internal ribosome entry to the initiation codon, such asATG, of a protein coding region, thereby leading to cap-independenttranslation of the gene. Various internal ribosome entry sites are knownto those of skill in the art, including, without limitation, IRESobtainable from viral or cellular mRNA sources, e.g., immunogloublinheavy-chain binding protein (BiP); vascular endothelial growth factor(VEGF); fibroblast growth factor 2; insulin-like growth factor;translational initiation factor eIF4G; yeast transcription factors TFIIDand HAP4; and IRES obtainable from, e.g., cardiovirus, rhinovirus,aphthovirus, HCV, Friend murine leukemia virus (FrMLV), and Moloneymurine leukemia virus (MoMLV). Those of skill in the art would be ableto select the appropriate IRES for use in the present invention.

In some embodiments, the linker comprises a nucleic acid sequence thatencodes for a self-cleaving peptide. As used herein, a “self-cleavingpeptide” or “2A peptide” refers to an oligopeptide that allow multipleproteins to be encoded as polyproteins, which dissociate into componentproteins upon translation. Use of the term “self-cleaving” is notintended to imply a proteolytic cleavage reaction. Various self-cleavingor 2A peptides are known to those of skill in the art, including,without limitation, those found in members of the Picornaviridae virusfamily, e.g., foot-and-mouth disease virus (FMDV), equine rhinitis Avirus (ERAVO, Thosea asigna virus (TaV), and porcine tescho virus-1(PTV-1); and carioviruses such as Theilovirus and encephalomyocarditisviruses. 2A peptides derived from FMDV, ERAV, PTV-1, and TaV arereferred to herein as “F2A,” “E2A,” “P2A,” and “T2A,” respectively.Those of skill in the art would be able to select the appropriateself-cleaving peptide for use in the present invention.

In some embodiments, a nucleic acid of the present disclosure comprisesa nucleic acid sequence comprising a CAR coding sequence and a dominantnegative receptor and/or a switch receptor coding sequence that isseparated by a linker comprising a T2A peptide sequence. In someembodiments, the T2A peptide sequence comprises the amino acid sequenceEGRGSLLTCGDVEENPGP (SEQ ID NO:139), which may be encoded by the nucleicacid sequence GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCC CT(SEQ ID NO:140). In some embodiments, the linker comprising a T2Apeptide sequence may further comprise a spacer sequence as describedherein. For example, the linker comprising a T2A peptide sequence mayfurther comprise a spacer sequence comprising the amino acid sequenceSGRSGGG (SEQ ID NO:141), which may be encoded by the nucleic acidsequence TCCGGAAGATCTGGCGGCGGA (SEQ ID NO:142).

In some embodiments, a nucleic acid of the present disclosure comprisesa nucleic acid sequence comprising a CAR coding sequence and a dominantnegative receptor and/or a switch receptor coding sequence that isseparated by a linker comprising a F2A peptide sequence. In someembodiments, the F2A peptide sequence comprises the amino acid sequenceVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO:143), which may be encoded by thenucleic acid sequence

(SEQ ID NO: 144) GTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCG.

In some embodiments, a linker further comprises a nucleic acid sequencethat encodes a furin cleavage site. Furin is a ubiquitously expressedprotease that resides in the trans-golgi and processes proteinprecursors before their secretion. Furin cleaves at the COOH— terminusof its consensus recognition sequence. Various furin consensusrecognition sequences (or “furin cleavage sites”) are known to those ofskill in the art, including, without limitation, Arg-X-Lys-Arg (SEQ IDNO:145) or Arg-X-Arg-Arg (SEQ ID NO:146), and Arg-X-X-Arg (SEQ IDNO:147), such as an Arg-Gln-Lys-Arg (SEQ ID NO:148), where X is anynaturally occurring amino acid. Another example of a furin cleavage siteis X1-Arg-X2-X3-Arg (SEQ ID NO:149), where X1 is Lys or Arg, X2 is anynaturally occurring amino acid, and X3 is Lys or Arg. Those of skill inthe art would be able to select the appropriate Furin cleavage site foruse in the present invention.

In some embodiments, the linker comprises a nucleic acid sequenceencoding a combination of a Furin cleavage site and a 2A peptide.Examples include, without limitation, a linker comprising a nucleic acidsequence encoding Furin and F2A, a linker comprising a nucleic acidsequence encoding Furin and E2A, a linker comprising a nucleic acidsequence encoding Furin and P2A, a linker comprising a nucleic acidsequence encoding Furin and T2A. Those of skill in the art would be ableto select the appropriate combination for use in the present invention.In such embodiments, the linker may further comprise a spacer sequencebetween the Furin and 2A peptide. Various spacer sequences are known inthe art, including, without limitation, glycine serine (GS) spacers suchas (GS)n, (GSGGS)n (SEQ ID NO:1) and (GGGS)n (SEQ ID NO:2), where nrepresents an integer of at least 1. Exemplary spacer sequences cancomprise amino acid sequences including, without limitation, GGSG (SEQID NO:4), GGSGG (SEQ ID NO:5), GSGSG (SEQ ID NO:6), GSGGG (SEQ ID NO:7),GGGSG (SEQ ID NO:8), GSSSG (SEQ ID NO:9), and the like. Those of skillin the art would be able to select the appropriate spacer sequence foruse in the present invention.

In some embodiments, a nucleic acid of the present disclosure comprisesa nucleic acid sequence comprising a CAR coding sequence and a dominantnegative receptor and/or a switch receptor coding sequence that isseparated by a Furin-(G45)2-T2A (F-GS2-T2A) linker. The F-GS2-T2A linkermay be encoded by the nucleic acid sequenceCGTGCGAAGAGGGGCGGCGGGGGCTCCGGCGGGGGAGGCAGTGAGGGCCGCGGCTCCCTGCTGACCTGCGGAGATGTAGAAGAGAACCCAGGCCCC (SEQ ID NO:150), and maycomprise the amino acid sequence RAKRGGGGSGGGGSEGRGSLLTCGDVEENPGP (SEQID NO:151). Those of skill in the art would appreciate that linkers ofthe present invention may include tolerable sequence variations.

In some embodiments, the present invention provides a nucleic acidcomprising a nucleic acid sequence encoding a dominant negative receptorand/or a switch receptor as described herein. In some embodiments, anucleic acid comprises a nucleic acid sequence encoding a dominantnegative receptor and/or a switch receptor and a nucleic acid sequenceencoding a CAR as described herein (e.g., a PSMA-CAR). In oneembodiment, the nucleic acid sequence encoding the dominant negativereceptor and/or the switch receptor and the nucleic acid sequenceencoding the CAR resides on separate nucleic acids. In one embodiment,the nucleic acid sequence encoding the dominant negative receptor and/orthe switch receptor and the nucleic acid sequence encoding the CARresides within the same nucleic acid. In such an embodiment, the nucleicacid sequence encoding the dominant negative receptor and/or the switchreceptor and the nucleic acid sequence encoding the CAR is separated bya linker as described herein.

For example, a nucleic acid of the present disclosure may comprise anucleic acid sequence encoding a dominant receptor, a linker, and anucleic acid sequence encoding a CAR. In one embodiment, the linkercomprises a nucleic acid sequence encoding a 2A peptide (e.g., T2A). Inan exemplary embodiment, a nucleic acid of the present disclosure maycomprise a nucleic acid sequence encoding a dominant negative receptorand/or a switch receptor and a nucleic acid sequence encoding a CARseparated by a linker sequence comprising a nucleic acid sequenceencoding T2A.

Accordingly, in one embodiment, a nucleic acid of the present disclosurecomprises from 5′ to 3′: a nucleic acid sequence encoding a dominantnegative receptor and/or a switch receptor, a nucleic acid sequenceencoding a linker, and a nucleic acid sequence encoding a CAR. In oneembodiment, a nucleic acid of the present disclosure comprises from 5′to 3′: a nucleic acid sequence encoding a CAR, a nucleic acid sequenceencoding a linker, and a nucleic acid sequence encoding a dominantnegative receptor and/or a switch receptor.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a dominant negativereceptor and/or a switch receptor, a nucleic acid sequence encoding alinker comprising T2A, and a nucleic acid sequence encoding a CAR. Inone embodiment, the dominant negative receptor is TGFβRII-DN. In oneembodiment, the CAR is a murine J591 PSMA-CAR.

Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingTGFβRII-DN, a nucleic acid sequence encoding a linker comprising T2A,and a nucleic acid sequence encoding a murine J591 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding TGFβRII-DN, a nucleic acid sequence encoding a linkercomprising T2A, and a nucleic acid sequence encoding a murine J591PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 152) ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCGGCAGCAGAAGCTGAGTTCATCCGGAAGATCTGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTAGAGCCACCATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCACGCCGCCAGACCTGGATCTGACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCATCTGTAAGGCCAGTCAAGATGTGGGTACTGCTGTAGACTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTATTGGGCATCCACTCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGACTTCACTCTCACCATTACTAACGTTCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAACAGCTATCCTCTCACGTTCGGTGCTGGGACCATGCTGGACCTGAAAGGAGGCGGAGGATCTGGCGGCGGAGGAAGTTCTGGCGGAGGCAGCGAGGTGCAGCTGCAGCAGAGCGGACCCGAGCTCGTGAAGCCTGGAACAAGCGTGCGGATCAGCTGCAAGACCAGCGGCTACACCTTCACCGAGTACACCATCCACTGGGTCAAGCAGTCCCACGGCAAGAGCCTGGAGTGGATCGGCAATATCAACCCCAACAACGGCGGCACCACCTACAACCAGAAGTTCGAGGACAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGCGAGGACAGCGCCGTGTACTATTGTGCCGCCGGTTGGAACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTGTCTAGCGCTAGCTCCGGAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In one embodiment, the CAR is a humanized J591 PSMA-CAR. Accordingly, inan exemplary embodiment, a nucleic acid of the present inventioncomprises from 5′ to 3′: a nucleic acid sequence encoding TGFβRII-DN, anucleic acid sequence encoding a linker comprising a 2A peptide (e.g.,T2A), and a nucleic acid sequence encoding a humanized J591 PSMA-CAR. Inone embodiment, a nucleic acid of the present disclosure comprises from5′ to 3′: a nucleic acid encoding a humanized PSMA-CAR, a nucleic acidencoding a linker comprising a 2A peptide (e.g., T2A), and a nucleicacid encoding a dominant negative receptor and/or a switch receptor.

In one embodiment, the CAR is a humanized J591 PSMA-CAR. Accordingly, inan exemplary embodiment, a nucleic acid of the present inventioncomprises from 5′ to 3′: a nucleic acid sequence encoding TGFβRII-DN, anucleic acid sequence encoding a linker comprising T2A, and a nucleicacid sequence encoding a humanized J591 PSMA-CAR. In one embodiment, thenucleic acid comprising from 5′ to 3′: a nucleic acid sequence encodingTGFβRII-DN, a nucleic acid sequence encoding a linker comprising T2A,and a nucleic acid sequence encoding a humanized J591 PSMA-CAR.

The humanized PSMA-CAR can comprise any of the heavy and light chainvariable regions disclosed in PCT Publication Nos. WO2017212250A1 andWO2018033749A1. For example, the humanized PSMA-CAR of the presentinvention can comprise an scFv comprising any of the heavy and lightchain variable regions disclosed therein. In some embodiments, thehumanized J591 PSMA-CAR comprises a humanized J591 PSMA binding domaincomprising a heavy and light chain variable region selected from any ofthe heavy and light chain variable region sequences set forth in Table19.

In one embodiment, the CAR is a human 1C3 PSMA-CAR. Accordingly, in anexemplary embodiment, a nucleic acid of the present invention comprisesfrom 5′ to 3′: a nucleic acid sequence encoding TGFβRII-DN, a nucleicacid sequence encoding a linker comprising T2A, and a nucleic acidsequence encoding a human 1C3 PSMA-CAR. In one embodiment, the nucleicacid comprising from 5′ to 3′: a nucleic acid sequence encodingTGFβRII-DN, a nucleic acid sequence encoding a linker comprising T2A,and a nucleic acid sequence encoding a human 1C3 PSMA-CAR, comprises thenucleic acid sequence set forth below:

(SEQ ID NO: 153) ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCGGCAGCAGAAGCTGAGTTCATCCGGAAGATCTGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTAGAGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCG C.

In one embodiment, the CAR is a human 2A10 PSMA-CAR. Accordingly, in anexemplary embodiment, a nucleic acid of the present invention comprisesfrom 5′ to 3′: a nucleic acid sequence encoding TGFβRII-DN, a nucleicacid sequence encoding a linker comprising T2A, and a nucleic acidsequence encoding a human 2A10 PSMA-CAR. In one embodiment, the nucleicacid comprising from 5′ to 3′: a nucleic acid sequence encodingTGFβRII-DN, a nucleic acid sequence encoding a linker comprising T2A,and a nucleic acid sequence encoding a human 2A10 PSMA-CAR, comprisesthe nucleic acid sequence set forth below:

(SEQ ID NO: 154) ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCGGCAGCAGAAGCTGAGTTCATCCGGAAGATCTGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTAGAGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In one embodiment, the CAR is a human 2F5 PSMA-CAR. Accordingly, in anexemplary embodiment, a nucleic acid of the present invention comprisesfrom 5′ to 3′: a nucleic acid sequence encoding TGFβRII-DN, a nucleicacid sequence encoding a linker comprising T2A, and a nucleic acidsequence encoding a human 2F5 PSMA-CAR. In one embodiment, the nucleicacid comprising from 5′ to 3′: a nucleic acid sequence encodingTGFβRII-DN, a nucleic acid sequence encoding a linker comprising T2A,and a nucleic acid sequence encoding a human 2F5 PSMA-CAR, comprises thenucleic acid sequence set forth below:

(SEQ ID NO: 155) ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCGGCAGCAGAAGCTGAGTTCATCCGGAAGATCTGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTAGAGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In one embodiment, the CAR is a human 2C6 PSMA-CAR. Accordingly, in anexemplary embodiment, a nucleic acid of the present invention comprisesfrom 5′ to 3′: a nucleic acid sequence encoding TGFβRII-DN, a nucleicacid sequence encoding a linker comprising T2A, and a nucleic acidsequence encoding a human 2C6 PSMA-CAR. In one embodiment, the nucleicacid comprising from 5′ to 3′: a nucleic acid sequence encodingTGFβRII-DN, a nucleic acid sequence encoding a linker comprising T2A,and a nucleic acid sequence encoding a human 2C6 PSMA-CAR, comprises thenucleic acid sequence set forth below:

(SEQ ID NO: 156) ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCGGCAGCAGAAGCTGAGTTCATCCGGAAGATCTGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTAGAGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGATCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encoding forTGFβRII-DN and a PSMA-CAR will be known to those of skill in the art.For example, in some embodiments, the nucleic acid sequence has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thenucleic acid sequence set forth in any one of SEQ ID NOs:152-156. In oneembodiment, the nucleic acid sequence encoding for TGFβRII-DN and murineJ591 PSMA-CAR comprises the nucleic acid sequence set forth in SEQ IDNO:152. In one embodiment, the nucleic acid sequence encoding forTGFβRII-DN and human 1C3 PSMA-CAR comprises the nucleic acid sequenceset forth in SEQ ID NO:153. In one embodiment, the nucleic acid sequenceencoding for TGFβRII-DN and human 2A10 PSMA-CAR comprises the nucleicacid sequence set forth in SEQ ID NO:154. In one embodiment, the nucleicacid sequence encoding for TGFβRII-DN and human 2F5 PSMA-CAR comprisesthe nucleic acid sequence set forth in SEQ ID NO:155. In one embodiment,the nucleic acid sequence encoding for TGFβRII-DN and human 2C6 PSMA-CARcomprises the nucleic acid sequence set forth in SEQ ID NO:156.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1-CTM-CD28. In one embodiment, the CAR is a human 1C3 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingPD1-CTM-CD28, a nucleic acid sequence encoding a linker comprising F2A,and a nucleic acid sequence encoding a human 1C3 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding PD1-CTM-CD28, a nucleic acid sequence encoding alinker comprising F2A, and a nucleic acid sequence encoding a human 1C3PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 157) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCG C.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1-CTM-CD28. In one embodiment, the CAR is a human 2A10 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingPD1-CTM-CD28, a nucleic acid sequence encoding a linker comprising F2A,and a nucleic acid sequence encoding a human 2A10 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding PD1-CTM-CD28, a nucleic acid sequence encoding alinker comprising F2A, and a nucleic acid sequence encoding a human 2A10PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 158) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1-CTM-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingPD1-CTM-CD28, a nucleic acid sequence encoding a linker comprising F2A,and a nucleic acid sequence encoding a human 2F5 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding PD1-CTM-CD28, a nucleic acid sequence encoding alinker comprising F2A, and a nucleic acid sequence encoding a human 2F5PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 159) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC. 

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1-CTM-CD28. In one embodiment, the CAR is a human 2C6 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingPD1-CTM-CD28, a nucleic acid sequence encoding a linker comprising F2A,and a nucleic acid sequence encoding a human 2C6 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding PD1-CTM-CD28, a nucleic acid sequence encoding alinker comprising F2A, and a nucleic acid sequence encoding a human 2C6PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 160) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGATCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encoding PD1-CTM-CD28and a PSMA-CAR will be known to those of skill in the art. For example,in some embodiments, the nucleic acid sequence has at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 81%, atleast 82%, at least 83%, at least 84%, at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99% sequence identity to the nucleicacid sequence set forth in any one of SEQ ID NOs:157-160. In oneembodiment, the nucleic acid sequence encoding for PD1-CTM-CD28 andhuman 1C3 PSMA-CAR comprises the nucleic acid sequence set forth in SEQID NO:157. In one embodiment, the nucleic acid sequence encoding forPD1-CTM-CD28 and human 2A10 PSMA-CAR comprises the nucleic acid sequenceset forth in SEQ ID NO:158. In one embodiment, the nucleic acid sequenceencoding for PD1-CTM-CD28 and human 2F5 PSMA-CAR comprises the nucleicacid sequence set forth in SEQ ID NO:159. In one embodiment, the nucleicacid sequence encoding for PD1-CTM-CD28 and human 2C6 PSMA-CAR comprisesthe nucleic acid sequence set forth in SEQ ID NO:160.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-PTM-CD28. In one embodiment, the CAR is a human 1C3PSMA-CAR. Accordingly, in an exemplary embodiment, a nucleic acid of thepresent invention comprises from 5′ to 3′: a nucleic acid sequenceencoding PD1^(A132L)-PTM-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 1C3PSMA-CAR. In one embodiment, the nucleic acid comprising from 5′ to 3′:a nucleic acid sequence encoding PD1^(A132L)-PTM-CD28, a nucleic acidsequence encoding a linker comprising F2A, and a nucleic acid sequenceencoding a human 1C3 PSMA-CAR, comprises the nucleic acid sequence setforth below:

(SEQ ID NO: 161) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-PTM-CD28. In one embodiment, the CAR is a human 2A10PSMA-CAR. Accordingly, in an exemplary embodiment, a nucleic acid of thepresent invention comprises from 5′ to 3′: a nucleic acid sequenceencoding PD1^(A132L)-PTM-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 2A10PSMA-CAR. In one embodiment, the nucleic acid comprising from 5′ to 3′:a nucleic acid sequence encoding PD1^(A132L)-PTM-CD28, a nucleic acidsequence encoding a linker comprising F2A, and a nucleic acid sequenceencoding a human 2A10 PSMA-CAR, comprises the nucleic acid sequence setforth below:

(SEQ ID NO: 162) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-PTM-CD28. In one embodiment, the CAR is a human 2F5PSMA-CAR. Accordingly, in an exemplary embodiment, a nucleic acid of thepresent invention comprises from 5′ to 3′: a nucleic acid sequenceencoding PD1^(A132)L_PTM-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 2F5PSMA-CAR. In one embodiment, the nucleic acid comprising from 5′ to 3′:a nucleic acid sequence encoding PD1^(A132L)-PTM-CD28, a nucleic acidsequence encoding a linker comprising F2A, and a nucleic acid sequenceencoding a human 2F5 PSMA-CAR, comprises the nucleic acid sequence setforth below:

(SEQ ID NO: 163) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-PTM-CD28. In one embodiment, the CAR is a human 2C6PSMA-CAR. Accordingly, in an exemplary embodiment, a nucleic acid of thepresent invention comprises from 5′ to 3′: a nucleic acid sequenceencoding PD1^(A132L)-PTM-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 2C6PSMA-CAR. In one embodiment, the nucleic acid comprising from 5′ to 3′:a nucleic acid sequence encoding PD1^(A132L)-PTM-CD28, a nucleic acidsequence encoding a linker comprising F2A, and a nucleic acid sequenceencoding a human 2C6 PSMA-CAR, comprises the nucleic acid sequence setforth below:

(SEQ ID NO: 164) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGATCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encodingPD1^(A132L)-PTM-CD28 and a PSMA-CAR will be known to those of skill inthe art. For example, in some embodiments, the nucleic acid sequence hasat least 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in any one of SEQ ID NOs:161-164. Inone embodiment, the nucleic acid sequence encoding forPD1^(A132L)-PTM-CD28 and human 1C3 PSMA-CAR comprises the nucleic acidsequence set forth in SEQ ID NO:161. In one embodiment, the nucleic acidsequence encoding for PD1^(A132L)-PTM-CD28 and human 2A10 PSMA-CARcomprises the nucleic acid sequence set forth in SEQ ID NO:162. In oneembodiment, the nucleic acid sequence encoding for PD1^(A132L)-PTM-CD28and human 2F5 PSMA-CAR comprises the nucleic acid sequence set forth inSEQ ID NO:163. In one embodiment, the nucleic acid sequence encoding forPD1^(A132L)-PTM-CD28 and human 2C6 PSMA-CAR comprises the nucleic acidsequence set forth in SEQ ID NO:164.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isTIM3-CD28. In one embodiment, the CAR is a human 1C3 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingTIM3-CD28, a nucleic acid sequence encoding a linker comprising F2A, anda nucleic acid sequence encoding a human 1C3 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding TIM3-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 1C3PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 165) ATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isTIM3-CD28. In one embodiment, the CAR is a human 2A10 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingTIM3-CD28, a nucleic acid sequence encoding a linker comprising F2A, anda nucleic acid sequence encoding a human 2A10 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding TIM3-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 2A10PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 166) ATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC. 

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isTIM3-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingTIM3-CD28, a nucleic acid sequence encoding a linker comprising F2A, anda nucleic acid sequence encoding a human 2F5 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding TIM3-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 2F5PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 167) ATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isTIM3-CD28. In one embodiment, the CAR is a human 2C6 PSMA-CAR.Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingTIM3-CD28, a nucleic acid sequence encoding a linker comprising F2A, anda nucleic acid sequence encoding a human 2C6 PSMA-CAR. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding TIM3-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 2C6PSMA-CAR, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 168) ATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGATCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGACGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGACGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAACGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGACGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encoding TIM3-CD28 anda PSMA-CAR will be known to those of skill in the art. For example, insome embodiments, the nucleic acid sequence has at least 60%, at least65%, at least 70%, at least 75%, at least 80%, at least 81%, at least82%, at least 83%, at least 84%, at least 85%, at least 86%, at least87%, at least 88%, at least 89%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99% sequence identity to the nucleic acidsequence set forth in any one of SEQ ID NOs:165-168. In one embodiment,the nucleic acid sequence encoding for TIM3-CD28 and human 1C3 PSMA-CARcomprises the nucleic acid sequence set forth in SEQ ID NO:165. In oneembodiment, the nucleic acid sequence encoding for TIM3-CD28 and human2A10 PSMA-CAR comprises the nucleic acid sequence set forth in SEQ IDNO:166. In one embodiment, the nucleic acid sequence encoding forTIM3-CD28 and human 2F5 PSMA-CAR comprises the nucleic acid sequence setforth in SEQ ID NO:167. In one embodiment, the nucleic acid sequenceencoding for TIM3-CD28 and human 2C6 PSMA-CAR comprises the nucleic acidsequence set forth in SEQ ID NO:168.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1-CTM-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CARcomprising an ICOS domain and a CD3zeta domain. Accordingly, in anexemplary embodiment, a nucleic acid of the present invention comprisesfrom 5′ to 3′: a nucleic acid sequence encoding PD1-CTM-CD28, a nucleicacid sequence encoding a linker comprising F2A, and a nucleic acidsequence encoding a human 2F5 PSMA-CAR comprising an ICOS domain and aCD3zeta domain. In one embodiment, the nucleic acid comprising from 5′to 3′: a nucleic acid sequence encoding PD1-CTM-CD28, a nucleic acidsequence encoding a linker comprising F2A, and a nucleic acid sequenceencoding a human 2F5 PSMA-CAR comprising an ICOS domain and a CD3zetadomain, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 217) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encoding PD1-CTM-CD28and a human 2F5 PSMA-CAR comprising an ICOS domain and a CD3zeta domainwill be known to those of skill in the art. For example, in someembodiments, the nucleic acid sequence has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the nucleic acid sequenceset forth in SEQ ID NO:217. In one embodiment, the nucleic acid sequenceencoding for PD1-CTM-CD28 and human 2F5 PSMA-CAR comprising an ICOSdomain and a CD3zeta domain comprises the nucleic acid sequence setforth in SEQ ID NO:217.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1-CTM-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CARcomprising a variant ICOS domain and a CD3zeta domain.

Accordingly, in an exemplary embodiment, a nucleic acid of the presentinvention comprises from 5′ to 3′: a nucleic acid sequence encodingPD1-CTM-CD28, a nucleic acid sequence encoding a linker comprising F2A,and a nucleic acid sequence encoding a human 2F5 PSMA-CAR comprising avariant ICOS domain and a CD3zeta domain. In one embodiment, the nucleicacid comprising from 5′ to 3′: a nucleic acid sequence encodingPD1-CTM-CD28, a nucleic acid sequence encoding a linker comprising F2A,and a nucleic acid sequence encoding a human 2F5 PSMA-CAR comprising avariant ICOS domain and a CD3zeta domain, comprises the nucleic acidsequence set forth below:

(SEQ ID NO: 218) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encoding PD1-CTM-CD28and a human 2F5 PSMA-CAR comprising a variant ICOS domain and a CD3zetadomain will be known to those of skill in the art. For example, in someembodiments, the nucleic acid sequence has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the nucleic acid sequenceset forth in SEQ ID NO:218. In one embodiment, the nucleic acid sequenceencoding for PD1-CTM-CD28 and human 2F5 PSMA-CAR comprising a variantICOS domain and a CD3zeta domain comprises the nucleic acid sequence setforth in SEQ ID NO:218.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-PTM-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CARcomprising an ICOS domain and a CD3zeta domain. Accordingly, in anexemplary embodiment, a nucleic acid of the present invention comprisesfrom 5′ to 3′: a nucleic acid sequence encoding PD1^(A132L)-PTM-CD28, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a human 2F5 PSMA-CAR comprising an ICOS domainand a CD3zeta domain. In one embodiment, the nucleic acid comprisingfrom 5′ to 3′: a nucleic acid sequence encoding PD1^(A132L)-PTM-CD28, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a human 2F5 PSMA-CAR comprising an ICOS domainand a CD3zeta domain, comprises the nucleic acid sequence set forthbelow:

(SEQ ID NO: 219) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCC CTCGC.

Tolerable variations of the nucleic acid sequence encodingPD1^(A132L)-PTM-CD28 and a human 2F5 PSMA-CAR comprising an ICOS domainand a CD3zeta domain will be known to those of skill in the art. Forexample, in some embodiments, the nucleic acid sequence has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thenucleic acid sequence set forth in SEQ ID NO:219. In one embodiment, thenucleic acid sequence encoding for PD1^(A132L)-PTM-CD28 and human 2F5PSMA-CAR comprising an ICOS domain and a CD3zeta domain comprises thenucleic acid sequence set forth in SEQ ID NO:219.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-PTM-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CARcomprising a variant ICOS domain and a CD3zeta domain. Accordingly, inan exemplary embodiment, a nucleic acid of the present inventioncomprises from 5′ to 3′: a nucleic acid sequence encodingPD1^(A132L)-PTM-CD28, a nucleic acid sequence encoding a linkercomprising F2A, and a nucleic acid sequence encoding a human 2F5PSMA-CAR comprising a variant ICOS domain and a CD3zeta domain. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding PD1^(A132L)-PTM-CD28, a nucleic acid sequence encodinga linker comprising F2A, and a nucleic acid sequence encoding a human2F5 PSMA-CAR comprising a variant ICOS domain and a CD3zeta domain,comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 220) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCC CTCGC.

Tolerable variations of the nucleic acid sequence encodingPD1^(A132L)-PTM-CD28 and a human 2F5 PSMA-CAR comprising a variant ICOSdomain and a CD3zeta domain will be known to those of skill in the art.For example, in some embodiments, the nucleic acid sequence has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thenucleic acid sequence set forth in SEQ ID NO:220. In one embodiment, thenucleic acid sequence encoding for PD1^(A132L)-PTM-CD28 and human 2F5PSMA-CAR comprising a variant ICOS domain and a CD3zeta domain comprisesthe nucleic acid sequence set forth in SEQ ID NO:220.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-4-1BB. In one embodiment, the CAR is a human 2F5 PSMA-CARcomprising an ICOS domain and a CD3zeta domain. Accordingly, in anexemplary embodiment, a nucleic acid of the present invention comprisesfrom 5′ to 3′: a nucleic acid sequence encoding PD1^(A132L)-4-1BB, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a human 2F5 PSMA-CAR comprising an ICOS domainand a CD3zeta domain. In one embodiment, the nucleic acid comprisingfrom 5′ to 3′: a nucleic acid sequence encoding PD1^(A132L)-4-1BB, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a human 2F5 PSMA-CAR comprising an ICOS domainand a CD3zeta domain, comprises the nucleic acid sequence set forthbelow:

(SEQ ID NO: 221) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTTATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAAAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCATTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACAT GCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encodingPD1^(A132L)-4-1BB and a human 2F5 PSMA-CAR comprising an ICOS domain anda CD3zeta domain will be known to those of skill in the art. Forexample, in some embodiments, the nucleic acid sequence has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thenucleic acid sequence set forth in SEQ ID NO:221. In one embodiment, thenucleic acid sequence encoding for PD1^(A132L)-4-1BB and human 2F5PSMA-CAR comprising an ICOS domain and a CD3zeta domain comprises thenucleic acid sequence set forth in SEQ ID NO:221.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isPD1^(A132L)-4-1BB. In one embodiment, the CAR is a human 2F5 PSMA-CARcomprising a variant ICOS domain and a CD3zeta domain. Accordingly, inan exemplary embodiment, a nucleic acid of the present inventioncomprises from 5′ to 3′: a nucleic acid sequence encodingPD1^(A132L)-4-1BB, a nucleic acid sequence encoding a linker comprisingF2A, and a nucleic acid sequence encoding a human 2F5 PSMA-CARcomprising a variant ICOS domain and a CD3zeta domain. In oneembodiment, the nucleic acid comprising from 5′ to 3′: a nucleic acidsequence encoding PD1^(A132L)-4-1BB, a nucleic acid sequence encoding alinker comprising F2A, and a nucleic acid sequence encoding a human 2F5PSMA-CAR comprising a variant ICOS domain and a CD3zeta domain,comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 222) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTTATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAAAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACA TGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encodingPD1^(A132L)-4-1BB and a human 2F5 PSMA-CAR comprising a variant ICOSdomain and a CD3zeta domain will be known to those of skill in the art.For example, in some embodiments, the nucleic acid sequence has at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least81%, at least 82%, at least 83%, at least 84%, at least 85%, at least86%, at least 87%, at least 88%, at least 89%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99% sequence identity to thenucleic acid sequence set forth in SEQ ID NO:222. In one embodiment, thenucleic acid sequence encoding for PD1^(A132L)-4-1BB and human 2F5PSMA-CAR comprising a variant ICOS domain and a CD3zeta domain comprisesthe nucleic acid sequence set forth in SEQ ID NO:222.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isTIM3-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CAR comprisingan ICOS domain and a CD3zeta domain. Accordingly, in an exemplaryembodiment, a nucleic acid of the present invention comprises from 5′ to3′: a nucleic acid sequence encoding TIM3-CD28, a nucleic acid sequenceencoding a linker comprising F2A, and a nucleic acid sequence encoding ahuman 2F5 PSMA-CAR comprising an ICOS domain and a CD3zeta domain. Inone embodiment, the nucleic acid comprising from 5′ to 3′: a nucleicacid sequence encoding TIM3-CD28, a nucleic acid sequence encoding alinker comprising F2A, and a nucleic acid sequence encoding a human 2F5PSMA-CAR comprising an ICOS domain and a CD3zeta domain, comprises thenucleic acid sequence set forth below:

(SEQ ID NO: 223) ATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGC CCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encoding TIM3-CD28 anda human 2F5 PSMA-CAR comprising an ICOS domain and a CD3zeta domain willbe known to those of skill in the art. For example, in some embodiments,the nucleic acid sequence has at least 60%, at least 65%, at least 70%,at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, atleast 84%, at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99% sequence identity to the nucleic acid sequence set forth inSEQ ID NO:223. In one embodiment, the nucleic acid sequence encoding forTIM3-CD28 and human 2F5 PSMA-CAR comprising an ICOS domain and a CD3zetadomain comprises the nucleic acid sequence set forth in SEQ ID NO:223.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a switch receptor, anucleic acid sequence encoding a linker comprising F2A, and a nucleicacid sequence encoding a CAR. In one embodiment, the switch receptor isTIM3-CD28. In one embodiment, the CAR is a human 2F5 PSMA-CAR comprisinga variant ICOS domain and a CD3zeta domain. Accordingly, in an exemplaryembodiment, a nucleic acid of the present invention comprises from 5′ to3′: a nucleic acid sequence encoding TIM3-CD28, a nucleic acid sequenceencoding a linker comprising F2A, and a nucleic acid sequence encoding ahuman 2F5 PSMA-CAR comprising a variant ICOS domain and a CD3zetadomain. In one embodiment, the nucleic acid comprising from 5′ to 3′: anucleic acid sequence encoding TIM3-CD28, a nucleic acid sequenceencoding a linker comprising F2A, and a nucleic acid sequence encoding ahuman 2F5 PSMA-CAR comprising a variant ICOS domain and a CD3zetadomain, comprises the nucleic acid sequence set forth below:

(SEQ ID NO: 224) ATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGC CCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encoding TIM3-CD28 anda human 2F5 PSMA-CAR comprising a variant ICOS domain and a CD3zetadomain will be known to those of skill in the art. For example, in someembodiments, the nucleic acid sequence has at least 60%, at least 65%,at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, atleast 83%, at least 84%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99% sequence identity to the nucleic acid sequenceset forth in SEQ ID NO:224. In one embodiment, the nucleic acid sequenceencoding for TIM3-CD28 and human 2F5 PSMA-CAR comprising a variant ICOSdomain and a CD3zeta domain comprises the nucleic acid sequence setforth in SEQ ID NO:224.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a first switch receptor,a nucleic acid sequence encoding a first linker comprising F2A, anucleic acid sequence encoding a second switch receptor, a nucleic acidencoding a second linker comprising F2A, and a nucleic acid sequenceencoding a CAR. In one embodiment, the first switch receptor isTIM3-CD28, and the second switch receptor is PD1^(A132L)-4-1BB. In oneembodiment, the first switch receptor is PD1^(A132L)-4-1BB, and thesecond switch receptor is TIM3-CD28. In one embodiment, the CAR is ahuman 2F5 PSMA-CAR comprising an ICOS domain and a CD3zeta domain. Inone embodiment, the first and second linkers are the same. In oneembodiment, the first and second linkers are different. Accordingly, inan exemplary embodiment, a nucleic acid of the present inventioncomprises from 5′ to 3′: a nucleic acid sequence encodingPD1^(A132L)-4-1BB, a nucleic acid sequence encoding a first linkercomprising F2A, a nucleic acid sequence encoding TIM3-CD28, a nucleicacid sequence encoding a second linker comprising F2A, and a nucleicacid sequence encoding a human 2F5 PSMA-CAR comprising an ICOS domainand a CD3zeta domain. In one embodiment, the nucleic acid comprisingfrom 5′ to 3′: a nucleic acid sequence encoding PD1^(A132L)-4-1BB, anucleic acid sequence encoding a first linker comprising F2A, a nucleicacid sequence encoding TIM3-CD28, a nucleic acid encoding a secondlinker comprising F2A, and a nucleic acid sequence encoding a human 2F5PSMA-CAR comprising an ICOS domain and a CD3zeta domain, comprises thenucleic acid sequence set forth below:

(SEQ ID NO: 225) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTTATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAAAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGGTGAAGCAGACGTTGAACTTCGATTTGCTCAAACTTGCCGGTGACGTGGAATCCAATCCGGGGCCGATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encodingPD1^(A132L)-4-1BB, TIM3-CD28, and a human 2F5 PSMA-CAR comprising anICOS domain and a CD3zeta domain will be known to those of skill in theart. For example, in some embodiments, the nucleic acid sequence has atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 81%, at least 82%, at least 83%, at least 84%, at least 85%, atleast 86%, at least 87%, at least 88%, at least 89%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99% sequence identity tothe nucleic acid sequence set forth in SEQ ID NO:225. In one embodiment,the nucleic acid sequence encoding for PD1^(A132L)-4-1BB, TIM3-CD28, anda human 2F5 PSMA-CAR comprising an ICOS domain and a CD3zeta domaincomprises the nucleic acid sequence set forth in SEQ ID NO:225.

In some embodiments, a nucleic acid of the present disclosure comprisesfrom 5′ to 3′: a nucleic acid sequence encoding a first switch receptor,a nucleic acid sequence encoding a first linker comprising F2A, anucleic acid sequence encoding a second switch receptor, a nucleic acidencoding a second linker comprising F2A, and a nucleic acid sequenceencoding a CAR. In one embodiment, the first switch receptor isTIM3-CD28, and the second switch receptor is PD1^(A132L)-4-1BB. In oneembodiment, the first switch receptor is PD1^(A132L)-4-1BB, and thesecond switch receptor is TIM3-CD28. In one embodiment, the CAR is ahuman 2F5 PSMA-CAR comprising a variant ICOS domain and a CD3zetadomain. In one embodiment, the first and second linkers are the same. Inone embodiment, the first and second linkers are different. Accordingly,in an exemplary embodiment, a nucleic acid of the present inventioncomprises from 5′ to 3′: a nucleic acid sequence encodingPD1^(A132L)-4-1BB, a nucleic acid sequence encoding a first linkercomprising F2A, a nucleic acid sequence encoding TIM3-CD28, a nucleicacid sequence encoding a second linker comprising F2A, and a nucleicacid sequence encoding a human 2F5 PSMA-CAR comprising a variant ICOSdomain and a CD3zeta domain. In one embodiment, the nucleic acidcomprising from 5′ to 3′: a nucleic acid sequence encodingPD1^(A132L)-4-1BB, a nucleic acid sequence encoding a first linkercomprising F2A, a nucleic acid sequence encoding TIM3-CD28, a nucleicacid encoding a second linker comprising F2A, and a nucleic acidsequence encoding a human 2F5 PSMA-CAR comprising a variant ICOS domainand a CD3zeta domain, comprises the nucleic acid sequence set forthbelow:

(SEQ ID NO: 226) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTTATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAAAAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGGTGAAGCAGACGTTGAACTTCGATTTGCTCAAACTTGCCGGTGACGTGGAATCCAATCCGGGGCCGATGTTTTCACATCTTCCCTTTGACTGTGTCCTGCTGCTGCTGCTGCTACTACTTACAAGGTCCTCAGAAGTGGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTTCTACACCCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCCTGTGTTTGAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGCTAAATGGGGATTTCCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGGGATCTACTGCTGCCGAATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTCATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGATGCTTACCACCAGGGGACATGGCCCAGCAGAGACACAGACACTGGGGAGCCTCCCTGACATAAATCTAACACAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGGTTGGCCAATGACTTACGGGACTCCGGAGCAACCATCAGATTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTACTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCGATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTCTGGTTACCCATAGGATGTGCAGCCTTTGTTGTAGTCTGCATTTTGGGATGCATACTTATTTGTTGGCTTACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGAACATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTAAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGCAGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC.

Tolerable variations of the nucleic acid sequence encodingPD1^(A132L)-4-1BB, TIM3-CD28, and a human 2F5 PSMA-CAR comprising avariant ICOS domain and a CD3zeta domain will be known to those of skillin the art. For example, in some embodiments, the nucleic acid sequencehas at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 81%, at least 82%, at least 83%, at least 84%, at least85%, at least 86%, at least 87%, at least 88%, at least 89%, at least90%, at least 91%, at least 92%, at least 93%, at least 94%, at least95%, at least 96%, at least 97%, at least 98%, at least 99% sequenceidentity to the nucleic acid sequence set forth in SEQ ID NO:226. In oneembodiment, the nucleic acid sequence encoding for PD1^(A132L)-4-1BB,TIM3-CD28, and a human 2F5 PSMA-CAR comprising a variant ICOS domain anda CD3zeta domain comprises the nucleic acid sequence set forth in SEQ IDNO:226.

In some embodiments, a nucleic acid of the present disclosure may beoperably linked to a transcriptional control element, e.g., a promoter,and enhancer, etc. Suitable promoter and enhancer elements are known tothose of skill in the art.

For expression in a bacterial cell, suitable promoters include, but arenot limited to, lad, lacZ, T3, T7, gpt, lambda P and trc. For expressionin a eukaryotic cell, suitable promoters include, but are not limitedto, light and/or heavy chain immunoglobulin gene promoter and enhancerelements; cytomegalovirus immediate early promoter; herpes simplex virusthymidine kinase promoter; early and late SV40 promoters; promoterpresent in long terminal repeats from a retrovirus; mousemetallothionein-I promoter; and various art-known tissue specificpromoters. Suitable reversible promoters, including reversible induciblepromoters are known in the art. Such reversible promoters may beisolated and derived from many organisms, e.g., eukaryotes andprokaryotes. Modification of reversible promoters derived from a firstorganism for use in a second organism, e.g., a first prokaryote and asecond a eukaryote, a first eukaryote and a second a prokaryote, etc.,is well known in the art. Such reversible promoters, and systems basedon such reversible promoters but also comprising additional controlproteins, include, but are not limited to, alcohol regulated promoters(e.g., alcohol dehydrogenase I (alcA) gene promoter, promotersresponsive to alcohol transactivator proteins (AlcR), etc.),tetracycline regulated promoters, (e.g., promoter systems includingTetActivators, TetON, TetOFF, etc.), steroid regulated promoters (e.g.,rat glucocorticoid receptor promoter systems, human estrogen receptorpromoter systems, retinoid promoter systems, thyroid promoter systems,ecdysone promoter systems, mifepristone promoter systems, etc.), metalregulated promoters (e.g., metallothionein promoter systems, etc.),pathogenesis-related regulated promoters (e.g., salicylic acid regulatedpromoters, ethylene regulated promoters, benzothiadiazole regulatedpromoters, etc.), temperature regulated promoters (e.g., heat shockinducible promoters (e.g., HSP-70, HSP-90, soybean heat shock promoter,etc.), light regulated promoters, synthetic inducible promoters, and thelike.

In some embodiments, the promoter is a CD8 cell-specific promoter, a CD4cell-specific promoter, a neutrophil-specific promoter, or anNK-specific promoter. For example, a CD4 gene promoter can be used; see,e.g., Salmon et al. Proc. Natl. Acad. Sci. USA (1993) 90:7739; andMarodon et al. (2003) Blood 101:3416. As another example, a CD8 genepromoter can be used. NK cell-specific expression can be achieved by useof an NcrI (p46) promoter; see, e.g., Eckelhart et al. Blood (2011)117:1565.

For expression in a yeast cell, a suitable promoter is a constitutivepromoter such as an ADH1 promoter, a PGK1 promoter, an ENO promoter, aPYK1 promoter and the like; or a regulatable promoter such as a GAL1promoter, a GAL10 promoter, an ADH2 promoter, a PHOS promoter, a CUP1promoter, a GALT promoter, a MET25 promoter, a MET3 promoter, a CYC1promoter, a HIS3 promoter, an ADH1 promoter, a PGK promoter, a GAPDHpromoter, an ADC1 promoter, a TRP1 promoter, a URA3 promoter, a LEU2promoter, an ENO promoter, a TP1 promoter, and AOX1 (e.g., for use inPichia). Selection of the appropriate vector and promoter is well withinthe level of ordinary skill in the art. Suitable promoters for use inprokaryotic host cells include, but are not limited to, a bacteriophageT7 RNA polymerase promoter; a trp promoter; a lac operon promoter; ahybrid promoter, e.g., a lac/tac hybrid promoter, a tac/trc hybridpromoter, a trp/lac promoter, a T7/lac promoter; a trc promoter; a tacpromoter, and the like; an araBAD promoter; in vivo regulated promoters,such as an ssaG promoter or a related promoter (see, e.g., U.S. PatentPublication No. 20040131637), a pagC promoter (Pulkkinen and Miller, J.Bacteriol. (1991) 173(1): 86-93; Alpuche-Aranda et al., Proc. Natl.Acad. Sci. USA (1992) 89(21): 10079-83), a nirB promoter (Harborne etal. Mol. Micro. (1992) 6:2805-2813), and the like (see, e.g., Dunstan etal., Infect. Immun. (1999) 67:5133-5141; McKelvie et al., Vaccine (2004)22:3243-3255; and Chatfield et al., Biotechnol. (1992) 10:888-892); asigma70 promoter, e.g., a consensus sigma70 promoter (see, e.g., GenBankAccession Nos. AX798980, AX798961, and AX798183); a stationary phasepromoter, e.g., a dps promoter, an spy promoter, and the like; apromoter derived from the pathogenicity island SPI-2 (see, e.g.,WO96/17951); an actA promoter (see, e.g., Shetron-Rama et al., Infect.Immun. (2002) 70:1087-1096); an rpsM promoter (see, e.g., Valdivia andFalkow Mol. Microbiol. (1996). 22:367); a tet promoter (see, e.g.,Hillen, W. and Wissmann, A. (1989) In Saenger, W. and Heinemann, U.(eds), Topics in Molecular and Structural Biology, Protein—Nucleic AcidInteraction. Macmillan, London, UK, Vol. 10, pp. 143-162); an SP6promoter (see, e.g., Melton et al., Nucl. Acids Res. (1984) 12:7035);and the like. Suitable strong promoters for use in prokaryotes such asEscherichia coli include, but are not limited to Trc, Tac, T5, T7, andPLambda. Non-limiting examples of operators for use in bacterial hostcells include a lactose promoter operator (Lad repressor protein changesconformation when contacted with lactose, thereby preventing the Ladrepressor protein from binding to the operator), a tryptophan promoteroperator (when complexed with tryptophan, TrpR repressor protein has aconformation that binds the operator; in the absence of tryptophan, theTrpR repressor protein has a conformation that does not bind to theoperator), and a tac promoter operator (see, e.g., deBoer et al., Proc.Natl. Acad. Sci. U.S.A. (1983) 80:21-25).

Other examples of suitable promoters include the immediate earlycytomegalovirus (CMV) promoter sequence. This promoter sequence is astrong constitutive promoter sequence capable of driving high levels ofexpression of any polynucleotide sequence operatively linked thereto.Other constitutive promoter sequences may also be used, including, butnot limited to a simian virus 40 (SV40) early promoter, a mouse mammarytumor virus (MMTV) or human immunodeficiency virus (HIV) long terminalrepeat (LTR) promoter, a MoMuLV promoter, an avian leukemia viruspromoter, an Epstein-Barr virus immediate early promoter, a Rous sarcomavirus promoter, the EF-1 alpha promoter, as well as human gene promoterssuch as, but not limited to, an actin promoter, a myosin promoter, ahemoglobin promoter, and a creatine kinase promoter. Further, theinvention should not be limited to the use of constitutive promoters.Inducible promoters are also contemplated as part of the invention. Theuse of an inducible promoter provides a molecular switch capable ofturning on expression of the polynucleotide sequence which it isoperatively linked when such expression is desired, or turning off theexpression when expression is not desired. Examples of induciblepromoters include, but are not limited to a metallothionine promoter, aglucocorticoid promoter, a progesterone promoter, and a tetracyclinepromoter.

In some embodiments, the locus or construct or transgene containing thesuitable promoter is irreversibly switched through the induction of aninducible system. Suitable systems for induction of an irreversibleswitch are well known in the art, e.g., induction of an irreversibleswitch may make use of a Cre-lox-mediated recombination (see, e.g.,Fuhrmann-Benzakein, et al., Proc. Natl. Acad. Sci. USA (2000) 28:e99,the disclosure of which is incorporated herein by reference). Anysuitable combination of recombinase, endonuclease, ligase, recombinationsites, etc. known to the art may be used in generating an irreversiblyswitchable promoter. Methods, mechanisms, and requirements forperforming site-specific recombination, described elsewhere herein, finduse in generating irreversibly switched promoters and are well known inthe art, see, e.g., Grindley et al. Annual Review of Biochemistry (2006)567-605; and Tropp, Molecular Biology (2012) (Jones & BartlettPublishers, Sudbury, Mass.), the disclosures of which are incorporatedherein by reference.

In some embodiments, a nucleic acid of the present disclosure furthercomprises a nucleic acid sequence encoding a TCR/CAR inducibleexpression cassette. In one embodiment, the TCR/CAR inducible expressioncassette is for the production of a transgenic polypeptide product thatis released upon TCR/CAR signaling. See, e.g., Chmielewski and Abken,Expert Opin. Biol. Ther. (2015) 15(8): 1145-1154; and Abken,Immunotherapy (2015) 7(5): 535-544. In some embodiments, a nucleic acidof the present disclosure further comprises a nucleic acid sequenceencoding a cytokine operably linked to a T-cell activation responsivepromoter. In some embodiments, the cytokine operably linked to a T-cellactivation responsive promoter is present on a separate nucleic acidsequence. In one embodiment, the cytokine is IL-12.

A nucleic acid of the present disclosure may be present within anexpression vector and/or a cloning vector. An expression vector caninclude a selectable marker, an origin of replication, and otherfeatures that provide for replication and/or maintenance of the vector.Suitable expression vectors include, e.g., plasmids, viral vectors, andthe like. Large numbers of suitable vectors and promoters are known tothose of skill in the art; many are commercially available forgenerating a subject recombinant construct. The following vectors areprovided by way of example, and should not be construed in anyway aslimiting: Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS,pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA);pTrc99A, pKK223-3, pKK233-3, pDR540, and pRITS (Pharmacia, Uppsala,Sweden). Eukaryotic: pWLneo, pSV2cat, pOG44, PXR1, pSG (Stratagene)pSVK3, pBPV, pMSG and pSVL (Pharmacia).

Expression vectors generally have convenient restriction sites locatednear the promoter sequence to provide for the insertion of nucleic acidsequences encoding heterologous proteins. A selectable marker operativein the expression host may be present. Suitable expression vectorsinclude, but are not limited to, viral vectors (e.g. viral vectors basedon vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest.Opthalmol. Vis. Sci. (1994) 35: 2543-2549; Borras et al., Gene Ther.(1999) 6: 515-524; Li and Davidson, Proc. Natl. Acad. Sci. USA (1995)92: 7700-7704; Sakamoto et al., H. Gene Ther. (1999) 5: 1088-1097; WO94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO95/00655); adeno-associated virus (see, e.g., Ali et al., Hum. GeneTher. (1998) 9: 81-86, Flannery et al., Proc. Natl. Acad. Sci. USA(1997) 94: 6916-6921; Bennett et al., Invest. Opthalmol. Vis. Sci.(1997) 38: 2857-2863; Jomary et al., Gene Ther. (1997) 4:683 690,Rolling et al., Hum. Gene Ther. (1999) 10: 641-648; Ali et al., Hum.Mol. Genet. (1996) 5: 591-594; Srivastava in WO 93/09239, Samulski etal., J. Vir. (1989) 63: 3822-3828; Mendelson et al., Virol. (1988) 166:154-165; and Flotte et al., Proc. Natl. Acad. Sci. USA (1993) 90:10613-10617); SV40; herpes simplex virus; human immunodeficiency virus(see, e.g., Miyoshi et al., Proc. Natl. Acad. Sci. USA (1997) 94:10319-23; Takahashi et al., J. Virol. (1999) 73: 7812-7816); aretroviral vector (e.g., Murine Leukemia Virus, spleen necrosis virus,and vectors derived from retroviruses such as Rous Sarcoma Virus, HarveySarcoma Virus, avian leukosis virus, human immunodeficiency virus,myeloproliferative sarcoma virus, and mammary tumor virus); and thelike.

Additional expression vectors suitable for use are, e.g., withoutlimitation, a lentivirus vector, a gamma retrovirus vector, a foamyvirus vector, an adeno-associated virus vector, an adenovirus vector, apox virus vector, a herpes virus vector, an engineered hybrid virusvector, a transposon mediated vector, and the like. Viral vectortechnology is well known in the art and is described, for example, inSambrook et al., 2012, Molecular Cloning: A Laboratory Manual, volumes1-4, Cold Spring Harbor Press, NY), and in other virology and molecularbiology manuals. Viruses, which are useful as vectors include, but arenot limited to, retroviruses, adenoviruses, adeno-associated viruses,herpes viruses, and lentiviruses.

In general, a suitable vector contains an origin of replicationfunctional in at least one organism, a promoter sequence, convenientrestriction endonuclease sites, and one or more selectable markers,(e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).

In some embodiments, an expression vector (e.g., a lentiviral vector)may be used to introduce the TCR/CAR and/or the dominant negativereceptor and/or switch receptor into an immune cell or precursor thereof(e.g., a T cell). Accordingly, an expression vector (e.g., a lentiviralvector) of the present invention may comprise a nucleic acid encodingfor a TCR/CAR and/or the dominant negative receptor and/or switchreceptor. In some embodiments, the expression vector (e.g., lentiviralvector) will comprise additional elements that will aid in thefunctional expression of the TCR/CAR and/or the dominant negativereceptor and/or switch receptor encoded therein. In some embodiments, anexpression vector comprising a nucleic acid encoding for a TCR/CARand/or the dominant negative receptor and/or switch receptor furthercomprises a mammalian promoter. In one embodiment, the vector furthercomprises an elongation-factor-1-alpha promoter (EF-la promoter). Use ofan EF-la promoter may increase the efficiency in expression ofdownstream transgenes (e.g., a TCR/CAR and/or the dominant negativereceptor and/or switch receptor encoding nucleic acid sequence).Physiologic promoters (e.g., an EF-la promoter) may be less likely toinduce integration mediated genotoxicity, and may abrogate the abilityof the retroviral vector to transform stem cells. Other physiologicalpromoters suitable for use in a vector (e.g., lentiviral vector) areknown to those of skill in the art and may be incorporated into a vectorof the present invention. In some embodiments, the vector (e.g.,lentiviral vector) further comprises a non-requisite cis acting sequencethat may improve titers and gene expression. One non-limiting example ofa non-requisite cis acting sequence is the central polypurine tract andcentral termination sequence (cPPT/CTS) which is important for efficientreverse transcription and nuclear import. Other non-requisite cis actingsequences are known to those of skill in the art and may be incorporatedinto a vector (e.g., lentiviral vector) of the present invention. Insome embodiments, the vector further comprises a posttranscriptionalregulatory element. Posttranscriptional regulatory elements may improveRNA translation, improve transgene expression and stabilize RNAtranscripts. One example of a posttranscriptional regulatory element isthe woodchuck hepatitis virus posttranscriptional regulatory element(WPRE). Accordingly, in some embodiments a vector for the presentinvention further comprises a WPRE sequence. Various posttranscriptionalregulator elements are known to those of skill in the art and may beincorporated into a vector (e.g., lentiviral vector) of the presentinvention. A vector of the present invention may further compriseadditional elements such as a rev response element (RRE) for RNAtransport, packaging sequences, and 5′ and 3′ long terminal repeats(LTRs). The term “long terminal repeat” or “LTR” refers to domains ofbase pairs located at the ends of retroviral DNAs which comprise U3, Rand U5 regions. LTRs generally provide functions required for theexpression of retroviral genes (e.g., promotion, initiation andpolyadenylation of gene transcripts) and to viral replication. In oneembodiment, a vector (e.g., lentiviral vector) of the present inventionincludes a 3′ U3 deleted LTR. Accordingly, a vector (e.g., lentiviralvector) of the present invention may comprise any combination of theelements described herein to enhance the efficiency of functionalexpression of transgenes. For example, a vector (e.g., lentiviralvector) of the present invention may comprise a WPRE sequence, cPPTsequence, RRE sequence, 5′LTR, 3′ U3 deleted LTR′ in addition to anucleic acid encoding for a TCR/CAR and/or the dominant negativereceptor and/or switch receptor.

Vectors of the present invention may be self-inactivating vectors. Asused herein, the term “self-inactivating vector” refers to vectors inwhich the 3′ LTR enhancer promoter region (U3 region) has been modified(e.g., by deletion or substitution). A self-inactivating vector mayprevent viral transcription beyond the first round of viral replication.Consequently, a self-inactivating vector may be capable of infecting andthen integrating into a host genome (e.g., a mammalian genome) onlyonce, and cannot be passed further. Accordingly, self-inactivatingvectors may greatly reduce the risk of creating a replication-competentvirus.

In some embodiments, a nucleic acid of the present invention may be RNA,e.g., in vitro synthesized RNA. Methods for in vitro synthesis of RNAare known to those of skill in the art; any known method can be used tosynthesize RNA comprising a sequence encoding a TCR/CAR and/or thedominant negative receptor and/or switch receptor of the presentdisclosure. Methods for introducing RNA into a host cell are known inthe art. See, e.g., Zhao et al. Cancer Res. (2010) 15: 9053. IntroducingRNA comprising a nucleotide sequence encoding a TCR/CAR and/or thedominant negative receptor and/or switch receptor of the presentdisclosure into a host cell can be carried out in vitro or ex vivo or invivo. For example, a host cell (e.g., an NK cell, a cytotoxic Tlymphocyte, etc.) can be electroporated in vitro or ex vivo with RNAcomprising a nucleotide sequence encoding a TCR/CAR and/or the dominantnegative receptor and/or switch receptor of the present disclosure.

In order to assess the expression of a polypeptide or portions thereof,the expression vector to be introduced into a cell may also containeither a selectable marker gene or a reporter gene, or both, tofacilitate identification and selection of expressing cells from thepopulation of cells sought to be transfected or infected through viralvectors. In some embodiments, the selectable marker may be carried on aseparate piece of DNA and used in a co-transfection procedure. Bothselectable markers and reporter genes may be flanked with appropriateregulatory sequences to enable expression in the host cells. Usefulselectable markers include, without limitation, antibiotic-resistancegenes.

Reporter genes are used for identifying potentially transfected cellsand for evaluating the functionality of regulatory sequences. Ingeneral, a reporter gene is a gene that is not present in or expressedby the recipient organism or tissue and that encodes a polypeptide whoseexpression is manifested by some easily detectable property, e.g.,enzymatic activity. Expression of the reporter gene is assessed at asuitable time after the DNA has been introduced into the recipientcells. Suitable reporter genes may include, without limitation, genesencoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secreted alkaline phosphatase, or the green fluorescentprotein gene (e.g., Ui-Tei et al., 2000 FEBS Letters 479: 79-82).

F. Modified Immune Cells

The present invention provides a modified immune cell or precursor cellthereof (e.g., a T cell), comprising a CAR and/or a dominant negativereceptor and/or a switch receptor. Accordingly, such modified cellspossess the specificity directed by the CAR that is expressed therein.For example, a modified cell of the present invention comprising aPSMA-CAR possesses specificity for PSMA on a target cell.

In some embodiments, a modified cell of the present invention comprisesa CAR. In one embodiment, a modified cell of the present inventioncomprises a CAR having affinity for a prostate-specific membrane antigen(PSMA) on a target cell. In some embodiments, a modified cell of thepresent invention comprises a dominant negative receptor and/or a switchreceptor. In one embodiment, a modified cell of the present inventioncomprises a dominant negative receptor capable of reducing the effect ofa negative signal transduction molecule in the microenvironment. In oneembodiment, a modified cell of the present invention comprises a switchreceptor capable of reducing the effect of a negative signaltransduction molecule in the microenvironment, and converting thenegative signal into a positive signal within the modified cell. In someembodiments, a modified cell of the present invention comprises a CARand a dominant negative receptor and/or a switch receptor. In oneembodiment, a modified cell of the present invention comprises a CARhaving affinity for PSMA on a target cell, and a dominant negativereceptor and/or a switch receptor. Modified cells comprising a dominantnegative receptor and/or a switch receptor of the present invention areable to engage negative signal transduction molecules (e.g., inhibitoryligands) in the microenvironment by virtue of their respectiveextracellular domains. In some embodiments, a modified cell of thepresent invention comprising a dominant negative receptor is capable ofreducing the effect of a negative signal transduction molecule in themicroenvironment, wherein the dominant negative receptor comprises anextracellular domain associated with the negative signal. In someembodiments, a modified cell of the present invention comprising aswitch receptor is capable of converting the effect of a negative signaltransduction molecule in the microenvironment into a positive signal,wherein the switch receptor comprises an extracellular domain associatedwith the negative signal and an intracellular domain associated with thepositive signal.

In an exemplary embodiment, a modified cell of the present inventioncomprises a dominant negative receptor that is capable of reducing theeffect of a negative signal transduction molecule. In one embodiment, amodified cell of the present invention comprises TGFβRII-DN.

In an exemplary embodiment, a modified cell of the present inventioncomprises a switch receptor that is capable of converting the effect ofa negative signal transduction molecule into a positive (e.g.,activating) signal within the modified cell. In one embodiment, amodified cell of the present invention comprises PD1-CTM-CD28. In oneembodiment, a modified cell of the present invention comprisesPD1^(A132L)-PTM-CD28. In one embodiment, a modified cell of the presentinvention comprises TIM3-CD28.

In an exemplary embodiment, a modified cell of the present inventioncomprises a PSMA-CAR and a dominant negative receptor that is capable ofreducing the effect of a negative signal transduction molecule. In oneembodiment, a modified cell of the present invention comprises a murineJ591 PSMA-CAR and TGFβRII-DN. In one embodiment, a modified cell of thepresent invention comprises a humanized J591 PSMA-CAR and TGFβRII-DN. Inone embodiment, a modified cell of the present invention comprises ahuman 1C3 PSMA-CAR and TGFβRII-DN. In one embodiment, a modified cell ofthe present invention comprises a human 2A10 PSMA-CAR and TGFβRII-DN. Inone embodiment, a modified cell of the present invention comprises ahuman 2F5 PSMA-CAR and TGFβRII-DN. In one embodiment, a modified cell ofthe present invention comprises a human 2C6 PSMA-CAR and TGFβRII-DN.Such modified cells (e.g., modified T cells) in addition to havingaffinity for PSMA on a target cell, are capable of reducing inhibitoryTGF-β signals from the microenvironment they reside in.

In an exemplary embodiment, a modified cell of the present inventioncomprises a PSMA-CAR and a switch receptor that is capable of convertingthe inhibitory effect of a negative signal transduction molecule into apositive signal within the modified cell. In one embodiment, a modifiedcell of the present invention comprises a murine J591 PSMA-CAR andPD1-CTM-CD28. In one embodiment, a modified cell of the presentinvention comprises a humanized J591 PSMA-CAR and PD1-PTM-CD28. In oneembodiment, a modified cell of the present invention comprises a human1C3 PSMA-CAR and PD1-CTM-CD28. In one embodiment, a modified cell of thepresent invention comprises a human 2A10 PSMA-CAR and PD1-CTM-CD28. Inone embodiment, a modified cell of the present invention comprises ahuman 2F5 PSMA-CAR and PD1-CTM-CD28. In one embodiment, a modified cellof the present invention comprises a human 2C6 PSMA-CAR andPD1-CTM-CD28. In one embodiment, a modified cell of the presentinvention comprises a murine J591 PSMA-CAR and PD1^(A132L)-PTM-CD28. Inone embodiment, a modified cell of the present invention comprises ahumanized J591 PSMA-CAR and PD1^(A132L)-PTM-CD28. In one embodiment, amodified cell of the present invention comprises a human 1C3 PSMA-CARand PD1^(A132L)-PTM-CD28. In one embodiment, a modified cell of thepresent invention comprises a human 2A10 PSMA-CAR andPD1^(A132L)-PTM-CD28. In one embodiment, a modified cell of the presentinvention comprises a human 2F5 PSMA-CAR and PD1^(A132L)-PTM-CD28. Inone embodiment, a modified cell of the present invention comprises ahuman 2C6 PSMA-CAR and PD1^(A132L)-PTM-CD28. In one embodiment, amodified cell of the present invention comprises a murine J591 PSMA-CARand TIM3-CD28. In one embodiment, a modified cell of the presentinvention comprises a humanized J591 PSMA-CAR and TIM3-CD28. In oneembodiment, a modified cell of the present invention comprises a human1C3 PSMA-CAR and TIM3-CD28. In one embodiment, a modified cell of thepresent invention comprises a human 2A10 PSMA-CAR and TIM3-CD28. In oneembodiment, a modified cell of the present invention comprises a human2F5 PSMA-CAR and TIM3-CD28. In one embodiment, a modified cell of thepresent invention comprises a human 2C6 PSMA-CAR and TIM3-CD28. In oneembodiment, a modified cell of the present invention comprises a murineJ591 PSMA-CAR and PD1-4-1BB. In one embodiment, a modified cell of thepresent invention comprises a humanized J591 PSMA-CAR and PD1-4-1BB. Inone embodiment, a modified cell of the present invention comprises ahuman 1C3 PSMA-CAR and PD1-4-1BB. In one embodiment, a modified cell ofthe present invention comprises a human 2A10 PSMA-CAR and PD1-4-1BB. Inone embodiment, a modified cell of the present invention comprises ahuman 2F5 PSMA-CAR and PD1-4-1BB. In one embodiment, a modified cell ofthe present invention comprises a human 2C6 PSMA-CAR and PD1-4-1BB. Inone embodiment, a modified cell of the present invention comprises amurine J591 PSMA-CAR and PD1^(A132L)-4-1BB. In one embodiment, amodified cell of the present invention comprises a humanized J591PSMA-CAR and PD1^(A132L)-4-1BB. In one embodiment, a modified cell ofthe present invention comprises a human 1C3 PSMA-CAR andPD1^(A132L)-4-1BB. In one embodiment, a modified cell of the presentinvention comprises a human 2A10 PSMA-CAR and PD1^(A132L)-4-1BB. In oneembodiment, a modified cell of the present invention comprises a human2F5 PSMA-CAR and PD1^(A132L)-4-1BB. In one embodiment, a modified cellof the present invention comprises a human 2C6 PSMA-CAR andPD1^(A132L)-4-1BB. In one embodiment, a modified cell of the presentinvention comprises a murine J591 PSMA-CAR and TGFβR-IL12Rβ1. In oneembodiment, a modified cell of the present invention comprises ahumanized J591 PSMA-CAR and TGFβR-IL12Rβ1. In one embodiment, a modifiedcell of the present invention comprises a human 1C3 PSMA-CAR andTGFβR-IL12Rβ1. In one embodiment, a modified cell of the presentinvention comprises a human 2A10 PSMA-CAR and TGFβR-IL12Rβ1. In oneembodiment, a modified cell of the present invention comprises a human2F5 PSMA-CAR and TGFβR-IL12Rβ1. In one embodiment, a modified cell ofthe present invention comprises a human 2C6 PSMA-CAR and TGFβR-IL12Rβ1.In one embodiment, a modified cell of the present invention comprises amurine J591 PSMA-CAR and TGFβR-IL12Rβ2. In one embodiment, a modifiedcell of the present invention comprises a humanized J591 PSMA-CAR andTGFβR-IL12Rβ2. In one embodiment, a modified cell of the presentinvention comprises a human 1C3 PSMA-CAR and TGFβR-IL12Rβ2. In oneembodiment, a modified cell of the present invention comprises a human2A10 PSMA-CAR and TGFβR-IL12Rβ2. In one embodiment, a modified cell ofthe present invention comprises a human 2F5 PSMA-CAR and TGFβR-IL12Rβ2.In one embodiment, a modified cell of the present invention comprises ahuman 2C6 PSMA-CAR and TGFβR-IL12Rβ2. Such modified cells (e.g.,modified T cells) in addition to having affinity for PSMA on a targetcell, are capable of converting inhibitory PD-1 or TGFβ signals from themicroenvironment into a positive (e.g., activating) signal within themodified cell. Such modified cells (e.g., modified T cells) in additionto having affinity for PSMA on a target cell, are capable of convertinginhibitory PD-1 or TIM-3 signals from the microenvironment into apositive (e.g., activating) CD28 signal within the modified cell.

In an exemplary embodiment, a modified cell of the present inventioncomprises a nucleic acid encoding a bispecific antibody. In oneembodiment, such modified cells can secrete the bispecific antibodyoutside of the modified cell. In one embodiment, a modified cell of thepresent invention comprises a nucleic acid encoding a bispecificantibody, wherein the bispecific antibody comprises more than oneantigen binding domain, wherein at least one antigen binding domainbinds to a negative signal transduction molecule (e.g., a negativesignal transduction molecule found in the microenvironment of themodified cell), and at least one antigen binding domain binds aco-stimulatory molecule on the surface of the modified cell. In oneembodiment, a modified cell of the present invention comprises a nucleicacid encoding a 13G4-1211 PD-L1/CD28 bispecific antibody as describedherein. In one embodiment, a modified cell of the present inventioncomprises a nucleic acid encoding a 10A5-1412 PD-L1/CD28 bispecificantibody as described herein. In one embodiment, a modified cell of thepresent invention comprises a nucleic acid encoding a 1B12-1412PD-L1/CD28 bispecific antibody as described herein. In one embodiment, amodified cell of the present invention comprises a nucleic acid encodinga TGFβR-1-1412 TGFβRII/CD28 bispecific antibody as described herein. Inone embodiment, a modified cell of the present invention comprises anucleic acid encoding a TGFβR-3-1412 TGFβRII/CD28 bispecific antibody asdescribed herein.

In an exemplary embodiment, a modified cell of the present inventioncomprises a PSMA-CAR, a dominant negative receptor and/or a switchreceptor, and may further comprise a nucleic acid encoding a bispecificantibody. Such modified cells (e.g., modified T cells) in addition tohaving affinity for PSMA on a target cell, are capable of reducinginhibitory signals from the microenvironment they reside in, andsecreting the bispecific antibody into the microenvironment they residein. In such cells, the activity of the bispecific antibody may furtherincrease the activation of the modified cell (e.g., modified T cell). Inone embodiment, a modified cell of the present invention comprises aPSMA-CAR selected from the group consisting of a murine J591 PSMA-CAR, ahumanized J591 PSMA-CAR, a human 1C3 PSMA-CAR, a human 2A10 PSMA-CAR, ahuman 2F5 PSMA-CAR, and a human 2C6 PSMA-CAR; TGFβRII-DN; and expressesand secretes a bispecific antibody selected from the group consisting ofa 13G4-1211 PD-L1/CD28 bispecific antibody, a 10A5-1412 PD-L1/CD28bispecific antibody, a 1B12-1412 PD-L1/CD28 bispecific antibody, aTGFβR-1-1412 TGFβRII/CD28 bispecific antibody, and a TGFβR-3-1412TGFβRII/CD28 bispecific antibody.

In an exemplary embodiment, a modified cell of the present inventioncomprises a PSMA-CAR, a switch receptor, and may further comprise anucleic acid encoding a bispecific antibody. Such modified cells (e.g.,modified T cells) in addition to having affinity for PSMA on a targetcell, are capable of converting inhibitory signals from themicroenvironment they reside in into a positive (e.g., activating)signal within the modified cell, and secreting the bispecific antibodyinto the microenvironment they reside in. In such cells, the activity ofthe bispecific antibody may further increase the activation of themodified cell (e.g., modified T cell). In one embodiment, a modifiedcell of the present invention comprises a PSMA-CAR selected from thegroup consisting of a murine J591 PSMA-CAR, a humanized J591 PSMA-CAR, ahuman 1C3 PSMA-CAR, a human 2A10 PSMA-CAR, a human 2F5 PSMA-CAR, and ahuman 2C6 PSMA-CAR; a switch receptor selected from the group consistingof a PD1-CTM-CD28 switch receptor, a PD1A132L-PTM-CD28 switch receptor,and a TIM3-CD28 switch receptor; and expresses and secretes a bispecificantibody selected from the group consisting of a 13G4-1211 PD-L1/CD28bispecific antibody, a 10A5-1412 PD-L1/CD28 bispecific antibody, a1B12-1412 PD-L1/CD28 bispecific antibody, a TGFβR-1-1412 TGFβRII/CD28bispecific antibody, and a TGFβR-3-1412 TGFβRII/CD28 bispecificantibody.

Any modified cell comprising a PSMA-CAR of the present invention, adominant negative receptor and/or a switch receptor of the presentinvention, and/or expresses and secretes a bispecific antibody of thepresent invention is envisioned, and can readily be understood and madeby a person of skill in the art in view of the disclosure herein.

G. Methods of Producing Modified Immune Cells

The present invention provides methods for producing or generating amodified immune cell or precursor thereof (e.g., a T cell) of theinvention for tumor immunotherapy, e.g., adoptive immunotherapy. Thecells generally are engineered by introducing one or more nucleic acidsencoding a subject CAR, dominant negative receptor and/or switchreceptor, and/or bispecific antibody, and/or combinations thereof.

In some embodiments, one or more nucleic acids encoding the subject CAR,dominant negative receptor and/or switch receptor, and/or bispecificantibody is introduced into a cell by an expression vector. Expressionvectors comprising a nucleic acid sequence encoding a subject CAR,dominant negative receptor and/or switch receptor, and/or bispecificantibody, and/or combinations thereof, of the present invention areprovided herein. Suitable expression vectors include lentivirus vectors,gamma retrovirus vectors, foamy virus vectors, adeno associated virus(AAV) vectors, adenovirus vectors, engineered hybrid viruses, naked DNA,including but not limited to transposon mediated vectors, such asSleeping Beauty, Piggybak, and Integrases such as Phi31. Some othersuitable expression vectors include Herpes simplex virus (HSV) andretrovirus expression vectors.

Adenovirus expression vectors are based on adenoviruses, which have alow capacity for integration into genomic DNA but a high efficiency fortransfecting host cells. Adenovirus expression vectors containadenovirus sequences sufficient to: (a) support packaging of theexpression vector and (b) to ultimately express the subject CAR,dominant negative receptor and/or switch receptor, and/or bispecificantibody, and/or combinations thereof, in the host cell. In someembodiments, the adenovirus genome is a 36 kb, linear, double strandedDNA, where a foreign DNA sequence (e.g., a nucleic acid encoding asubject CAR, dominant negative receptor and/or switch receptor, and/orbispecific antibody, and/or combinations thereof) may be inserted tosubstitute large pieces of adenoviral DNA in order to make theexpression vector of the present invention (see, e.g., Danthinne andImperiale, Gene Therapy (2000) 7(20): 1707-1714).

Another expression vector is based on an adeno associated virus, whichtakes advantage of the adenovirus coupled systems. This AAV expressionvector has a high frequency of integration into the host genome. It caninfect non-dividing cells, thus making it useful for delivery of genesinto mammalian cells, for example, in tissue cultures or in vivo. TheAAV vector has a broad host range for infectivity. Details concerningthe generation and use of AAV vectors are described in U.S. Pat. Nos.5,139,941 and 4,797,368.

Retrovirus expression vectors are capable of integrating into the hostgenome, delivering a large amount of foreign genetic material, infectinga broad spectrum of species and cell types and being packaged in specialcell lines. The retrovirus vector is constructed by inserting a nucleicacid (e.g., a nucleic acid encoding a subject CAR, dominant negativereceptor and/or switch receptor, and/or bispecific antibody, and/orcombinations thereof) into the viral genome at certain locations toproduce a virus that is replication defective. Though the retrovirusvectors are able to infect a broad variety of cell types, integrationand stable expression of the subject CAR, dominant negative receptorand/or switch receptor, and/or bispecific antibody, and/or combinationsthereof, requires the division of host cells.

Lentivirus vectors are derived from lentiviruses, which are complexretroviruses that, in addition to the common retroviral genes gag, pol,and env, contain other genes with regulatory or structural function(see, e.g., U.S. Pat. Nos. 6,013,516 and 5,994,136). Some examples oflentiviruses include the Human Immunodeficiency Viruses (HIV-1, HIV-2)and the Simian Immunodeficiency Virus (SIV). Lentivirus vectors havebeen generated by multiply attenuating the HIV virulence genes, forexample, the genes env, vif, vpr, vpu and nef are deleted making thevector biologically safe. Lentivirus vectors are capable of infectingnon-dividing cells and can be used for both in vivo and ex vivo genetransfer and expression, e.g., of a nucleic acid encoding a subject CAR,dominant negative receptor and/or switch receptor, and/or bispecificantibody, and/or combinations thereof (see, e.g., U.S. Pat. No.5,994,136).

Expression vectors including a nucleic acid of the present disclosurecan be introduced into a host cell by any means known to persons skilledin the art. The expression vectors may include viral sequences fortransfection, if desired. Alternatively, the expression vectors may beintroduced by fusion, electroporation, biolistics, transfection,lipofection, or the like. The host cell may be grown and expanded inculture before introduction of the expression vectors, followed by theappropriate treatment for introduction and integration of the vectors.The host cells are then expanded and may be screened by virtue of amarker present in the vectors. Various markers that may be used areknown in the art, and may include hprt, neomycin resistance, thymidinekinase, hygromycin resistance, etc. As used herein, the terms “cell,”“cell line,” and “cell culture” may be used interchangeably. In someembodiments, the host cell an immune cell or precursor thereof, e.g., aT cell, an NK cell, or an NKT cell.

The present invention also provides genetically engineered cells whichinclude and stably express a subject CAR, dominant negative receptorand/or switch receptor, and/or bispecific antibody, and/or combinationsthereof, of the present disclosure. In some embodiments, the geneticallyengineered cells are genetically engineered T-lymphocytes (T cells),naive T cells (TN), memory T cells (for example, central memory T cells(TCM), effector memory cells (TEM)), natural killer cells (NK cells),and macrophages capable of giving rise to therapeutically relevantprogeny. In one embodiment, the genetically engineered cells areautologous cells.

Modified cells (e.g., comprising a subject CAR, dominant negativereceptor and/or switch receptor, and/or expresses and secretes abispecific antibody, and/or combinations thereof) may be produced bystably transfecting host cells with an expression vector including anucleic acid of the present disclosure. Additional methods to generate amodified cell of the present disclosure include, without limitation,chemical transformation methods (e.g., using calcium phosphate,dendrimers, liposomes and/or cationic polymers), non-chemicaltransformation methods (e.g., electroporation, optical transformation,gene electrotransfer and/or hydrodynamic delivery) and/or particle-basedmethods (e.g., impalefection, using a gene gun and/or magnetofection).Transfected cells expressing a subject CAR, dominant negative receptorand/or switch receptor, and/or bispecific antibody, and/or combinationsthereof, of the present disclosure may be expanded ex vivo.

Physical methods for introducing an expression vector into host cellsinclude calcium phosphate precipitation, lipofection, particlebombardment, microinjection, electroporation, and the like. Methods forproducing cells including vectors and/or exogenous nucleic acids arewell-known in the art. See, e.g., Sambrook et al. (2001), MolecularCloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York.Chemical methods for introducing an expression vector into a host cellinclude colloidal dispersion systems, such as macromolecule complexes,nanocapsules, microspheres, beads, and lipid-based systems includingoil-in-water emulsions, micelles, mixed micelles, and liposomes.

Lipids suitable for use can be obtained from commercial sources. Forexample, dimyristyl phosphatidylcholine (“DMPC”) can be obtained fromSigma, St. Louis, Mo.; dicetyl phosphate (“DCP”) can be obtained from K& K Laboratories (Plainview, N.Y.); cholesterol (“Choi”) can be obtainedfrom Calbiochem-Behring; dimyristyl phosphatidylglycerol (“DMPG”) andother lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham,Ala.). Stock solutions of lipids in chloroform or chloroform/methanolcan be stored at about −20° C. Chloroform may be used as the onlysolvent since it is more readily evaporated than methanol. “Liposome” isa generic term encompassing a variety of single and multilamellar lipidvehicles formed by the generation of enclosed lipid bilayers oraggregates. Liposomes can be characterized as having vesicularstructures with a phospholipid bilayer membrane and an inner aqueousmedium. Multilamellar liposomes have multiple lipid layers separated byaqueous medium. They form spontaneously when phospholipids are suspendedin an excess of aqueous solution. The lipid components undergoself-rearrangement before the formation of closed structures and entrapwater and dissolved solutes between the lipid bilayers (Ghosh et al.,1991 Glycobiology 5: 505-10). Compositions that have differentstructures in solution than the normal vesicular structure are alsoencompassed. For example, the lipids may assume a micellar structure ormerely exist as non-uniform aggregates of lipid molecules. Alsocontemplated are lipofectamine-nucleic acid complexes.

Regardless of the method used to introduce exogenous nucleic acids intoa host cell or otherwise expose a cell to the inhibitor of the presentinvention, in order to confirm the presence of the nucleic acids in thehost cell, a variety of assays may be performed. Such assays include,for example, molecular biology assays well known to those of skill inthe art, such as Southern and Northern blotting, RT-PCR and PCR;biochemistry assays, such as detecting the presence or absence of aparticular peptide, e.g., by immunological means (ELISAs and Westernblots) or by assays described herein to identify agents falling withinthe scope of the invention.

In one embodiment, the nucleic acids introduced into the host cell areRNA. In another embodiment, the RNA is mRNA that comprises in vitrotranscribed RNA or synthetic RNA. The RNA may be produced by in vitrotranscription using a polymerase chain reaction (PCR)-generatedtemplate. DNA of interest from any source can be directly converted byPCR into a template for in vitro mRNA synthesis using appropriateprimers and RNA polymerase. The source of the DNA may be, for example,genomic DNA, plasmid DNA, phage DNA, cDNA, synthetic DNA sequence or anyother appropriate source of DNA.

PCR may be used to generate a template for in vitro transcription ofmRNA which is then introduced into cells. Methods for performing PCR arewell known in the art. Primers for use in PCR are designed to haveregions that are substantially complementary to regions of the DNA to beused as a template for the PCR. “Substantially complementary,” as usedherein, refers to sequences of nucleotides where a majority or all ofthe bases in the primer sequence are complementary. Substantiallycomplementary sequences are able to anneal or hybridize with theintended DNA target under annealing conditions used for PCR. The primerscan be designed to be substantially complementary to any portion of theDNA template. For example, the primers can be designed to amplify theportion of a gene that is normally transcribed in cells (the openreading frame), including 5′ and 3′ UTRs. The primers may also bedesigned to amplify a portion of a gene that encodes a particular domainof interest. In one embodiment, the primers are designed to amplify thecoding region of a human cDNA, including all or portions of the 5′ and3′ UTRs. Primers useful for PCR are generated by synthetic methods thatare well known in the art. “Forward primers” are primers that contain aregion of nucleotides that are substantially complementary tonucleotides on the DNA template that are upstream of the DNA sequencethat is to be amplified. “Upstream” is used herein to refer to alocation 5, to the DNA sequence to be amplified relative to the codingstrand. “Reverse primers” are primers that contain a region ofnucleotides that are substantially complementary to a double-strandedDNA template that are downstream of the DNA sequence that is to beamplified. “Downstream” is used herein to refer to a location 3′ to theDNA sequence to be amplified relative to the coding strand.

Chemical structures that have the ability to promote stability and/ortranslation efficiency of the RNA may also be used. The RNA preferablyhas 5′ and 3′ UTRs. In one embodiment, the 5′ UTR is between zero and3000 nucleotides in length. The length of 5′ and 3′ UTR sequences to beadded to the coding region can be altered by different methods,including, but not limited to, designing primers for PCR that anneal todifferent regions of the UTRs. Using this approach, one of ordinaryskill in the art can modify the 5′ and 3′ UTR lengths required toachieve optimal translation efficiency following transfection of thetranscribed RNA.

The 5′ and 3′ UTRs can be the naturally occurring, endogenous 5′ and 3′UTRs for the gene of interest. Alternatively, UTR sequences that are notendogenous to the gene of interest can be added by incorporating the UTRsequences into the forward and reverse primers or by any othermodifications of the template. The use of UTR sequences that are notendogenous to the gene of interest can be useful for modifying thestability and/or translation efficiency of the RNA. For example, it isknown that AU-rich elements in 3′ UTR sequences can decrease thestability of mRNA. Therefore, 3′ UTRs can be selected or designed toincrease the stability of the transcribed RNA based on properties ofUTRs that are well known in the art.

In one embodiment, the 5′ UTR can contain the Kozak sequence of theendogenous gene. Alternatively, when a 5′ UTR that is not endogenous tothe gene of interest is being added by PCR as described above, aconsensus Kozak sequence can be redesigned by adding the 5′ UTRsequence. Kozak sequences can increase the efficiency of translation ofsome RNA transcripts, but does not appear to be required for all RNAs toenable efficient translation. The requirement for Kozak sequences formany mRNAs is known in the art. In other embodiments the 5′ UTR can bederived from an RNA virus whose RNA genome is stable in cells. In otherembodiments various nucleotide analogues can be used in the 3′ or 5′ UTRto impede exonuclease degradation of the mRNA.

To enable synthesis of RNA from a DNA template without the need for genecloning, a promoter of transcription should be attached to the DNAtemplate upstream of the sequence to be transcribed. When a sequencethat functions as a promoter for an RNA polymerase is added to the 5′end of the forward primer, the RNA polymerase promoter becomesincorporated into the PCR product upstream of the open reading framethat is to be transcribed. In one embodiment, the promoter is a T7polymerase promoter, as described elsewhere herein. Other usefulpromoters include, but are not limited to, T3 and SP6 RNA polymerasepromoters. Consensus nucleotide sequences for T7, T3 and SP6 promotersare known in the art.

In one embodiment, the mRNA has both a cap on the 5′ end and a 3′poly(A) tail which determine ribosome binding, initiation of translationand stability mRNA in the cell. On a circular DNA template, forinstance, plasmid DNA, RNA polymerase produces a long concatamericproduct which is not suitable for expression in eukaryotic cells. Thetranscription of plasmid DNA linearized at the end of the 3′ UTR resultsin normal sized mRNA which is not effective in eukaryotic transfectioneven if it is polyadenylated after transcription.

On a linear DNA template, phage T7 RNA polymerase can extend the 3′ endof the transcript beyond the last base of the template (Schenborn andMierendorf, Nuc Acids Res., 13:6223-36 (1985); Nacheva andBerzal-Herranz, Eur. J. Biochem., 270:1485-65 (2003).

The polyA/T segment of the transcriptional DNA template can be producedduring PCR by using a reverse primer containing a polyT tail, such as100T tail (size can be 50-5000 T), or after PCR by any other method,including, but not limited to, DNA ligation or in vitro recombination.Poly(A) tails also provide stability to RNAs and reduce theirdegradation. Generally, the length of a poly(A) tail positivelycorrelates with the stability of the transcribed RNA. In one embodiment,the poly(A) tail is between 100 and 5000 adenosines.

Poly(A) tails of RNAs can be further extended following in vitrotranscription with the use of a poly(A) polymerase, such as E. colipolyA polymerase (E-PAP). In one embodiment, increasing the length of apoly(A) tail from 100 nucleotides to between 300 and 400 nucleotidesresults in about a two-fold increase in the translation efficiency ofthe RNA. Additionally, the attachment of different chemical groups tothe 3′ end can increase mRNA stability. Such attachment can containmodified/artificial nucleotides, aptamers and other compounds. Forexample, ATP analogs can be incorporated into the poly(A) tail usingpoly(A) polymerase. ATP analogs can further increase the stability ofthe RNA.

5′ caps also provide stability to RNA molecules. In a preferredembodiment, RNAs produced by the methods disclosed herein include a 5′cap. The 5′ cap is provided using techniques known in the art anddescribed herein (Cougot, et al., Trends in Biochem. Sci., 29:436-444(2001); Stepinski, et al., RNA, 7:1468-95 (2001); Elango, et al.,Biochim. Biophys. Res. Commun., 330:958-966 (2005)).

In some embodiments, the RNA is electroporated into the cells, such asin vitro transcribed RNA. Any solutes suitable for cell electroporation,which can contain factors facilitating cellular permeability andviability such as sugars, peptides, lipids, proteins, antioxidants, andsurfactants can be included.

In some embodiments, a nucleic acid encoding a subject CAR, dominantnegative receptor and/or switch receptor, and/or bispecific antibody,and/or combinations thereof, of the present disclosure will be RNA,e.g., in vitro synthesized RNA. Methods for in vitro synthesis of RNAare known in the art; any known method can be used to synthesize RNAcomprising a sequence encoding a subject CAR, dominant negative receptorand/or switch receptor, and/or bispecific antibody, and/or combinationsthereof. Methods for introducing RNA into a host cell are known in theart. See, e.g., Zhao et al. Cancer Res. (2010) 15: 9053. Introducing RNAcomprising a nucleotide sequence encoding a subject CAR, dominantnegative receptor and/or switch receptor, and/or bispecific antibody,and/or combinations thereof, into a host cell can be carried out invitro or ex vivo or in vivo. For example, a host cell (e.g., an NK cell,a cytotoxic T lymphocyte, etc.) can be electroporated in vitro or exvivo with RNA comprising a nucleotide sequence encoding a subject CAR,dominant negative receptor and/or switch receptor, and/or bispecificantibody, and/or combinations thereof.

The disclosed methods can be applied to the modulation of T cellactivity in basic research and therapy, in the fields of cancer, stemcells, acute and chronic infections, and autoimmune diseases, includingthe assessment of the ability of the genetically modified T cell to killa target cancer cell.

The methods also provide the ability to control the level of expressionover a wide range by changing, for example, the promoter or the amountof input RNA, making it possible to individually regulate the expressionlevel. Furthermore, the PCR-based technique of mRNA production greatlyfacilitates the design of the mRNAs with different structures andcombination of their domains.

One advantage of RNA transfection methods of the invention is that RNAtransfection is essentially transient and a vector-free. A RNA transgenecan be delivered to a lymphocyte and expressed therein following a briefin vitro cell activation, as a minimal expressing cassette without theneed for any additional viral sequences. Under these conditions,integration of the transgene into the host cell genome is unlikely.Cloning of cells is not necessary because of the efficiency oftransfection of the RNA and its ability to uniformly modify the entirelymphocyte population.

Genetic modification of T cells with in vitro-transcribed RNA (IVT-RNA)makes use of two different strategies both of which have beensuccessively tested in various animal models. Cells are transfected within vitro-transcribed RNA by means of lipofection or electroporation. Itis desirable to stabilize IVT-RNA using various modifications in orderto achieve prolonged expression of transferred IVT-RNA.

Some IVT vectors are known in the literature which are utilized in astandardized manner as template for in vitro transcription and whichhave been genetically modified in such a way that stabilized RNAtranscripts are produced. Currently protocols used in the art are basedon a plasmid vector with the following structure: a 5′ RNA polymerasepromoter enabling RNA transcription, followed by a gene of interestwhich is flanked either 3′ and/or 5′ by untranslated regions (UTR), anda 3′ polyadenyl cassette containing 50-70 A nucleotides. Prior to invitro transcription, the circular plasmid is linearized downstream ofthe polyadenyl cassette by type II restriction enzymes (recognitionsequence corresponds to cleavage site). The polyadenyl cassette thuscorresponds to the later poly(A) sequence in the transcript. As a resultof this procedure, some nucleotides remain as part of the enzymecleavage site after linearization and extend or mask the poly(A)sequence at the 3′ end. It is not clear, whether this nonphysiologicaloverhang affects the amount of protein produced intracellularly fromsuch a construct.

In another aspect, the RNA construct is delivered into the cells byelectroporation. See, e.g., the formulations and methodology ofelectroporation of nucleic acid constructs into mammalian cells astaught in US 2004/0014645, US 2005/0052630A1, US 2005/0070841A1, US2004/0059285A1, US 2004/0092907A1. The various parameters includingelectric field strength required for electroporation of any known celltype are generally known in the relevant research literature as well asnumerous patents and applications in the field. See e.g., U.S. Pat. Nos.6,678,556, 7,171,264, and U.S. Pat. No. 7,173,116. Apparatus fortherapeutic application of electroporation are available commercially,e.g., the MedPulser™ DNA Electroporation Therapy System(Inovio/Genetronics, San Diego, Calif.), and are described in patentssuch as U.S. Pat. Nos. 6,567,694; 6,516,223, 5,993,434, 6,181,964, U.S.Pat. Nos. 6,241,701, and 6,233,482; electroporation may also be used fortransfection of cells in vitro as described e.g. in US20070128708A1.Electroporation may also be utilized to deliver nucleic acids into cellsin vitro. Accordingly, electroporation-mediated administration intocells of nucleic acids including expression constructs utilizing any ofthe many available devices and electroporation systems known to those ofskill in the art presents an exciting new means for delivering an RNA ofinterest to a target cell.

In some embodiments, the immune cells (e.g. T cells) can be incubated orcultivated prior to, during and/or subsequent to introducing the nucleicacid molecule encoding the subject CAR, dominant negative receptorand/or switch receptor, and/or bispecific antibody, and/or combinationsthereof. In some embodiments, the cells (e.g. T cells) can be incubatedor cultivated prior to, during or subsequent to the introduction of thenucleic acid molecule encoding the subject CAR, dominant negativereceptor and/or switch receptor, and/or bispecific antibody, and/orcombinations thereof, such as prior to, during or subsequent to thetransduction of the cells with a viral vector (e.g. lentiviral vector)encoding the subject CAR, dominant negative receptor and/or switchreceptor, and/or bispecific antibody, and/or combinations thereof. Insome embodiments, the method includes activating or stimulating cellswith a stimulating or activating agent (e.g. anti-CD3/anti-CD28antibodies) prior to introducing the nucleic acid molecule encoding thesubject CAR, dominant negative receptor and/or switch receptor, and/orbispecific antibody, and/or combinations thereof.

In some embodiments, where the nucleic acid sequences encoding thesubject CAR, dominant negative receptor and/or switch receptor, and/orbispecific antibody, and/or combinations thereof, of the presentinvention reside on one or more separate nucleic acid sequences, theorder of introducing each of the one or more nucleic acid sequences mayvary. For example, a nucleic acid sequence encoding a subject CAR anddominant negative receptor and/or switch receptor may first beintroduced into the host cell, followed by introduction of a nucleicacid sequence encoding a subject bispecific antibody. For example, anucleic acid sequence encoding a subject bispecific antibody may firstbe introduced into the host cell, followed by introduction of a nucleicacid sequence encoding a subject CAR and dominant negative receptorand/or switch receptor. In some embodiments, each of the one or morenucleic acid sequences are introduced into the host cell simultaneously.Those of skill in the art will be able to determine the order in whicheach of the one or more nucleic acid sequences are introduced into thehost cell.

H. Sources of Immune Cells

Prior to expansion, a source of immune cells is obtained from a subjectfor ex vivo manipulation. Sources of target cells for ex vivomanipulation may also include, e.g., autologous or heterologous donorblood, cord blood, or bone marrow. For example, the source of immunecells may be from the subject to be treated with the modified immunecells of the invention, e.g., the subject's blood, the subject's cordblood, or the subject's bone marrow. Non-limiting examples of subjectsinclude humans, dogs, cats, mice, rats, and transgenic species thereof.Preferably, the subject is a human.

Immune cells can be obtained from a number of sources, including blood,peripheral blood mononuclear cells, bone marrow, lymph node tissue,spleen tissue, umbilical cord, lymph, or lymphoid organs. Immune cellsare cells of the immune system, such as cells of the innate or adaptiveimmunity, e.g., myeloid or lymphoid cells, including lymphocytes,typically T cells and/or NK cells. Other exemplary cells include stemcells, such as multipotent and pluripotent stem cells, including inducedpluripotent stem cells (iPSCs). In some aspects, the cells are humancells. With reference to the subject to be treated, the cells may beallogeneic and/or autologous. The cells typically are primary cells,such as those isolated directly from a subject and/or isolated from asubject and frozen.

In certain embodiments, the immune cell is a T cell, e.g., a CD8+ T cell(e.g., a CD8+ naive T cell, central memory T cell, or effector memory Tcell), a CD4+ T cell, a natural killer T cell (NKT cells), a regulatoryT cell (Treg), a stem cell memory T cell, a lymphoid progenitor cell ahematopoietic stem cell, a natural killer cell (NK cell) or a dendriticcell. In some embodiments, the cells are monocytes or granulocytes,e.g., myeloid cells, macrophages, neutrophils, dendritic cells, mastcells, eosinophils, and/or basophils. In an embodiment, the target cellis an induced pluripotent stem (iPS) cell or a cell derived from an iPScell, e.g., an iPS cell generated from a subject, manipulated to alter(e.g., induce a mutation in) or manipulate the expression of one or moretarget genes, and differentiated into, e.g., a T cell, e.g., a CD8+ Tcell (e.g., a CD8+ naive T cell, central memory T cell, or effectormemory T cell), a CD4+ T cell, a stem cell memory T cell, a lymphoidprogenitor cell or a hematopoietic stem cell.

In some embodiments, the cells include one or more subsets of T cells orother cell types, such as whole T cell populations, CD4+ cells, CD8+cells, and subpopulations thereof, such as those defined by function,activation state, maturity, potential for differentiation, expansion,recirculation, localization, and/or persistence capacities,antigen-specificity, type of antigen receptor, presence in a particularorgan or compartment, marker or cytokine secretion profile, and/ordegree of differentiation. Among the sub-types and subpopulations of Tcells and/or of CD4+ and/or of CD8+ T cells are naive T (TN) cells,effector T cells (TEFF), memory T cells and sub-types thereof, such asstem cell memory T (TSCM), central memory T (TCM), effector memory T(TEM), or terminally differentiated effector memory T cells,tumor-infiltrating lymphocytes (TIL), immature T cells, mature T cells,helper T cells, cytotoxic T cells, mucosa-associated invariant T (MAIT)cells, naturally occurring and adaptive regulatory T (Treg) cells,helper T cells, such as TH1 cells, TH2 cells, TH3 cells, TH17 cells, TH9cells, TH22 cells, follicular helper T cells, alpha/beta T cells, anddelta/gamma T cells. In certain embodiments, any number of T cell linesavailable in the art, may be used.

In some embodiments, the methods include isolating immune cells from thesubject, preparing, processing, culturing, and/or engineering them. Insome embodiments, preparation of the engineered cells includes one ormore culture and/or preparation steps. The cells for engineering asdescribed may be isolated from a sample, such as a biological sample,e.g., one obtained from or derived from a subject. In some embodiments,the subject from which the cell is isolated is one having the disease orcondition or in need of a cell therapy or to which cell therapy will beadministered. The subject in some embodiments is a human in need of aparticular therapeutic intervention, such as the adoptive cell therapyfor which cells are being isolated, processed, and/or engineered.Accordingly, the cells in some embodiments are primary cells, e.g.,primary human cells. The samples include tissue, fluid, and othersamples taken directly from the subject, as well as samples resultingfrom one or more processing steps, such as separation, centrifugation,genetic engineering (e.g. transduction with viral vector), washing,and/or incubation. The biological sample can be a sample obtaineddirectly from a biological source or a sample that is processed.Biological samples include, but are not limited to, body fluids, such asblood, plasma, serum, cerebrospinal fluid, synovial fluid, urine andsweat, tissue and organ samples, including processed samples derivedtherefrom.

In some aspects, the sample from which the cells are derived or isolatedis blood or a blood-derived sample, or is or is derived from anapheresis or leukapheresis product. Exemplary samples include wholeblood, peripheral blood mononuclear cells (PBMCs), leukocytes, bonemarrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node,gut associated lymphoid tissue, mucosa associated lymphoid tissue,spleen, other lymphoid tissues, liver, lung, stomach, intestine, colon,kidney, pancreas, breast, bone, prostate, cervix, testes, ovaries,tonsil, or other organ, and/or cells derived therefrom. Samples include,in the context of cell therapy, e.g., adoptive cell therapy, samplesfrom autologous and allogeneic sources.

In some embodiments, the cells are derived from cell lines, e.g., T celllines. The cells in some embodiments are obtained from a xenogeneicsource, for example, from mouse, rat, non-human primate, and pig. Insome embodiments, isolation of the cells includes one or morepreparation and/or non-affinity based cell separation steps. In someexamples, cells are washed, centrifuged, and/or incubated in thepresence of one or more reagents, for example, to remove unwantedcomponents, enrich for desired components, lyse or remove cellssensitive to particular reagents. In some examples, cells are separatedbased on one or more property, such as density, adherent properties,size, sensitivity and/or resistance to particular components.

In some examples, cells from the circulating blood of a subject areobtained, e.g., by apheresis or leukapheresis. The samples, in someaspects, contain lymphocytes, including T cells, monocytes,granulocytes, B cells, other nucleated white blood cells, red bloodcells, and/or platelets, and in some aspects contains cells other thanred blood cells and platelets. In some embodiments, the blood cellscollected from the subject are washed, e.g., to remove the plasmafraction and to place the cells in an appropriate buffer or media forsubsequent processing steps. In some embodiments, the cells are washedwith phosphate buffered saline (PBS). In some aspects, a washing step isaccomplished by tangential flow filtration (TFF) according to themanufacturer's instructions. In some embodiments, the cells areresuspended in a variety of biocompatible buffers after washing. Incertain embodiments, components of a blood cell sample are removed andthe cells directly resuspended in culture media. In some embodiments,the methods include density-based cell separation methods, such as thepreparation of white blood cells from peripheral blood by lysing the redblood cells and centrifugation through a Percoll or Ficoll gradient.

In one embodiment, immune are obtained cells from the circulating bloodof an individual are obtained by apheresis or leukapheresis. Theapheresis product typically contains lymphocytes, including T cells,monocytes, granulocytes, B cells, other nucleated white blood cells, redblood cells, and platelets. The cells collected by apheresis may bewashed to remove the plasma fraction and to place the cells in anappropriate buffer or media, such as phosphate buffered saline (PBS) orwash solution lacks calcium and may lack magnesium or may lack many ifnot all divalent cations, for subsequent processing steps. Afterwashing, the cells may be resuspended in a variety of biocompatiblebuffers, such as, for example, Ca-free, Mg-free PBS. Alternatively, theundesirable components of the apheresis sample may be removed and thecells directly resuspended in culture media.

In some embodiments, the isolation methods include the separation ofdifferent cell types based on the expression or presence in the cell ofone or more specific molecules, such as surface markers, e.g., surfaceproteins, intracellular markers, or nucleic acid. In some embodiments,any known method for separation based on such markers may be used. Insome embodiments, the separation is affinity- or immunoaffinity-basedseparation. For example, the isolation in some aspects includesseparation of cells and cell populations based on the cells' expressionor expression level of one or more markers, typically cell surfacemarkers, for example, by incubation with an antibody or binding partnerthat specifically binds to such markers, followed generally by washingsteps and separation of cells having bound the antibody or bindingpartner, from those cells having not bound to the antibody or bindingpartner.

Such separation steps can be based on positive selection, in which thecells having bound the reagents are retained for further use, and/ornegative selection, in which the cells having not bound to the antibodyor binding partner are retained. In some examples, both fractions areretained for further use. In some aspects, negative selection can beparticularly useful where no antibody is available that specificallyidentifies a cell type in a heterogeneous population, such thatseparation is best carried out based on markers expressed by cells otherthan the desired population. The separation need not result in 100%enrichment or removal of a particular cell population or cellsexpressing a particular marker. For example, positive selection of orenrichment for cells of a particular type, such as those expressing amarker, refers to increasing the number or percentage of such cells, butneed not result in a complete absence of cells not expressing themarker. Likewise, negative selection, removal, or depletion of cells ofa particular type, such as those expressing a marker, refers todecreasing the number or percentage of such cells, but need not resultin a complete removal of all such cells.

In some examples, multiple rounds of separation steps are carried out,where the positively or negatively selected fraction from one step issubjected to another separation step, such as a subsequent positive ornegative selection. In some examples, a single separation step candeplete cells expressing multiple markers simultaneously, such as byincubating cells with a plurality of antibodies or binding partners,each specific for a marker targeted for negative selection. Likewise,multiple cell types can simultaneously be positively selected byincubating cells with a plurality of antibodies or binding partnersexpressed on the various cell types.

In some embodiments, one or more of the T cell populations is enrichedfor or depleted of cells that are positive for (marker+) or express highlevels (marker^(high)) of one or more particular markers, such assurface markers, or that are negative for (marker⁻) or expressrelatively low levels (marker^(low)) of one or more markers. Forexample, in some aspects, specific subpopulations of T cells, such ascells positive or expressing high levels of one or more surface markers,e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and/orCD45RO+ T cells, are isolated by positive or negative selectiontechniques. In some cases, such markers are those that are absent orexpressed at relatively low levels on certain populations of T cells(such as non-memory cells) but are present or expressed at relativelyhigher levels on certain other populations of T cells (such as memorycells). In one embodiment, the cells (such as the CD8+ cells or the Tcells, e.g., CD3+ cells) are enriched for (i.e., positively selectedfor) cells that are positive or expressing high surface levels ofCD45RO, CCR7, CD28, CD27, CD44, CD 127, and/or CD62L and/or depleted of(e.g., negatively selected for) cells that are positive for or expresshigh surface levels of CD45RA. In some embodiments, cells are enrichedfor or depleted of cells positive or expressing high surface levels ofCD 122, CD95, CD25, CD27, and/or IL7-Ra (CD 127). In some examples, CD8+T cells are enriched for cells positive for CD45RO (or negative forCD45RA) and for CD62L. For example, CD3+, CD28+ T cells can bepositively selected using CD3/CD28 conjugated magnetic beads (e.g.,DYNABEADS® M-450 CD3/CD28 T Cell Expander).

In some embodiments, T cells are separated from a PBMC sample bynegative selection of markers expressed on non-T cells, such as B cells,monocytes, or other white blood cells, such as CD14. In some aspects, aCD4+ or CD8+ selection step is used to separate CD4+ helper and CD8+cytotoxic T cells. Such CD4+ and CD8+ populations can be further sortedinto sub-populations by positive or negative selection for markersexpressed or expressed to a relatively higher degree on one or morenaive, memory, and/or effector T cell subpopulations. In someembodiments, CD8+ cells are further enriched for or depleted of naive,central memory, effector memory, and/or central memory stem cells, suchas by positive or negative selection based on surface antigensassociated with the respective subpopulation. In some embodiments,enrichment for central memory T (TCM) cells is carried out to increaseefficacy, such as to improve long-term survival, expansion, and/orengraftment following administration, which in some aspects isparticularly robust in such sub-populations. In some embodiments,combining TCM-enriched CD8+ T cells and CD4+ T cells further enhancesefficacy.

In embodiments, memory T cells are present in both CD62L+ andCD62L-subsets of CD8+ peripheral blood lymphocytes. PBMC can be enrichedfor or depleted of CD62L-CD8+ and/or CD62L+CD8+ fractions, such as usinganti-CD8 and anti-CD62L antibodies. In some embodiments, a CD4+ T cellpopulation and a CD8+ T cell sub-population, e.g., a sub-populationenriched for central memory (TCM) cells. In some embodiments, theenrichment for central memory T (TCM) cells is based on positive or highsurface expression of CD45RO, CD62L, CCR7, CD28, CD3, and/or CD 127; insome aspects, it is based on negative selection for cells expressing orhighly expressing CD45RA and/or granzyme B. In some aspects, isolationof a CD8+ population enriched for TCM cells is carried out by depletionof cells expressing CD4, CD 14, CD45RA, and positive selection orenrichment for cells expressing CD62L. In one aspect, enrichment forcentral memory T (TCM) cells is carried out starting with a negativefraction of cells selected based on CD4 expression, which is subjectedto a negative selection based on expression of CD 14 and CD45RA, and apositive selection based on CD62L. Such selections in some aspects arecarried out simultaneously and in other aspects are carried outsequentially, in either order. In some aspects, the same CD4expression-based selection step used in preparing the CD8+ cellpopulation or subpopulation, also is used to generate the CD4+ cellpopulation or sub-population, such that both the positive and negativefractions from the CD4-based separation are retained and used insubsequent steps of the methods, optionally following one or morefurther positive or negative selection steps.

CD4+ T helper cells are sorted into naive, central memory, and effectorcells by identifying cell populations that have cell surface antigens.CD4+ lymphocytes can be obtained by standard methods. In someembodiments, naive CD4+ T lymphocytes are CD45RO−, CD45RA+, CD62L+, CD4+T cells. In some embodiments, central memory CD4+ cells are CD62L+ andCD45RO+. In some embodiments, effector CD4+ cells are CD62L− and CD45RO.In one example, to enrich for CD4+ cells by negative selection, amonoclonal antibody cocktail typically includes antibodies to CD14,CD20, CD11b, CD16, HLA-DR, and CD8. In some embodiments, the antibody orbinding partner is bound to a solid support or matrix, such as amagnetic bead or paramagnetic bead, to allow for separation of cells forpositive and/or negative selection.

In some embodiments, the cells are incubated and/or cultured prior to orin connection with genetic engineering. The incubation steps can includeculture, cultivation, stimulation, activation, and/or propagation. Insome embodiments, the compositions or cells are incubated in thepresence of stimulating conditions or a stimulatory agent. Suchconditions include those designed to induce proliferation, expansion,activation, and/or survival of cells in the population, to mimic antigenexposure, and/or to prime the cells for genetic engineering, such as forthe introduction of a recombinant antigen receptor. The conditions caninclude one or more of particular media, temperature, oxygen content,carbon dioxide content, time, agents, e.g., nutrients, amino acids,antibiotics, ions, and/or stimulatory factors, such as cytokines,chemokines, antigens, binding partners, fusion proteins, recombinantsoluble receptors, and any other agents designed to activate the cells.In some embodiments, the stimulating conditions or agents include one ormore agent, e.g., ligand, which is capable of activating anintracellular signaling domain of a TCR complex. In some aspects, theagent turns on or initiates TCR/CD3 intracellular signaling cascade in aT cell. Such agents can include antibodies, such as those specific for aTCR component and/or costimulatory receptor, e.g., anti-CD3, anti-CD28,for example, bound to solid support such as a bead, and/or one or morecytokines. Optionally, the expansion method may further comprise thestep of adding anti-CD3 and/or anti CD28 antibody to the culture medium(e.g., at a concentration of at least about 0.5 ng/ml). In someembodiments, the stimulating agents include IL-2 and/or IL-15, forexample, an IL-2 concentration of at least about 10 units/mL.

In another embodiment, T cells are isolated from peripheral blood bylysing the red blood cells and depleting the monocytes, for example, bycentrifugation through a PERCOLL™ gradient. Alternatively, T cells canbe isolated from an umbilical cord. In any event, a specificsubpopulation of T cells can be further isolated by positive or negativeselection techniques.

The cord blood mononuclear cells so isolated can be depleted of cellsexpressing certain antigens, including, but not limited to, CD34, CD8,CD14, CD19, and CD56. Depletion of these cells can be accomplished usingan isolated antibody, a biological sample comprising an antibody, suchas ascites, an antibody bound to a physical support, and a cell boundantibody.

Enrichment of a T cell population by negative selection can beaccomplished using a combination of antibodies directed to surfacemarkers unique to the negatively selected cells. A preferred method iscell sorting and/or selection via negative magnetic immunoadherence orflow cytometry that uses a cocktail of monoclonal antibodies directed tocell surface markers present on the cells negatively selected. Forexample, to enrich for CD4⁺ cells by negative selection, a monoclonalantibody cocktail typically includes antibodies to CD14, CD20, CD11b,CD16, HLA-DR, and CD8.

For isolation of a desired population of cells by positive or negativeselection, the concentration of cells and surface (e.g., particles suchas beads) can be varied. In certain embodiments, it may be desirable tosignificantly decrease the volume in which beads and cells are mixedtogether (i.e., increase the concentration of cells), to ensure maximumcontact of cells and beads. For example, in one embodiment, aconcentration of 2 billion cells/ml is used. In one embodiment, aconcentration of 1 billion cells/ml is used. In a further embodiment,greater than 100 million cells/ml is used. In a further embodiment, aconcentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 millioncells/ml is used. In yet another embodiment, a concentration of cellsfrom 75, 80, 85, 90, 95, or 100 million cells/ml is used. In furtherembodiments, concentrations of 125 or 150 million cells/ml can be used.Using high concentrations can result in increased cell yield, cellactivation, and cell expansion.

T cells can also be frozen after the washing step, which does notrequire the monocyte-removal step. While not wishing to be bound bytheory, the freeze and subsequent thaw step provides a more uniformproduct by removing granulocytes and to some extent monocytes in thecell population. After the washing step that removes plasma andplatelets, the cells may be suspended in a freezing solution. While manyfreezing solutions and parameters are known in the art and will beuseful in this context, in a non-limiting example, one method involvesusing PBS containing 20% DMSO and 8% human serum albumin, or othersuitable cell freezing media. The cells are then frozen to −80° C. at arate of 1° C. per minute and stored in the vapor phase of a liquidnitrogen storage tank. Other methods of controlled freezing may be usedas well as uncontrolled freezing immediately at −20° C. or in liquidnitrogen.

In one embodiment, the population of T cells is comprised within cellssuch as peripheral blood mononuclear cells, cord blood cells, a purifiedpopulation of T cells, and a T cell line. In another embodiment,peripheral blood mononuclear cells comprise the population of T cells.In yet another embodiment, purified T cells comprise the population of Tcells.

In certain embodiments, T regulatory cells (Tregs) can be isolated froma sample. The sample can include, but is not limited to, umbilical cordblood or peripheral blood. In certain embodiments, the Tregs areisolated by flow-cytometry sorting. The sample can be enriched for Tregsprior to isolation by any means known in the art. The isolated Tregs canbe cryopreserved, and/or expanded prior to use. Methods for isolatingTregs are described in U.S. Pat. Nos. 7,754,482, 8,722,400, and9,555,105, and U.S. patent application Ser. No. 13/639,927, contents ofwhich are incorporated herein in their entirety.

I. Expansion of Immune Cells

Whether prior to or after modification of cells to express a subjectCAR, dominant negative receptor, and/or switch receptor, and/orbispecific antibody, and/or combinations thereof, the cells can beactivated and expanded in number using methods as described, forexample, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964;5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869;7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; andU.S. Publication No. 20060121005. For example, the T cells of theinvention may be expanded by contact with a surface having attachedthereto an agent that stimulates a CD3/TCR complex associated signal anda ligand that stimulates a co-stimulatory molecule on the surface of theT cells. In particular, T cell populations may be stimulated by contactwith an anti-CD3 antibody, or an antigen-binding fragment thereof, or ananti-CD2 antibody immobilized on a surface, or by contact with a proteinkinase C activator (e.g., bryostatin) in conjunction with a calciumionophore. For co-stimulation of an accessory molecule on the surface ofthe T cells, a ligand that binds the accessory molecule is used. Forexample, T cells can be contacted with an anti-CD3 antibody and ananti-CD28 antibody, under conditions appropriate for stimulatingproliferation of the T cells. Examples of an anti-CD28 antibody include9.3, B-T3, XR-CD28 (Diaclone, Besancon, France) and these can be used inthe invention, as can other methods and reagents known in the art (see,e.g., ten Berge et al., Transplant Proc. (1998) 30(8): 3975-3977; Haanenet al., J. Exp. Med. (1999) 190(9): 1319-1328; and Garland et al., J.Immunol. Methods (1999) 227(1-2): 53-63).

Expanding T cells by the methods disclosed herein can be multiplied byabout 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80fold, 90 fold, 100 fold, 200 fold, 300 fold, 400 fold, 500 fold, 600fold, 700 fold, 800 fold, 900 fold, 1000 fold, 2000 fold, 3000 fold,4000 fold, 5000 fold, 6000 fold, 7000 fold, 8000 fold, 9000 fold, 10,000fold, 100,000 fold, 1,000,000 fold, 10,000,000 fold, or greater, and anyand all whole or partial integers therebetween. In one embodiment, the Tcells expand in the range of about 20 fold to about 50 fold.

Following culturing, the T cells can be incubated in cell medium in aculture apparatus for a period of time or until the cells reachconfluency or high cell density for optimal passage before passing thecells to another culture apparatus. The culturing apparatus can be ofany culture apparatus commonly used for culturing cells in vitro.Preferably, the level of confluence is 70% or greater before passing thecells to another culture apparatus. More preferably, the level ofconfluence is 90% or greater. A period of time can be any time suitablefor the culture of cells in vitro. The T cell medium may be replacedduring the culture of the T cells at any time. Preferably, the T cellmedium is replaced about every 2 to 3 days. The T cells are thenharvested from the culture apparatus whereupon the T cells can be usedimmediately or cryopreserved to be stored for use at a later time. Inone embodiment, the invention includes cryopreserving the expanded Tcells. The cryopreserved T cells are thawed prior to introducing nucleicacids into the T cell.

In another embodiment, the method comprises isolating T cells andexpanding the T cells. In another embodiment, the invention furthercomprises cryopreserving the T cells prior to expansion. In yet anotherembodiment, the cryopreserved T cells are thawed for electroporationwith the RNA encoding the chimeric membrane protein.

Another procedure for ex vivo expansion cells is described in U.S. Pat.No. 5,199,942 (incorporated herein by reference). Expansion, such asdescribed in U.S. Pat. No. 5,199,942 can be an alternative or inaddition to other methods of expansion described herein. Briefly, exvivo culture and expansion of T cells comprises the addition to thecellular growth factors, such as those described in U.S. Pat. No.5,199,942, or other factors, such as flt3-L, IL-1, IL-3 and c-kitligand. In one embodiment, expanding the T cells comprises culturing theT cells with a factor selected from the group consisting of flt3-L,IL-1, IL-3 and c-kit ligand.

The culturing step as described herein (contact with agents as describedherein or after electroporation) can be very short, for example lessthan 24 hours such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, or 23 hours. The culturing step as describedfurther herein (contact with agents as described herein) can be longer,for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or more days.

Various terms are used to describe cells in culture. Cell culture refersgenerally to cells taken from a living organism and grown undercontrolled condition. A primary cell culture is a culture of cells,tissues or organs taken directly from an organism and before the firstsubculture. Cells are expanded in culture when they are placed in agrowth medium under conditions that facilitate cell growth and/ordivision, resulting in a larger population of the cells. When cells areexpanded in culture, the rate of cell proliferation is typicallymeasured by the amount of time required for the cells to double innumber, otherwise known as the doubling time.

Each round of subculturing is referred to as a passage. When cells aresubcultured, they are referred to as having been passaged. A specificpopulation of cells, or a cell line, is sometimes referred to orcharacterized by the number of times it has been passaged. For example,a cultured cell population that has been passaged ten times may bereferred to as a P10 culture. The primary culture, i.e., the firstculture following the isolation of cells from tissue, is designated P0.Following the first subculture, the cells are described as a secondaryculture (P1 or passage 1). After the second subculture, the cells becomea tertiary culture (P2 or passage 2), and so on. It will be understoodby those of skill in the art that there may be many population doublingsduring the period of passaging; therefore the number of populationdoublings of a culture is greater than the passage number. The expansionof cells (i.e., the number of population doublings) during the periodbetween passaging depends on many factors, including but is not limitedto the seeding density, substrate, medium, and time between passaging.

In one embodiment, the cells may be cultured for several hours (about 3hours) to about 14 days or any hourly integer value in between.Conditions appropriate for T cell culture include an appropriate media(e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15,(Lonza)) that may contain factors necessary for proliferation andviability, including serum (e.g., fetal bovine or human serum),interleukin-2 (IL-2), insulin, IFN-gamma, IL-4, IL-7, GM-CSF, IL-10,IL-12, IL-15, TGF-beta, and TNF-α. or any other additives for the growthof cells known to the skilled artisan. Other additives for the growth ofcells include, but are not limited to, surfactant, plasmanate, andreducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Mediacan include RPMI 1640, AIM-V, DMEM, MEM, α-MEM, F-12, X-Vivo 15, andX-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, andvitamins, either serum-free or supplemented with an appropriate amountof serum (or plasma) or a defined set of hormones, and/or an amount ofcytokine(s) sufficient for the growth and expansion of T cells.Antibiotics, e.g., penicillin and streptomycin, are included only inexperimental cultures, not in cultures of cells that are to be infusedinto a subject. The target cells are maintained under conditionsnecessary to support growth, for example, an appropriate temperature(e.g., 37° C.) and atmosphere (e.g., air plus 5% CO₂).

The medium used to culture the T cells may include an agent that canco-stimulate the T cells. For example, an agent that can stimulate CD3is an antibody to CD3, and an agent that can stimulate CD28 is anantibody to CD28. A cell isolated by the methods disclosed herein can beexpanded approximately 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60fold, 70 fold, 80 fold, 90 fold, 100 fold, 200 fold, 300 fold, 400 fold,500 fold, 600 fold, 700 fold, 800 fold, 900 fold, 1000 fold, 2000 fold,3000 fold, 4000 fold, 5000 fold, 6000 fold, 7000 fold, 8000 fold, 9000fold, 10,000 fold, 100,000 fold, 1,000,000 fold, 10,000,000 fold, orgreater. In one embodiment, the T cells expand in the range of about 20fold to about 50 fold, or more. In one embodiment, human T regulatorycells are expanded via anti-CD3 antibody coated KT64.86 artificialantigen presenting cells (aAPCs). In one embodiment, human T regulatorycells are expanded via anti-CD3 antibody coated K562 artificial antigenpresenting cells (aAPCs). Methods for expanding and activating T cellscan be found in U.S. Pat. Nos. 7,754,482, 8,722,400, and 9,555,105,contents of which are incorporated herein in their entirety.

In one embodiment, the method of expanding the T cells can furthercomprise isolating the expanded T cells for further applications. Inanother embodiment, the method of expanding can further comprise asubsequent electroporation of the expanded T cells followed byculturing. The subsequent electroporation may include introducing anucleic acid encoding an agent, such as transducing the expanded Tcells, transfecting the expanded T cells, or electroporating theexpanded T cells with a nucleic acid, into the expanded population of Tcells, wherein the agent further stimulates the T cell. The agent maystimulate the T cells, such as by stimulating further expansion,effector function, or another T cell function.

J. Methods of Treatment

The modified cells (e.g., T cells) described herein may be included in acomposition for immunotherapy. The composition may include apharmaceutical composition and further include a pharmaceuticallyacceptable carrier. A therapeutically effective amount of thepharmaceutical composition comprising the modified T cells may beadministered.

In one aspect, the invention includes a method for adoptive celltransfer therapy comprising administering to a subject in need thereof amodified T cell of the present invention. In another aspect, theinvention includes a method of treating a disease or condition in asubject comprising administering to a subject in need thereof apopulation of modified T cells.

Also included is a method of treating a disease or condition in asubject in need thereof comprising administering to the subject amodified cell (e.g., modified T cell) of the present invention. In oneembodiment, the method of treating a disease or condition in a subjectin need thereof comprises administering to the subject a modified cell(e.g., a modified T cell) comprising a subject CAR, dominant negativereceptor and/or switch receptor, and/or a bispecific antibody, and/orcombinations thereof. In one embodiment, the method of treating adisease or condition in a subject in need thereof comprisesadministering to the subject a modified cell (e.g., a modified T cell)comprising a subject CAR (e.g., a CAR having affinity for PSMA on atarget cell) and a dominant negative receptor and/or switch receptor. Inone embodiment, the method of treating a disease or condition in asubject in need thereof comprises administering to the subject amodified cell (e.g., a modified T cell) comprising a subject CAR (e.g.,a CAR having affinity for PSMA on a target cell), a dominant negativereceptor and/or switch receptor, and wherein the modified cell iscapable of expressing and secreting a bispecific antibody.

Methods for administration of immune cells for adoptive cell therapy areknown and may be used in connection with the provided methods andcompositions. For example, adoptive T cell therapy methods aredescribed, e.g., in U.S. Patent Application Publication No. 2003/0170238to Gruenberg et al; U.S. Pat. No. 4,690,915 to Rosenberg; Rosenberg(2011) Nat Rev Clin Oncol. 8(10):577-85). See, e.g., Themeli et al.(2013) Nat Biotechnol. 31(10): 928-933; Tsukahara et al. (2013) BiochemBiophys Res Commun 438(1): 84-9; Davila et al. (2013) PLoS ONE 8(4):e61338. In some embodiments, the cell therapy, e.g., adoptive T celltherapy is carried out by autologous transfer, in which the cells areisolated and/or otherwise prepared from the subject who is to receivethe cell therapy, or from a sample derived from such a subject. Thus, insome aspects, the cells are derived from a subject, e.g., patient, inneed of a treatment and the cells, following isolation and processingare administered to the same subject.

In some embodiments, the cell therapy, e.g., adoptive T cell therapy, iscarried out by allogeneic transfer, in which the cells are isolatedand/or otherwise prepared from a subject other than a subject who is toreceive or who ultimately receives the cell therapy, e.g., a firstsubject. In such embodiments, the cells then are administered to adifferent subject, e.g., a second subject, of the same species. In someembodiments, the first and second subjects are genetically identical. Insome embodiments, the first and second subjects are genetically similar.In some embodiments, the second subject expresses the same HLA class orsupertype as the first subject.

In some embodiments, the subject has been treated with a therapeuticagent targeting the disease or condition, e.g., the tumor, prior toadministration of the cells or composition containing the cells. In someaspects, the subject is refractory or non-responsive to the othertherapeutic agent. In some embodiments, the subject has persistent orrelapsed disease, e.g., following treatment with another therapeuticintervention, including chemotherapy, radiation, and/or hematopoieticstem cell transplantation (HSCT), e.g., allogenic HSCT. In someembodiments, the administration effectively treats the subject despitethe subject having become resistant to another therapy.

In some embodiments, the subject is responsive to the other therapeuticagent, and treatment with the therapeutic agent reduces disease burden.In some aspects, the subject is initially responsive to the therapeuticagent, but exhibits a relapse of the disease or condition over time. Insome embodiments, the subject has not relapsed. In some suchembodiments, the subject is determined to be at risk for relapse, suchas at a high risk of relapse, and thus the cells are administeredprophylactically, e.g., to reduce the likelihood of or prevent relapse.In some aspects, the subject has not received prior treatment withanother therapeutic agent.

In some embodiments, the subject has persistent or relapsed disease,e.g., following treatment with another therapeutic intervention,including chemotherapy, radiation, and/or hematopoietic stem celltransplantation (HSCT), e.g., allogenic HSCT. In some embodiments, theadministration effectively treats the subject despite the subject havingbecome resistant to another therapy.

The modified immune cells of the present invention can be administeredto an animal, preferably a mammal, even more preferably a human, totreat a cancer. In addition, the cells of the present invention can beused for the treatment of any condition related to a cancer, especiallya cell-mediated immune response against a tumor cell(s), where it isdesirable to treat or alleviate the disease. The types of cancers to betreated with the modified cells or pharmaceutical compositions of theinvention include, carcinoma, blastoma, and sarcoma, and certainleukemia or lymphoid malignancies, benign and malignant tumors, andmalignancies e.g., sarcomas, carcinomas, and melanomas. Other exemplarycancers include but are not limited breast cancer, prostate cancer,ovarian cancer, cervical cancer, skin cancer, pancreatic cancer,colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma,leukemia, lung cancer, thyroid cancer, and the like. The cancers may benon-solid tumors (such as hematological tumors) or solid tumors. Adulttumors/cancers and pediatric tumors/cancers are also included.

Solid tumors are abnormal masses of tissue that usually do not containcysts or liquid areas. Solid tumors can be benign or malignant.Different types of solid tumors are named for the type of cells thatform them (such as sarcomas, carcinomas, and lymphomas). Examples ofsolid tumors, such as sarcomas and carcinomas, include fibrosarcoma,myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and othersarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreaticcancer, breast cancer, lung cancers, ovarian cancer, prostate cancer,hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma,adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma,papillary thyroid carcinoma, pheochromocytomas sebaceous glandcarcinoma, papillary carcinoma, papillary adenocarcinomas, medullarycarcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bileduct carcinoma, choriocarcinoma, Wilms' tumor, cervical cancer,testicular tumor, seminoma, bladder carcinoma, melanoma, and CNS tumors(such as a glioma (such as brainstem glioma and mixed gliomas),glioblastoma (also known as glioblastoma multiforme) astrocytoma, CNSlymphoma, germinoma, medulloblastoma, Schwannoma craniopharyogioma,ependymoma, pinealoma, hemangioblastoma, acoustic neuroma,oligodendroglioma, menangioma, neuroblastoma, retinoblastoma and brainmetastases).

Carcinomas that can be amenable to therapy by a method disclosed hereininclude, but are not limited to, esophageal carcinoma, hepatocellularcarcinoma, basal cell carcinoma (a form of skin cancer), squamous cellcarcinoma (various tissues), bladder carcinoma, including transitionalcell carcinoma (a malignant neoplasm of the bladder), bronchogeniccarcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma,lung carcinoma, including small cell carcinoma and non-small cellcarcinoma of the lung, adrenocortical carcinoma, thyroid carcinoma,pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostatecarcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous glandcarcinoma, papillary carcinoma, papillary adenocarcinoma,cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductalcarcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma,embryonal carcinoma, Wilm's tumor, cervical carcinoma, uterinecarcinoma, testicular carcinoma, osteogenic carcinoma, epithelialcarcinoma, and nasopharyngeal carcinoma.

Sarcomas that can be amenable to therapy by a method disclosed hereininclude, but are not limited to, fibrosarcoma, myxosarcoma, liposarcoma,chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma,angiosarcoma, endotheliosarcoma, lymphangiosarcoma,lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's sarcoma,leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.

Prostate adenocarcinoma is an extremely common and lethal disease.Prostate cancer is the most common malignancy among men. Prostate canceris the second-leading cause of cancer-related deaths among men,accounting for an estimated 10% of annual male cancer deaths. PSMA ishighly expressed in malignant prostate tissue, with low-levels ofexpression in some normal human tissues. Under normal physiologicconditions, PSMA is expressed in the prostate gland (secretory acinarepithelium), kidney (proximal tubules), nervous system glia (astrocytesand Schwann cells), and the small intestine (jejunal brush border). PSMAis much more highly expressed in prostate epithelium and issignificantly upregulated in malignant prostate tissues. PSMA expressionin normal cells has been found to be 100-fold to 1000-fold less than inprostate carcinoma cells. PSMA expression increases significantly duringthe transformation from benign prostatic hyperplasia to prostaticadenocarcinoma. PSMA expression has been found to be directly correlatedwith the histologic grade of malignant prostate tissue and increaseswith more advanced disease (i.e. highest PSMA expression found inprostate cancer metastases in lymph node and bone).

In one embodiment, the methods of the invention are useful for treatingprostate cancer, for example advanced castrate-resistant prostatecancer. It should be readily understood by one of ordinary skill in theart that any type of cancer wherein the PSMA tumor antigen is expressed,can be treated using the methods of the present invention. For example,neovascular expression of PSMA was found in non-small cell lung cancer,see, e.g., PLoS One. 2017 Oct. 27; 12(10). Accordingly, the methods ofthe invention may also be useful for treating non-small cell lung cancer(NSCLC).

In certain exemplary embodiments, the modified immune cells of theinvention are used to treat prostate cancer. In one embodiment, a methodof the present disclosure is used to treat castrate-resistant prostatecancer. In one embodiment, a method of the present disclosure is used totreat advanced castrate-resistant prostate cancer. In one embodiment, amethod of the present disclosure is used to treat metastaticcastrate-resistant prostate cancer. In one embodiment, a method of thepresent disclosure is used to treat metastatic castrate-resistantprostate cancer, wherein the patient with metastatic castrate-resistantprostate cancer has ≥10% tumor cells expressing PSMA. In one embodiment,a method of the present disclosure is used to treat castrate-resistantprostate adenocarcinoma, wherein the patient has castrate levels oftestosterone (e.g., <50 ng/mL) with or without the use of androgendeprivation therapy.

In certain embodiments, the subject is provided a secondary treatment.Secondary treatments include but are not limited to chemotherapy,radiation, surgery, and medications.

Cells of the invention can be administered in dosages and routes and attimes to be determined in appropriate pre-clinical and clinicalexperimentation and trials. Cell compositions may be administeredmultiple times at dosages within these ranges. Administration of thecells of the invention may be combined with other methods useful totreat the desired disease or condition as determined by those of skillin the art.

The cells of the invention to be administered may be autologous, withrespect to the subject undergoing therapy.

The administration of the cells of the invention may be carried out inany convenient manner known to those of skill in the art. The cells ofthe present invention may be administered to a subject by aerosolinhalation, injection, ingestion, transfusion, implantation ortransplantation. The compositions described herein may be administeredto a patient transarterially, subcutaneously, intradermally,intratumorally, intranodally, intramedullary, intramuscularly, byintravenous (i.v.) injection, or intraperitoneally. In other instances,the cells of the invention are injected directly into a site ofinflammation in the subject, a local disease site in the subject, alymphnode, an organ, a tumor, and the like.

In some embodiments, the cells are administered at a desired dosage,which in some aspects includes a desired dose or number of cells or celltype(s) and/or a desired ratio of cell types. Thus, the dosage of cellsin some embodiments is based on a total number of cells (or number perkg body weight) and a desired ratio of the individual populations orsub-types, such as the CD4+ to CD8+ ratio. In some embodiments, thedosage of cells is based on a desired total number (or number per kg ofbody weight) of cells in the individual populations or of individualcell types. In some embodiments, the dosage is based on a combination ofsuch features, such as a desired number of total cells, desired ratio,and desired total number of cells in the individual populations.

In some embodiments, the populations or sub-types of cells, such as CD8⁺and CD4⁺ T cells, are administered at or within a tolerated differenceof a desired dose of total cells, such as a desired dose of T cells. Insome aspects, the desired dose is a desired number of cells or a desirednumber of cells per unit of body weight of the subject to whom the cellsare administered, e.g., cells/kg. In some aspects, the desired dose isat or above a minimum number of cells or minimum number of cells perunit of body weight. In some aspects, among the total cells,administered at the desired dose, the individual populations orsub-types are present at or near a desired output ratio (such as CD4⁺ toCD8⁺ ratio), e.g., within a certain tolerated difference or error ofsuch a ratio.

In some embodiments, the cells are administered at or within a tolerateddifference of a desired dose of one or more of the individualpopulations or sub-types of cells, such as a desired dose of CD4+ cellsand/or a desired dose of CD8+ cells. In some aspects, the desired doseis a desired number of cells of the sub-type or population, or a desirednumber of such cells per unit of body weight of the subject to whom thecells are administered, e.g., cells/kg. In some aspects, the desireddose is at or above a minimum number of cells of the population orsubtype, or minimum number of cells of the population or sub-type perunit of body weight. Thus, in some embodiments, the dosage is based on adesired fixed dose of total cells and a desired ratio, and/or based on adesired fixed dose of one or more, e.g., each, of the individualsub-types or sub-populations. Thus, in some embodiments, the dosage isbased on a desired fixed or minimum dose of T cells and a desired ratioof CD4⁺ to CD8⁺ cells, and/or is based on a desired fixed or minimumdose of CD4⁺ and/or CD8⁺ cells.

In certain embodiments, the cells, or individual populations ofsub-types of cells, are administered to the subject at a range of aboutone million to about 100 billion cells, such as, e.g., 1 million toabout 50 billion cells (e.g., about 5 million cells, about 25 millioncells, about 500 million cells, about 1 billion cells, about 5 billioncells, about 20 billion cells, about 30 billion cells, about 40 billioncells, or a range defined by any two of the foregoing values), such asabout 10 million to about 100 billion cells (e.g., about 20 millioncells, about 30 million cells, about 40 million cells, about 60 millioncells, about 70 million cells, about 80 million cells, about 90 millioncells, about 10 billion cells, about 25 billion cells, about 50 billioncells, about 75 billion cells, about 90 billion cells, or a rangedefined by any two of the foregoing values), and in some cases about 100million cells to about 50 billion cells (e.g., about 120 million cells,about 250 million cells, about 350 million cells, about 450 millioncells, about 650 million cells, about 800 million cells, about 900million cells, about 3 billion cells, about 30 billion cells, about 45billion cells) or any value in between these ranges.

In some embodiments, the dose of total cells and/or dose of individualsub-populations of cells is within a range of between at or about 1×10⁵cells/kg to about 1×10¹¹ cells/kg, 10⁴,and at or about 10¹¹cells/kilograms (kg) body weight, such as between 10⁵ and 10⁶ cells/kgbody weight, for example, at or about 1×10⁵ cells/kg, 1.5×10⁵ cells/kg,2×10⁵ cells/kg, or 1×10⁶ cells/kg body weight. For example, in someembodiments, the cells are administered at, or within a certain range oferror of, between at or about 10⁴ and at or about 10⁹ T cells/kilograms(kg) body weight, such as between 10⁵ and 10⁶ T cells/kg body weight,for example, at or about 1×10⁵ T cells/kg, 1.5×10⁵ T cells/kg, 2×10⁵ Tcells/kg, or 1×10⁶ T cells/kg body weight. In other exemplaryembodiments, a suitable dosage range of modified cells for use in amethod of the present disclosure includes, without limitation, fromabout 1×10⁵ cells/kg to about 1×10⁶ cells/kg, from about 1×10⁶ cells/kgto about 1×10⁷ cells/kg, from about 1×10⁷ cells/kg about 1×10⁸ cells/kg,from about 1×10⁸ cells/kg about 1×10⁹ cells/kg, from about 1×10⁹cells/kg about 1×10¹⁰ cells/kg, from about 1×10¹⁰ cells/kg about 1×10¹¹cells/kg. In an exemplary embodiment, a suitable dosage for use in amethod of the present disclosure is about 1×10⁸ cells/kg. In anexemplary embodiment, a suitable dosage for use in a method of thepresent disclosure is about 1×10⁷ cells/kg. In other embodiments, asuitable dosage is from about 1×10⁷ total cells to about 5×10⁷ totalcells. In some embodiments, a suitable dosage is from about 1×10⁸ totalcells to about 5×10⁸ total cells. In some embodiments, a suitable dosageis from about 1.4×10⁷ total cells to about 1.1×10⁹ total cells. In anexemplary embodiment, a suitable dosage for use in a method of thepresent disclosure is about 7×10⁹ total cells. In an exemplaryembodiment, a suitable dosage is from about 1×10⁷ total cells to about3×10⁷ total cells.

In some embodiments, the dose of total cells and/or dose of individualsub-populations of cells is within a range of between at or about 1×10⁵cells/m² to about 1×10¹¹ cells/m². In an exemplary embodiment, the doseof total cells and/or dose of individual sub-populations of cells iswithin a range of between at or about 1×10⁷/m² to at or about 3×10⁷/m².In an exemplary embodiment, the dose of total cells and/or dose ofindividual sub-populations of cells is within a range of between at orabout 1×10⁸/m² to at or about 3×10⁸/m². In some embodiments, the dose oftotal cells and/or dose of individual sub-populations of cells is themaximum tolerated dose by a given patient.

In some embodiments, the cells are administered at or within a certainrange of error of between at or about 10⁴ and at or about 10⁹ CD4⁺and/or CD8⁺ cells/kilograms (kg) body weight, such as between 10⁵ and10⁶ CD4⁺ and/or CD8⁺ cells/kg body weight, for example, at or about1×10⁵ CD4⁺ and/or CD8⁺ cells/kg, 1.5×10⁵ CD4⁺ and/or CD8⁺ cells/kg,2×10⁵ CD4⁺ and/or CD8⁺ cells/kg, or 1×10⁶ CD4⁺ and/or CD8⁺ cells/kg bodyweight. In some embodiments, the cells are administered at or within acertain range of error of, greater than, and/or at least about 1×10⁶,about 2.5×10⁶, about 5×10⁶, about 7.5×10⁶, or about 9×10⁶ CD4⁺ cells,and/or at least about 1×10⁶, about 2.5×10⁶, about 5×10⁶, about 7.5×10⁶,or about 9×10⁶ CD8+ cells, and/or at least about 1×10⁶, about 2.5×10⁶,about 5×10⁶, about 7.5×10⁶, or about 9×10⁶ T cells. In some embodiments,the cells are administered at or within a certain range of error ofbetween about 10⁸ and 10¹² or between about 10¹⁰ and 10¹¹ T cells,between about 10⁸ and 10¹² or between about 10¹⁰ and 10¹¹ CD4⁺ cells,and/or between about 10⁸ and 10¹² or between about 10¹⁰ and 10¹¹ CD8⁺cells.

In some embodiments, the cells are administered at or within a toleratedrange of a desired output ratio of multiple cell populations orsub-types, such as CD4+ and CD8+ cells or sub-types. In some aspects,the desired ratio can be a specific ratio or can be a range of ratios,for example, in some embodiments, the desired ratio (e.g., ratio of CD4⁺to CD8⁺ cells) is between at or about 5:1 and at or about 5:1 (orgreater than about 1:5 and less than about 5:1), or between at or about1:3 and at or about 3:1 (or greater than about 1:3 and less than about3:1), such as between at or about 2:1 and at or about 1:5 (or greaterthan about 1:5 and less than about 2:1, such as at or about 5:1, 4.5:1,4:1, 3.5:1, 3:1, 2.5:1, 2:1, 1.9:1, 1.8:1, 1.7:1, 1.6:1, 1.5:1, 1.4:1,1.3:1, 1.2:1, 1.1:1, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6,1:1.7, 1:1.8, 1:1.9:1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, or 1:5. In someaspects, the tolerated difference is within about 1%, about 2%, about3%, about 4% about 5%, about 10%, about 15%, about 20%, about 25%, about30%, about 35%, about 40%, about 45%, about 50% of the desired ratio,including any value in between these ranges.

In some embodiments, a dose of modified cells is administered to asubject in need thereof, in a single dose or multiple doses. In someembodiments, a dose of modified cells is administered in multiple doses,e.g., once a week or every 7 days, once every 2 weeks or every 14 days,once every 3 weeks or every 21 days, once every 4 weeks or every 28days. In an exemplary embodiment, a single dose of modified cells isadministered to a subject in need thereof. In an exemplary embodiment, asingle dose of modified cells is administered to a subject in needthereof by rapid intravenous infusion.

For the prevention or treatment of disease, the appropriate dosage maydepend on the type of disease to be treated, the type of cells orrecombinant receptors, the severity and course of the disease, whetherthe cells are administered for preventive or therapeutic purposes,previous therapy, the subject's clinical history and response to thecells, and the discretion of the attending physician. The compositionsand cells are in some embodiments suitably administered to the subjectat one time or over a series of treatments.

In some embodiments, the cells are administered as part of a combinationtreatment, such as simultaneously with or sequentially with, in anyorder, another therapeutic intervention, such as an antibody orengineered cell or receptor or agent, such as a cytotoxic or therapeuticagent. The cells in some embodiments are co-administered with one ormore additional therapeutic agents or in connection with anothertherapeutic intervention, either simultaneously or sequentially in anyorder. In some contexts, the cells are co-administered with anothertherapy sufficiently close in time such that the cell populationsenhance the effect of one or more additional therapeutic agents, or viceversa.

In some embodiments, the cells are administered prior to the one or moreadditional therapeutic agents. In some embodiments, the cells areadministered after the one or more additional therapeutic agents. Insome embodiments, the one or more additional agents includes a cytokine,such as IL-2, for example, to enhance persistence. In some embodiments,the methods comprise administration of a chemotherapeutic agent.

Following administration of the cells, the biological activity of theengineered cell populations in some embodiments is measured, e.g., byany of a number of known methods. Parameters to assess include specificbinding of an engineered or natural T cell or other immune cell toantigen, in vivo, e.g., by imaging, or ex vivo, e.g., by ELISA or flowcytometry. In certain embodiments, the ability of the engineered cellsto destroy target cells can be measured using any suitable method knownin the art, such as cytotoxicity assays described in, for example,Kochenderfer et al., J. Immunotherapy, 32(7): 689-702 (2009), and Hermanet al. J. Immunological Methods, 285(1): 25-40 (2004). In certainembodiments, the biological activity of the cells is measured byassaying expression and/or secretion of one or more cytokines, such asCD 107a, IFNy, IL-2, and TNF. In some aspects the biological activity ismeasured by assessing clinical outcome, such as reduction in tumorburden or load.

In some embodiments, a specific dosage regimen of the present disclosureincludes a lymphodepletion step prior to the administration of themodified T cells. In an exemplary embodiment, the lymphodepletion stepincludes administration of cyclophosphamide and/or fludarabine.

In some embodiments, the lymphodepletion step includes administration ofcyclophosphamide at a dose of between about 200 m g/m²/day and about2000 mg/m²/day (e.g., 200 mg/m²/day, 300 mg/m²/day, or 500 mg/m²/day).In an exemplary embodiment, the dose of cyclophosphamide is about 300mg/m²/day. In some embodiments, the lymphodepletion step includesadministration of fludarabine at a dose of between about 20 mg/m²/dayand about 900 mg/m²/day (e.g., 20 mg/m²/day, 25 mg/m²/day, 30 mg/m²/day,or 60 mg/m²/day). In an exemplary embodiment, the dose of fludarabine isabout 30 mg/m²/day.

In some embodiment, the lymphodepletion step includes administration ofcyclophosphamide at a dose of between about 200 mg/m²/day and about 2000mg/m²/day (e.g., 200 mg/m²/day, 300 mg/m²/day, or 500 mg/m²/day), andfludarabine at a dose of between about 20 mg/m²/day and about 900mg/m²/day (e.g., 20 mg/m²/day, 25 mg/m²/day, 30 mg/m²/day, or 60mg/m²/day). In an exemplary embodiment, the lymphodepletion stepincludes administration of cyclophosphamide at a dose of about 300mg/m²/day, and fludarabine at a dose of about 30 mg/m²/day.

In an exemplary embodiment, for a subject having castrate-resistantprostate cancer, the subject receives lymphodepleting chemotherapy priorto the administration of the modified T cells. In an exemplaryembodiment, for a subject having castrate-resistant prostate cancer, thesubject receives lymphodepleting chemotherapy including at or about 500mg/m² to at or about 1 g/m² of cyclophosphamide by intravenous infusion.In an exemplary embodiment, for a subject having castrate-resistantprostate cancer, the subject receives lymphodepleting chemotherapyincluding at or about 500 mg/m² to at or about 1 g/m² ofcyclophosphamide by intravenous infusion about 3 days (±1 day) prior toadministration of the modified T cells. In an exemplary embodiment, fora subject having castrate-resistant prostate cancer, the subjectreceives lymphodepleting chemotherapy including at or about 500 mg/m² toat or about 1 g/m² of cyclophosphamide by intravenous infusion up to 4days prior to administration of the modified T cells. In an exemplaryembodiment, for a subject having castrate-resistant prostate cancer, thesubject receives lymphodepleting chemotherapy including at or about 500mg/m² to at or about 1 g/m² of cyclophosphamide by intravenous infusion4 days prior to administration of the modified T cells. In an exemplaryembodiment, for a subject having castrate-resistant prostate cancer, thesubject receives lymphodepleting chemotherapy including at or about 500mg/m² to at or about 1 g/m² of cyclophosphamide by intravenous infusion3 days prior to administration of the modified T cells. In an exemplaryembodiment, for a subject having castrate-resistant prostate cancer, thesubject receives lymphodepleting chemotherapy including at or about 500mg/m² to at or about 1 g/m² of cyclophosphamide by intravenous infusion2 days prior to administration of the modified T cells.

In an exemplary embodiment, for a subject having castrate-resistantprostate cancer, the subject receives lymphodepleting chemotherapyincluding 300 mg/m² of cyclophosphamide by intravenous infusion 3 daysprior to administration of the modified T cells. In an exemplaryembodiment, for a subject having castrate-resistant prostate cancer, thesubject receives lymphodepleting chemotherapy including 300 mg/m² ofcyclophosphamide by intravenous infusion for 3 days prior toadministration of the modified T cells.

In an exemplary embodiment, for a subject having castrate-resistantprostate cancer, the subject receives lymphodepleting chemotherapyincluding fludarabine at a dose of between about 20 mg/m²/day and about900 mg/m²/day (e.g., 20 mg/m²/day, 25 mg/m²/day, 30 mg/m²/day, or 60mg/m²/day). In an exemplary embodiment, for a subject havingcastrate-resistant prostate cancer, the subject receives lymphodepletingchemotherapy including fludarabine at a dose of 30 mg/m² for 3 days.

In an exemplary embodiment, for a subject having castrate-resistantprostate cancer, the subject receives lymphodepleting chemotherapyincluding cyclophosphamide at a dose of between about 200 mg/m²/day andabout 2000 mg/m²/day (e.g., 200 mg/m²/day, 300 mg/m²/day, or 500mg/m²/day), and fludarabine at a dose of between about 20 mg/m²/day andabout 900 mg/m²/day (e.g., 20 mg/m²/day, 25 mg/m²/day, 30 mg/m²/day, or60 mg/m²/day). In an exemplary embodiment, for a subject havingcastrate-resistant prostate cancer, the subject receives lymphodepletingchemotherapy including cyclophosphamide at a dose of about 300mg/m²/day, and fludarabine at a dose of 30 mg/m² for 3 days.

It is known in the art that one of the adverse effects followinginfusion of CAR T cells is the onset of immune activation, known ascytokine release syndrome (CRS). CRS is immune activation resulting inelevated inflammatory cytokines. Clinical and laboratory measures rangefrom mild CRS (constitutional symptoms and/or grade-2 organ toxicity) tosevere CRS (sCRS; grade ≥3 organ toxicity, aggressive clinicalintervention, and/or potentially life threatening). Clinical featuresinclude: high fever, malaise, fatigue, myalgia, nausea, anorexia,tachycardia/hypotension, capillary leak, cardiac dysfunction, renalimpairment, hepatic failure, and disseminated intravascular coagulation.Dramatic elevations of cytokines including interferon-gamma, granulocytemacrophage colony-stimulating factor, IL-10, and IL-6 have been shownfollowing CAR T-cell infusion. The presence of CRS generally correlateswith expansion and progressive immune activation of adoptivelytransferred cells. It has been demonstrated that the degree of CRSseverity is dictated by disease burden at the time of infusion aspatients with high tumor burden experience a more sCRS.

Accordingly, the invention provides for, following the diagnosis of CRS,appropriate CRS management strategies to mitigate the physiologicalsymptoms of uncontrolled inflammation without dampening the antitumorefficacy of the engineered cells (e.g., CAR T cells). CRS managementstrategies are known in the art. For example, systemic corticosteroidsmay be administered to rapidly reverse symptoms of sCRS (e.g., grade 3CRS) without compromising initial antitumor response.

In some embodiments, an anti-IL-6R antibody may be administered. Anexample of an anti-IL-6R antibody is the Food and DrugAdministration-approved monoclonal antibody tocilizumab, also known asatlizumab (marketed as Actemra, or RoActemra). Tocilizumab is ahumanized monoclonal antibody against the interleukin-6 receptor(IL-6R). Administration of tocilizumab has demonstrated near-immediatereversal of CRS.

In some embodiments, the methods of the invention involve selecting andtreating a subject having failed at least one prior course of standardof cancer therapy. For example, a suitable subject may have had aconfirmed diagnosis of relapsed prostate cancer. In some embodiments,the methods of the invention involve selecting and treating a subjecthaving had at least one prior course of standard of cancer therapy. Forexample, a suitable subject may have had prior therapy with at least onestandard 17a lyase inhibitor or second-generation anti-androgen therapyfor the treatment of metastatic castrate resistant prostate cancer.

In an exemplary embodiment, a suitable subject is a subject havingmetastatic castrate resistant prostate cancer. In an exemplaryembodiment, a suitable subject is a subject having metastatic castrateresistant prostate cancer having ≥10% tumor cells expressing PSMA asdemonstrated by immunohistochemistry analysis on fresh tissue.

In some embodiments, a suitable subject is a subject that hasradiographic evidence of osseous metastatic disease and/or measurable,non-osseous metastatic disease (nodal or visceral).

In some embodiments, a suitable subject is a subject that has an ECOGperformance status of 0-1.

In some embodiments, a suitable subject is a subject that has adequateorgan function, as defined by: serum creatinine ≤1.5 mg/dl or creatinineclearance ≥60 cc/min; and/or serum total bilirubin <1.5×ULN; serumALT/AST<2×ULN.

In some embodiments, a suitable subject is a subject that has adequatehematologic reserve as defined by: Hgb>10 g/dl; PLT>100 k/ul; and/orANC>1.5 k/ul.

In some embodiments, a suitable subject is a subject that is nottransfusion dependent.

In some embodiments, a suitable subject is a subject that has evidenceof progressive castrate resistant prostate adenocarcinoma, as definedby: castrate levels of testosterone (<50 ng/ml) with or without the useof androgen deprivation therapy; and/or evidence of one of the followingmeasures of progressive disease: soft tissue progression by RECIST 1.1criteria, osseous disease progression with 2 or more new lesions on bonescan (as per PCWG2 criteria), increase in serum PSA of at least 25% andan absolute increase of 2 ng/ml or more from nadir (as per PCWG2criteria).

In some embodiments, a suitable subject has had previous treatment withat least one second-generation androgen signaling inhibitor. In someembodiments, a suitable subject has had previous treatment withabiraterone. In some embodiments, a suitable subject has had previoustreatment with enzalutamide.

In some embodiments, a suitable subject has ≥10% tumor cells expressingPSMA by immunohistochemistry (IHC) on a metastatic tissue biopsy.

In some embodiments, a suitable subject has radiographic evidence formetastatic disease (osseous or nodal/visceral).

In some embodiments, a suitable subject has ≤4 lines of therapy formetastatic CRPC.

K. Pharmaceutical Compositions and Formulations

Also provided are populations of immune cells of the invention,compositions containing such cells and/or enriched for such cells, suchas in which cells expressing the recombinant receptor make up at least50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, ormore of the total cells in the composition or cells of a certain typesuch as T cells or CD8+ or CD4+ cells. Among the compositions arepharmaceutical compositions and formulations for administration, such asfor adoptive cell therapy. Also provided are therapeutic methods foradministering the cells and compositions to subjects, e.g., patients.

Also provided are compositions including the cells for administration,including pharmaceutical compositions and formulations, such as unitdose form compositions including the number of cells for administrationin a given dose or fraction thereof. The pharmaceutical compositions andformulations generally include one or more optional pharmaceuticallyacceptable carrier or excipient. In some embodiments, the compositionincludes at least one additional therapeutic agent.

The term “pharmaceutical formulation” refers to a preparation which isin such form as to permit the biological activity of an activeingredient contained therein to be effective, and which contains noadditional components which are unacceptably toxic to a subject to whichthe formulation would be administered. A “pharmaceutically acceptablecarrier” refers to an ingredient in a pharmaceutical formulation, otherthan an active ingredient, which is nontoxic to a subject. Apharmaceutically acceptable carrier includes, but is not limited to, abuffer, excipient, stabilizer, or preservative. In some aspects, thechoice of carrier is determined in part by the particular cell and/or bythe method of administration. Accordingly, there are a variety ofsuitable formulations. For example, the pharmaceutical composition cancontain preservatives. Suitable preservatives may include, for example,methylparaben, propylparaben, sodium benzoate, and benzalkoniumchloride. In some aspects, a mixture of two or more preservatives isused. The preservative or mixtures thereof are typically present in anamount of about 0.0001% to about 2% by weight of the total composition.Carriers are described, e.g., by Remington's Pharmaceutical Sciences16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriersare generally nontoxic to recipients at the dosages and concentrationsemployed, and include, but are not limited to: buffers such asphosphate, citrate, and other organic acids; antioxidants includingascorbic acid and methionine; preservatives (such asoctadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;benzalkonium chloride; benzethonium chloride; phenol, butyl or benzylalcohol; alkyl parabens such as methyl or propyl paraben; catechol;resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecularweight (less than about 10 residues) polypeptides; proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, histidine, arginine, or lysine; monosaccharides,disaccharides, and other carbohydrates including glucose, mannose, ordextrins; chelating agents such as EDTA; sugars such as sucrose,mannitol, trehalose or sorbitol; salt-forming counter-ions such assodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionicsurfactants such as polyethylene glycol (PEG).

Buffering agents in some aspects are included in the compositions.Suitable buffering agents include, for example, citric acid, sodiumcitrate, phosphoric acid, potassium phosphate, and various other acidsand salts. In some aspects, a mixture of two or more buffering agents isused. The buffering agent or mixtures thereof are typically present inan amount of about 0.001% to about 4% by weight of the totalcomposition. Methods for preparing administrable pharmaceuticalcompositions are known. Exemplary methods are described in more detailin, for example, Remington: The Science and Practice of Pharmacy,Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).

The formulations can include aqueous solutions. The formulation orcomposition may also contain more than one active ingredient useful forthe particular indication, disease, or condition being treated with thecells, preferably those with activities complementary to the cells,where the respective activities do not adversely affect one another.Such active ingredients are suitably present in combination in amountsthat are effective for the purpose intended. Thus, in some embodiments,the pharmaceutical composition further includes other pharmaceuticallyactive agents or drugs, such as chemotherapeutic agents, e.g.,asparaginase, busulfan, carboplatin, cisplatin, daunorubicin,doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate,paclitaxel, rituximab, vinblastine, and/or vincristine. Thepharmaceutical composition in some embodiments contains the cells inamounts effective to treat or prevent the disease or condition, such asa therapeutically effective or prophylactically effective amount.Therapeutic or prophylactic efficacy in some embodiments is monitored byperiodic assessment of treated subjects. The desired dosage can bedelivered by a single bolus administration of the cells, by multiplebolus administrations of the cells, or by continuous infusionadministration of the cells.

Formulations include those for oral, intravenous, intraperitoneal,subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal,sublingual, or suppository administration. In some embodiments, the cellpopulations are administered parenterally. The term “parenteral,” asused herein, includes intravenous, intramuscular, subcutaneous, rectal,vaginal, and intraperitoneal administration. In some embodiments, thecells are administered to the subject using peripheral systemic deliveryby intravenous, intraperitoneal, or subcutaneous injection. Compositionsin some embodiments are provided as sterile liquid preparations, e.g.,isotonic aqueous solutions, suspensions, emulsions, dispersions, orviscous compositions, which may in some aspects be buffered to aselected pH. Liquid preparations are normally easier to prepare thangels, other viscous compositions, and solid compositions. Additionally,liquid compositions are somewhat more convenient to administer,especially by injection. Viscous compositions, on the other hand, can beformulated within the appropriate viscosity range to provide longercontact periods with specific tissues. Liquid or viscous compositionscan comprise carriers, which can be a solvent or dispersing mediumcontaining, for example, water, saline, phosphate buffered saline,polyol (for example, glycerol, propylene glycol, liquid polyethyleneglycol) and suitable mixtures thereof.

Sterile injectable solutions can be prepared by incorporating the cellsin a solvent, such as in admixture with a suitable carrier, diluent, orexcipient such as sterile water, physiological saline, glucose,dextrose, or the like. The compositions can contain auxiliary substancessuch as wetting, dispersing, or emulsifying agents (e.g.,methylcellulose), pH buffering agents, gelling or viscosity enhancingadditives, preservatives, flavoring agents, and/or colors, dependingupon the route of administration and the preparation desired. Standardtexts may in some aspects be consulted to prepare suitable preparations.

Various additives which enhance the stability and sterility of thecompositions, including antimicrobial preservatives, antioxidants,chelating agents, and buffers, can be added. Prevention of the action ofmicroorganisms can be ensured by various antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, and sorbic acid.Prolonged absorption of the injectable pharmaceutical form can bebrought about by the use of agents delaying absorption, for example,aluminum monostearate and gelatin.

The formulations to be used for in vivo administration are generallysterile. Sterility may be readily accomplished, e.g., by filtrationthrough sterile filtration membranes.

The contents of the articles, patents, and patent applications, and allother documents and electronically available information mentioned orcited herein, are hereby incorporated by reference in their entirety tothe same extent as if each individual publication was specifically andindividually indicated to be incorporated by reference. Applicantsreserve the right to physically incorporate into this application anyand all materials and information from any such articles, patents,patent applications, or other physical and electronic documents.

While the present invention has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of theinvention. It will be readily apparent to those skilled in the art thatother suitable modifications and adaptations of the methods describedherein may be made using suitable equivalents without departing from thescope of the embodiments disclosed herein. In addition, manymodifications may be made to adapt a particular situation, material,composition of matter, process, process step or steps, to the objective,spirit and scope of the present invention. All such modifications areintended to be within the scope of the claims appended hereto. Havingnow described certain embodiments in detail, the same will be moreclearly understood by reference to the following examples, which areincluded for purposes of illustration only and are not intended to belimiting.

EXAMPLES

The invention is now described with reference to the following Examples.These Examples are provided for the purpose of illustration only, andthe invention is not limited to these Examples, but rather encompassesall variations that are evident as a result of the teachings providedherein.

The materials and methods employed in these experiments are nowdescribed.

RNA CAR Construct Design:

Four human scFvs specifically targeting human PSMA, 1C3, 2A10, 2C6 and2F5, were synthesized from IDT as gBlocks. CARs with 4-1BB-zeta (BBZ)were assembled by overlapping PCR and cloned into the RNA in vitrotranscription vector pD-A. The pD-A vector was optimized for T celltransfection, CAR expression and RNA production. The four human PSMACARs and one mouse PSMA CAR (J591) were linearized by Spel digestionprior to RNA IVT. The T7 mScript Standard mRNA Production System(Cellscript, Inc., Madison, Wis.) was utilized to generate capped/tailedIVT RNA. The IVT RNA was purified by RNeasy Mini Kit (Qiagen, Inc.,Valencia, Calif.). Purified RNA was eluted in RNase-free water at 1-2mg/mL and stored at −80° C. until use. RNA integrity was confirmed by260/280 absorbance and visually on an Agarose gel.

Lenti CAR Construct Design:

All PSMA CARs were subcloned into pTRPE Lenti vectors. Switch receptor:PD1.CD28-F2A (SW), PD1^(A132L)PTM.CD28-F2A (SW*) and a dominant negativeTGFRβII sequence, dnTGFRβII-T2A (dn), were then subcloned into eachLenti vector followed by human PSMA scFv.

Examples of sequences comprised by a Lenti vector are as follows:

1C3 (SEQ ID NO: 169) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGCAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAACAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCGTCCCCTGGGGATCGAGGTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAATCAGGGAAAGCTCCTAAGCTCCTGATCTTTGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAACAGTTATCCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAA AACCACGACGCCAGCGCCGCG2A10 (SEQ ID NO: 170) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGTAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGCAAACTGGTTTCCTCTGGTCCTCCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAACAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCTATGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAACCACGACGCCAGC GCCGCG 2F5(SEQ ID NO: 171) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCAACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACAAACTGGTTTCCTCTGGTCCTTCGATCTCTGGGGCCGTGGCACCCTGGTCACTGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCGGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAATCAAAACCACGAC GCCAGCGCCGCG 2C6(SEQ ID NO: 172) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTGCAGCTGGTGCAGTCTGGATCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAACTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTATCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGTCCCGGGTATACCAGCAGTTGGACTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCTGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCCCTATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAACCAC GACGCCAGCGCCGCGPD1.CD28-F2A (SW) (SEQ ID NO: 173)ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCG PD1^(A132L-)PTM.CD28-F2A (SW*)(SEQ ID NO: 174) ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGCTGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGTTGGTGTCGTGGGCGGCCTGCTGGGCAGCCTGGTGCTGCTAGTCTGGGTCCTGGCCGTCATCAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCC AACCCAGGGCCGdnTGERβII-T2A (dn) (SEQ ID NO: 175)ATGGGTCGGGGGCTGCTCAGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCTACCGCGTTAACCGGCAGCAGAAGCTGAGTTCATCCGGAAGATCTGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTAGAGCCACC

Transduction Protocol:

Bulk T cells (CD4 and CD8) obtained from the Human Immunology Core werediluted to 10⁶ cells/mL, and stimulated with CD3/28 beads (T cellexpanders, Invitrogen) at a cell:bead ratio of 1:3. Transductions ofpackaged lentiviral vectors were performed on day 1 post-stimulationusing a MOI of 3:1, and allowed to expand in a 37° C./5% CO₂ incubator.

Transduction Efficacy:

The CAR transduction efficacy was evaluated by flow cytometry usingBiotin-SP-AffiniPure Goat Anti-Mouse IgG (Cat #: 115-065-072, JacksonImmunoResearch Labs) or Biotin-SP-AffiniPure Rabbit Anti-Human IgG (Cat#: 309-065-082, Jackson ImmunoResearch Labs) followed by StreptavidinAPC (Cat #: 17-4317-82, eBioscience) or Streptavidin PE (Cat #: 554061,BD Pharmingen). APC anti-human CD279 (PD-1) antibody (Cat #: 329908,BioLegend) and Human TGF-beta RII APC-conjugated Antibody (Catalog #FAB241A, R&D systems) were used to examine the switch receptor ordominant negative TGFRβII portion.

T Cell Expansion:

Cells were fed and split every 2 days starting at day 3 poststimulation. T cells were de-beaded at day 4 and frozen at day 10 forlater use.

RNA Electroporation:

Resting T cells were electroporated with 10 or 20 μg IVT PSMA RNA CARsusing BTX830 at 500 V and 700 μs. Nalm6.CBG or K562 cells wereelectroporated with 5 μg or 15 μg PSMA IVT RNA using BTX830 at 300 V and500 μs. PC3.PSMA cells were electroporated with 0.5 μg, 2 μg or 5 μgPDL1 IVT RNA using BTX830 at 300 V and 500 is. Followingelectroporation, the cells were immediately placed in pre-warmed culturemedia at 37° C. and 5% CO₂. 18 hr later, PSMA or PDL1 electroporatedtumor cells were stained by APC anti-human PSMA (FOLH1) antibody (Cat #:342507, BioLegend) or APC anti-human CD274 (PDL-1 or B7-H1) antibody(Cat #: 17-5983-42, BD Biosciences) and analyzed by Flow Cytometry.

Cell Counting:

At various time-points during the expansion-resting cycles, cells weregently mixed and a 40 μL aliquot of cells was collected from knownculture volume and placed into accuvettes (Beckman Coulter) with 20 mLIsoton II Diluent Buffer for counting using a Coulter Multisizer 3(Beckman Coulter) in accordance with the CCI laboratory SOP. Theseassays determined cell concentration, total cell numbers, growth rates,and cell volumes and were used to calculate dilution volumes anddetermine when cells were rested for freezing.

Quantitative-PCR:

Primary cells or tumor cell lines were lysed and passed through QIAshredder (Cat #79656). Total RNA was extracted by RNeasy Mini kit (Cat#74104) according to the manufacturer's protocol. Reverse transcription(Cat #: 11904-018, Invitrogen) was performed to obtain cDNA. cDNA wassubjected to quantitative PCR with primers specific for

PSMA: (F primer: (SEQ ID NO: 176) AGGAAGTCTCAAAGTGCCCT, R primer:(SEQ ID NO: 177) GAACAACAGCTGCTCCACTC) or GAPDH: (F primer:(SEQ ID NO: 178) GCTACACTGAGCACCAGGTGGTCTC, R primer: (SEQ ID NO: 179)CCCAGCAGTGAGGGTCTCTCTCTTC).

ELISA for IL-2 and IFN-γ:

The T cells or target cells were washed and suspended in R10 medium at1×10⁶ cells/mL. Approximately 0.1 mL of each cell line was added to awell of a 96-well plate (Corning) and incubated at 37° C. for 18 to 20hours. The supernatant was harvested and subjected to ELISA.

CD107a Assay:

An E:T ratio of 1:2 (5×10⁴ effectors: 1×10⁵ targets) of cells wereprepared in 100 μL of R10 medium and plated in a 96 well plate. 10 μL ofphycoerythrin-labeled anti-CD107a Ab was added and the plate wasincubated at 37° C. for 1 hour. Golgi Stop (2 ul Golgi Stop in 3 ml R10medium, 10 ul/well; BD Biosciences, 51-20921(Z) was added and the platewas incubated for another 2.5 hours. Then 2 μL FITC-anti-CD8 (Cat #:551347, BD Pharmingen) and 2 uL APC-anti-CD3 (Cat #: 555342, BDPharmingen) was added and incubated at 37° C. for 30 min. Afterincubation, the samples were washed with FACS buffer and analyzed byflow cytometry.

Luciferase Based CTL Assay:

Nalm6-CBG, PC3-CBG, PC3.PSMA-CBG tumor cells were resuspended at 1×10⁵cells/mL in R10 medium and incubated with different ratios of T cells(e.g. 10:1, 5:1, 2.5 etc.) for 18 hr at 37° C. Equal volume of substratewas added and the luminescence was immediately determined. Results arereported as percent killing based on luciferase activity in wells withonly tumor in the absence of T cells (% killing=100−((RLU from well witheffector and target cell co-culture)/(RLU from well with targetcells)×100)).

PC3.PSMA Tumor Model:

2E6 PC3.PSMA.7SC cells transduced with click beetle were injected to themice (i.v.), and 28 days later, 2E6 PSMA CAR-T positive transduced Tcells were injected to the tumor bearing mice (i.v.). Bioluminescenceimaging (BLI) was conducted at multiple time points.

The results of the experiments are now described.

Example 1: Human RNA PSMA CARs have Equivalent Anti-Tumor Activity asMouse RNA PSMA CAR, J591

Four human RNA CARs targeting PSMA were constructed using one of fourscFv sequences, 1C3 (SEQ ID NO:169), 2A10 (SEQ ID NO:170), 2C6 (SEQ IDNO:172) and 2F5 (SEQ ID NO:171), (from U.S. Patent Application, US2009/0297438 A1, incorporated by reference herein in its entirety).ScFvs were linked to a CD8 transmembrane domain and 4-1BB and CD3 zetaintracellular signaling domains. Purified RNA was visualized on anAgarose gel (FIG. 1A) and electroporated into resting human primary Tcells. All CARs had nearly 100% CAR expression under the conditiontested. 10 ug of IVT RNA CARs, whether it was human or mouse PSMA CAR,reached maximal mean fluorescence intensity (MFI) for CAR expression;thus, 10 ug IVT RNA was used for further experiments (FIG. 1B). CARexpression varied among different human CARs, the highest MFI for CARexpression being 1C3.BBZ. The MFI for mouse J591 CAR expression was 4fold higher than that of 1C3.BBZ; however, since the species of antibodyorigins differ, 10 ug mouse J591 RNA CAR was also used for furtherexperiments.

Full length PSMA was cloned into a PD-A vector for optimal RNAexpression. Purified RNA was visualized on an Agarose gel (FIG. 1A),electroporated into Nalm6.CBG or K562 tumor cells and the expression ofPSMA was analyzed by flow cytometry (FIG. 1C). 15 ug and 5 ug PSMA RNAwas used for further experiments for Nalm6.CBG and K562 tumor cellsrespectively. PC3.PSMA.PSCA.CBG tumor cells were constructed previouslywith diminishing PSMA expression (37.5%) (FIG. 1C). Limited dilutionswere performed for PC3.PSMA.CBG tumor cell line and 7 single cell cloneswere isolated and combined to be a new cell line, PC3.PSMA.7SC.CBG (FIG.1D).

Nalm6.CBG or K562 electroporated with PSMA RNA, PC3 or PC3.PSMA.PSCA.CBGtumor cells were co-cultured with various PSMA RNA CARs. CD107a assays,Luciferase based CTL assays and ELISA assays were performed to determinethe functionality of the four new human CARs. All four human PSMA CARshad equivalent de-granulation activity as mouse PSMA CAR, J591, whenco-cultured with PSMA positive cells (FIG. 2A). However, three out offour human PSMA CARs exerted higher non-specific activation toward PC3cells than J591 CAR (FIG. 2A). All four human CARs had comparablecytotoxicity and anti-tumor activity toward PSMA positive cells comparedwith the J591 CAR (FIG. 2B and FIG. 2C). Cytokine production was PSMAtarget specific for 1C3.BBZ, 2A10.BBZ and 2F5.BBZ CARs (FIG. 2C).

Example 2: Human Lenti PSMA CARs Specifically Target PSMA Positive Cells

The four human PSMA CARs were subcloned into pTRPE Lenti vector. Primaryhuman T cells transduced with human PSMA CARs had different CARexpression levels: 40% for 1C3.BBZ, 66% for 2A10.BBZ, 50% for 2C6.BBZand 61% for 2F5.BBZ (FIG. 3A). A dominant negative TGFRβII sequence waslinked to the mouse J591.BBZ CAR via a T2A sequence(dnTGFRβII-J591.BBZ). Nalm6.CBG electroporated with PSMA RNA, PC3 orPC3.PSMA.CBG cells were co-cultured with various PSMA Lenti CARs. CD107aassays, Luciferase based CTL assays and ELISA assays were performed todetermine the functionality of the four new human PSMA Lenti CARs, andcompared with mouse J591 CAR. 1C3.BBZ, 2A10.BBZ and 2F5.BBZ exertedsimilar anti-tumor activity in the de-granulation assay and Luciferasebased Killing assay as dnTGFRβII-J591 (FIG. 3B and FIG. 3C). In terms ofcytokine production, all four human PSMA Lenti CARs elicited specificIL-2 and INF-γ production but the amount varied among the human CARs(FIG. 3D).

Example 3: Construction of Switch Receptor or Dominant Negative-TGFRβIILinked-Human Lenti CARs

A switch receptor (PD1.CD28), comprising a truncated extracellulardomain of PD1 and the transmembrane and cytoplasmic signaling domains ofCD28 was designed and linked to each human PSMA CAR via a T2A sequence.A point mutation at the 132 (99 for mouse) position from Alanine toLeucine on PD1 increases its affinity with PDL1 by two fold (Zhang etal. Immunity 20, 337-347, 2004). Thus, the second version of switchreceptor, “PD1^(A132L)PTM.CD28” (with truncated extracellular andtransmembrane domains of PD1 and cytoplasmic signaling domain of CD28)was linked to each human PSMA CAR. The dominant negative TGFRβIIsequence was subcloned into each human PSMA CARs as well. Flow cytometrywas performed to examine the transduction efficiency of each switchreceptor-CAR (FIG. 4A) and dnTGFRβII CAR (FIG. 4B). A distinct CAR/PD1double positive population was observed for all switch receptor-CARtransduced T cells. The transduction efficiency was similar between thehuman PSMA Lenti CARs and their two switch receptor counterparts (FIG.4A). Each 2C6 CAR had the lowest transduction efficiency. There was noseparate dnTGFRβII population but a clear shift was observed for eachdnTGFRβII-linked human PSMA CAR (FIG. 4B).

To examine the functionality of the switch receptors, various amounts ofPDL1 RNA, 0.5 ug, 2 ug, and 5 ug, were electroporated into PC3.PSMAcells (FIG. 4C). The PC3.PSMA cells electroporated with 5 ug PDL1 RNAwere co-cultured with each PSMA CAR. dnTGFRβII-J591.BBZ was normalizedto a transduction efficiency of 50% prior to the co-cultured experiment.Three out of four human PSMA CARs and their switch receptors ordnTGFRβII counterparts showed comparable de-granulation activity withdnTGFRβII-J591.BBZ CAR when co-cultured with PSMA positive cells (FIG.4D, FIG. 4E, and FIG. 4F). 2C6.BBZ CAR and its relevant counterpartsdemonstrated a lower degranulation activity which might be due to lowertransduction efficiency (FIG. 4G). All four human PSMA CARs and theirswitch receptor or dnTGFRβII counterparts showed similar cytotoxicitytoward PC3.PSMA cells (FIG. 4H). All human PSMA CARs elicited comparableamounts of cytokine with dnTGFRβII-J591.BBZ CAR (FIG. 4I). Each switchreceptor CAR secreted almost two fold higher IL-2 compared with theirnon-switch receptor or dnTGFRβII CAR counterparts when co-cultured withPDL1 electroporated PC3.PSMA cells (FIG. 4I).

Example 4: PC3.PSMA.7SC Xenograft Model

The following six human PSMA CARs were selected for use in PC3.PSMA.7SCmouse xenograft model: 1C3.BBZ, PD1CD28.1C3.BBZ, 2A10.BBZ,PD1CD28.2A10.BBZ, dnTGFRβII-2A10.BBZ and dnTGFRβII-J591.BBZ. CARexpression was tested by flow cytometry (FIG. 5A and FIG. 5B). MouseJ591.BBZ Lenti CAR was included in the functional test. All the PSMACARs tested showed similar degranulation activity in the CD107a assay(FIG. 5C and FIG. 5D) and comparable killing activity in the Luciferasebased CTL assay, with 2A10.BBZ being the lowest and dnTGFRβII-J591.BBZbeing the highest (FIG. 5E). Each switch receptor CAR secreted almosttwo fold higher IL-2 comparing with their non-switch receptor ordnTGFRβII CAR counterparts when co-cultured with PDL1 electroporatedPC3.PSMA.7SC cells (FIG. 5F).

To ensure the safety of using the above-mentioned human PSMA CARs, apanel of primary human cells (Table 1) was tested for PSMA expression byquantitative PCR (FIG. 5G). Normalized by Nalm6.CBG, all primary cellstested had various PSMA expression levels even for PC3 cells which onlyhad limited reactivity toward PSMA RNA CARs (FIG. 2A) but not PSMA LentiCARs (FIG. 5H) (PSMA expression is 1800 fold higher for PC3.PSMA thanPC3 cells). HREpC, HSAEpC and HPMEC human primary were co-cultured withabove-mentioned CARs. CD107a and ELISA assays were performed. All PSMACARs tested had minimal detectable de-granulation activity whenco-culturing with HPMEC (FIG. 5H and FIG. 5I). PD1CD28.1C3.BBZ elicitedincreased IL-2, compared with 1C3.BBZ when co-cultured with HPMEC (FIG.5J). Even though the level of cytokine elicited by primary human cells,specifically, HPMEC is negligible when compared to that by PC3.PSMA.7SC(FIG. 5J as compared to FIG. 5F).

TABLE 1 Primary human cells tested for PSMA expression HRCEpC HumanRenal Cortical Epithelial Cells Hn2 Primary human Neuron hNP1 HumanNeuronal progenitors hMSC-BM Human Mesenchymal Stem Cells from BoneMarrow HPASMC Human Pulmonary Artery Smooth Muscle Cells HCM Humancardiac myocytes HOB Human Osteoblasts HAoSMC Human Aortic Smooth MuscleCells HREpC Human Renal Epithelial Cells HPAEC Human Pulmonary ArteryEndothelial Cells Kera Kerotinocyte HSAEpC Human Small Airway EpithelialCells HPMEC Human Pulmonary Microvascular Endothelial Cells

The in vivo NSG mouse experiment was designed for 7 groups (five miceper group) to test the six above-mentioned PSMA CARs plus anon-transduced control group. 2E6 PC3.PSMA.7SC cells transduced withclick beetle green were injected in the mice (i.v.) and 28 days later,2E6 CAR positive transduced T cells were injected into the tumor bearingmice (i.v.). Bioluminescence imaging (BLI) was conducted at differenttime points: day 27, 34, 42, 49 post tumor injection (FIG. 5K and FIG.5L). Without being bound by any theory, the results of this experimentindicated that all the PSMA CARs tested had comparable anti-tumoractivity as dnTGFRβII.J591.BBZ.

FIG. 6 shows the different domains of a dnTGFRII-T2A PSMA-CAR construct,and a pTRPE dnTGFRII-T2A PSMA CAR vector map.

Example 5: In Vivo Tumor Control by PSMA CAR-T Cells

Transduction Protocol:

Bulk T cells (CD4 and CD8) obtained from the Human Immunology Core werediluted to 10⁶ cells/ml, and stimulated with CD3/28 beads (T cellexpanders, Invitrogen) at a cell:bead ratio of 1:3. Transductions ofpackaged lentiviral vectors were performed on day 1 post-stimulationusing a MOI of 3:1, and allowed to expand in a 37° C./5% CO₂ incubator.

Transduction Efficacy:

The transduction efficacy was evaluated by flow cytometry using the PEanti-human TCR V138 antibody (Cat #: 348104, BioLegend) and APCanti-human CD279 (PD-1) antibody (Cat #: 329908, BioLegend).

T Cell Expansion:

Cells were fed and split every 2 days starting day 3 post stimulation. Tcells were de-beaded at day 3 or day 4 and frozen at day 12 for lateruse.

Cell Counting:

At various time-points during the expansion-resting cycles, cells weregently mixed and a 40 μl aliquot of cells was collected from knownculture volume and placed into accuvettes (Beckman Coulter) with 20 mlIsoton II Diluent Buffer for counting using a Coulter Multisizer 3(Beckman Coulter) in accordance with the CCI laboratory SOP. Theseassays determined cell concentration, total cell numbers, growth rates,and cell volumes and were used to calculate dilution volumes anddetermine when cells were rested for freezing.

ELISA for IL-2 and IFNγ:

The T cells were washed and suspended in R10 medium at 1×10⁶ cells/ml.Approximately 0.1 ml of each cell line was added to a well of a 96-wellplate (Corning) and incubated at 37° C. for 18 to 20 hours. Thesupernatant was harvested and subjected to ELISA.

Cd107A Assay:

The cells were plated at an effector:target (E:T) cell ratio of 1:1 (10⁵effectors:10⁵ targets) in 160 μl of R/10 medium in a 96-well plate. Ananti-CD107a antibody was added and incubated with the cells for 1 hourat 37° C. before Golgi Stop was added and incubated for an additional2.5 hours. The anti-CD8 and anti-CD3 antibodies were added and incubatedat 37° C. for 30 min. After incubation, the samples were washed once andsubjected to flow cytometry with a BD Accuri C6. The data were analyzedwith the FlowJo software.

PC3-PMSA Tumor Models:

1E6 PC3-PMSA-CBG were injected to the mice subcutaneously (s.c.), and 21days later, lentiviral transduced T cells were injected to the tumorbearing mice intravenously (i.v.). Bioluminescence imaging (BLI) andtumor measurements were conducted at multiple time points.

Results:

The sequences set forth in Table 2 were generated and tested for theirability to control tumors in vivo.

TABLE 2 PSMA CAR in combination with various switch receptor sequencesSEQ ID FIGURE NO: Ref. Sequence CAR Switch Description 111 B 2F5BBZ2F5BBZ N/A comprises a 2F5 scFv, a 4-1BB or costimulatory domain, and aCD3 112 zeta intracellular signaling domain 159 C PD1CD2 2F5BBZ PD1-CD28comprises a PD1-CD28 switch 8.2F5BBZ and a 2F5BBZ PSMA CAR 163 D PD1*CD2F5BBZ PD1^(A132L)_ comprises a PD1^(A132L)_CD28 28.2F5BBZ CD28 switchand a 2F5BBZ PSMA CAR 209 E 2F5ICOSz 2F5ICOSz N/A comprises a 2F5 scFv,an ICOS or costimulatory domain, and a CD3 210 zeta intracellularsignaling domain 211 F 2F5ICOSz 2F5ICOSz N/A comprises a 2F5 scFv, avariant or YMNM YMNM ICOS costimulatory domain 212 comprising a YMNMmotif, and a CD3 zeta intracellular signaling domain 217 G PD1CD22F5ICOSz PD1-CD28 comprises a PD1-CD28 switch or 8.2F5ICOSz and a2F5ICOSz PSMA CAR 227 218 H PD1CD2 2F5ICOSzY PD1-CD28 comprises aPD1-CD28 or 8.2F5IC MNM switch and a 232 OSzYMNM 2F5ICOSzYMNM PSMA CAR219 I PD1*CD 2F5ICOSz PD1^(A132L)_ comprises a PD1^(A132L)_CD28 or28.2F5IC CD28 switch and a 2F5ICOSz 233 OSz PSMA CAR 220 J PD1*CD2F5ICOSzY PD1^(A132L)_ comprises a PD1^(A132L)_CD28 28.2F5IC MNM CD28switch and a OSzYMNM 2F5ICOSzYMNM PSMA CAR 221 K PD1*BB. 2F5ICOSzPD1^(A132L)_ comprises a PD1^(A132L)_41BB or 2F5ICOSz 41BB switch and a2F5ICOSz 229 PSMA CAR 222 L PD1*BB. 2F5ICOSzY PD1^(A132L)_ comprises aPD1^(A132L)_41BB or 2F5ICOS MNM 41BB switch and a 2F5ICOSzYMNM 234 zYMNMPSMA CAR 223 M TIM3CD 2F5ICOSz TIM3-CD28 comprises a TIM3-CD28 28.2F5ICswitch and a 2F5ICOSz OSz PSMA CAR 224 N TIM3CD 2F5ICOSzY TIM3-CD28comprises a TIM3-CD28 switch or 28.2F5IC MNM and a 2F5ICOSzYMNM 235OSzYMNM PSMA CAR 225 O PD1*BB. 2F5ICOSz PD1^(A132L)_ comprises aPD1^(A132L)_41BB TIM3CD 41BB; and switch, a TIM3-CD28 switch, 28.2F5ICTIM3-CD28 and a 2F5ICOSz PSMA CAR OSz 226 P PD1*BB. 2F5ICOSzYPD1^(A132L)_ comprises a PD1^(A132L)_41BB switch, or TIM3CD MNM 41BB;and a TIM3-CD28 switch, and a 236 28.2F5IC TIM3-CD28 2F5ICOSzYMNM PSMACAR OSzYM NM

PSMA CARs with either ICOS or ICOS.YMNM signaling domain and combinationof CAR+PD1 (or Tim3) switch receptors were constructed and cloned into alentiviral vector (see, Table 2 for sequences). The CAR expressionlevels in transduced T cells were comparable for most of the CARconstructs (FIG. 7), and the switch receptors were expressed properly(FIG. 8). When stimulated with PSMA positive cell lines PC3.PSMA orPC3.PSMA.PD-L1 and examined for CD107a upregulation, PSMA CAR withICOS.YMNM signaling domain (ICOS ymnm) showed significantly higherCD107a expression compared to wild type ICOS (ICOS) or 4-1BB (41BB) CARs(FIG. 9). GranzymeB expression for both ICOS and ICOS.YMNM PSMA CARswere similar to 4-1BB PSMA CAR (FIG. 10). Cytokine production (IL-2 andIFN-gamma) of the PD1 switch receptors co-transduced with PSMA CARscomprising ICOS, ICOS.YMNM, or 4-1BB were significantly higher whenstimulated with PD-L1 expressing PC3.PSMA cells (FIGS. 11A and 11B).

FIG. 12 and shows the quantification of bioluminescence imaging of NSGmice bearing PC3-PSMA.CBG induced tumors treated with T cells transducedwith the CARs as indicated, up to 86 days (FIG. 12A), and up to 151 days(FIG. 12B). FIG. 13 shows the tumor size of NSG mice bearingPC3-PSMA.CBG induced tumors treated with T cells transduced with theCARs as indicated, up to 164 days. As shown, both ICOS (2F5.ICOSz) andICOS.YMNM PSMA CARs (2F5.ICOSzYMNM) showed worse tumor control than the4-1BB PSMA CAR (2F5.BBZ). The PD1-CD28 switch receptor improved the PSMACAR with 4-1BB costimulatory domain (PD1.CD28.2F5.BBZ), but not for ICOS(PD1CD28.2F5ICOSz) or ICOS.YMNM (PD1CD28.2F5ICOSzYMNM) PSMA CARs. BothPD1.CD28.2F5.BBZ and PD1CD28.2F5ICOSzYMNM showed inferior tumor controlcompared to 4-1BB PMSA CAR. When these ICOS based CARs were co-deliveredto T cells with a high affinity PD1 switch receptor with 4-1BB signalingdomain (PD1*BB), the tumor can be controlled as efficiently as 4-1BBPMSA CAR. As shown in FIGS. 14A-14F, T cells co-delivered with ICOS.YMNMCAR and PD1 switch receptor with 4-1BB signaling domain(PD1*BB.2F5ICOSzYMNM) eliminated tumors. FIG. 14G provides a list of theT cells in order of tumor control capabilities.

Example 7: PSMA CAR-T Cells to Co-Express Bispecific Antibodies for PD1to CD28 Switch or TGF Beta Receptor II to CD28 Switch

Five bispecific antibodies using scFvs that could bind PD-L1 (10A5, 13G4and 1B12, see, e.g., PCT Publication No. WO2007005874A2) or TGF betareceptor II (aTGFbRII-1 and aTGFbRII-3 (TGFb1 and TGFb3, see, e.g., U.S.Pat. No. 8,147,834) and an anti-CD28 scFv (1412, see, e.g., U.S. Pat.No. 7,585,960) were designed and the genes were synthesized by PCR.Sequence verified DNA was cloned into PGEM.64A based RNA in vitrotranscription vector to generate pGEM.aTGFbR-1-1412 andpGEM.aTGFbR-3-1412. See, e.g., PCT Publication No. WO2016122738A1.

PSMA CAR-T cells are generated that co-express a bispecific antibodyselected from the above described.

Example 8: Manufacture and Administration of Clinical CART-PSMA-TGFβRDNAutologous T Cells

CART-PSMA-TGFβRDN investigational cell product manufacturing, finalformulation, testing, and labeling were performed as described below,according to The Clinical Cell and Vaccine Production Facility's (CVPF)standard operating protocols (SOPs). The CVPF is a unit within theDivision of Transfusion Medicine and Therapeutic Pathology in theDepartment of Pathology and Laboratory Medicine at the University ofPennsylvania. Within the Division, in addition to the CVPF and theapheresis collection facility, there is a separate hematopoietic stemcell processing laboratory that is responsible for bone marrow andperipheral blood stem cell products primarily dedicated to support theclinical hematopoietic stem cell transplantation service. The CVPF is aregistered HCT Facility and accredited by the Foundation for theAccreditation of Cellular Therapy (FACT).

Dynabeads CD3/C28 CTS™ (formerly named ClinExVivo) beads were used for Tcell activations and expansions.

CART-PSMA-TGFβRDN investigational product manufacturing was initiatedfrom a leukapheresis product. Based on the constitution of theleukaphereis product, as assessed by Beckman Coulter Multisizer and BDFACS Calibur devices, the following occured: depletion of monocytes viacounterflow centrifugal elutriation on the TerumoBCT Elutra, whichemploys a single use closed system disposable set, washing step using asemi-automated, closed-system device Haemonetics CellSaver 5, and/orFicoll separation of the buffy fraction of the PBMCs. On day 0, theCART-PSMATGFβRDN manufacturing process was initiated with activation ofT lymphocytes with the Dynabeads CD3/CD28 CTS beads. The PSMA-TGFbRIIDNCAR LV vector was added on Day 1 at the total final MOI. Vectortransduction occured between days 1 and 3. On day 3, the cells werewashed and media was replaced. Cultures were allowed to continueexpansion in the GE Wave Bioreactor System. On the final day of theculture, cells were harvested and concentrated using the Cell SaverPrior to harvest, the cell product was placed on the Baxter MaxSep forremoval of the Dynabeads CD3/CD28 CTS beads. Following bead removal, thecell expansion was washed using the Haemonetics Cell Saver 5 to removeresidual vector, viral particles, and cell debris. CART-PSMA-TGFβRDNcells were resuspended in cryopreservation media containing 31.25%Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 1% Dextran 40 and 5%Dextrose, 5% Human Serum Albumin, and 7.5% DMSO. Cells were frozen inCryostore Ethylene-Vinyl Acetate (EVA) (OriGen Biomedical) or equivalentclear bags using a controlled-rate freezer.

Cryopreserved CART-PSMA-TGFβRDN:

Each infusion bag contained ˜10-50 mL of cells. Cryopreserved cells werealso retained in small aliquots in identical cell concentrations to theinfusion dose and used as sentinel vials for performing a viability andendotoxin test prior to infusions, and for stability testing.

Leukapheresis Collection and Cell Separation/Enrichment:

Autologous peripheral blood lymphocytes were obtained via leukapheresiscollection at the Apheresis Unit at the Hospital of the University ofPennsylvania (HUP). Cryopreserved historical apheresis productscollected from the patient prior to study entry may be usable forCART-PSMA-TGFβRDN cell manufacturing. If used, the sample must have beencollected at an appropriately certified apheresis center and the productmust have met adequate mononuclear cell yields.

Approximately 10-15 L of blood was processed on the COBE SpectraApheresis System or equivalent system to obtain a population ofapproximately 5×10⁹ white blood cells. In addition to the screeningtesting requirements provided in the protocol, blood from all apheresisdonors underwent infectious disease testing performed by the AmericanRed Cross National Testing Laboratory.

The apheresis product was transported in an insulated container to theCVPF, and temperature was logged upon receipt. Samples were removed forbacterial and fungal cultures, real-time phenotyping by flow cytometry,and research and correlative study purposes. Apheresis products werecryopreserved or processed by elutriation. After Elutriation or cellwashing, the cell number was determined on the Coulter Multisizer M3/M4and viability by trypan blue dye exclusion assay. Elutriated productswere cryopreserved or proceeded to further processing. Cryopreservedapheresis or elutriated products were thawed and washed prior to cultureto remove cryopreservation medium. These products were then processedvia either 1) washing and seeding of elutriated lymphocytes, 2) positiveselection with CD3/CD28 beads, or 3) Ficoll based gradient separationfor further T-cell selection.

Culture Initiation and Expansion:

Enriched lymphocytes were stimulated with Dynabeads CD3/CD28 CTS instatic tissue culture flasks at an approximate range of 8×10⁵-1×10⁶cells in XVIVO-15 media supplemented with 5% human AB Serum, 2 mML-GlutaMAX, 20 mM Hepes, 1 mM Sodium Pyruvate, 1% MEM Vitamin EssentialMixture, 10 mM N-Acetylcysteine, and 100 IU/ml IL-2 (Modified X-VIVO 15Media). Beads were added at a 3:1 bead to cell ratio. On day 5 ofculture, if an acceptable cell number was achieved, cells weretransferred to the WAVE 2/10EH Bioreactor for expansion to theappropriate cell number allowing for harvest, electroporation, samplingand final formulation. On the final day of the culture, cells wereharvested and concentrated using the Cell Saver Wash system. Prior toharvest, the cell product was placed on the Baxter MaxSep for removal ofthe anti-CD3/CD28 magnetic microbeads. Post-harvest, the expanded Tcells were resuspended at 2×10⁶ cells per mL of X-VIVO mediasupplemented with 5% Human AB Serum. Cells were placed in a 37° C.incubator overnight.

CART-PSMA-TGFBRDN Dose Formulation:

The dose formulation started at a dose of 1-3×10⁷/m² CART-PSMA-TGFBRDNcells for one cohort, and a dose of 1-3×10⁸/m² for other cohorts. Dosingwas based on anti-PSMA CAR expression. The total dose was formulated asa single dose.

Final Formulation:

Post-incubation, after all release testing samples and archives wereremoved, the cells were resuspended in infusible cryopreservation mediacontaining 31.25% PlasmaLyte-A, 31.25% Dextrose (5%) in NaCl (0.45%),7.5% DMSO, 5% Human Serum Albumin, and 1% Low Molecular Weight Dextran(LMD).

Product Administration:

Cell thawing: The cells were thawed at the CVPF or at the bedside usinga water bath or comparable device maintained at 36° C. to 38° C. bytrained personnel. There should be no frozen clumps left in thecontainer by the time it is connected to the I.V. tube. If theCART-PSMA-TGFβRDN cell product appeared to have a damaged or leakingbag, or be compromised, it was not infused, and was returned to theCVPF.

Administration: The infusion took place in an isolated room in the CTRCor elsewhere in the Hospital of the University of Pennsylvania, usingprecautions for immunosuppressed patients. Prior to the infusion, twoindividuals independently verified the information on the infusionproduct label in the presence of the subject and confirmed that theinformation is correctly matched to the participant. Cells were infusedwithin approximately 30 minutes after thaw. The CART cells were infusedintravenously into an 18 gauge intravenous catheter, either through aperipheral vein (preferred) or central vein. Macrodrip intravenoustubing was used to infuse the CART cells by gravity (i.e., without aninfusion pump) at a rate of approximately ˜10 mL/minute through a latexfree-Y-type blood set with a 3-way stopcock. A leukoreduction filter wasnot used for the infusion of the CART cell product. Emergency medicalequipment (i.e., emergency trolley) was available during the infusion incase the subject had an allergic response, or severe hypotensive crisis,or any other reaction to the infusion. Vital signs (temperature,respiration rate, pulse, blood pressure, and oxygen saturation by pulseoximetry) were measured prior, and after the infusion. If the subject'svital signs were not satisfactory and stable, vital signs werecontinually monitored at a minimum of every hour or as clinicallyindicated until stable. The subject was discharged after the physicianmanaging their care has determined the subject was in satisfactorycondition.

Example 9: CART-PSMA-TGFβRDN Clinical Trial Design

This protocol tested the safety of 2 dose-levels of CART-PSMA-TGFβRDNcells administered intravenously alone or after lymphodepletion with amoderate dose of cyclophosphamide administered three days prior toCART-PSMA-TGFβRDN cells. The dose escalation followed a 3+3 design.CART-PSMA-TGFβRDN cells were permanently modified to be directed to thePSMA protein with an anti-PSMA CAR fused to the signaling domains of4-1BB and TCR. The study population included patients with castrateresistant prostate cancer with radiographic evidence of lymph node,visceral, or osseous metastases. All patients must have progressed aftertherapy with at least one standard 17a lyase inhibitor orsecond-generation anti-androgen therapy.

The date the first patient was dosed was Aug. 31, 2017.

As part of informed consent, subjects were asked for permission to testtheir tumor for PSMA as one of the eligibility criteria. Evaluation ofPSMA expression on a fresh tumor biopsy was preferred; however, if abiopsy was not feasible or clinically appropriate, then archived tissuefrom a recent metastatic tissue biopsy was used to determine eligibilityif obtained within prior 90 days.

Patients with confirmed ≥10% of tumor cells with PSMA expression and whomeet all other inclusion criteria were eligible to participate.

Cohort 1 subjects (N=3 or 6) received a single dose of 1-3×10⁷/m²lentivirally transduced CART-PSMA-TGFβRDN cells on day 0 without anyconditioning chemotherapeutic regimen. If the number of manufactured CART cells did not meet the pre-specified minimum infused dose of 1×10⁷/m²cells, then the dose was not administered, and the subject was replacedin the study. If 1 DLT/3 subjects occurs, the study enrolls anadditional 3 subjects at this dose level. If 0 DLT/3 subjects or 1 DLT/6subjects occurs, the study advances to Cohort 2. If 2 DLT/3 subjectsoccurs at dose of 1-3×10⁷/m² cells, then enrollment in this Cohort isstopped and the dose is de-escalated by 10-fold to 1-3×10⁶ cells/m²(Cohort −1). In this situation, up to 6 subjects are enrolled in Cohort−1.

Cohort 2 subjects (N=3 or 6) received a single dose of 1-3×10⁸/m²lentivirally transduced CART-PSMA-TGFβRDN cells on day 0 without anyconditioning chemotherapeutic regimen. If the number of manufactured CART cells did not meet the protocol-specified minimum of 1×10⁸/m² cells,but does meet the minimum dose requirement of at least 1×10⁷/m² cells,then the subject receives the dose and was not included in the DLTassessment for Cohort 2. This subject would be replaced for DLTassessment at this dose. If, the number of manufactured CAR T cells didnot meet the pre-specified minimum infused dose as outlined for Cohort1, then no dose was administered, and the subject was replaced in thestudy. If 1 DLT/3 subjects occurs, the study enrolls an additional 3subjects at this dose level. If 0 DLT/3 subjects or 1 DLT/6 subjectsoccur, the study advances to Cohort 3. If 2 DLT/3 subjects occur, thenthe study stops and declares maximum tolerated dose (MTD).

Cohorts 1 and 2 served to identify the MTD of CART-PSMA-TGFβRDN cells.The MTD is defined as the highest dose at which 0/3 or 1/6 DLTs occur.

Cohort 3 subjects (N=3 or 6) received a single infusion at the MTD oflentivirally transduced CART-PSMA-TGFβRDN cells on day 0, following asingle dose of 1.0 gram/m² of cyclophosphamide administered up to 4 daysprior to the CAR T cells (day −3±1 day). If 0 DLT/3 subjects occur, thestudy enrolls an additional 3 patients to confirm tolerability. If 1DLT/3 subject occurs, the study enrolls an additional 3 subjects at thisdose level. If two of the initial three subjects experience a DLT, threeadditional patients are accrued with a dose-reduction in thelymphodepleting chemotherapy to 500 mg/m² administered up to 4 daysprior to the CAR T cells (day −3±1 day).

Subjects were enrolled serially. Infusions were staggered to allowassessment of DLTs for cohort progression, expansion, or dosede-escalation. The infusions for the first 2 subjects in each cohortwere staggered by 28 days; the second subject was not infused until 28days after the infusion of the first subject. The 2nd and 3rd subjectsin each cohort were infused and followed in parallel but only after the1st subject in that cohort completed the day 28 visit without DLT.

DLT was defined as any new grade 3 or greater adverse event at leastpossibly related to the T cell regimen that occurred within 28 days of Tcell infusion. If 1 DLT occurs in the first 3 subjects treated at a doselevel, the study enrolls an additional 3 subjects at that dose level. If2 DLT/3 subjects occur, then the study stops and declares maximumtolerated dose, except for Cohort 1, where a 10-fold dose de-escalationoccurs. If 0 DLT/3 subjects or 1 DLT/6 subjects at a dose level, thestudy advances to the next Cohort. For cohort 3, if two of the initialthree subjects experience a DLT, three additional patients are accruedwith a dose-reduction in the lymphodepleting chemotherapy to 500 mg/m²administered up to 4 days prior to the CAR T cells (day −3±1 day).Otherwise, if 0-1 DLT/3 subjects occur in cohort 3, the study enrolls anadditional 3 patients to confirm tolerability.

Subjects were followed up for safety assessments and researchassessments. Subjects returned for study follow-up on Days 1, 3, 7, 10,14, 21, and 28 for safety assessments. On Day 28 (±5), disease stagingwas performed with a CT chest/abdomen/pelvis, bone scan, and serum PSA.The reasons for this early imaging assessment at day 28 were to assessfor systemic inflammation effects and to monitor disease status at thetime of the expected homing of CART-PSMA-TGFβRDN cells. Repeat diseaseassessments (including imaging) were performed at Months 3 and 6 and asstandard of care thereafter. If a subject had relevant imaging data (CTabd/pelvis, MRI abd/pelvis, bone scan) within 4 weeks of Month 3 and/or6 performed as part of their standard of care, this was not repeated atMonth 3 and/or 6.

Adverse event reporting began at the time of consent and continues untilthe subject is off-study. While on study, subjects were continuallyreassessed for evidence of acute and cumulative toxicity. Upondiscontinuation from the primary follow-up phase, subjects enterlong-term follow-up for up to 5 years from their CART-PSMA-TGFβRDNinfusion. During long-term follow-up, subjects are monitored for delayedadverse events that may be associated with the administration of theCART-PSMA-TGFβRDN cells.

Peripheral blood samples were obtained at defined time points to monitorfor measures of safety and efficacy. Additional blood and tissue samples(e.g. fluids, tissue biopsy) that were obtained for clinical indicationsmay also be sent for research analysis. At any time that tissue or bodyfluids were obtained (for example, drainage of pleural fluid or ascitesfluid), fluid samples that would otherwise be discarded were usedinstead for research purposes. These studies include, but were notlimited to, CART-PSMA-TGFβRDN cell persistence by Q-PCR and inflammationmarker assessment with a Luminex-based cytokine and chemokine panel.

In case of unexpected AEs, additional blood and tissues were collectedfor research analysis, focused at evaluating the potential causality ofthe unexpected event with the infused CART-PSMA-TGFβRDN cells. Theadditional samples collected for research did not exceed 3 tablespoonsof blood twice in one week, and one tissue sample collection procedurefor per month.

Inclusion criteria:

-   -   1. Metastatic castrate resistant prostate cancer    -   2. ≥10% tumor cells expressing PSMA as demonstrated by        immunohistochemistry analysis on biopsied tissue.    -   3. Radiographic evidence of osseous metastatic disease and/or        measurable, non-osseous metastatic disease (nodal or visceral)    -   4. Patients ≥18 years of age    -   5. ECOG performance status of 0-1    -   6. Adequate organ function, as defined by:        -   a. Serum creatinine ≤1.5 mg/dl or creatinine clearance ≥60            cc/min        -   b. Serum total bilirubin <1.5×ULN        -   c. Serum ALT/AST<2×ULN    -   7. Adequate hematologic reserve within 4 weeks of study        enrollment as defined by:        -   a. Hgb>10 g/dl        -   b. PLT>100 k/ul        -   c. ANC>1.5 k/ul        -   Note: Subjects must not be transfusion dependent    -   8. Evidence of progressive castrate resistant prostate        adenocarcinoma, as defined by:        -   a. Castrate levels of testosterone (<50 ng/ml) with or            without the use of androgen-deprivation therapy AND        -   b. Evidence of one of the following measures of progressive            disease in the 12 weeks preceding study enrollment:            -   i. soft tissue progression by RECIST 1.1 criteria            -   ii. osseous disease progression with 2 or more new                lesions on bone scan (as per PCWG2 criteria)            -   iii. increase in serum PSA of at least 25% and an                absolute increase of 2 ng/ml or more from nadir (as per                PCWG2 criteria)    -   9. Prior therapy with at least one standard 17a lyase inhibitor        or second-generation anti-androgen therapy for the treatment of        metastatic castrate resistant prostate cancer    -   10. Provides written informed consent    -   11. Subjects of reproductive potential must agree to use        acceptable birth control methods.

Exclusion Criteria:

-   -   1. Prior treatment with an immune-based therapy for the        treatment of prostate cancer, including cancer vaccine therapies        (such as SipuleucelT, PROSTVAC), immune checkpoint inhibitors,        radium-223 and immunoconjugate therapies    -   2. History of an active non-curative non-prostate primary        malignancy within the prior 5 years    -   3. Subjects who require the chronic use of systemic        corticosteroid therapy    -   4. Subjects who have received >3 prior therapies for the        treatment of castrate resistant prostate cancer (excluding        luteinizing hormone-releasing hormone agonists or antagonists,        or first generation anti-androgen therapies). This includes        subjects who received Taxotere in non-castrate resistant        setting.    -   5. Subjects with Class III/IV cardiovascular disability        according to the New York Heart Association Classification (see        Attachment 2)    -   6. Subjects with symptomatic vertebral metastases affecting        spinal cord function (as determined by clinical history,        physical exam, or MRI imaging)    -   7. History of active autoimmune disease requiring        immunosuppressive therapy    -   8. Patients with ongoing or active infection.    -   9. History of allergy or hypersensitivity to study product        excipients (human serum albumin, DMSO, and Dextran 40)    -   10. Active hepatitis B, hepatitis C or HIV infection.

Example 10: Phase 1 Clinical Safety Data

A total of six subjects have been infused and two subjects remain onstudy as of Jul. 25, 2018. Three subjects were infused in Cohort 1 andthree subjects were infused in Cohort 2. Thus, Cohort 2 was filled. Incontract to Cohort 1, all three subjects infused in Cohort 2 experiencedcytokine release syndrome (CRS): two subjects had grade 3 CRS and onesubject had grade 1 CRS, all of which developed within 12 hours CARTcell infusion. These toxicities were managed per protocol/institutionalguidelines and resolved. Thus, Cohort 2 was completed without a DLT.

The study Site Initiation Visit was held on Wednesday, Feb. 22, 2017 andthe study was activated on Mar. 8, 2017. As of Jul. 25, 2018, theclinical site consented 8 subjects. Of the 8 subjects consented therewas 1 screen failure, 1 subject withdrew prior to treatment, and 6subjects were infused.

Table 3 shows a summary of the demographics of screened subjects (N=8).

TABLE 3 Demographics of screened subjects Subject Sex Age at ScreenReason for Infused Reason for ID Cohort (F/M) Consent Race Fail (Y/N)Screen Fail (Y/N) End of Study 1 32816- N/A M 66 Caucasian Y Excluded NScreen 01 based on Failure prior immune therapy 2 32816- 1 M 55Caucasian N N/A Y Death; 02 Neutropenic Sepsis* 3 32816- N/A M 67Caucasian N N/A N Subject 03 Withdrew Consent 4 32816- 1 M 50 CaucasianN N/A Y Death; 04 Disease Progression* 5 32816- 1 M 71 Caucasian N N/A YDisease 05 Progression 6 32816- 2 M 72 Caucasian N N/A Y Disease 06Progression 7 32816- 2 M 73 Caucasian N N/A Y Active on 07 Study 832816- 2 M 64 Caucasian N Y Active on 08 Study N/A = not applicable*Death occurred during long term follow up. Therefore, this event didnot qualify as a PDAE and determined unrelated to the IP.

Table 4 shows a summary of the current protocol status for infusedsubjects (N=6).

TABLE 4 Current protocol status for infused subjects Last Study Visit/Protocol Adverse Related Serious Subject Date of Last Visit Off-StudyDate/ Deviation Events Adverse Adverse Study ID in Primary Study Reason(Y/N) (Y/N) Events (Y/N) Events (Y/N) Status 1 32816- Day 28/ Nov. 16,2017/Death N Y Y Y Off- 02 Sep. 29, 2017 (Neutropenic Sepsis) Study 232816- Month 3/ May 19, 2018/Death N Y N N Off- 04 Feb. 15, 2018(Disease Progression) Study 3 32816- Month 6/ Jun. 13, 2018/ N Y Y YOff- 05 May 22, 2018 Disease Progression Study 4 32816- Day 28 / Jun.17, 2018/ Y Y Y Y Off- 06 Jul. 13, 2018 Disease Progression Study 532816- Month 2/ N/A N Y Y Y On- 07 Jul. 9, 2018 Study 6 32816- Day 28/N/A Y Y Y Y On- 08 Jul. 25, 2018 Study

Table 5 shows a summary of deviations or exceptions for infused subjects(N=6).

TABLE 5 Deviations or exceptions for infused subjects Date ProtocolException or Description Status of Exception or Deviation of ExceptionException or Subject ID Deviation Identified or Deviation Deviation32816-02 Exception Apr. 24, 2017 Subject had repeate Sponsor approved;screening biopsy as approved by all initial biopsied material localregulatory was determined review communities to be insufficient for PSMAexpression analysis as it contained fat, marrow tissue 32816-04 NoDeviations or Exceptions to report 32816-05 No Deviations or Exceptionsto report 32816-06 Deviation Jun. 12, 2018 Subject was infused Sponsoron Jun. 11, 2018; acknowledgment the vital signs communicated to thesource documentation site Aug. 7, 2018; was lost during the did notrequire real subject's transfer time reporting as it to the ICU and didnot affect subject therefore there is safety. Corrective no record ofthe and preventative subject's protocol- action plan being required pre-and implemented. post-infusion vital signs 32816-07 No Deviations orExceptions to report 32816-08 Deviation Mar. 29, 2018 The studypathologist Sponsor approved; performed PSMA IRB approved; didexpression testing on a not require real time specimen collected asreporting as it did not standard of care prior to affect subject safety.the patient signing the Corrective and pre-screening informedpreventative action consent form plan implemented.

Table 6 shows a summary of infusion dates and doses among infusedsubjects (N=6).

TABLE 6 PSMA-TGFβRDN infusion dates and dose summary among infusedsubjects Transduction Cells Infused Efficiency Total CART- CART-PSMA-Met Target % Subject Infusion Total PSMA-TGFβRDN TGFβRDN Met Target % scFv scFv Flow ID Cohort Date Cell Dose Cell Dose Cell Dose/m² Dose (Y/N)Flow (%) (Y/N) 1 32816- 1 Aug. 31, 2017 9.25 × 10⁷ 5.61 × 10⁷ 3 × 10⁷/m²Y 60.5 Y 02 2 32816- 1 Nov. 13, 2017 1.20 × 10⁸ 7.56 × 10⁷ 3 × 10⁷/m² Y62.9 Y 04 3 32816- 1 Nov. 20, 2017 7.66 × 10⁷ 5.58 × 10⁷ 3 × 10⁷/m² Y72.7 Y 05 4 32816- 2 Jun. 11, 2018 1.05 × 10⁹ 7.29 × 10⁸ 3 × 10⁸/m² Y69.7 Y 06 5 32816- 2 May 7, 2018 1.18 × 10⁹ 6.60 × 10⁸ 3 × 10⁸/m² Y 56.1Y 07 6 32816- 2 Jun. 27, 2018 1.13 × 10⁹ 6.36 × 10⁸ 3 × 10⁸/m² Y 56.4 Y08

Table 7 is a summary of disease response for infused subjects (N=6).

TABLE 7 Disease response for infused subjects Overall Tumor ResponseSubject Response Day Month Month Month ID Cohort Criteria 28 2 3 6 132816- 1 RECIST NE N/A N/A N/A 02 1.1 Bone New N/A N/A N/A Scan Lesions2 32816- 1 RECIST NE Not PD N/A 04 1.1 Assessed Bone No New Not New N/AScan Lesions Assessed Lesions 3 32816- 1 RECIST SD Not SD PD 05 1.1Assessed Bone New Not New No Scan Lesions Assessed Lesions New Lesions 432816- 2 RECIST PD N/A N/A N/A 06 1.1 Bone Not N/A N/A N/A Scan Assessed5 32816- 2 RECIST SD Not Pend- Pend- 07 1.1 Assessed ing ing Bone No NewNot Pend- Pend- Scan Lesions Assessed ing ing 6 32816- 2 RECIST PD Pend-Pend- Pend- 08 1.1 ing ing ing Bone New Pend- Pend- Pend- Scan Lesionsing ing ing NE = Not Evaluable PD = Progressive Disease SD = StableDisease Pending = Subject has not yet reached this time point NotAssessed = An assessment was not done at this time point N/A = Notapplicable/Subject discontinued primary follow-up prior to this timepoint

Table 8 is a summary of serum PSA levels for infused subjects (N=6).

TABLE 8 Serum PSA levels for infused patients (data provided in ng/mL)Pre- Subject Infusion Day Month Month Month ID Cohort Screening Safety28 2 3 6 Unscheduled 1 32816- 1 163.80 237.80 167.40 317.10¥ N/A N/A(Day +20) 02 162.20 2 32816- 1  9.35  7.60  10.45  19.79 38.11 N/A — 043 32816- 1  17.83  10.47  14.01  11.75 18.77 47.31 — 05 4 32816- 2 14.26  41.75 132.20 N/A N/A N/A — 06 5 32816- 2 219.30 324.30 340.50372.50 Pend- Pend- (Day +10 07 ing ing 286.80 (Day +14) 285.40 (Day +21)341.60 6 32816- 2  70.56 134.50 197.10 Pend- Pend- Pend- — 08 ing inging N/A = not applicable ¥ = Subject entered LTFU on Nov. 1, 2017; Month2 PSA was drawn on Nov. 2, 2017 — = no unscheduled data for this subjectPending = subject has not yet reached this time point

Table 9 is a summary showing PSMA-TGFβRDN cell marking in the peripheralblood by qPCR for infused subjects (N=6).

TABLE 9 PSMA-TGFβRDN cell marking in the peripheral blood by qPCR forinfused subjects (data provided in copies/microgram genomic DNA) Pre-Day Day Subject Infusion 0 0 Day Day Day Day Day Day Day Month MonthMonth ID Cohort Safety pre post 1 3 7 10 14 21 28 2 3 6 32816- 1 ND ND 85.15  4.53 101.82 343.7 1412.81 110.46 11.46  8.04 N/A N/A N/A 0232816- 1 ND ND 151.6  ND  25.90  417.31 3351.64 216.02 27.02 ND ND NDN/A 04 32816- 1 ND ND  46.99  5.95  9.23 ND  33.38  43.61  7.85 14.50 NDND ND 05 32816- 2 ND ND 394.94 16.87 201.73 3099.79 1084.13 218.64 Not26.96 N/A N/A N/A 06 Collected 32816- 2 ND ND 530.57 16.27  89.39 457.40  151.45  84.31 43.40 14.50 Not Yet Pend- Pend- 07 Resulted inging 32816- 2 ND ND 422.92 63.32  96.76  253.85  217.28 114.46 72.06 NotYet Pend- Pend- Pend- 08 Resulted ing ing ing ND = not detected N/A =not applicable—subject discontinued primary follow-up priot to thisvisit Pending = subject has not yet reached this time point NotCollected = Research samples were not collected for analysis Not YetResulted = Sample has not yet been tested

Table 10 is a summary showing PSMA-TGFβRDN cell marking in other tissuesby qPCR for infused subjects (N=6).

TABLE 10 PSMA-TGFβRDN cell marking in other tissues by qPCR for infusedsubjects (data provided in copies/microgram genomic DNA) Subject IDCohort Time Point Sample Type Results 32816-02 1 Day 10 Tumor (1A FFPEtissue curls) 122.32 Tumor (2A FFPE tissue culrs) 57.99 Day 21 Other(BMBMX core cells) ND Other (Marrow) 27.12 Month 2   Other (BMBMX corecells) ND 32816-04 1 Day 10 Tumor (HS17-37343-1A 133.36 Right Iliac)Tumor (HS17-37343-1B 211.16 Right Iliac) 32816-05 1 Day 10 Tumor(Retroperitoneal 758.51 lymph node) 32816-06 2 Day 10 Tumor BX curls98.24 32816-07 2 Day 10 Tumor BX curls ND 32816-08 2 No other tissuedata at this time FFPE = Formalin-fixed, paraffin embedded BMBMX = Bonemarrow biopsy BX = Biopsy ND = Not detected

Table 11 is a summary showing percent PSMA positive tumor cells forenrolled subjects as determined by immunohistochemistry (N=7).

TABLE 11 Percent PSMA positive tumor cells for enrolled subjects SubjectTime- Sample Results ID Cohort point Type Location (%) 1 32816- 1Screen- Fresh Right iliac bone ND, 02 ing biopsy in- sufficient Screen-Fresh Bladder 100 ing Day 10 Fresh Bladder 100 2 32816- NA Screen- FreshRight external 100 03 ing iliac lymph node 3 32816- 1 Screen- ArchivedIliac bone  30 04 ing Day 10 Fresh Left iliac bone  75 4 32816- 1Screen- Fresh Left retroperitoneal 100 05 ing lymph node Day 10 FreshLeft retroperitoneal 100 lymph node 5 32816- 2 Screen- Fresh Para aorticlymph  25 06 ing node Day 10 Fresh Para aortic lymph 100 node 6 32816- 2Screen- Fresh Posterior vertebra 100 07 ing Day 10 Fresh L1 vertebra  807 32816- 2 Screen- Fresh Bladder 100 08 ing Day 10 Fresh Primary 70-80NA = Not assigned ND = Not detected

Example 11: Phase 1 Clinical Trial of PSMA-Directed/TGFβ-InsensitiveCAR-T Cells in Metastatic Castration-Resistant Prostate Cancer

Background:

Adoptive immunotherapy with CAR-T cells has transformative potential forthe treatment of cancer. A primary challenge to the success of thesetherapies in prostate cancer is the immunosuppressive microenvironment,including high levels of TGFβ, encountered by re-directed T cells upontumor infiltration. Importantly, these immunosuppressive functions ofTGFβ can be inhibited in T cells using a dominant negative TGFβ receptor(TGFβRdn), thereby enhancing antitumor immunity. In in vivo disseminatedtumor models, co-expression of TGFβRdn on PSMA-directed CAR-T cells ledto increased T cell proliferation, enhanced cytokine secretion,long-term persistence, and greater induction of tumor eradication.Mechanisms of adaptive tumor resistance are unknown.

FIG. 15 shows the efficacy of CART-PSMA-TGFβRdn cells in in vivodisseminated tumor models. FIG. 15A is a graph showing thatCART-PSMA-TGFβRdn cells demonstrated enhanced antigen-specificproliferation versus CART-PSMA over 42 days co-culture and repetitivestimulation with PSMA-expressing tumor cells. FIG. 15B is a graphshowing that in vivo, CART-PSMA-TGFβRdn cells demonstrated significantlyincreased tumor reduction compared to CART-PSMA, as measured by BLIimaging weekly to assess tumor burden. FIG. 15C are photographs showingthe location and systemic burden of tumor with weekly BLI assessment.Abbreviations used in FIG. 15: Pbbz=CAR-T PSMA;dnTGFBR2-T2A-Pbbz=CART-PSMA-TGFβRdn; 19bbz=anti-CD19 CAR.

Study Design:

Study Overview: A first-in-human phase 1 clinical trial was initiated toevaluate the safety and preliminary efficacy of lentivirally-transducedPSMA-directed/TGFβ-insensitive CAR-T cells (CART-PSMA-TGFβRdn) in menwith treatment-refractory metastatic castrate resistant prostate cancer(CRPC) (NCT03089203). In preliminary dose-escalation cohorts, patientsreceived a single dose of 1-3×10⁷/m² (Cohort 1) or 1-3×10⁸/m² (Cohort 2)CART-PSMA-TGFβRdn cells without lymphodepleting chemotherapy in a 3+3design. In Cohort 3, patients receive the maximum tolerated dose (MTD)of CART-PSMA-TGFβRdn cells following lymphodepleting chemotherapy withCyclophosphamide 300 mg/m² and Fludarabine 30 mg/m² for 3 days. Alltreated patients underwent metastatic tumor biopsies at baseline, aswell as on day +10 following the CAR-T cell infusion.

Key Eligibility Criteria:

Metastatic CRPC, with previous treatment with at least onesecond-generation androgen signaling inhibitor (abiraterone orenzalutamide); ≥10% tumor cells expressing PSMA by IHC on metastatictissue biopsy; radiographic evidence for metastatic disease (osseous ornodal/visceral); ≤4 lines of therapy for metastatic CRPC.

Study Schema:

FIG. 16 shows the study schema used in this clinical trial.

Correlative Analyses:

Quantitative PCR of CART-PSMA-TGFβRdn DNA was performed at serialtimepoints to evaluate for CAR-T expansion and persistence in peripheralblood and trafficking to target tissues. Bioactivity ofCART-PSMA-TGFβRdn cells in peripheral blood was evaluated throughLuminex analyses of immune and inflammatory factors. Circulating tumormaterial was collected at serial time points and correlated withclinical response.

Study Status and Preliminary Findings:

Six patients received CART-PSMA-TGFβRdn cell infusions at the specifieddose levels (Cohort 1, N=3; Cohort 2, N=3). All CART-PSMA-TGFβRdninfusion products met target transduction efficiency. No dose limitingtoxicitities were observed in preliminary dose escalation.

Evaluation of CAR-T cellular kinetics via qPCR of CART-PSMA-TGFβRdn DNAdemonstrated peripheral blood T cell expansion (FIG. 17), as well astumor tissue trafficking in post-treatment tumor biopsies (Table 17).

TABLE 17 CART-PSMA-TGFβRDN cell trafficking: qPCR detection in tissuebiopsy samples in infused subjects Subject ID Cohort Time Point SampleType Results* 32816-02 1 Day 10 Bladder (FFPE 122.32 tissue curls)Bladder (FFPE 57.99 tissue curls) Day 21 Bone marrow ND biopsy core Bonemarrow 27.12 Month 2    Bone marrow ND biopsy core 32816-04 1 Day 10Bone (FFPE 133.36 tissue curls) Bone (FFPE 211.16 tissue curls) 32816-051 Day 10 Lymph node 758.51 (FFPE tissue) 32816-06 2 Day 10 Lymph node98.24 (FFPE tissue) 32816-07 2 Day 10 Bone (FFPE ND tissue curls)32816-08 2 Data analysis pending *copies/ug gDNA FFPE = formalin-fixed,paraffin embedded ND = not detected

In Cohort 2, two patients developed anticipated Grade 3 cytokine releasesyndrome (CRS), which is a critical marker of biologic activity withCAR-T therapy, and one patient developed Grade 3 CAR-T neurotoxicityrequiring corticosteroids.

Marked increases in inflammatory cytokines (IL-6, IL-15, IL-2, IFNgamma)and ferritin correlated with all Grade 3 CRS events (Subject 32816-06:FIG. 18A; and subject 32816-07: FIG. 18B). All CRS events rapidlyresolved with tocilizumab (anti-IL6R) rescue.

Cohort 3 enrollment (MTD with lymphodepleting chemotherapy) begain inSeptember 2018.

Example 12: Cohorts 1 and 2 Observations and Case Study

FIG. 19 shows a graph of prostate specific antigen (PSA) response amongCohort 1 and Cohort 2 patients.

Subject 32816-07:

74 year old with metastatic castration resistant prostate cancer (mCRPC;initial diagnosis: May 2014). Fever to 103F several hourspost-PSMA-TGFβRDN CART infusion (no lymphodepletion) was observed.Hypotension was observed approximately 6 hours post-PSMA-TGFβRDN CART at83/44 mmHg nadir. Hypotension was managed with crystalloid infusion (nopharmacologic management required during ICU admission) and tocilizumabwith resolution by the following day after PSMA-TGFβRDN CART infusion.

Cytokine release syndrome (CRS) was observed in patient 32816-07following PSMA-TGFβRDN CART-infusion (FIG. 20A). In FIG. 20A, the lefty-axis indicates the level of PSMA-TGFβRDN CART in peripheral blood incopies/ug of genomic DNA (32816-07), and the right y-axis indicates thelevel of IL-6 in pg/ml (IL6). CRS was accompanied by transient PSAdecrease (FIG. 20B). In FIG. 20B, the left y-axis indicates the serumlevel of C-reactive protein (CRP) in mg/L and the right y-axis indicatesthe serum level of ferritin in ng/L.

PSMA Positive CTC Observations in Cohorts 1 and 2:

Table 18 shows a summary of the number of PSMA-positive circulatingtumor cells (CTCs) detected in each subject across various time points,the data of which is graphed in FIG. 21.

TABLE 18 PSMA-positive CTCs in Cohorts 1 and 2 Week-8 Day 10 Post- Day28 Post- Month 3 Post- Screening Infusion Infusion Infusion SubjectTotal # PSMA + Total # PSMA + Total # PSMA + Total # PSMA + Cohort IDCTC CTCs (%) CTC CTCs (%) CTC CTCs (%) CTC CTCs (%) 1 32816- 248 144 421241 230 117 788 409 02  (58.1%) (57.2%) (50.9%) (51.9%) 32816-  3  3 Offstudy 03 (100.0%) 32816-  3  2  0  0  15  11  3  1 04  (66.7%) (73.3%) (33.3%) 32816-  1  0  1  0  0  0  3  3 05  (0.0%)  (0.0%) (100.0%) 232816-  12  12  3  0  0  0  0 Off 06 (100.0%) study 32816-  13 —  3  2 0  0  0  0 07 32816-  3 — Pending 08

The disclosures of each and every patent, patent application, andpublication cited herein are hereby incorporated herein by reference intheir entirety. While this invention has been disclosed with referenceto specific embodiments, it is apparent that other embodiments andvariations of this invention may be devised by others skilled in the artwithout departing from the true spirit and scope of the invention. Theappended claims are intended to be construed to include all suchembodiments and equivalent variations.

What is claimed:
 1. A method of treating a cancer in a subject in needthereof, the method comprising administering to the subject atherapeutically effective amount of a composition comprising a modifiedimmune cell comprising: (a) a chimeric antigen receptor (CAR) havingaffinity for a prostate specific membrane antigen (PSMA) on a targetcell, wherein the CAR comprises the amino acid sequence set forth in SEQID NO:105; and (b) a dominant negative receptor consisting of the aminoacid sequence set forth in SEQ ID NO:115.
 2. A method of treating acancer in a subject in need thereof, the method comprising administeringto the subject a therapeutically effective amount of a compositioncomprising a modified immune cell comprising: (a) a chimeric antigenreceptor (CAR) having affinity for a prostate specific membrane antigen(PSMA) on a target cell, wherein the CAR comprises the amino acidsequence set forth in SEQ ID NO:105; and (b) a truncated dominantnegative variant of TGF-β receptor type II comprising the amino acidsequence set forth in SEQ ID NO:115.
 3. A method of treating a cancer ina subject in need thereof, the method comprising administering to thesubject a therapeutically effective amount of a composition comprising amodified immune cell comprising: (a) a chimeric antigen receptor (CAR)having affinity for a prostate specific membrane antigen (PSMA) on atarget cell, wherein the CAR comprises an antigen binding domain, atransmembrane domain, and an intracellular domain, and wherein theantigen binding domain comprises: (i) a heavy chain variable region (VH)that comprises the consensus sequence of SEQ ID NO:183, and/or (ii) alight chain variable region (VL) that comprises the consensus sequenceof SEQ ID NO:184; and (b) a dominant negative receptor and/or switchreceptor.
 4. The method of claim 3, wherein the VH comprises thesequence of SEQ ID NO:191.
 5. The method of claim 3, wherein the VLcomprises the sequence of SEQ ID NO:192.
 6. The method of claim 3,wherein the antigen binding domain comprises an antibody or anantigen-binding fragment thereof.
 7. The method of claim 6, wherein theantigen-binding fragment is selected from the group consisting of a Fab,a single-chain variable fragment (scFv), and a single-domain antibody.8. The method of claim 3, wherein the transmembrane domain comprises atransmembrane region derived from CD8.
 9. The method of claim 8, whereinthe transmembrane region comprises the amino acid sequence of SEQ IDNO:88.
 10. The method of claim 3, wherein the transmembrane domainfurther comprises a hinge region derived from CD8.
 11. The method ofclaim 10, wherein the hinge region comprises the amino acid sequence ofSEQ ID NO:86.
 12. The method of claim 3, wherein the intracellulardomain comprises two signaling domains selected from the groupconsisting of a 4-1BB signaling domain, a CD3 zeta signaling domain, andan ICOS signaling domain.
 13. The method of claim 3, wherein theintracellular domain comprises: (a) two signaling domains selected fromthe group consisting of a 4-1BB signaling domain comprising the aminoacid sequence of SEQ ID NO:92, (c) a CD3 zeta signaling domaincomprising the amino acid sequence of SEQ ID NO:97 or SEQ ID NO:100, and(c) an ICOS signaling domain comprising the amino acid sequence of SEQID NO:203.
 14. The method of claim 3, wherein the dominant negativereceptor is a truncated dominant negative variant of TGF-β receptor typeII.
 15. The method of claim 14, wherein the truncated dominant negativevariant of TGF-β receptor type II comprises the amino acid sequence setforth in SEQ ID NO:115.
 16. The method of claim 3, wherein the modifiedimmune cell is a T cell.
 17. The method of claim 16, wherein the T cellis an autologous cell or an allogeneic cell.
 18. The method of claim 3,wherein the modified cell is derived from a human cell.
 19. The methodof claim 3, further comprising administering to the subject alymphodepleting chemotherapy, wherein the lymphodepleting chemotherapycomprises administering to the subject a therapeutically effectiveamount of cyclophosphamide at about 200 mg/m²/day to about 2000mg/m2/day, and/or fludarabine at about 20 mg/m²/day to about 900mg/m²/day.
 20. The method of claim 3, wherein the cancer is a prostatecancer selected from the group consisting of castrate-resistant prostatecancer, advanced castrate-resistant prostate cancer, and metastaticcastrate-resistant prostate cancer.